0001144204-15-065395.txt : 20151113 0001144204-15-065395.hdr.sgml : 20151113 20151113165623 ACCESSION NUMBER: 0001144204-15-065395 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151113 DATE AS OF CHANGE: 20151113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medite Cancer Diagnostics, Inc. CENTRAL INDEX KEY: 0000075439 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364296006 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-00935 FILM NUMBER: 151229918 BUSINESS ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 4078490290 MAIL ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: CytoCore Inc DATE OF NAME CHANGE: 20060815 FORMER COMPANY: FORMER CONFORMED NAME: MOLECULAR DIAGNOSTICS INC DATE OF NAME CHANGE: 20011009 FORMER COMPANY: FORMER CONFORMED NAME: AMPERSAND MEDICAL CORP DATE OF NAME CHANGE: 19990527 10-Q 1 v424204_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended September 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to .

Commission File number 000-00935

MEDITE CANCER DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	36-4296006
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

4203 SW 34 ^th Street, Orlando, FL	32811
(Address of principal executive offices)	(Zip Code)

(407) 996-9630

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Name of each exchange on which registered
None		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨ (not required) ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rue 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ¨	Accelerated Filer ¨

Non-Accelerated Filer ¨	Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

COMMON STOCK, $0.001 PAR VALUE, at November 13, 2015: 20,766,206

MEDITE Cancer Diagnostics, Inc.

Form 10-Q

For the Quarterly Period Ended September 30, 2015

TABLE OF CONTENTS

		Page
PART I. – FINANCIAL INFORMATION

Item 1.	Financial Statements

a) Condensed Consolidated Balance Sheets – September 30, 2015 (unaudited) and December 31, 2014		3

b) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) — Three and Nine months Ended September 30, 2015 and 2014 (unaudited)		4

c) Condensed Consolidated Statements of Cash Flows – Nine months ended September 30, 2015 and September 30, 2014 (unaudited)		6

d) Notes to Condensed Consolidated Financial Statements (unaudited)		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 4.	Controls and Procedures	19

PART II. — OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults upon Senior Securities	20

Item 6.	Exhibits	21

SIGNATURES		22

EXHIBIT INDEX

Exhibit 31.1 Section 302 Certification of Chief Executive Officer
Exhibit 31.2 Section 302 Certification of Chief Financial Officer
Exhibit 32.1 Section 906 Certification of Chief Executive Officer
Exhibit 32.2 Section 906 Certification of Chief Financial Officer

PART I. — FINANCIAL INFORMATION

MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands except shares and per share amounts)

	September 30,			December 31,
	2015			2014
	(unaudited)
Assets

Current assets:
Cash	$	347		$	230
Accounts receivable, net		1,302			1,991
Inventories		4,161			3,415
Prepaid expenses and other current assets		208			154
Total current assets		6,018			5,790

Property and equipment, net		2,016			2,091
In-process research and development		4,620			4,620
Trademarks, trade names		1,240			1,240
Goodwill		2,453			2,453
Other assets		398			245
Total assets	$	16,745		$	16,439

Liabilities and Stockholders’ Equity

Current liabilities:
Secured lines of credit and current portion of long-term debt	$	1,764		$	2,555
Account payable and accrued expenses		4,025			4,134
Advances – related parties		85			110
Total current liabilities		5,874			6,799
Long-term debt, net of current portion		981			1,209
Total liabilities		6,855			8,008

Commitments and contingencies

Stockholders’ equity :
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 and 373,355 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively (liquidation value of all classes of preferred stock $1,121 and $2,871 as of September 30, 2015 and December 31, 2014, respectively)		962			1,487
Common stock, $0.001 par value; 3.5 billion shares authorized, 20,766,206 and 19,427,331 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively		21			19
Additional paid-in capital		8,343			5,763
Treasury stock		(327	)		(327	)
Accumulated other comprehensive loss		(479	)		(149	)
Retained earnings		1,370			1,638
Total stockholders’ equity		9,890			8,431

Total liabilities and stockholders’ equity	$	16,745		$	16,439

The accompanying notes are an integral part of these condensed consolidated financial statements.

MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands, except shares and per share amounts)

	Three Months Ended September 30,
	2015			2014
	(unaudited)			(unaudited)

Net sales	$	2,662		$	2,785
Cost of revenues		1,493			1,198
Gross profit		1,169			1,587

Operating expenses
Depreciation and amortization expense		30			48
Research and development		222			317
Selling, general and administrative		785			1,260
Total operating expenses		1,037			1,625
Operating income (loss)		132			(38	)

Other expenses
Interest expense		46			71
Other expenses		11			2
Total other expenses		57			73

Income (loss) before income taxes		75			(111	)

Income tax expense (benefit)		16			(8	)
Net income (loss)		59			(119	)

Preferred dividend		(23	)		(18	)

Net income (loss) applicable to common stockholders	$	36		$	(137	)

Condensed consolidated statements of comprehensive income (loss)
Net income (loss)		59			(119	)
Other comprehensive income (loss)
Foreign currency translation adjustments		(170	)		45

Comprehensive (loss)	$	(111	)	$	(74	)

Earnings (loss) per share
Net income (loss) applicable to common stockholders		36			(137	)
Basic and diluted earnings (loss) per share		-			(0.01	)
Weighted average basic and diluted shares outstanding		20,484,936			19,345,231

The accompanying notes are an integral part of these condensed consolidated financial statements.

MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands, except shares and per share amounts)

	Nine Months Ended September 30,
	2015			2014
	(unaudited)			(unaudited)

Net sales	$	7,081		$	8,694
Cost of revenues		4,028			4,456
Gross profit		3,053			4,238

Operating expenses
Depreciation and amortization expense		95			126
Research and development		825			762
Selling, general and administrative		2,191			2,902

Total operating expenses		3,111			3,790
Operating income (loss)		(58	)		448

Other expenses
Interest expense		157			221
Other expenses		61			153
Total other expenses		218			374

Income (loss) before income taxes		(276	)		74

Income tax expense (benefit)		(9	)		24
Net income (loss)		(267	)		50

Preferred dividend		(69	)		(54	)

Net (loss) applicable to common stockholders	$	(336	)	$	(4	)

Condensed consolidated statements of comprehensive income (loss)
Net income (loss)		(267	)		50
Other comprehensive income (loss)
Foreign currency translation adjustments		(330	)		41

Comprehensive income (loss)	$	(597	)	$	91

Earnings (loss) per share
Net (loss) applicable to common stockholders		(336	)		(4	)
Basic and diluted earnings (loss) per share		(.01	)		-
Weighted average basic and diluted shares outstanding		20,051,206			17,683,284

The accompanying notes are an integral part of these condensed consolidated financial statements.

MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)

	Nine Months Ended September 30,
	2015			2014
	(unaudited)			(unaudited)
Cash flows from operating activities:
Net income (loss)	$	(267	)	$	50
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation		95			126
Non cash interest		-			4
Changes in assets and liabilities:
Accounts receivable, net		689			56
Inventories		(746	)		(1,058	)
Prepaid expenses and other current assets		(54	)		(150	)
Accounts payable and accrued liabilities		(109	)		(391	)
Net cash used in operating activities		(392	)		(1,363	)

Cash flows from investing activities:
Purchases of equipment		(19	)		(391	)
Increase (decrease) in other assets		(154	)		1
Net cash used in investing activities		(173	)		(390	)

Cash flows from financing activities:
Net advances (repayments) on lines of credit and long-term debt		(791	)		180
Term note repayments		(228	)		(159	)
Proceeds from sale of common stock, net issuance costs of $28		2,056			1,842
Net advances from (repayment to) related parties		(25	)		9
Net cash provided by financing activities		1,012			1,783

Effect of exchange rates on cash		(330	)		21
Net increase in cash		117			140
Cash at beginning of year		230			75

Cash at end of the period	$	347		$	215

Supplemental disclosure of cash flow information:
Cash paid for interest	$	103		$	149
Cash paid for income taxes	$	68		$	16

Supplemental schedule of non-cash financing activity:
Conversion of preferred stock to common stock	$	525		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

MEDITE CANCER DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular data in thousands, except shares and per share amounts)

Note 1.

Organization and Summary of Significant Accounting Policies

MEDITE Cancer Diagnostics, Inc., (“MDIT”, “MEDITE” or the “Company”) was incorporated in Delaware in December 1998.

These statements include the accounts of MEDITE Cancer Diagnostics, Inc., (former CytoCore, Inc., the “Company”, “we” and “us”) and its wholly owned subsidiaries, which consists of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany, MEDITE GmbH, Salzburg, Austria, MEDITE Lab Solutions, Inc. (formerly MEDITE Inc.), Orlando, USA, MEDITE sp. z o.o., Zilona-Gora, Poland and CytoGlobe, GmbH, Burgdorf, Germany.

In April 2014, the shareholders of the Company consummated a transaction in which 100% of the issued and outstanding shares of MEDITE Enterprise, Inc., were acquired by CytoCore, Inc. in exchange for the issuance by CytoCore, Inc., of 15,000,000 shares of its common stock to the shareholders of the Company. The result of this transaction was for the Company and its wholly owned subsidiaries to become wholly owned subsidiaries of CytoCore, Inc., a US public company. In addition, the shareholders of the Company became the majority owners of CytoCore, Inc., which resulted in the transaction being accounted for as a reverse merger, in which the financial statements of MEDITE Enterprise, Inc. and its subsidiaries became those of CytoCore, Inc., now MEDITE Cancer Diagnostics, Inc.

MEDITE is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. By acquiring MEDITE the company changed from solely research operations to an operating company with 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry.

Consolidation, Basis of Presentation and Significant Estimates

The accompanying condensed consolidated financial statements for the periods ended September 30, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings	33 yrs
Machinery and equipment	3-10 yrs
Office furniture and equipment	2-10 yrs
Vehicles	5 yrs
Computer equipment	3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through September 30, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.

Recent Accounting Pronouncements

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory”. The amendments require an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The Company does not expect this amendment to have a material impact on its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of the consolidation guidance for legal entities such as limited partnerships, limited liability corporations and securitization structures. The amendments in the ASU affect the consolidation evaluation for reporting organizations and simplifies the current US GAAP requirements by reducing the number of consolidation models. The guidance is effective for fiscal years and interim reporting periods beginning on or after December 15, 2015. The Company does not expect this standard to have a material impact on its statements of operations, statements of cash flows or financial position.

In May 2014, the FASB issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supersedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.

Note 2.

Reverse Merger

In January 2014, the Company and the previous owners of MEDITE Enterprise, Inc. entered into an agreement to merge with the former CytoCore, Inc. The merger required as a pre-requisite that among other items CytoCore settle certain outstanding payroll amounts in stock and that CytoCore complete a private placement with gross proceeds of a minimum of $2 million, which was later amended to $1.5 million. On April 3, 2014 CytoCore issued 697,234 shares of its common stock in satisfaction of approximately $1.6 million in outstanding accrued payroll. On April 4, 2014 the Company closed on a private placement in which it received gross proceeds of $1.5 million and issued 955,875 shares of its common stock. The merger closed on April 4, 2014 with the previous owners of MEDITE Enterprise, Inc. receiving 14,687,500 shares of the Company’s common stock. An additional 312,500 shares remained to be issued because certain conditions had not been fulfilled in accordance with the agreement to complete the exchange for 100% of the issued and outstanding stock of MEDITE Enterprise, Inc. The remaining 312,500 shares were issued in October 2015. The consideration paid was determined based upon the number of shares outstanding from the former CytoCore, Inc. of approximately 3,502,700 common shares outstanding before the merger at $1.60 per share (the same price per share in the concurrent private placement noted above).

Because the owners of MEDITE Enterprise, Inc. received approximately 81.1% of the then issued and outstanding stock of the Company, the merger was treated as a reverse acquisition, in which for accounting purposes MEDITE Enterprise, Inc. acquired CytoCore, Inc.

Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

	In thousands
Assets acquired
Cash	$	1
Other current assets		12
Property and equipment		81
Trade names /trademarks		1,240
In-Process research and development		4,620
Goodwill		2,453
		8,407

Liabilities assumed
Accounts payable & accrued expenses		3,220
Related party advances		102
Loans payable		21
		3,343

Consideration paid in the form of common stock	$	5,064

The Company is treating the fair value assigned to trade names/trademarks as indefinite lived intangibles. The in process research and development covers four separate areas (a) breast pap device and related consumables (b) new biomarkers (c) a new stain and (d) the SoftKit. Until the Company either completes development or abandons such development, the in-process research and development costs are treated as indefinite lived intangible assets. If the Company is successful in these development projects, it expects the in-process research and development will be amortized over an approximate 15 year life.

Note 3.

Inventories

The following is a summary of the components of inventories (in thousands):

	September 30,		December 31,
	2015		2014
	(unaudited)
Raw materials	$	1,934	$	1,229
Work in progress		225		33
Finished Goods		2,002		2,153

	$	4,161	$	3,415

No amounts were reserved for obsolete inventory as of September 30, 2015 and December 31, 2014.

Note 4.

Property and Equipment

The following is a summary of the components of property and equipment (in thousands):

	September 30,			December 31,
	2015			2014
	(unaudited)
Land	$	215		$	233
Buildings		1192			1,291
Machinery and equipment		546			529
Office furniture and equipment		295			265
Vehicles		42			103
Computer equipment		111			110
Construction in progress		521			559
Less: Accumulated depreciation		(906	)		(999	)
	$	2,016		$	2,091

Depreciation expense amounted to approximately $95,000 and $126,000 for the nine months ended September 30, 2015 and 2014, respectively.

Note 5.

Long-term Debts and Lines of Credit

The Company’s outstanding note payable indebtedness was as follows as of (in thousands):

	September 30,		December 31,
	2015		2014
	(unaudited)
Hannoversche Volksbank credit line #1	$	1,169	$	1,880
Hannoversche Volksbank credit line #2		399		465
Hannoversche Volksbank term loan #1		62		135
Hannoversche Volksbank term loan #2		50		81
Hannoversche Volksbank term loan #3		203		270
Ventana Medical Systems, Inc. Promissory Note		21		21
Denture DZ Equity Partners Participation right		841		912
	$	2,745	$	3,764

In July 2006, MEDITE GmbH, Burgdorf, entered into a master line of credit agreement #1 with Hannoversche Volksbank. The line of credit was amended in 2012 and was later amended to increase the credit limit to Euro 1.8 million ($2.0 million as of September 30, 2015). In January 2015, the master credit line was reduced to Euro 1.6 million ($1.8 million as of September 30, 2015) and further reduced to the original Euro 500,000 ($560,865 as of September 30, 2015) and subsequently increased to Euro 1.1 million ($1.2 million as of September 30, 2015) effective July 1, 2015. Borrowings on the master line of credit agreement #1 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the company and defined in the agreement. Interest rates depending on the type of advance elected ranged from 3.77 – 8.00% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of MEDITE GmbH, Burgdorf, a mortgage on the buildings owned by the Company and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company.

In June 2012, CytoGlobe, GmbH, Burgdorf, entered into a line of credit agreement #2 with Hannoversche Volksbank. The line of credit granted a maximum borrowing authority of Euro 400,000 ($448,692 as of September 30, 2015). Borrowings on the master line of credit agreement #2 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the Company and defined in the agreement. Interest rates depending on the type of advance elected ranged from 3.77 – 8.00% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of CytoGlobe GmbH, Burgdorf and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and the state of Lower Saxony (Germany) to support high-tech companies in the area.

In December 2006, MEDITE GmbH, Burgdorf, entered into a Euro 500,000 ($560,865 as of September 30, 2015) term loan agreement #1 with Hannoversche Volksbank with an interest rate of 3.4% per annum. The term loan has a maturity of September 2016 and requires semi-annual principal payments of approximately Euro 27,780 ($31,162 as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and a mortgage on the property of the Company.

In June 2006, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($448,692 as of September 30, 2015) term loan #2 with Hannoversche Volksbank with an interest rate of 3.6 % per annum. The term loan has a maturity of June 2016, requires 18 semi-annual principal repayments of approximately Euro 22,220 ($24,928 as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and is collateralized by subordinated assignments of all of the receivables and inventories of MEDITE GmbH, Burgdorf and also has a subordinated pledge of share term life insurance policies.

In November 2008, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($448,692 as of September 30, 2015) term loan #3 with Hannoversche Volksbank with an interest rate of 4.7% per annum. The term loan has a maturity of December 31, 2018, and requires quarterly principal repayments of Euro 13,890 ($15,581as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and is collateralized by a partial subordinated pledge of the receivables and inventory of MEDITE GmbH, Burgdorf.

In March 2009, the Company entered into a participation rights agreement in the form of a debenture with a mezzanine lender who advanced the Company up to Euro 1.5 million, ($1.7 million as of September 30, 2015) in two tranches of Euro 750,000 each, ($841,298 as of September 30, 2015). The first tranche was paid to the Company at closing with the second tranche being conditioned on MEDITE GmbH, Burgdorf and its subsidiaries hitting certain performance targets. Those targets were not met and the second tranche was never called. The debenture pays interest at the rate of 12.15% per annum and matures at December 31, 2016.

As of the date of filing, the remaining balance of approximately $21,000 on the note payable to Ventana Medical Systems, Inc. was in default. However, on February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. will accept $38,281 as payment in full for all outstanding principal and accrued interest. The $38,281 has been included in current portion of long-term debt on the consolidated balance sheet. As part of this agreement, Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the Company’s common stock. Prior to the execution of this agreement, the Company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.

During 2015, the Company reduced their floating lines of credit and term loans with Hannoversche Volksbank by $1,019 net of currency fluctuations.

Note 6.

Related Party Advances

At September 30, 2015 and December 31, 2014, the Company owed its then CFO and Chairman of the Board for prior advances of approximately $85,000 and $110,000 respectively.

Note 7.

Common Stock

During the nine months ended September 30, 2015, the Company issued 1,338,875 shares of unregistered stock to qualified individuals pursuant to exemptions from registration under Regulation D and Section 4(2) of the Securities Act of 1933 at 1.60 for proceeds of $2,134,000, net of $81,000 of issuance costs. Further, the Company issued 12,000 shares of common stock in a Series D Preferred Stock conversion as further discussed in Note 8. During the third quarter ended September 30, 2015 the Company issued 1,086,250 shares of common stock at $1.60 for proceeds of $600,000 to the President of UNIC Medical of China. UNIC is the Company’s distributor in China and other Asian countries.

Note 8.

Preferred Stock and Warrants

A summary of the Company’s preferred stock as of September 30, 2015 and December 31, 2014 is as follows.

	September 30,		December 31,
	2015		2014
	(unaudited)
	Shares Issued &		Shares Issued &
Offering	Outstanding		Outstanding
Series A convertible		47,250		47,250
Series B convertible, 10% cumulative dividend		93,750		93,750
Series C convertible, 10% cumulative dividend		38,333		38,333
Series D convertible, 10% cumulative dividend		-		175,000
Series E convertible, 10% cumulative dividend		19,022		19,022
Total Preferred Stock		198,355		373,355

As of September 30, 2015 and December 31, 2014, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation for the six months ended Septebmer 30, 2015.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:	$4.50 per share, $212,625
Conversion Price:	$10,303 per share
Conversion Rate:	0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)
Voting Rights:	None
Dividends:	None
Conversion Period:	Any time

Series B Convertible Preferred Stock

Liquidation Value:	$4.00 per share, $375,000
Conversion Price:	$1,000 per share
Conversion Rate:	0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2001
Conversion Period:	Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $548,788 and $520,665, respectively.

Series C Convertible Preferred Stock

Liquidation Value:	$3.00 per share, $115,000
Conversion Price:	$600 per share
Conversion Rate:	0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing March 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $160,038 and $151,413, respectively.

Series D Convertible Preferred Stock

Liquidation Value:	$1,000 per share, $ 525,000
Conversion Price:	$1,000 per share
Conversion Rate:	.01—Liquidation Value divided by Conversion Price ($10.00/$1,000)
Voting Rights:	None
Dividends:	10%—Quarterly—Commencing April 30, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $0 and $660,000, respectively.

Series E Convertible Preferred Stock

Liquidation Value:	$22.00 per share, $418,488
Conversion Price:	$800.00 per share
Conversion Rate:	.0275—Liquidation Value divided by Conversion Price ($22.00/$800)
Voting Rights:	Equal in all respects to holders of common shares
Dividends:	10%—Quarterly—Commencing May 31, 2002
Conversion Period:	Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $585,948 and $558,173 respectively.

Warrants outstanding

							Weighted
			Weighted				Average
			Average		Aggregate		Remaining
			Exercise		Intrinsic		Contractual
	Warrants		Price		Value		Life (Years)
Outstanding at December 31, 2014		143,308	$	2.64		—		6.46
Granted		—		—		—		—
Exercised		—		—		—		—
Expired		—		—		—		—
Outstanding at September 30, 2015		143,308	$	2.64		—		6.46

Note 9.

Commitments and Contingencies

The Company currently leases 12 vehicles for sales and service employees, delivery and other purposes with expirations ranging from November 2015 through June 2018. The current minimum monthly payment for these vehicle leases is approximately $5,463.

The Company has several operating leases for office, laboratory and manufacturing space. The Company’s operating lease for one of its German facilities can be cancelled by either party with a 3 months’ notice, its Poland facility can be terminated by either party with a six month notice. Monthly rent payments for the German and Poland facilities are Euro 4,000 ($4,487 as of September 30, 2015) and PLN 6,240 ($1,660 as of June 30, 2015) respectively. The Company’s laboratory facility in Chicago, IL terminates June 30, 2016 and requires monthly payments of $1,070. The Company also subleases its former Chicago laboratory facility for $3,948 per month. The lease for this facility terminates October 30, 2016 and requires monthly rent payments of $4,394. The Company’s Orlando facility has escalating rents ranging from $2,416 to $2,563 per month and terminates July 31, 2018. The total aggregate monthly lease payments (net of the sublease) required on these leases is approximately $10,051.

The Company also leases IT Hardware and Software for 3-D Design which require aggregate monthly lease payments of $1,645 through March 2018.

In 2014, the Company became a defendant in a lawsuit brought by D&D Technologies, Inc. (“D&D”) in the state of New Jersey for breach of contract and breach of implied covenant of good faith that allegedly occurred in 2013 for failure to pay for past contractual services. The original complaint was dismissed and then refiled by D&D. D&D is seeking damages over $86,000 plus equitable relief. In the second quarter of 2015, the Company and D&D reached a settlement agreement with D&D Technologies, Inc for $15,000. This amount was paid during the third quarter.

The Company’s former auditor L.J. Soldinger and Associates filed a claim against the Company in Illinois’ Lake County Superior Court. The Company believes the claims are without merit and has adequately reserved for costs associated with the claim.

Note 10.

Segment Information

The Company operates in one operating segment. However, the Company has assets and operations in the United States, Germany and Poland. The first quarter numbers included in the nine month period ended September 30, 2014 represent MEDITE as a private company before the reverse merger with the former CytoCore Inc. After April 3, 2014, results reflect the combination of both companies. The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560). The following tables show the breakdown of the Company’s operations and assets by region (in thousands):

	United States				Germany				Poland				Total
	Sep. 30, 2015		Dec. 31, 2014		Sep.30, 2015		Dec. 31, 2014		Sep. 30, 2015		Dec. 31, 2014		Sep. 30, 2015		Dec. 31, 2014
Assets	$	9,125	$	9,387	$	7,416	$	6,989	$	204	$	63	$	16,745	$	16,439
Property & equipment, net		87		98		1,924		1,985		5		8		2,016		2,091
Intangible assets		8,313		8,313		-		-		-		-		8,313		8,313

	United States						Germany				Poland					Total
	Sep. 30, 2015			Sep. 30, 2014			Sep. 30, 2015		Sep. 30, 2014		Sep. 30, 2015			Sep 30, 2014		Sep. 30, 2015			Sep. 30, 2014
Revenues	$	928		$	1,321		$	6,114	$	7,373	$	39		$	0	$	7,081		$	8,694
Net income (loss)		(552	)		(182	)		339		232		(54	)		-		(267	)		50

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Caution Regarding Forward-Looking Statements

This report contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our ability to raise capital; our ability to retain key employees; our ability to engage third party distributors to sell our products; economic conditions; technological advances in the medical field; demand and market acceptance risks for new and existing products, technologies, and healthcare services; the impact of competitive products and pricing; U.S. and international regulatory, trade, and tax policies; product development risks, including technological difficulties; ability to enforce patents; and foreseeable and unforeseeable foreign regulatory and commercialization factors, our ability to develop new products and respond to technological changes in the markets in which we compete, our ability to obtain government approvals of our products, our ability to market our products, changes in third-party reimbursement procedures, and such other factors that may be identified from time to time in our Securities and Exchange Commission ("SEC") filings and other public announcements including those set forth under the caption “Risk Factors” in Part 1, Item 1A of our Annual Report on Form 10-K/A for the year ended December 31, 2014. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Except as required by law, we assume no duty to update or revise our forward-looking statements.

Overview of MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics, Inc. (the “Company”, “we”, or “us”), formerly CytoCore, Inc., is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. Depending upon the type of cancer, segments within the current target market of approximately $5.8 billion are growing at annual rates between 10 and 30%.

By acquiring MEDITE in 2014, the Company changed from just research operations to an operating company with 76 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry. Both company structures and cultures were successfully merged to one new company organization.

Several synergies were realized with this strategy, for example cost reduction of the former CytoCore research segment by about 50 %, complementary products in the cytology product segment which is now addressing all components from cell collection through cell processing to diagnostic tools like cancer markers and screening systems. Some of them are already selling and some are in a late stage of development expecting to sell within one or two years.

The cancer markers developed by the former CytoCore, Inc. over the last three years are showing excellent results in internal studies but have not yet been tested in formal clinical trials. In our opinion, one of the tests based upon these biomarkers has the potential for displacing the current expensive Human Papilloma Virus (HPV) testing methods in both initial and follow up testing, resulting in less costs for the patient, laboratory and payer. The test may identify cancerous and precancerous cells regardless of the presence of HPV. The Company hopes to market the test globally outside the United States in 2016, and in the United States by 2017.

Another major business focus for 2015 is the Chinese market, which the Company entered in 2014. It is the fastest growing, and by 2016 management expects it will be the largest, market for the Company’s products. This is due to our Chinese distributor UNIC Medical who was successful in receiving the Chinese Food & Drug Administration (“CFDA”) approval for all MEDITE histology laboratory devices. The UNIC sales team now can sell MEDITE products in China, and currently successfully is doing so. During the nine months ended September 30, 2015, the Company trained 50 UNIC sales employees and representatives to sell MEDITE equipment. During the third quarter MEDITE and UNIC attended a larger Chinese Cytology show and presented MEDITE’s cytology product line. Also, together with UNIC, the Company is part of a government supported project to standardize the histology laboratory process using MEDITE equipment and consumables for processing part of the process, MEDITE immuno-assays, and the UNIC technology for digitalization and computer aided diagnostics utilizing the latest cloud technology.

Several other innovative product developments are realized or going to be realized before end of 2015. In the first quarter, the Company’s important German priority patent for the fully automated histology lab, a Lab-In-One unit, was granted. This technology is demanded by the market, following the trend toward higher automation in the industry and has the ability to change the competition in histology.

To sell the Company’s complete cytology product line set “SureThin” also in the US, a US Food and Drug Administration (“FDA”) application is required to be submitted and approved, which currently is under preparation using data by a study made in Germany and is expected to be submitted in 2016. The use with the currently highest market volume for products is in cervical cancer screening, but increasingly also in non-gynecology applications such as lung cancer screening.

The Company operates in one industry segment for cancer diagnostics instruments and consumables for histology and cytology laboratories.

Definition:	Histology - Cancer diagnostics based on the structures of cells in tissues
	Cytology - Cancer diagnostics based on the structures of individual cells

Cancers and precancerous conditions are defined in terms of structural abnormalities in cells. For this reason, cytology is widely used for the detection of such conditions, while histology is typically used for the confirmation, identification and characterization of the cellular abnormalities detected by cytology. Other diagnostics methods, such as marker-based assays, provide additional information that can supplement, but which cannot replace cytology and histology. The trend towards more personalized treatment of cancer increases the need for cytology, histology and assays for identifying and testing the best treatment alternatives. We believe that this segment will therefore be increasingly important for future development of strategies to fight the “cancer epidemic” (World Health Organization: World Cancer Report 2014) which expects approximately a 50 % increase in cancer cases worldwide within the next 20 years.

This segment sees a trend toward, and demand for, higher automation for more throughput in bigger laboratories, process standardization, digitalization of cell and tissue slides and computer aided diagnostic systems, while also looking for cost effective solutions. In the US, the Patient Protection and Affordable Care Act is a national example for the industry. More people have health insurance, and therefore can afford early cancer screening, while at the same time the payers for health care continue looking for cost reductions.

MEDITE acts as a one-stop-shop for histology (also known as anatomic pathology) laboratories either as part of a hospital, as part of a chain of laboratories or individually. It is one out of only four companies offering all equipment and consumables for these type of laboratories worldwide. The MEDITE Brand stands for innovative and high quality products – most equipment made in Germany – and competitive pricing.

For the cytology market, MEDITE offers a wide range of consumable products and equipment; in particular for liquid-based-cytology, which is an important tool in cancer screening and detection in the field of cervical, bladder, breast, lung and other cancer types. We also developed an innovative new type of easy to use standardized staining solutions, and a very innovative and effective early cancer detection marker-based assay. These new developments are cost effective solutions able to replace more expensive competitive products, and therefore are also becoming the first choice for the growing demand in emerging countries.

All of the Company’s operations during the reporting period were conducted and managed within this segment, with management teams reporting directly to our Chief Executive and Operating Officers. For information on revenues, profit or loss and total assets, among other financial data, attributable to our operations, see the unaudited condensed consolidated financial statements included herein.

Outlook

Due to promising new products and distributions contracts executed in the last two years, management believes the profitability and cash-flow of the business will grow and improve. However, significant on-going operating expenditures may be necessary to manufacture and market new and existing products to achieve the accelerated sales growth targets outlined in the Company’s business plan. To realize the planned growth potential, management will focus its efforts on 1.) Finishing and gaining approval for the products currently under development and 2.) Increase direct sales in the USA and continue to expand Chinese market sales by broadening the Company’s collaborations with the local distributor UNIC. We also will work on continuously optimizing manufacturing cost to increase our gross margin. Implementation of our plans will be contingent upon securing substantial additional debt and/or equity financing. If we are unable to obtain additional capital or generate profitable sales revenues, we may be required to curtail product development and other activities.

Currently, approximately 85 % of the Company’s sales are generated in Euro currency. During the third quarter ended September 30, 2014, on average, $1.3560 was received for every Euro. During the first nine months of 2015, the average exchange rate of Euro for dollars dropped to $1.1151 which had an influence of 18% on the revenues. Therefore, the Company’s revenues translated from Euro into dollars may be down year over year if the exchange rate remains at that level or lower during the remainder of 2015. The Company is working to lessen the impact of the Euro’s decline versus the dollar by increasing the percentage of overall product sales in the United States and other countries such as China whose currency is not pegged to the Euro.

The Company believes the combination of MEDITE Enterprise, Inc. with CytoCore, Inc. will expedite the development and marketability of CytoCore’s cytology products which include collection devices, image analysis software, special stains and immuno-assays. Currently, the recent launch of new products, the positive impact from several new initiatives, and some recently executed distribution contracts in the United States, Europe and China are some primary positive factors assisting growth.

Results of Operations

The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements presented in Part I, Item 1 of this Quarterly Report and the notes thereto, and our audited consolidated financial statements and notes thereto, as well as our Management’s Discussion and Analysis contained in our Annual Report on Form 10-K/A for the year ended December 31, 2014 filed with the SEC on May 8, 2015.

The results of the Company for the nine months ended September 30, 2015, include the results of the entire MEDITE Cancer Diagnostics, Inc. group (consolidated former CytoCore, Inc. with MEDITE Enterprise, Inc.) while the results for the nine months period ended September 30, 2014, reflect operations for MEDITE Enterprise, Inc. only from January 1 through April 4, 2014 and the combined companies of CytoCore, Inc and Medite Enterprise, Inc. for the period of April 5 through September 30, 2014.

Three months ended September 30, 2015 as compared to the three months ended September 30, 2014 (in thousand USD)

Revenue

Revenue for the three months ended September 30, 2015, was $2,662 as compared to $2,785 for the three months ended September 30, 2014. Due to the fact that approximately 85% of all sales are invoiced in Euro currency, the recent fluctuation of the USD/EURO exchange rate had a major impact of approximately $400 on the revenue decrease. On a comparable exchange rate, the revenue of the third quarter 2015 would have been increased by approximately 10%. Revenue of almost $0.5 million related to a public tender won in Mexico will be invoiced in the fourth quarter while most of the manufacturing for the product was finished by the end of the third quarter ended September 30, 2015.

Costs of Revenue

Cost of revenues were $1,493, or 56% of the revenues for the three months ended September 30, 2015 as compared to $1,198 or 43% of the revenues for the three months ended September 30, 2014. More sales through international distributors as compared to higher margin direct sales is the major reason for the decreased gross margin.

Research and Development

Research and development expenses are an important part of our business to keep our existing products competitive, and to develop new innovative solutions with interesting market potential that will help us grow future revenues. These expenses include research work for cancer marker consumables and developing work, including engineering and industrial design, for histology and cytology laboratories worldwide. Major parts of these expenses are payroll-related costs for in-house scientific research, mechanical and electrical engineering, instrument related software development staff, prototype expenses and material purchased for R&D.

For the third quarter 2015, research and development expenses decreased to $222 compared to $317 for the third quarter 2014. This was partly caused by the lower USD/Euro exchange rate and by shifting engineering capacity from Germany to the lower cost country of Poland. We expect to continue to expend considerable effort and resources to continue to grow our product offerings.

Selling, General and Administrative

For the third quarter ended September 30, 2015, SG&A expenses were $785 as compared to $1,260 for the third quarter ended September 30, 2014. The decrease of $475 is partly caused by the lower exchange rate in addition to the management’s ability to reduce administrative expenses with the former CytoCore, Inc. business.

Operating Income (Loss)

The operating income of $132 for the third quarter ended September 30, 2015 compared to an operating loss of $38 for the third quarter ended September 30, 2014 is due primarily to the decrease of administrative and R&D expenses.

Interest Expense

Interest expenses decreased by 35% to $46 in the third quarter ended September 30, 2015 compared to $71 for the third quarter ended September 30, 2014, due to the decreased use of lines of credit and repayment of term loans, both used for working capital financing of the European entities.

Net Income (Loss)

The net income for the third quarter ended September 30, 2015, increased by $178 and totaled $59 as compared to net loss of $119 for the third quarter ended September 30, 2014. As noted above the primary reason for the profit in the third quarter 2015 was the management’s ability to decrease administrative and R&D expenses more than the decrease of gross margin for the quarter.

Nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 (in thousand USD)

Revenue

Revenue for the nine months ended September 30, 2015, was $7,081 as compared to $8,694 for the nine months ended September 30, 2014. Due to the fact that approximately 85% of all sales are invoiced in Euro currency, the recent fluctuation of the USD/EURO exchange rate had a major impact of approximately $1.1 million on the revenue decrease. Revenue of almost $0.5 million related to a public tender won in Mexico will be invoiced in the fourth quarter while most of the manufacturing for the product was finished by the end of the third quarter ended September 30, 2015.

Costs of Revenue

Cost of revenues were $4,028, or 57% of the revenues for the nine months ended September 30, 2015 as compared to $4,456 or 51% of the revenues for the nine months ended September 30, 2014. More sales through international distributors as compared to higher margin direct sales is the major reason for the decreased gross margin.

Research and Development

For the first nine months of 2015, research and development expenses increased to $825 compared to $762 for the first nine months of 2014. This increase of $63 or 8% is the result of the inclusion of MEDITE Poland and the CytoCore expenses for the entire period of the first nine months of 2015. The Polish operations were not started until the end of 3^rd quarter 2014 and CytoCore’s expenses for 2014 did not include expenses prior to April 3, 2014, the effective merger date. We expect to continue to expend considerable effort and resources to continue to grow our product offerings.

Selling, General and Administrative

For the nine months ended September 30, 2015, SG&A expenses were $2,191 as compared to $ 2,902 for the first nine months ended September 30, 2014. The decrease of $711 for the first nine months of 2014 compared to the first nine months of 2015 was mainly caused by management’s ability to reduce administrative expenses in the former CytoCore, Inc. business.

Operating Income (Loss)

The operating loss of $58 for the first nine months of 2015 compares to an operating profit of $448 for the first nine months of 2014 is due primarily by the decrease in the gross profit of $1,185 partly offset by the decrease in administrative expenses of $711.

Interest Expense

Interest expenses decreased by 29% to $157 in the nine months ended September 30, 2015 compared to $221 for the nine months ended Septbember 30, 2014 due to the decreased use of lines of credit and repayment of term loans, both used for working capital financing of the European entities.

Net Income (Loss)

The net income (loss) for the nine month ended September 30, 2015, totaled $(267) as compared to net income of $50 for the nine months ended September 30, 2014 is due primary to a decrease in gross profit.

Liquidity and Capital Resources

For the nine months ended September 30, 2015, the Company issued a total of 1,338,875 shares of unregistered stock to qualified individuals pursuant to exemptions from registration under Regulation D and Section 4(2) of the Securities Act of 1933 at 1.60 for proceeds of $2,134,000, net of $81,000 of issuance costs. During the third quarter ended September 30, 2015 the Company issued 375,000 shares of common stock at $1.60 for proceeds of $600,000 to the President of UNIC Medical of China. UNIC Medical is the Company’s distributor for China and other Asian countries.

The Company therefore increased its equity ratio from 51.3% as of December 31, 2014 to 59.1% by the third quarter ended September 30, 2015. It also reduced total liability by $1,153 during the nine months ended September 30, 2015.

Due to promising new products and distributions contracts executed in the last two years, management believes the profitability and cash flow of the business will grow and improve. However, significant on-going operating expenditures may be necessary to manufacture and market new and existing products to achieve the accelerated sales growth targets outlined in the Company’s business plan. To realize the planned growth potential management will focus its efforts on 1.) Finishing and gaining approval for the products currently under development and 2.) Increase direct sales in the USA and continue to expand Chinese market sales by broadening the Company’s collaborations with the local distributor UNIC. We also will work on continuously optimizing manufacturing cost to increase our gross margin. Implementation of our plans will be contingent upon securing substantial additional debt and/or equity financing. If we are unable to obtain additional capital or generate profitable sales revenues, we may be required to curtail product development and other activities. Approximately, $1.9 million of accrued liabilities represents unpaid wages and vacation benefits. We believe subject to employee approval at least 75% of this liability will be converted into equity. In summary, management believes current working capital is sufficient to fund current operations.

A part of the Company’s outstanding indebtedness under its master credit line #1 with Hannoversche Volksbank availability was reduced by Euro 500 ($561 as of September 30, 2015) effective July 1, 2015. The bank has agreed to work with the Company as we raise additional equity and maintain the current level of funding. Should the bank demand additional reductions in the line of credit, the Company is confident additional financing can be obtained through completion of the private placement still outstanding or obtain bank funding elsewhere at equivalent terms.

Off-Balance Sheet Arrangements

As of September 30, 2015, we did not have any relationships with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that the information we are required to disclose in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Part II. Other Information

Item 1. Legal Proceedings.

The appealed verdict between Hologic Deutschland GmbH and the Company was decided by the court in October 2015 completely in favor of the Company. The previously imposed possible penalties for the Company are no longer valid.

The Company’s former auditor L.J. Soldinger and Associates filed a claim against the Company in Illinois’ Lake County Superior Court. The case was later transferred to Federal District Court in Chicago, Illinois. The Company believes the claims are without merit and is adequately reserved for costs associated with the claim.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended September 30, 2015 the Company sold 375,000 shares of common stock to the President of UNIC Medical, a distributor-customer of the Company, at a per share price of $1.60, pursuant to Regulation S of the Securities Act of 1933. This person is a foreign national.

We issued the foregoing securities in reliance on the safe harbor and exemptions from registration provided by Regulation S of the Securities Act of 1933, as amended. No investor who participated in the offering was a U.S. citizen, and the offering was conducted by the officers and directors of the Company without the participation of any underwriters, and no commissions were paid to any person.

Item 3. Defaults upon Senior Securities.

As of the end of the third quarter, the remaining balance of approximately $21,000 on the note payable to Ventana Medical Systems, Inc. was in default. However, on February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. will accept $38,281 as payment in full for all outstanding principal and accrued interest. The $21,000 has been included in current portion of long-term debt on the consolidated balance sheet and $17,281 has been included in account payable and accrued expenses on the consolidated balance sheet. As part of this agreement, Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the Company’s common stock. Prior to the execution of this agreement, the Company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.

Item 6. Exhibits

Exhibit
Number		Description

31.1		Section 302 certification by the principal executive officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

31.2		Section 302 certification by the chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

32.1		Section 906 certification by the principal executive pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

32.2		Section 906 certification by the chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

101.INS		XBRL Instance

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation

101.DEF		XBRL Taxonomy Extension Definition

101.LAB		XBRL Taxonomy Extension Labels

101.PRE		XBRL Taxonomy Extension Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDITE Cancer Diagnostics, Inc.

Date: November 13, 2015	/s/ Michaela Ott
	Michaela Ott
	Chief Executive Officer

Date: November 13, 2015	/s/ Robert F. McCullough, Jr.
	Robert F. McCullough, Jr.
	Chief Financial Officer

EX-31.1 2 v424204_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

Certification of Principal Executive Officer

Section 302 Certification

I, Michaela Ott, certify that:

1. I have reviewed this quarterly report on Form 10-Q for MEDITE CANCER DIAGNOSTICS, INC.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and the internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:

November 13, 2015

/s/ Michaela Ott

Michaela Ott, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 v424204_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

Certification of Principal Financial Officer

Section 302 Certification

I, Robert F. McCullough, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of MEDITE CANCER DIAGNOSTICS, INC;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:

November 13, 2015

/s/ Robert F. McCullough, Jr.

Robert F. McCullough, Jr., Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 v424204_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MEDITE CANCER DIAGNOSTICS, INC. (the “Company”) on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michaela Ott, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



By:	/s/ Michaela Ott	Dated:	November 13, 2015
	Michaela Ott
Title:	Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 v424204_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MEDITE CANCER DIAGNOSTICS, INC. (the “Company”) on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert F. McCullough, Jr,, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



By:	/s/ Robert F. McCullough, Jr.	Dated:	November 13, 2015
	Robert F. McCullough, Jr.
Title:	Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 mdit-20150930.xml XBRL INSTANCE DOCUMENT 0000075439 2014-01-01 2014-09-30 0000075439 2015-01-01 2015-09-30 0000075439 2014-07-01 2014-09-30 0000075439 2015-07-01 2015-09-30 0000075439 2015-09-30 0000075439 2015-11-13 0000075439 2014-12-31 0000075439 2013-12-31 0000075439 2014-09-30 0000075439 mdit:MediteEnterpriseMember 2014-04-30 0000075439 mdit:MediteEnterprisesIncMember 2014-01-01 2014-01-31 0000075439 mdit:MediteEnterprisesIncMember 2014-04-01 2014-04-04 0000075439 mdit:MediteEnterprisesIncMember mdit:AccruedPayrollSettlementMember 2014-04-01 2014-04-03 0000075439 mdit:MediteEnterprisesIncMember 2014-04-04 0000075439 us-gaap:MinimumMember mdit:MediteEnterprisesIncMember 2014-01-01 2014-01-31 0000075439 mdit:MediteEnterprisesIncMember 2015-01-01 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine1Member 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine2Member 2015-09-30 0000075439 mdit:HannoversechVolksbankTermLoan1Member 2015-09-30 0000075439 mdit:HannoversechVolksbankTermLoan2Member 2015-09-30 0000075439 mdit:HannoversechVolksbankTermLoan3Member 2015-09-30 0000075439 mdit:ParticipationRightsMember 2015-09-30 0000075439 mdit:VentanaMedicalSystemsMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine1Member 2014-12-31 0000075439 mdit:HannoversechVolksbankCreditLine2Member 2014-12-31 0000075439 mdit:HannoversechVolksbankTermLoan1Member 2014-12-31 0000075439 mdit:HannoversechVolksbankTermLoan2Member 2014-12-31 0000075439 mdit:HannoversechVolksbankTermLoan3Member 2014-12-31 0000075439 mdit:ParticipationRightsMember 2014-12-31 0000075439 mdit:VentanaMedicalSystemsMember 2014-12-31 0000075439 mdit:MediteGmbhBurgdorfMember 2012-12-31 0000075439 mdit:MediteGmbhBurgdorfMember 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLines1Member 2015-01-31 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLines1Member 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines1Member mdit:MediteGmbhBurgdorfMember 2015-01-01 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLines2Member 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines1Member mdit:MediteGmbhBurgdorfMember us-gaap:MinimumMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines1Member mdit:MediteGmbhBurgdorfMember us-gaap:MaximumMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines3Member mdit:CytoglobeGmbhBurgdorfMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines3Member mdit:CytoglobeGmbhBurgdorfMember us-gaap:MinimumMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLines3Member mdit:CytoglobeGmbhBurgdorfMember us-gaap:MaximumMember 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLine4Member 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLine4Member 2015-01-01 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLine5Member 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksbankCreditLine5Member 2015-01-01 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksBankCreditLine6Member 2015-09-30 0000075439 mdit:MediteGmbhBurgdorfMember mdit:HannoversechVolksBankCreditLine6Member 2015-01-01 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine7Member mdit:TrancheOneMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine7Member mdit:TrancheTwoMember 2015-09-30 0000075439 mdit:HannoversechVolksbankCreditLine7Member 2015-09-30 0000075439 mdit:VentanaMedicalSystemsIncMember 2015-09-30 0000075439 mdit:VentanaMedicalSystemsIncMember 2015-02-01 2015-02-23 0000075439 mdit:VentanaMedicalSystemsIncMember 2015-02-23 0000075439 mdit:HannoverscheVolksbankMember 2015-01-01 2015-09-30 0000075439 us-gaap:SeriesDPreferredStockMember 2015-01-01 2015-09-30 0000075439 mdit:PresidentOfUnicMedicalOfChinaMember 2015-07-01 2015-09-30 0000075439 mdit:PresidentOfUnicMedicalOfChinaMember 2015-09-30 0000075439 country:PL 2015-01-01 2015-06-30 0000075439 mdit:ChicagoLaboratoryFacilityMember 2015-01-01 2015-09-30 0000075439 mdit:SubleaseMember 2015-01-01 2015-09-30 0000075439 us-gaap:MinimumMember mdit:OrlandoFacilityMember 2015-01-01 2015-09-30 0000075439 us-gaap:MaximumMember mdit:OrlandoFacilityMember 2015-01-01 2015-09-30 0000075439 mdit:OrlandoFacilityMember 2015-01-01 2015-09-30 0000075439 country:DE 2015-01-01 2015-09-30 0000075439 mdit:ItHardwareAndSoftwareMember 2015-01-01 2015-09-30 0000075439 country:US 2015-09-30 0000075439 country:PL 2015-09-30 0000075439 country:US 2014-12-31 0000075439 country:PL 2014-12-31 0000075439 country:DE 2015-09-30 0000075439 country:DE 2014-12-31 0000075439 country:US 2014-01-01 2014-09-30 0000075439 country:PL 2014-01-01 2014-09-30 0000075439 country:US 2015-01-01 2015-09-30 0000075439 country:PL 2015-01-01 2015-09-30 0000075439 country:DE 2014-01-01 2014-09-30 0000075439 us-gaap:WarrantMember 2014-12-31 0000075439 us-gaap:WarrantMember 2015-01-01 2015-09-30 0000075439 us-gaap:WarrantMember 2015-09-30 0000075439 us-gaap:WarrantMember 2014-01-01 2014-12-31 0000075439 us-gaap:SeriesBPreferredStockMember 2015-09-30 0000075439 us-gaap:SeriesBPreferredStockMember 2015-01-01 2015-09-30 0000075439 us-gaap:SeriesBPreferredStockMember 2014-01-01 2014-12-31 0000075439 us-gaap:SeriesAPreferredStockMember 2015-09-30 0000075439 us-gaap:SeriesCPreferredStockMember 2015-09-30 0000075439 us-gaap:SeriesCPreferredStockMember 2015-01-01 2015-09-30 0000075439 us-gaap:SeriesCPreferredStockMember 2014-01-01 2014-12-31 0000075439 us-gaap:SeriesDPreferredStockMember 2015-09-30 0000075439 us-gaap:SeriesDPreferredStockMember 2014-01-01 2014-12-31 0000075439 us-gaap:SeriesEPreferredStockMember 2015-09-30 0000075439 us-gaap:SeriesEPreferredStockMember 2015-01-01 2015-09-30 0000075439 us-gaap:SeriesEPreferredStockMember 2014-01-01 2014-12-31 0000075439 us-gaap:BuildingMember 2015-01-01 2015-09-30 0000075439 us-gaap:MinimumMember us-gaap:MachineryAndEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:MaximumMember us-gaap:MachineryAndEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:MinimumMember mdit:OfficeFurnitureAndEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:MaximumMember mdit:OfficeFurnitureAndEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:VehiclesMember 2015-01-01 2015-09-30 0000075439 us-gaap:MinimumMember us-gaap:ComputerEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:MaximumMember us-gaap:ComputerEquipmentMember 2015-01-01 2015-09-30 0000075439 us-gaap:SeriesAPreferredStockMember 2014-12-31 0000075439 us-gaap:SeriesBPreferredStockMember 2014-12-31 0000075439 us-gaap:SeriesCPreferredStockMember 2014-12-31 0000075439 us-gaap:SeriesDPreferredStockMember 2014-12-31 0000075439 us-gaap:SeriesEPreferredStockMember 2014-12-31 0000075439 us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:EUR iso4217:PLN xbrli:pure 10-Q false 2015-09-30 2015 Q3 Medite Cancer Diagnostics, Inc. 0000075439 --12-31 Smaller Reporting Company MDIT 20766206

347000

230000

1302000

1991000

4161000

3415000

208000

154000

6018000

5790000

2016000

2091000

2453000

398000

245000

16745000

16439000

1764000

2555000

4025000

4134000

85000

110000

5874000

6799000

981000

1209000

6855000

8008000

962000

1487000

21000

19000

8343000

5763000

327000

-479000

-149000

1370000

1638000

9890000

8431000

16745000

16439000

4620000 1240000 4620000 1240000

2785000

2662000

1198000

1493000

317000

222000

1260000 785000

-38000

132000

71000

46000

73000

57000

-8000

16000

-119000

59000

18000

23000

-137000

36000

45000

-170000

-74000

-111000

-0.01

48000

30000

2000

11000

19345231000

20484936000

1587000

1169000

75000

-111000

7081000

8694000

4028000

4456000

3053000

4238000

95000

126000

825000

762000

2191000 2902000

3111000

3790000

-58000

448000

157000

221000

61000

153000

218000

374000

-276000

74000

-9000

24000

-267000

50000

69000

54000

-336000

-4000

-330000

41000

-597000

91000

-0.01

20051206000

17683284000

126000

1058000

150000

-391000

-1363000

391000

-390000

1842000

1783000

21000

140000

75000

215000

16000

149000

-56000

-1000

4000

-180000

159000

-689000

746000

54000

-109000

-392000

19000

-173000

791000

2056000

1012000

-330000

117000

103000

68000

525000

95000

154000

-25000

9000

228000

15000000

1500000

697234

14687500

1600000

955875

312500

2000000

3502700 1.6 0.811

1000

3220000

102000

21000

5064000

1240000 4620000

81000

12000

P15Y

1934000

1229000

225000

33000

2002000

2153000

215000

233000

1192000

1291000

546000

529000

295000

265000

42000 103000 111000 110000

521000

559000

906000

999000

95000

126000

1169000

399000

62000

50000

203000

841000

21000

1880000

465000

135000

81000

270000

912000

21000

1800000

2000000

1600000

1800000

500000

1100000

0.0377

0.0800

400000

0.0377

0.0800

500000

0.034

27780

400000

0.036

22220

400000

0.047

13890

1700000

750000

0.1215

21000

1750000

656250

1019

12000

1.60

2134000

81000

12000

1086250

1.60

5463

6240

3948

10051

1070

4394

2416

2563

2018-07-31 2016-06-30

4000

1645

86000

15000

9125000

204000

9387000

63000

87000

5000

98000

8000

8313000

7416000

6989000

1924000

1985000

1321000

928000

39000

-182000

-552000

-54000

7081000

8694000

6114000

7373000

339000

232000

143308

2.64

0 0 0

P6Y5M16D

P0Y P0Y P0Y

P6Y5M16D

375000

1000

548788

520665

4.00

0.000040

4.50

115000

600 0.000050

160038

151413

3.00

1000

525000

1000

660000

0.100

418488

800.00

585948

558173

22.00

1037000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Acquired In-Process Research and Development</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Goodwill</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P33Y

P3Y

P10Y

P2Y

P10Y

P5Y

P3Y

P5Y

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:</div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In thousands</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="87%"> <div style="CLEAR:both;CLEAR: both">Assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Trade names /trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,240</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">In-Process research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,620</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,407</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="87%"> <div style="CLEAR:both;CLEAR: both">Liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Accounts payable & accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Related party advances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">102</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Loans payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,343</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Consideration paid in the form of common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,064</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

8407000

3343000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Note 4.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Property and Equipment</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of the components of property and equipment (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Land</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,291</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">546</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">529</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Vehicles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Construction in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Less: Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(906)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(999)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; CLEAR: both"> Depreciation expense amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">95,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">126,000</font> for the nine months ended September 30, 2015 and 2014, respectively.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following is a summary of the components of property and equipment (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Land</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">215</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Buildings</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,291</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">546</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">529</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">295</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Vehicles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">103</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Construction in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Less: Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(906)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(999)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Note 5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Long-term Debts and Lines of Credit</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company’s outstanding note payable indebtedness was as follows as of (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank credit line #1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,169</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,880</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank credit line #2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">203</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Ventana Medical Systems, Inc. Promissory Note</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Denture DZ Equity Partners Participation right</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">841</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">912</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,764</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> In July 2006, MEDITE GmbH, Burgdorf, entered into a master line of credit agreement #1 with Hannoversche Volksbank. The line of credit was amended in 2012 and was later amended to increase the credit limit to Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.8</font> million ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.0</font> million as of September 30, 2015). In January 2015, the master credit line was reduced to Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.6</font> million ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million as of September 30, 2015) and further reduced to the original Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">560,865</font> as of September 30, 2015) and subsequently increased to Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.1</font> million ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million as of September 30, 2015) effective July 1, 2015. Borrowings on the master line of credit agreement #1 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the company and defined in the agreement. Interest rates depending on the type of advance elected ranged from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.77</font>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.00</font>% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of MEDITE GmbH, Burgdorf, a mortgage on the buildings owned by the Company and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2012, CytoGlobe, GmbH, Burgdorf, entered into a line of credit agreement #2 with Hannoversche Volksbank. The line of credit granted a maximum borrowing authority of Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">448,692</font> as of September 30, 2015). Borrowings on the master line of credit agreement #2 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the Company and defined in the agreement. Interest rates depending on the type of advance elected ranged from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.77</font>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.00</font>% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of CytoGlobe GmbH, Burgdorf and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and the state of Lower Saxony (Germany) to support high-tech companies in the area.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> In December 2006, MEDITE GmbH, Burgdorf, entered into a Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">560,865</font> as of September 30, 2015) term loan agreement #1 with Hannoversche Volksbank with an interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.4</font>% per annum. The term loan has a maturity of September 2016 and requires semi-annual principal payments of approximately Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,780</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,162</font> as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and a mortgage on the property of the Company.</div> <font style="FONT-SIZE: 10pt">  </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In June 2006, MEDITE GmbH, Burgdorf, entered into a Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">448,692</font> as of September 30, 2015) term loan #2 with Hannoversche Volksbank with an interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.6</font> % per annum. The term loan has a maturity of June 2016, requires 18 semi-annual principal repayments of approximately Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22,220</font></font> ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,928</font> as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and is collateralized by subordinated assignments of all of the receivables and inventories of MEDITE GmbH, Burgdorf and also has a subordinated pledge of share term life insurance policies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2008, MEDITE GmbH, Burgdorf, entered into a Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> ($448,692 as of September 30, 2015) term loan #3 with Hannoversche Volksbank with an interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.7</font>% per annum. The term loan has a maturity of December 31, 2018, and requires quarterly principal repayments of Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13,890</font> ($15,581as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and is collateralized by a partial subordinated pledge of the receivables and inventory of MEDITE GmbH, Burgdorf.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2009, the Company entered into a participation rights agreement in the form of a debenture with a mezzanine lender who advanced the Company up to Euro 1.5 million, ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million as of September 30, 2015) in two tranches of Euro <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> each, ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">841,298</font> as of September 30, 2015). The first tranche was paid to the Company at closing with the second tranche being conditioned on MEDITE GmbH, Burgdorf and its subsidiaries hitting certain performance targets. Those targets were not met and the second tranche was never called. The debenture pays interest at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.15</font>% per annum and matures at December 31, 2016.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of the date of filing, the remaining balance of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,000</font> on the note payable to Ventana Medical Systems, Inc. was in default. However, on February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. will accept $38,281 as payment in full for all outstanding principal and accrued interest. The $38,281 has been included in current portion of long-term debt on the consolidated balance sheet. As part of this agreement, Ventana Medical Systems, Inc. has agreed to convert $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.75</font> million stated value of Series D Preferred stock and all outstanding accrued dividends of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">656,250</font> for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000</font> shares of the Company’s common stock. Prior to the execution of this agreement, the Company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font>During 2015, the Company reduced their floating lines of credit and term loans with Hannoversche Volksbank by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,019</font> net of currency fluctuations.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company’s outstanding note payable indebtedness was as follows as of (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank credit line #1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,169</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,880</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank credit line #2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">399</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Hannoversche Volksbank term loan #3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">203</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">270</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Ventana Medical Systems, Inc. Promissory Note</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Denture DZ Equity Partners Participation right</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">841</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">912</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,764</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2745000

3764000

600000

1338875

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A summary of the Company’s preferred stock as of September 30, 2015 and December 31, 2014 is as follows.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares Issued &</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares Issued &</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Offering</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>Series A convertible</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series B convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series C convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series D convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series E convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>198,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>373,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Summary of Preferred Stock Terms</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series A Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">212,625</font></font></div> </div> </div> </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,303</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.00044</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font>/$10,303)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Any</font> time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><strong><i><font style="FONT-SIZE: 10pt">Series B Convertible Preferred Stock</font></i></strong></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">375,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0040</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font>/$1,000)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 31, 2001</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">548,788</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">520,665</font>, respectively.</font></div> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series C Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0050</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font>/$600)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 31, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,038</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">151,413</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series D Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 525,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">.01Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font>/$1,000)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> 10%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 30, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">660,000</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Series E Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">418,488</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">800.00</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> .0275Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.00</font>/$800)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Equal in all respects to holders of common shares</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 31, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">585,948</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">558,173</font> respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Warrants outstanding</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Life (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>143,308</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>143,308</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

198355

373355

47250

93750

38333

19022

47250

93750

38333

175000

19022

1660

2016-10-30

0.001

10000000

198355

373355

1121000

2871000

0.001

3500000000

20766206

19427331

560865

1200000

448692

560865

31162

448692

24928

841298

212625

10303 0.0000044 0.000275

0.1

2001-03-31 2002-03-31 2002-04-30 2002-05-31 10%Quarterly Commencing March 31, 2001 10% Quarterly Commencing March 31, 2002 10% Quarterly Commencing March 31, 2002 10% Quarterly Commencing May 31, 2002

0.1

47250

93750

38333

175000

19022

1625000

448692

15581

1500000

38281

Any time Any time Any time Any time Any time

None

The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560).

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">Note 1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">Organization and Summary of Significant Accounting Policies</font></b></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">MEDITE Cancer Diagnostics, Inc., (“MDIT”, “MEDITE” or the “Company”) was incorporated in Delaware in December 1998.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">These statements include the accounts of MEDITE Cancer Diagnostics, Inc., (former CytoCore, Inc., the “Company”, “we” and “us”) and its wholly owned subsidiaries, which consists of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany, MEDITE GmbH, Salzburg, Austria, MEDITE Lab Solutions, Inc. (formerly MEDITE Inc.), Orlando, USA, MEDITE sp. z o.o., Zilona-Gora, Poland and CytoGlobe, GmbH, Burgdorf, Germany.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">In April 2014, the shareholders of the Company consummated a transaction in which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the issued and outstanding shares of MEDITE Enterprise, Inc., were acquired by CytoCore, Inc. in exchange for the issuance by CytoCore, Inc., of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000,000</font> shares of its common stock to the shareholders of the Company. The result of this transaction was for the Company and its wholly owned subsidiaries to become wholly owned subsidiaries of CytoCore, Inc., a US public company. In addition, the shareholders of the Company became the majority owners of CytoCore, Inc., which resulted in the transaction being accounted for as a reverse merger, in which the financial statements of MEDITE Enterprise, Inc. and its subsidiaries became those of CytoCore, Inc., now MEDITE Cancer Diagnostics, Inc.</font><font style="FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">MEDITE is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. By acquiring MEDITE the company changed from solely research operations to an operating company with 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Consolidation, Basis of Presentation and Significant Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements for the periods ended September 30, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 24.45pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"> </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 24.45pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <table style="BORDER-BOTTOM: #000000; BORDER-LEFT: #000000; LINE-HEIGHT: 115%; WIDTH: 80%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: #000000; BORDER-RIGHT: #000000" cellspacing="0" cellpadding="0" width="80%"> <tr> <td style="BORDER-LEFT: #000000; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 35%; PADDING-RIGHT: 0in; BORDER-TOP: #000000; BORDER-RIGHT: #000000; PADDING-TOP: 0in" valign="bottom" width="35%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Buildings</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="65%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font> yrs</font></div> </td> </tr> <tr> <td style="BORDER-LEFT: #000000; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-RIGHT: #000000; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Machinery and equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> yrs</font></div> </td> </tr> <tr> <td style="white-space:nowrap; BORDER-LEFT: #000000; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-RIGHT: #000000; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Office furniture and equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> yrs</font></div> </td> </tr> <tr> <td style="BORDER-LEFT: #000000; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-RIGHT: #000000; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Vehicles</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> yrs</font></div> </td> </tr> <tr> <td style="BORDER-BOTTOM: #000000; BORDER-LEFT: #000000; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-RIGHT: #000000; PADDING-TOP: 0in" valign="bottom"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Computer equipment</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>-<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> yrs<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 24.45pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"> </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Acquired In-Process Research and Development</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of Indefinite Lived Intangible Assets Other Than Goodwill</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Goodwill</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt">These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through September 30, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory”. The amendments require an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The Company does not expect this amendment to have a material impact on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of the consolidation guidance for legal entities such as limited partnerships, limited liability corporations and securitization structures. The amendments in the ASU affect the consolidation evaluation for reporting organizations and simplifies the current US GAAP requirements by reducing the number of consolidation models. The guidance is effective for fiscal years and interim reporting periods beginning on or after December 15, 2015. The Company does not expect this standard to have a material impact on its statements of operations, statements of cash flows or financial position.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> In May 2014, the FASB issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supersedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

4487

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Note 2.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Reverse Merger</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> In January 2014, the Company and the previous owners of MEDITE Enterprise, Inc. entered into an agreement to merge with the former CytoCore, Inc. The merger required as a pre-requisite that among other items CytoCore settle certain outstanding payroll amounts in stock and that CytoCore complete a private placement with gross proceeds of a minimum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> million, which was later amended to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million. On April 3, 2014 CytoCore issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 697,234</font> shares of its common stock in satisfaction of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font> million in outstanding accrued payroll. On April 4, 2014 the Company closed on a private placement in which it received gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 955,875</font> shares of its common stock. The merger closed on April 4, 2014 with the previous owners of MEDITE Enterprise, Inc. receiving <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,687,500</font> shares of the Company’s common stock. An additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 312,500</font> shares remained to be issued because certain conditions had not been fulfilled in accordance with the agreement to complete the exchange for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the issued and outstanding stock of MEDITE Enterprise, Inc. The remaining 312,500 shares were issued in October 2015. The consideration paid was determined based upon the number of shares outstanding from the former CytoCore, Inc. of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,502,700</font> common shares outstanding before the merger at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.6</font>0 per share (the same price per share in the concurrent private placement noted above).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Because the owners of MEDITE Enterprise, Inc. received approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81.1</font>% of the then issued and outstanding stock of the Company, the merger was treated as a reverse acquisition, in which for accounting purposes MEDITE Enterprise, Inc. acquired CytoCore, Inc.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:</div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In thousands</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="87%"> <div style="CLEAR:both;CLEAR: both">Assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Cash</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Property and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Trade names /trademarks</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,240</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">In-Process research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,620</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">8,407</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="87%"> <div style="CLEAR:both;CLEAR: both">Liabilities assumed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Accounts payable & accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,220</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Related party advances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">102</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Loans payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,343</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="87%"> <div style="CLEAR:both;CLEAR: both">Consideration paid in the form of common stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,064</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is treating the fair value assigned to trade names/trademarks as indefinite lived intangibles. The in process research and development covers four separate areas (a) breast pap device and related consumables (b) new biomarkers (c) a new stain and (d) the SoftKit. Until the Company either completes development or abandons such development, the in-process research and development costs are treated as indefinite lived intangible assets. If the Company is successful in these development projects, it expects the in-process research and development will be amortized over an approximate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> year life.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 11%; PADDING-RIGHT: 0.8pt"> <div><font style="FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Note 3.</b></font></div> </td> <td style="WIDTH: 89%; PADDING-RIGHT: 0.8pt"> <div><font style="FONT-SIZE: 10pt"><b>Inventories</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of the components of inventories (in thousands):</div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 93%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,934</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,229</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both">Finished Goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,002</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,153</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="68%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,161</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,415</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> No amounts were reserved for obsolete inventory as of September 30, 2015 and December 31, 2014.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Note 8.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Preferred Stock and Warrants</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s preferred stock as of September 30, 2015 and December 31, 2014 is as follows.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares Issued &</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Shares Issued &</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Offering</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>Series A convertible</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>47,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series B convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series C convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,333</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series D convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Series E convertible, 10% cumulative dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Total Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>198,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>373,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of September 30, 2015 and December 31, 2014, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings <i>per Share</i>”, these dividends were added to the net loss in the net loss per share calculation for the six months ended Septebmer 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Summary of Preferred Stock Terms</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series A Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">212,625</font></font></div> </div> </div> </div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,303</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.00044</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.50</font>/$10,303)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Any</font> time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><strong><i><font style="FONT-SIZE: 10pt">Series B Convertible Preferred Stock</font></i></strong></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">375,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0040</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.00</font>/$1,000)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 31, 2001</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">548,788</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">520,665</font>, respectively.</font></div> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series C Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">600</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0050</font>Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font>/$600)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 31, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,038</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">151,413</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Series D Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 525,000</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">.01Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font>/$1,000)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">None</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> 10%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">April 30, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">660,000</font>, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Series E Convertible Preferred Stock</font></i></strong></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="25%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Liquidation Value:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="75%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.00</font> per share, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">418,488</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Price:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">800.00</font> per share</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Rate:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> .0275Liquidation Value divided by Conversion Price ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.00</font>/$800)</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Voting Rights:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Equal in all respects to holders of common shares</font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"> Dividends:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%QuarterlyCommencing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 31, 2002</font></font></div> </td> </tr> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Conversion Period:</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Any time</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">585,948</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">558,173</font> respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Warrants outstanding</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Life (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>143,308</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>143,308</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="11%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Note 10.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 89%; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="89%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Segment Information</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The Company operates in one operating segment. However, the Company has assets and operations in the United States, Germany and Poland. The first quarter numbers included in the nine month period ended September 30, 2014 represent MEDITE as a private company before the reverse merger with the former CytoCore Inc. After April 3, 2014, results reflect the combination of both companies. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560).</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables show the breakdown of the Company’s operations and assets by region (in thousands):</font></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>United States</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Germany</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Poland</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep.30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>9,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>9,387</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>6,989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>204</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>16,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>16,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Property & equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>1,924</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>1,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>2,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>2,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>United States</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Germany</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Poland</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>928</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>1,321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>6,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,081</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>8,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(552)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(182)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>232</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(267)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following tables show the breakdown of the Company’s operations and assets by region (in thousands):</font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>United States</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Germany</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Poland</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep.30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Dec. 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>9,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>9,387</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>6,989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>204</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>16,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>16,439</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Property & equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>1,924</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>1,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>2,016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>2,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>8,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>United States</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Germany</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Poland</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Sep. 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>928</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>1,321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>6,114</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,373</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>7,081</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>8,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(552)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(182)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>232</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>(267)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1100000

EX-101.SCH 7 mdit-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Reverse Merger link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Long-term Debts and Lines of Credit link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Related Party Advances link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Preferred Stock and Warrants link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Reverse Merger (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Long-term Debts and Lines of Credit (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Preferred Stock and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Organization and Summary of Significant Accounting Policies - (Additional Information) (Detail) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Reverse Merger - (Estimated Purchase Price Allocation) (Detail) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Reverse Merger - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Inventories - (Summary of the Components of Inventories) (Detail) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Long-term Debts and Lines of Credit (Detail) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Long-term Debts and Lines of Credit - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Related Party Advances - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock) (Detail) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock) (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Detail) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Segment Information (Detail) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Segment Information - (Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 mdit-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 mdit-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 mdit-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Debt Disclosure [Abstract] Debt Disclosure [Text Block] Long-term Debts and Lines of Credit Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Common Stock Disclosure [Text Block] Common Stock The entire disclosure for common stock. Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Preferred Stock Disclosure [Text Block] Preferred Stock and Warrants The entire disclosure for preferred stock and warrants. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Segment Information Accounting Policies [Abstract] Consolidation, Policy [Policy Text Block] Principle of Consolidation, Basis of Presentation and Significant Estimates Revenue Recognition, Dividends [Policy Text Block] Revenue Recognition Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Research and Development Expense, Policy [Policy Text Block] Research and Development In Process Research and Development, Policy [Policy Text Block] Acquired In-Process Research and Development Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles Impairment of Indefinite Lived Intangible Assets Other Than Goodwill [Policy Text Block] Impairment of Indefinite Lived Intangible Assets Other Than Goodwill Disclosure of accounting policy for the impairment of indefinite lived intangible assets other than goodwill . Property Plant And Equipment Useful Life [Table Text Block] Property Plant And Equipment Useful Life Tabular disclosure of property plant and equipment useful life. Business Combinations [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Statement Of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Assets [Abstract] Assets Assets Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash Cash at beginning of year Cash at end of the period Accounts Receivable, Net, Current, Total Accounts receivable, net Inventory, Net, Total Inventories Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Property & equipment, net Finite Lived In Process Research And Development In-process research and development Finite Lived In Process Research And Development Finite Lived Trademarks And Trade Names Trademarks, trade names Finite Lived Trademarks And Trade Names Goodwill Goodwill Liabilities Current [Abstract] Current liabilities: Commitments and Contingencies Commitments and contingencies Line of Credit, Current Secured lines of credit and current portion of long-term debt Accounts Payable and Accrued Liabilities, Current, Total Account payable and accrued expenses Due To Related Parties Current Advances - related parties Liabilities, Current, Total Total current liabilities Long-term Debt, Excluding Current Maturities, Total Long-term debt, net of current portion Liabilities, Total Total liabilities Liabilities and Stockholders Equity [Abstract] Liabilities and Stockholders’ Equity Stockholders Equity [Abstract] Stockholders’ equity : Preferred Stock Value Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 and 373,355 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively (liquidation value of all classes of preferred stock $1,121 and $2,871 as of September 30, 2015 and December 31, 2014, respectively) Common Stock Value Common stock, $0.001 par value; 3.5 billion shares authorized, 20,766,206 and 19,427,331 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively Additional Paid in Capital, Total Additional paid-in capital Treasury Stock Value Treasury stock Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit), Total Retained earnings Stockholders Equity Attributable to Parent, Total Total stockholders' equity Beginning Balance Ending Balance Liabilities and Equity, Total Total liabilities and stockholders' equity Inventory Disclosure [Abstract] Schedule of Inventory, Noncurrent [Table Text Block] Schedule of Inventory Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment Schedule of Debt [Table Text Block] Outstanding note payable indebtedness Stockholders' Equity (Deficit) [Abstract] Preferred Stock Shares Table [Text Block] Summary of Company's Preferred Stock Summary of Company's Preferred Stock Preferred Stock Shares Preferred Stock Terms Table [Text Block] Summary of Preferred Stock Terms Summary of Preferred Stock Terms Preferred Stock Terms Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building [Member] Machinery and Equipment [Member] Vehicles [Member] Computer Equipment [Member] Range [Axis] Range [Domain] Minimum [Member] Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Medite Enterprise [Member] Business Acquisition [Line Items] Business Acquisition, Percentage of Voting Interests Acquired Percentage of ownership interests acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts payable & accrued expenses Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Related Party Advances Related party advances Amount of related party advances due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Loans payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Consideration paid in the form of common stock Medite Enterprises, inc [Member] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Accrued Payroll Settlement [Member] Proceeds from Issuance of Private Placement Proceeds from private placement Stock Issued During Period, Shares, Acquisitions Number of shares issued on acquisitions Merger (in shares) Stock Issued During Period, Value, Acquisitions Value of shares issued on acquisitions Merger Stock Issued During Period, Shares, New Issues Number of shares issued Sale of common stock (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Number of additional shares issued on acquisitions Reverse Acquisition Percentage Of Share Issued Reverse acquisition percentage of share issued Inventory, Current [Table] Inventory [Axis] Inventory [Domain] Inventory [Line Items] Inventory, Raw Materials, Gross Raw materials Inventory, Work in Process, Gross Work in progress Inventory, Finished Goods, Gross Finished Goods Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per shares) Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Liquidation Preference, Value Preferred Stock, Liquidation Preference, Value (in dollars) Preferred Stock, Liquidation Value Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per shares) Common Stock Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common Stock, Shares, Issued Land Land Buildings and Improvements, Gross Buildings Machinery and Equipment, Gross Machinery and equipment Furniture and Fixtures, Gross Office furniture and equipment Vehicles Gross Vehicles Amount before accumulated depreciation of tangible personal property used to produce goods and services, vehicles. Computer and Communications Equipment Gross Computer equipment Computer And Communications Equipment, Gross Construction in Progress, Gross Construction in progress Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Disclosure Fixed Assets Additional Information [Abstract] Disclosure - Fixed Assets - Additional Information [Abstract] Depreciation, Total Depreciation expense Depreciation expense Line of Credit Facility [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Hannoversech Volksbank Credit line 1 [Member] Hannoversche Volksbank credit line 1 [Member] Hannoversech Volksbank Credit line 2 [Member] Hannoversche Volksbank credit line 2 [Member] Hannoversech Volksbank term loan 1 [Member] Hannoversche Volksbank term loan 1 [Member] Hannoversech Volksbank term loan 2 [Member] Hannoversche Volksbank term loan 2 [Member] Hannoversech Volksbank term loan 3 [Member] Hannoversche Volksbank term loan 3 [Member] Ventana Medical Systems [Member] Ventana Medical Systems, Inc. Promissory Note [Member] Line of Credit Facility [Line Items] Medite GmbH, Burgdorf [Member] CytoGlobe, GmbH, Burgdorf [Member] Hannoversech Volksbank Credit lines 1 [Member] Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] Hannoversech Volksbank Credit lines 2 [Member] Hannoversech Volksbank Credit lines 2 Issued in July 2006 [Member] Hannoversech Volksbank Credit lines 3 [Member] Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] Hannoversech Volksbank Credit line 4 [Member] Hannoversech Volksbank term loan 1 Issued in December 2006 [Member] Hannoversech Volksbank Credit line 5 [Member] Hannoversech Volksbank term loan 2 Issued in June 2006 [Member] Hannoversech Volks bank Credit Line 6 [Member] Hannoversech Volksbank term loan 3 Issued in November 2008 [Member] Hannoversech Volks bank Credit Line 6 [Member] Hannoversech Volksbank Credit line 7 [Member] Participation Rights Agreement In March 2009 [Member] Tranche [Axis] Tranche [Domain] Tranche One [Member] Tranche Two [Member] Subsequent Event Type [Axis] Debt Instrument, Face Amount Debt instrument face amount Debt Instrument, Interest Rate, Stated Percentage Line of Credit Facility, Periodic Payment, Principal Principal repayments Schedule of Stock by Class [Table] Class of Stock [Domain] Sale of Stock [Axis] Sale of Stock [Domain] Share Price Stock Issued During Period, Value, New Issues Sale of common stock Stock Issued During Period, Shares, Issued for Services Series Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series B Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Class Of Stock [Line Items] Class of Stock [Line Items] Preferred Stock Dividend Rate Percentage Convertible preferred stock, cumulative dividend rate Preferred Stock, Dividends Convertible preferred stock, cumulative dividend rate Stock Conversion Price Per Share Preferred Stock, Conversion Price Stock Conversion, price per share Preferred Stock Conversion Rate Preferred stock, conversion Rate Preferred Stock, Conversion Rate Preferred Stock, Conversion Rate Preferred Stock Voting Rights Preferred stock, voting Rights Preferred Stock Conversion Period Preferred Stock, Conversion Period Preferred Stock Conversion Period Preferred Stock, Amount of Preferred Dividends in Arrears Preferred stock, cumulative and undeclared dividends in arrears Preferred Stock, Cumulative and undeclared dividends in arrears Preferred Stock Liquidation Preference Preferred stock, liquidation Value per share Preferred stock, liquidation Value per share EX-101.PRE 11 mdit-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2015 $ / shares
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.50
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 4.00
Preferred Stock Dividend Frequency Of Payment	10%—Quarterly Commencing March 31, 2001
Preferred stock, dividend date of commencement	Mar. 31, 2001
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 3.00
Preferred Stock Dividend Frequency Of Payment	10% Quarterly Commencing March 31, 2002
Preferred stock, dividend date of commencement	Mar. 31, 2002
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 1,000
Preferred Stock Dividend Frequency Of Payment	10% Quarterly Commencing March 31, 2002
Preferred stock, dividend date of commencement	Apr. 30, 2002
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation Value per share	$ 22.00
Preferred Stock Dividend Frequency Of Payment	10% Quarterly Commencing May 31, 2002
Preferred stock, dividend date of commencement	May 31, 2002

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`">';4^Q4T!0%<2K MTMWDT3N>>Y-QSJ:G=T^.PFAENCY,BS9&=\)8J%LR*I3649^4F?5&Q73KY\RI M>J'FQ,1DA&^7BE3&K!5AT;A/61EUEG_V,8G"?5A)8HFJX, M\:FCL,U_K;PZ7]!,/73Q1\8O[Z[TU`TUH=7NQ>IRE;J$]-NT2&KXEL/FPJ^2 M:9.'YOKYAQ7Y_I?/LO$2EZ:[\.I1;Q@L=S:F?"Z-TOVV43U:O[BW=O&?VX3R M4S74C)U/A3[J+;LD%=\D-;#4^D_>KSNEMIZ^99@+=_A1M,I3YRY+D.UY\-?1`#&TX[A,2/<@B0'!(D1P628Q\DQP%(CD.0'$<@.8Y!P902P,$%`````@`)X=M1TAU!>[%````*P(```L` M``!?.0Q M(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^#*G*_=ITJK$"2+8CCVG! MD4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V[M,41Y26M#;3"&>6X9MY M6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V+YRO+0O]C^AY%.!)T:'B M1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P"4$L#!!0````(`">';4>[ MF$,ZMP$``*X:```:````>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<`94`*S=LU1MH8*`$^I/.&/7NK2P,_LP7%R3?IDW;Y,R[ M:)XTTT4;R_EC.%7IT+6Q/O1Q\M:JV$?TK)X[89CK$-( MT9U/&H+8!MX;@M`&[AR"V`;N'8+0!OX>BM0&_EZ*U`;R5] M:Z./;8[>"O16CMX*]%:.W@KT5H[>"O16CMX*]%:.W@KT5H[>"O16CMX&]#:. MW@;T-H[>!O0VTEX)VBSAZ&U`;^/H;4!OX^AM0&_CZ&U`;^/H;4!OX^AM0&_C MZ.V!WIZCMP=Z>X[>'NCM.7I[H+';4?W MQ_.-U@(``*8+```0````9&]C4')O<',O87!P+GAM;+U6WV^;,!#^5RR>NH>4 M-.FZ+4J1&""M4II4)6N?73B(5;"9[:"F?_T.:#*2.K3D87F)?=QWO[Z[DZ=< M#2=W4A0@-0-%7O*,JPD*KZV5UL7$ME6T@IRJ4+ZQF]N,\6?UNU@* MGVIHH_8_--975$*,3O>L[X2USJ\-YIE56&]%>0IQ6_?]QVTM'D"J*M.+T?D0 M?[L2;.6-;:`QX^D=95(YTU)/2HBTD&\TE?I4EF(15:2KAR7&IRSR1!54QVNK MI))1KBVBV"M>1U;CMI'6YZQ06CJ/0CZK%8!64WLGK(]MW?:973J7XUH#3_N: M]BXSYZUL>WE7DB73&:A%E_D^EJ'/:%N)R;+6RWYH@+H])P#6V([GAC2LD MKUV2W)4*Q=N,YS*C=$)"1DJ1%S#R6.!)!;D"E(H\H-+Y$,(7'9&+^_ M+;A-[3+XLV9%19Y1=29X.M`@<^+#DU8U`A<#KD8,T3.[OX<,-T9,JM[<$#"'+**35F1Z!<3K M1:@/FK*L5Q-L8^S?!&-S$W1CS&O:O#2Z8VMOCW>5%F9^NALT[(\9FR>_&V.> M_&[,CQ/R>>R_(\G@\T/:U6PF`#;WEJ1WSZ3V>^?@=6/OO\J=OU!+`P04```` M"``GAVU'$GU?%CX!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--;\(P M#(;_RM1["0'!I*KTL$T[#6G2F#;MEB4&,IH/)4:E_W[!E'9?%VZ[U;7?QZ_C MI)2^D"[`8W`>`FJ(5P=3VUA(O\BVB+Y@+,HM&!%'J<*FY-H%(S"%8<.\D#NQ M`389C^?,``HE4+`C,/<],:M*)0L90*`+'5[)'N_WH2:8D@QJ,&`Q,C[B+*N> M[J^ MJFF:43.ENC0P9Z_+ARRZX/SM.-DW?X-ATPWQ;QV?#=)V46,-%^Z6-(J62Y\$4A!ET!ZULQ?A M"/-%3+"X?_\`B9>#.B%=MAVTC0LJ5G2_ANCX';4>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]' M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D M$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X% M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:C MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^' MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90: MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0 MUL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD MGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V& MF&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F M<]%L^P>E1M'V5;SOX% M^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^ MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$ MKYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9 M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&UL MK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2 MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\, M$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MB MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4 M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$% M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`)X=M1VWC?L=_`@`` MO`P```T```!X;"]S='EL97,N>&ULS9?=;MHP%,=?Q3+3U$H32:@:VC6)-%5" MFM2A2N5B=Y63.&#)'YGC,.CEGF=/M2>I/P(!5$IAM((;.^<<_\[?YB0GB2HU MI_AA@K$",T9Y%<.)4N57SZNR"6:HZHH2<^TIA&1(Z4LY]JI28I179A&C7L_W M0X\APF$2\9H-F*I`)FJN8A@N3<"MOQ4YCN'CV>=?M5`WGX`;.U\Z'?_Q_&;3 M?F8=YQ`XQO<\AD%X";VW0[N^OQULG!OP<$_X:^P-='\_]"OD#?#5#O"_/W^W MG'/K>?&DKW>`[^^&6\"MYR5PWS=@KZF5)"H$;TNF!YTAB:HG,$54QP9Y#B- MH=_\WIXN;>EV,-LCE*YO3QN2J$1*8F%&)TD@72@FF)SE!8\$1-Q%P=QP:Q8)M"K M45G2^3=*QIQA)]:9!J*YVH4/MN"3""VH8"(D>=+QIA`R;<`2@BF6BF2KEM\2 ME2,\4TT%>[-BF\)#M_R>FHY_:JT:78(??3P')[>F8E*NSY9:?W_O4.]II^N-.VU MEKVT@K0F5!&^T(#,2];0Z*9KW;1MUYJ9S]I.;;T*I?I38BV+AN6X0#55]V0J ME'7&L)W?&?E!N(P:+1$Q;.<_<$YJ9E]'O?9[)7D&4$L#!!0````(`">';4?A M&``/Z`,``(L.```/````>&PO=V]R:V)O;VLN>&ULE9=1<]HX$(#_BL9/N8<< M6#(D84IG*'!WS!"2B9GF6=@"-+$E3I))FU_?E1VNZZ+ZPA.6L3YII4]K[R<[ M>M7F9:/U"_E6%LJ.S#C:.W<8]7HVVXN2VS_U02CX;ZM-R1TTS:ZGMUN9B9G. MJE(HUZ/]_K!G1,&=U,KNY<%&[S3[$9H]&,%SNQ?"E44#*[E4T>=/=K25A?@J MC`4PX8?#BI=B''TK(E)PZ^:Y="(?1PDT]:MHW3#5X4LE"]\8]`=1S\-.H3X: MDNE<-+#U7MKG]S\BDHLMKPJWALF>QAU',4TH'38,_]A7*5XM!OH;A&=.'L6: M;\91/R*\-%FAE=%'4O_T?="4:P_]V!.3J9M1YT?//D=V(<#?L`/$HK-[*0[OLX MJJ\+X2/I_1)*O?P_KXBJ%^>TQ62B<$@2@"T4M!#($8`K$/@](U M_-S/5PB4(%!R*6B`0`,$&EP*&B+0$(&&YZ`'L^-*OM5;1#CL7%J5)3??B=Z2 M5.X0Z`:!;LY!3^((9T"0>V%VPJ!^MZC?[7F_A3J"-&"QL*C3'>IT=][IT4!N M,""8G_'\WTH>O'E8L3YVK'].6&JUNX835Y*9V#A;@Y92">L#G^+YQRU=`[X^ M^6PF`WYQ[[&)\ MJ8SQ#49A&^.`CMVH6XS"@L8!0]MFDRM(JH6P?V`$UC4.^(HD#_6GV%8:L#7L M>Q"%;:4!6SO%IQ2C6NDUH&V7?C`WC,(FTX#)`7&"T6&3:<#DSFVG.,%2[#(- MN-R-PBF68J]IP.M?#+HF5W/K9-EDC0HG&XJ]IO^;9@$UR>%#!J;("[]X&(6] MIMV9UT\)A>?V@DPQ"OM-/YR/R=5,."X+O(,,J\X^KOHI4(S"JK-+56=8=895 M9P'5NU&M3XG6MT1`]?#K(A@@MIW])F^?WAMG*FCL%<.VLX#MW6^>;EUQC M%+8]"=@>3*'G!S#!JB!HJ/ MS!=4\--\%R4#_^KT[7LHLL:1KX2@Z*F*8@KW'M12\[I>:,BG$NKS#U!+`P04 M````"``GAVU'S&;\$$L"``#R!P``&````'AL+W=OU%I=%F(?S/CM:LWP8HN'>\ M59=2Z@Y8Y'#TG:J&MJ)B+>#TO`V>T6:/8BTQBE\5[853!WKP!\;>=>/':1N$ M>@RTID>I0Q!5W.B>UK6.I,@?0]`OIC:Z]7OT;V:Z:O@'(NB>U;^KDRS5:,,` MG.B97&OYQOKO=)A#H@,>62W,%QRO0K+F;@E`0SYM6;6F[.V?&`TVOP$/!CP: M(OQ?0S08HM%@EP[:D9EYO1!)BIRS'HB.Z-U&&R7G.HB*#-1DA&F:Y;*]MR+, MX4V'F2AV5H&-`HT*J&)[`7@*V&''CGV`O:N('@.BV0PB8X^,/7YLCV?VV-AC M8T^\"^`JTL>`9`9(''LV!;068!6)521QM'X,26>0U(&LO+-P%0L`V0R0.7;D M/R@3R8*3LIHA5J[?>U1V$\F"L[*>(=:N/_9MQG[M;`8.LS3%X8)-1^'\7H4N MRG^PIIHEE']N+W(C9'[*1+-:0,%S"G8CK/T45X/#!93Y/4:1&P'Y*5:36@U> M0)E?=^3>9AQY[^.@N9\!9_`8[LVDJ;2\?>\7E[-CD=?LF+ MO",7^I/P2]4*<&!2)7J3X\^,2:J&$3ZIO%"J!WALU/0L=353=6Z?)-N0K+N_ ML.,S7_P%4$L#!!0````(`">';4>WR:MBR@,``.H1```8````>&PO=V]R:W-H M965T&ULC9C);MLP$(9?1?"]D69(:@D<`[6*HCT4*'IHSTI, MQT*UN)(2MV]?;7&'S+#AQ5K\S_#G]FFD[:7M?O8GK8?@=UTU_=WF-`SGVS#L M'TZZ+OJ;]JR;\9]CV]7%,%YVCV%_[G1QF(/J*L0HBL.Z*)O-;CO?^]KMMNW3 M4)6-_MH%_5-=%]V?O:[:R]T&-B\WOI6/IV&Z$>ZVX37N4-:ZZ5? M:])_;4Z!]/PE^\>YNZ/]^Z+7>5O]*`_#:70;;8*#/A9/U?"MO7S2:Q_4E/"A MK?KY-WAXZH>V?@G9!'7Q>SF6S7R\+/^DT1K&!^`:@-<`D/\-$&N`L`+"Q=G< MKP_%4.RV77L)^G,QS3;<=RFWX/.4Q)/M%@HN$ M4^2&0ETEX=@^:P(M$SC'BR4^?CM>6/%BCI=+?&):;)9.+))DE@C):G*J01&] M[4-:/B3UD;(^%HF:)2`B9(T8HBR#MYTHRXFB3C+6B2*-2(B!=4)%0H+'W,:6 MDY@X(6-*G<2D$8S8<JR2UG*34 M";L`]JDQ(A"S3DR1SRK)+"<9=2)8)QE=)3&R$Y@[14XG$-DLB M0,F;<:O<;EY1$:@;Q;L!.OY2L>.7NU5N-S8>`:D;=C'L5\VZ4S-^[1JBT8R' M%QNU0%DK>-:NFG4&XD2R`YA;,BDR#S\V70"Q6*6\@]80P0CQCVJ)YN= M2-DI>7:NFJ6XB5/%SY.A2J/(8S^AS4ZD[+2W_EI2FIJ8T^0NC=O)J[*2UI6D MYG-GL&F'E':2K^B0EHU9S%=TA@ADZF/&1AW2\E+RH$):.B*_Y-`L+SVT&!Z"YE+-GK4B8D;^7GXE%_*;K'LNF#^W887_#G M=_MCVPYZ3!;=C'OBI(O#]:+2QV$Z3<;S;OD4L5P,[?GER\KU\\[N+U!+`P04 M````"``GAVU'[4[6TSL"``#S!P``&````'AL+W=OAPVX=U9<9>>5VQLZ1M3UYY(,Y=A_GO#:%L7(=1>!UX M:T^-U`.@KL`M[M!VI!%[(EE.I,:N9?4]*_<^I`MWW-_L4L5^GOL"!;1G^V!]DH6Q@& M!W+$9RK?V/B53&M(=<(]H\)\!_NSD*R[AH1!AS_LL^W-<[1O\G(*\P>@*0#= M`J+D84`\!<2S`&#-S+H^8XGKBK,Q$`/6OW:T4CC7253F0"U&F*[9+CMZJ=.L M`A>=YP[96`09!/F([1V1WA"@YO=*H)D$,O&)E%XND!HF@_7AU'H*+1LG,*'&-2J]1XDY4%G&:>GU<+,YC%UNT M269>]29^S2?_#)IO99*Z-MR8V%LFM383\A>-"J,B?J)M\9I*[)LAK MDC]5P\O4HDLQD+HC%ZR`Q'LF%0GO3GD MCXQ)HO+!%_4/:=0-?.M02[4@V7*_8VSU?_P%02P,$%`````@` M)X=M1X64IN6S!```^A<``!@```!X;"]W;W)K?MHL[N**;5Y ML2WYJR)_%L6?XN96-S_;DU*=]:LLJO9M=>JZR]JVV]U)E7G[6E]4U?]SJ)LR M[_K+YFBWET;E^S&H+&QP'-\N\W.UVF[&>]^;[::^=L6Y4M\;J[V69=[\&ZNB MOKVMQ.I^X\?Y>.J&&_9V8S_B]N=25>VYKJQ&'=Y6W\0Z@VA`1N*OL[JUZ+^NLK+TZY->B^U'??E>S!CDDW-5%.WY:NVO;U>4]9&65 M^:_I^UR-W[?IG]"9P_@`F`/@$?!HAP]PYP#W,\#[,L";`SS3%N0<(+46[$G[ M.')IWN7;35/?K/:2#_-)K'N\&9+TF:U^N-KQA-VWSW8":"=B0.'`-9!@P@_9/CQ-DBTD6>RFJXV5.\9[4WQ$FZ@F M)1,23)WP?>"@A$!!*#DHQ5#@A(*#,@R%?N0]U^1IFCRD*7!831,BI^)ZDS`Q9)TER]F0B`9!JPF#+F.9$MHTXPFWP2T82T7%E2YAB M"$3$KRL$BAP#2<+1C<7!HGQ6U,S,/79'^< MF;FC[*Q(",.OWREAA&2+D!$(P&!C(G1[%,0?V<&/!?4^7A-FV-F0$L1?F+ZD M*60VRXIT\07V*WYP$\+PCI(2!L3"W"4.&ACL881NCL+'FGC'GQGY MQ2*;$.9E80U)*07\VI;1]DQ4Z98ML&>'[*2)!?'2A><),R\+JPQAV&V@*\8]+2B%^YYI12!K4"G3_!NS?_(8C!N*F_.PCS(O@/3ZEE,OGRBAEHDKW M;A#(Y4*#K2?H/@GP?`[/S)=SF#"+^4X!'-_/MF0BB/W^W13"[_NI+13"8'$[I;`G%+?D\#DE:2WP%0BG]K22DD MHX5R8RHRD:4;)N#729--,.CF!('!\A"@XXFEY0$SR\L#H1:7!T*9+`^Z00$V M*/[=*)Z9J96%&3PAT=01Y]7A-Q)F6+;0X+(JW:``&U3$;R2`O/(Y7NA%2Q4C MKYF1ZTEP%_31G(X4X"Q4CN0,_-"%4*^?C0XV2]4)SRN.J0&IK<]BJJ1R2,V/+-A5`#N#QY-\O".Q1:]ME[64, MS-OJMUOH$;"^J.Y7?Y1R\-Z;NNV?5\=A.#WY?K\]RJ;L/ZN3;,?_[%77E,-X MVAW\_M3)#FMK'((C]IJS:U6:MK[UTF[4Z#W75RI?.Z\]-4W9_1!UG([3$.4X\^;+&1=3R.-F7\O@W[DG`+-X^OH?^ER1_NO92\+ M5?^L=L-Q=!NLO)W.$$Q6F*`H>^X@L'Y%9 M1_0X/K;B8Z..+&;KF"61G<*LPI0`QH]M)):-Q+3!=BI/C!P!Z\)4.$QI:GE( MS58ZW%*9%9\9-6#*UI`9#N,T8ZLP-9%#*R&PEV=@&F&3Y(MFSO(I"=F9+Z@* M@LBA*_`?6H!A1[`SER^:)5$4\FZ("%Q6"Z!M!LT;[4YOD%;-3Q-5BS=QH<_?\& MVW2#F+CA.0TQO:_NW'V$<0Y>;,1!0KRP67)(B)>$=5Q0EI0$-K8PX"XX3<1)$1#'M,%54&4.=BQL8=` M[/#[`9I(PR#B,4Q4D(;H8,<&'R*QPY,/"=.0W^N)R*4S-O604`]XZJ')LQ%% M//6H*DD=H(U#I2@/[;,7!K#B"['-DOY]?6%9-J+J"_8,YYPY8X^+2>EW MTP-8]"FX-`?<6SOL"3%U#X*:.S6`=']:I06U+M0=,8,&V@22X"1+DD%&BUG$EXU,J,05/\Y`E?3`:?XDGAC76]]@I0%67@-$R`-4Q)I:`_X M.=U7N4<$P"\&DUGMD?=^4NK=!S^:`TZ\!>!06Z]`W7*&"CCW0J[PQZQY+>F) MZ_U%_5OHUKD_40.5XK]98WMG-L&H@9:.W+ZIZ3O,+3QXP5IQ$[ZH'HU5XD+! M2-#/N#(9UBG^V=W/M&U"-A.RA;#4V2;D,R&_$D(%$IV%OEZHI66AU83,0/UE MIWL'UU[$*2/7C`EA.*Z8/9=IEA3D[(5N,,>(R2)F01"GOEDBNRUQS%;T;*M` MM48\/OV_0OZEB3SP[^9LAAH!S^I[I@TZ*2LN_5PX:U2%IRWY.X!H]X] MQB7@T%J_W;F]CO,9`ZN&RVM;GGSY%U!+`P04````"``GAVU'V.?T29T!``"Q M`P``&````'AL+W=O6CFM&^N`'` MDU>MC-O3P?MQQYAK!M#"W>$()OSIT&KA0VI[YD8+HDTDK1@OBD],"VEH7:7: MDZTKG+R2!IXL<9/6POX]@,)Y3S?T7'B6_>!C@=456WFMU&"<1$,L='OZL-D= MRHA(@%\29G<1D^C]B/@2DQ_MGA;1`BAH?%0083G!(R@5A4+C/XOF6\M(O(S/ MZM_2M,']43AX1/5;MGX(9@M*6NC$I/PSSM]A&>$^"C:H7/J29G(>]9E"B1:O M>94FK7/^\Z58:.\3^$+@-P26&R6;7X47=65Q)FX4\>PVNP"W420HD^#-I31- MGZNG>L-YQ4Y1Z`ISR!B>,2N"!?5W6_#K%@=^0>)OET<;C\6*&\$ MRB10_G?$:TQYTX1=[*D&VZ>KXTB#D_%Y\];J>CL?>#J3-WA=C:*'G\+VTCAR M1!].-AUJA^@AF"CN[BD9POM9$P6=C^'G$-M\I7+B<3P_D/65UO\`4$L#!!0` M```(`">';4>B&'NHH`$``+$#```8````>&PO=V]R:W-H965T&ULA5/;;J,P$/T5RQ]0$TC:*B)(35>KW8>5JCZTSPX,8-7VL+8)W;^O+X0F M4;5]P3/#.6?.^%).:-YL#^#(NY+:[FCOW+!ES-8]*&YO<`#M_[1H%'<^-1VS M@P'>1)*2+,^R6Z:XT+0J8^W)5"6.3@H-3X;842EN_NU!XK2C*WHJ/(NN=Z'` MJI(MO$8HT%:@)@;:'7U8;??K@(B`%P&3/8M)\'Y`?`O)[V9'LV`!)-0N*'"_ M'.$1I`Q"OO'?6?.S92">QR?UGW%:[_[`+3RB?!6-Z[W9C)(&6CY*]XS3+YA' MV`3!&J6-7U*/UJ$Z42A1_#VM0L=U2G^*8J9]3;H*(5R;>FXUIG#Y5C]4JWY3L&(0N,/N$R1-F03"O_F6+_++% M/C^CY]_3BRN'1:07L\/;[P765P+K*+#^[XB7F+NK)NQL3Q68+EX=2VHQF0TGOW\^22&A=".]\ M;-*52HG#X?1`EE=:?0!02P,$%`````@`)X=M1TUH59.A`0``KP,``!@```!X M;"]W;W)K8:P;0PEWA"";\Z=!JX4-J>^9&"Z)-)*T8+XHO3`MI:%VEVH.M*YR\D@8> M+'&3UL+^/8#">4]+>BD\RG[PL<#JBBV\5FHP3J(A%KH]O2UWAVU$),!O";-; MQ21Z/R(^Q>1GNZ=%M``*&A\51%A.<`=*1:'0^/FL^=HR$M?Q1?T^31O<'X6# M.U1_9.N'8+:@I(5.3,H_XOP#SB-<1\$&E4M?TDS.H[Y0*-'B):_2I'7.?S;\ M3/N8P,\$OA!NBF0\-THVOPLOZLKB3-PHXMF5NP"W420HD^#-I31-GZNGFG^K MV"GJO($<,H0G2+D@6!#_L`-_V^'`5W3^.7WSSN`FT3>Y.[_Y7&#[3F";!+;_ MFW`-*5>8W(.M=E2#[=/%<:3!R?B\=4MUN9NWZ0C9*[RN1M'#+V%[:1PYH@_G MFHZT0_003!17UY0,X?4LB8+.Q_!KB&V^4#GQ.%Z>Q_)&ZW]02P,$%`````@` M)X=M1PJ*GNN?`0``L0,``!D```!X;"]W;W)K&UL MC5/+;MLP$/P5@A\02K*2%H8L($Y1)(<`00[MF996$A&2JY*4E?Y]^9`5VPC: M7L3=U3%WAY*30\&*(G93BYO<>),X[FM-3X57T@PL%5E=L MY;5"@;8"-3'0[>A]OMV7`1$!/P3,]BPFP?L!\2TD3^V.9L$"2&A<4.!^.<(# M2!F$?.-?B^9'RT`\CT_JW^.TWOV!6WA`^5.T;O!F,TI:Z/@DW2O.C[",T"AW7.?TI\X7V.:%8",5*^)I%XZE1M/F-.UY7!F=B M1Q[.+M]ZN`DB7IEX;S:F_=,6Q66+?7%& M+_Y-WUPYW$3Z9G'X'_W+*X$R"I1_'?$2<^V2G>VI`M/'JV-)@Y-V:?/6ZGH[ M[XMX)A_PNAIY#\_<]$);:H?HP)O(;FXI&?S[61,)G0OA%Q^;=*52 MXG`\/9#UE=9_`%!+`P04````"``GAVU'^WSG,J`!``"Q`P``&0```'AL+W=O M8 M;090W-[A"-K_Z=`H[GQJ>F9'`[R-)"59GF7W3'&A:5W%VI.I*YR<%!J>#+&3 M4MS\.X#$>4\W]%QX%OW@0H'5%5MYK5"@K4!-#'1[^K#9'_9%;>$3Y M1[1N\&8S2EKH^"3=,\X_8!EA&P0;E#9^23-9A^I,H43QU[0*'=%T9G(D=>3B[S<[#31#QRL1[LS&-TZ?JJ=X41<5. M0>@*].$7>RI`M/'JV-)@Y-V:?/6ZGH['_)X)F_PNAIY#[^XZ86VY(C.GVP\U`[1 M@3>1W6TI&?S[61,)G0OA%Q^;=*52XG`\/Y#UE=;_`5!+`P04````"``GAVU' MJ+K![:`!``"Q`P``&0```'AL+W=OBJ\B*YWH<"JDBV\1BC0 M5J`F!MH=?5AM]^N`B(`_`B9[%I/@_8#X&I)?S8YFP0)(J%U0X'XYPB-(&81\ MX[=9\Z-E()[')_4?<5KO_L`M/*+\*QK7>[,9)0VT?)3N!:>?,(]P&P1KE#9^ M23U:A^I$H43Q][0*'=JU5Q5[)C$+K`[!,F3Y@%P;SZIRWRRQ;[_(R>?T\O MKAP6D5[,#N^_%UA?":RCP/K+$2\QFZLF[&Q/%9@N7AU+:ARU2YNW5)?;^9#' M,_F`5^7`._C-32>T)0=T_F3CH;:(#KR)[.:6DMZ_GR61T+H0WOO8I"N5$H?# MZ8$LK[3Z#U!+`P04````"``GAVU'%3IN7Z`!``"Q`P``&0```'AL+W=ONYS0O-H>P)%W);7=TMZY8<.8K7M0 MW%[A`-K_:=$H[GQH.F8'`[R))"59GF4W3'&A:57&W+.I2AR=%!J>#;&C4MS\ MVX'$:4M7=$Z\B*YW(<&JDBV\1BC05J`F!MHMO5UM=D5`1,`?`9,]V9/@?8_X M&H*G9DNS8`$DU"XH<+\"D6;]]SQJC0X$3OP,+O5QL--$/'*Q'NS,8S=I^RA6JU_E>P0A,XP MNX3)$V9!,*_^:8G\O,0N/Z'GW]/7%P[7D;Y.U8OL>X'B0J"(`L67+9YABLLF MVT)7MT?K)QJ"VB`V\B MN[JFI/?O9PDDM"YL_84@)EVI%#@RO-+J/U!+`P04````"``GAVU'T?1! MNI\!``"Q`P``&0```'AL+W=OWQ)0UNAY26>F9QSYHPO MY83FU?8`CKPKJ>V6]LX-&\9LW8/B]@H'T/Y/BT9QYU/3,3L8X$TD*:5F6L/9JJQ-%)H>'1$#LJQ)K2/XV6YH%"R"A=D&!^^4`]R!E$/*-WV;- MKY:!>!H?U1_BM-[]GENX1_DB&M=[LQDE#;1\E.X)IS\PCW`=!&N4-GY)/5J' MZDBA1/'WM`H=URG]N;F=:=\3\IF0+X3;+!I/C:+-W]SQJC0X$3OP<':KC8>; M(.*5B?=F8QJG3]5#M2KRDAV"T!EFES!YPBP(YM6_;9&?M]CE)_3\9_KZPN$Z MTM>SP_7/`L6%0!$%BO^.>(XI+IJPDSU58+IX=2RI<=0N;=Y276[G71[/Y`M> ME0/OX!\WG="6[-'YDXV'VB(Z\":RJVM*>O]^ED1"ZT)XXV.3KE1*'`['![*\ MTNH34$L#!!0````(`">';4<*E+:=H@$``+`#```9````>&PO=V]R:W-H965T M@!+WJ509I_TU@X[2DW=@V3F"@=0 M[D^+6C+K4MU1,VA@32!)0?,TO::2<9549:@]ZZK$T0JNX%D3,TK)]+\#")SV M29:<"R^\ZZTOT*JD"Z_A$I3AJ(B&=I_<9;M#X1$!\(?#9%8Q\=Z/B*\^>6KV M2>HM@(#:>@7FEA/<@Q!>R#5^FS4_6WKB.CZK/X1IG?LC,W"/XB]O;._,I@EI MH&6CL"\X/<(\PM8+UBA,^))Z-!;EF9(0R=[CRE58I_AGF\^T[PGY3,@7PFT: MC,=&P>8O9EE5:IR(&9@_NVSGX-J+.&7BO)F0ANEC]51EQ;:D)R_T!7.(F#QB M%@1UZM^VR+^V..0K>OXS?7/A0K+BYZ$%7 M6RI!=^'F&%+CJ&S&ULA5/+;MLP$/P5 M@A\0RK*<)H8L($X1M(<"00[MF996$A&2JY*4E?Y]^9`5VPB2B[B[FIF=Y:.< MT+S:'L"1-R6UW='>N6'+F*U[4-S>X`#:_VG1*.Y\:CIF!P.\B20E69YEMTQQ MH6E5QMJSJ4H!%=[T*!525;>(U0H*U`30RT M._JPVNZ+@(B`WP(F>Q:3X/V`^!J2G\V.9L$"2*A=4.!^.<(C2!F$?.._L^9[ MRT`\CT_J3W%:[_[`+3RB_",:UWNS&24-M'R4[@6G'S"/L`F"-4H;OZ0>K4-U MHE"B^%M:A8[KE/[D]S/M8T(^$_*%<)=%XZE1M/F=.UZ5!B=B!Q[.;K7UJQ6Q5W)CD'H`K-/F#QA%@3SZA^VR"];[/,S>OXU?7WE\P&RRJR;L;$\5F"Y>'4MJ'+5+F[=4E]OYD,8=7 MY<`[^,5-)[0E!W3^9..AMH@.O(GL9D-)[]_/DDAH70B_^=BD*Y42A\/I@2RO MM/H/4$L#!!0````(`">';4=_!#IP'P(``$H'```9````>&PO=V]R:W-H965T MXU;6DU M`^("K;-OOX#6$8;$WA0._N?_#BD:P)P_*) M=Z357\Y<,*QT*"Y0=H+@DTUB%"9QG$.&FS:J2KOV*JJ27Q5M6O(J@+PRAL6_ M/:&\WT4HNB^\-9=:F058E7#*.S6,M++A+1#DO(N>T7:/4B.QBM\-Z>5L#DSQ M!\[?3?#SM(MB4P.AY*B,!=;#C;P02HV3)O\=33^9)G$^O[M_M]O5Y1^P)"^< M_FE.JM;5QA$XD3.^4O7&^Q]DW$-F#(^<2OL+CE>I.+NG1(#ACV%L6COVPY=U M/*:%$Y(Q(?$2X`"R97[#"E>EX#V0'39_'MIJN3`FVAGHVJ0-[>Z'U5N%,E3" MFS%R-/M!DPR:20&U>Q"1N(A],DM/EM-3K\+4IJ=CA0\8K#R#E358C09I<(NN M9K4,R3Q(YAAD08BKR9I'`,UD&(J]DL0]8>9#TW MR,,[<34/'+R-!]DX!DD0XFK290B*_1L4.Q:K\!5R1=D#G"\W%:XHO4#'/]:H]2QV(0YCJB(/0Z<]3I&Q,6V=`F._-JJH:E- MJ].S\9S87ODIK\H.7\@O+"Y-*\&!*]UQ;;,]WU@_;%%!R5F9: MZ+D86OT0*-[=7Z[I^:S^`U!+`P04````"``GAVU'>DG^T:,!``"Q`P``&0`` M`'AL+W=OQ-W5S.PL'^6$YLWV`(Y\**GM MCO;.#5O&;-V#XO8.!]#^3XM&<>=3TS$[&.!-)"G)BBR[9XH+3:LRUEY,5>+H MI-#P8H@=E>+FSQXD3CN:TU/A572]"P56E6SA-4*!M@(U,=#NZ&.^W:\#(@)^ M"9CL64R"]P/B6TA^-#N:!0L@H79!@?OE"$\@91#RC=]GS<^6@7@>G]2_Q6F] M^P.W\(3RMVA<[\UFE#30\E&Z5YR^PSS")@C6*&W\DGJT#M6)0HGB'VD5.JY3 M^G/_=:;=)A0SH5@(7[)H/#6*-I^YXU5I<")VX.'L\JV'FR#BE8GW9F,:IT_5 M8Y4_Y"4[!J$+S#YABH19$,RKWVQ17+;8%V?TXM_TU97#5:2O4O?-?PBLKP36 M46`]CUC<'/$2L[IJPL[V5('IXM6QI,91N[1Y2W6YG8]%/)-/>%4.O(.?W'1" M6W)`YT\V'FJ+Z,";R.XVE/3^_2R)A-:%\,'')EVIE#@<3@]D>:757U!+`P04 M````"``GAVU'[/&9'J(!``"Q`P``&0```'AL+W=OP)$/);7=T]ZY8<>8K7M0W#[@`-K_:=$H[GQJ M.F8'`[R))"59GF6/3'&A:57&VJNI2AR=%!I>#;&C4MS\.X#$:4]7]%QX$UWO M0H%5)5MXC5"@K4!-#+1[^K3:'8J`B(#?`B9[$9/@_8CX'I*?S9YFP0)(J%U0 MX'XYP3-(&81\X[^SYF?+0+R,S^K?X[3>_9%;>$;Y1S2N]V8S2AIH^2C=&TX_ M8!YA$P1KE#9^23U:A^I,H43QC[0*'=WVGFX"2)>F7AO-J9Q^E0]5:MM4;)3$+K"'!(F3Y@%P;SZW1;Y M=8M#?D'/OZ:O;QRN(WV=NN>/7PL4-P)%%"CF$3=W1[S&W#9A%WNJP'3QZEA2 MXZA=VKRENMS.ISR>R2>\*@?>P2]N.J$M.:+S)QL/M45TX$UD#QM*>O]^ED1" MZT*X];%)5RHE#H?S`UE>:?4?4$L#!!0````(`">';4<+D7Z4HP$``+$#```9 M````>&PO=V]R:W-H965T6C&-&\V0[`D0\E MM=UEG7/]EE);=:"XO<,>M/_3H%'<^=2TU/8&>!U)2E*6YS^HXD)G91%K+Z8L M<'!2:'@QQ`Y*D1H:/DCWBN-OF$:X#X(52AN_I!JL0W6B9$3QC[0* M'=UY.+O%UL--$/'*Q'NS,8W3 MI^JQ7*S7!3T&H0O,/F%8PLP(ZM5OMF"7+?;LC,Z^IR^O'"XC?9FZL\WW`JLK M@5446$TC;FZ.>(GY>=6$GNVI`M/&JV-)A8-V:?/FZGP['^(ATB]X6?2\A6=N M6J$M.:#S)QL/M4%TX$WD=_<9Z?S[F1,)C0OAVL5_4$L# M!!0````(`">';4?1)M'BH@$``+$#```9````>&PO=V]R:W-H965TV.#LZ-6\9L,X#B]@Y'T/Y/AT9Q MYU/3,SL:X&TD*:UE6LO9BZPLE)H>'%$#LIQ!Z?U+_%:;W[`[?PA/*W:-W@S6:4M-#Q2;I7 MG+_#,L)]$&Q0VO@ES60=JA.%$L4_TBIT7.?TI\P7VFU"L1"*E?"01>.I4;3Y MS!VO*X,SL2,/9Y=O/=P$$:],O#<;TSA]JA[K_"&KV#$(76#V"5,DS(I@7OUF MB^*RQ;XXHQ?_IF^N'&XB?9.Z;_ZC?WDE4$:!;:)3O;4P6FCU?' MD@8G[=+FK=7U=CX6\4P^X74U\AY^*@=H@-O(KN[IV3P[V=- M)'0NA%]];-*52HG#\?1`UE=:_P502P,$%`````@`)X=M1U_0#1NB`0``L0,` M`!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RI+< M!H8L($Y1M(<"00[MF996$A&2JY*4E?Y]^;`4VS"0B[B[FIF=Y:.:T;S9`<"1 M=R6UW=/!N7''F&T&4-P^X`C:_^G0*.Y\:GIF1P.\C20E69YE7YCB0M.ZBK47 M4U;NA2>!7]X$*!U15;>:U0H*U`30QT>_JTV1W* M@(B`WP)F>Q&3X/V(^!:2G^V>9L$"2&A<4.!^.<$S2!F$?.._9\V/EH%X&2_J MW^.TWOV16WA&^4>T;O!F,TI:Z/@DW2O./^`\PC8(-BAM_))FL@[50J%$\?>T M"AW7.?TI%]I]0GXFY"OA,8O&4Z-H\QMWO*X,SL2./)S=9N?A)HAX9>*]V9C& MZ5/U5&\>BXJ=@M`5YI`P><*L".;5[[;(KUL<\@MZ_CF]N'%81'J1NA?EYP+E MC4`9!_C% M32^T)4=T_F3CH7:(#KR)[&%+R>#?SYI(Z%P(O_K8I"N5$H?C\D#65UK_!U!+ M`P04````"``GAVU'QOA/9+X!``![!```&0```'AL+W=OETH): M5^H*FT8#+0))<$SB.,&",AEE:>B]ZBQ5K>5,PJM&IA6"ZG]GX*H[19OHUGAC M56U]`V`'.O9`S_CMH?EIZXG1_4_\>3NO27ZB!%\7_L,+6+FPA7)L/:]4]V9*"M$\A`("/A$(?@O5&( M^8U:FJ5:=<@TU/]WFZ.#:R_BE)'+9D(93M]WK]GFD*3XZH5FF'./(3UF1&"G MOFI!YA9G,J&3^_3M(N$VT+=#PL?[`KN%P"X([`:!P^H1YYBG^R;[AMW9=@+#B4UF\?W5[WEZ,OK&IN5WW\ MWF3_`5!+`P04````"``GAVU'S7B09:,!``"Q`P``&0```'AL+W=OP)$/);7=T=ZY8#;&C4MS\VX/$ M:4=7]%1X$UWO0H%5)5MXC5"@K4!-#+0[^KC:[HN`B(#?`B9[%I/@_8#X'I*? MS8YFP0)(J%U0X'XYPA-(&81\X[^SYF?+0#R/3^K/<5KO_L`M/*'\(QK7>[,9 M)0VT?)3N#:<7F$?8!,$:I8U?4H_6H3I1*%'\(ZU"QW5*?XI\IMTFY#,A7PC? MLV@\-8HV?W#'J]+@1.S`P]FMMAYN@HA7)MZ;C6FJA*-DQ"%U@]@F3 M)\R"8%[]9HO\LL4^/Z/G7]/75P[7D;Y.W8N'KP6**X$B"A3SB)N;(UYB[J^: ML+,]56"Z>'4LJ7'4+FW>4EUNYV,\1/8)K\J!=_"+FTYH2P[H_,G&0VT1'7@3 MV=V&DMZ_GR61T+H0?O.Q258%7SAS9@[X MP.0]%^^R9$RACZ9NY28HE>K682CW)6NH?.(=:_6=(Q<-57HI3J'L!*,'&]34 M(8FB)&QHU09%;O=>19'SLZJKEKT*),]-0\6?+:MYOPEP<-UXJTZE,AMAD8=3 MW*%J6"LKWB+!CIO@&:^W)#$0B_A9L5[>S)$I?L?YNUE\/VR"R-3`:K97AH+J MX<)>6%T;)IWY]TCZF=,$WLZO[%^M7%W^CDKVPNM?U4&5NMHH0`=VI.=:O?'^ M&QLU+`WAGM?27M'^+!5OKB$!:NC',%:M'?OA3I*-8?<#R!A`IH`A3S@DLF5^ MH8H6N>`]DATU+P^O-5P8$LV,=&W2+JWZ8?=2X"S-PXLA1Q>`PJC&WX8JQP]9A@`0@6EB`>";+'!$M`L+RI0!_JN\_(Q7@\ MI00D21P"C^>4`H)TKLP5(%AYR'0Q\>,D&4B2.02+QP0X@B/IQ/%LM//]XX:/6!:4>>:!-L.L!#Z=B:`*+<$.H8X9L"1!P4T`R&SU4(S MD-A'K0/"/C\LZ!CBF`%[?(P)-`-9SE8+S4`2'[7)?[]2X4TWT#!QLDV/1'M^ M;M7PVY]VI\;JF=ANXA->Y!T]L1]4G*I6HAU7NB>Q[[:VTT-9O$74$L#!!0````(`">';4<1??&6W@$``%T% M```9````>&PO=V]R:W-H965TV$[=_7%T(!H:7E`7O,.6?.#+;SGHMW60,H M],%H*_=>K52WPUB>:V!$/O`.6OVEXH(1I4-QP;(30$I+8A2'OI]B1IK6*W*[ M]BJ*G%\5;5IX%4A>&2/B]Q-0WN^]P+LOO#676ID%7.1XY)4-@U8VO$4"JKWW M-=@=,X.P@!\-]'(R1\;[B?-W$WPK]YYO+`"%LS(*1`\W.`"E1D@G_C5H_DUI MB-/Y7?W95JO=GXB$`Z<_FU+5VJSOH1(J_8&V3@@'0C@2@OA30C00HG\EQ`,A7A"P*\4VXD@4*7+! M>R0[8G9'L--P842T,M+52QO:_KK56Q$&48YO1FB&>7*8T&'6$(<9(EF#'&>0 M(!XQ6)M<=1HNG(96(!H$DFV!:"$068'8"J0+DZVKU$$2E\//TC3TTS7@80H, MOL1A%D7!MJ-XX2B>.`J#=%L@60@D_]N3="&0SAQDJW]NCGG<3I(MDF2;C3]F MTWXFOGT6B?!D8W?D`M^)N#2M1">N]!FQQZ/B7(&6\Q]T8VI]UXT!A4J9::;G MPAU_%RC>W2^S\48M_@!02P,$%`````@`)X=M1^P*2M17`@``6@@``!D```!X M;"]W;W)K&ULC9;;CML@$(9?Q?(#K#GXE,BQU$U5 MM1>55GO17I.$Q-;:Q@62;-^^&)P46-KX)@;RSWS_Q`RDNC+^)AI*9?3>=X/8 MQ(V4XSI)Q+ZA/1%/;*2#^N;(>$^DFO)3(D9.R4$']5V"`,B3GK1#7%=Z[877 M%3O+KAWH"X_$N>\)__U,.W;=Q#"^+;RVIT9."TE=)?>X0]O30;1LB#@];N)/ M<+V%V231BA\MO0IK'$WF=XR]39-OATT,)@^THWLYI2#J<:%;VG53)D7^-2?] MRYP"[?$M^Q==KK*_(X)N6?>S/=4)_1ONS MD*R_A<113][-LQWT\VJ^*<$<%@Y`0&*"Z3CL8E'X'$"["7`.D%J$A2NQ\%4822%EL#'A-0CI#8!P2#":#*#0(\9 MF!^%1RD<2AJD%!8ES9>\]=*CE!8% M9T%(:4%0F@7KW9;6UG!$_W2R\IRLG'K#5E;VFTM!\9@"@=^MP&F4?$&*#PT/ M':OA7IE%QBM>U)'0[VF('%`9!B%[JX$%/0/]UH=.[Z-5F(/M?;"@;:#?_]`Y M`#`(8^P3`.-TP4Z"_B$`G5,`AT^:662V;`;RU`,EUBTPDA/]3OBI'42T8U)= M*/HN.3(FJB_@-02P,$%``` M``@`)X=M1_K^L<*C`@``U0H``!D```!X;"]W;W)K&ULE5;=DMH@%'Z53!Y@`P22N*/.5-U.>]&9G;UHKUE%S6P2;,!U^_8%@FZ@ M6/'&!/Q^SCEP"-,3[]_$GC&9?+1-)V;I7LK#8Y:)]9ZU5#SP`^O4/UO>MU2J M8;_+Q*%G=&-(;9,A`(JLI767SJ=F[KF?3_E1-G7'GOM$'-N6]G\6K.&G60K3 M\\1+O=M+/9'-I]F%MZE;UHF:=TG/MK/T"WQ\0@9B$#]K=A*C]T0'_\KYFQY\ MW\Q2H&-@#5M++4'5XYTM6=-H)>7\VXI^>FKB^/VL_M6DJ\)_I8(M>?.KWLB] MBA:DR89MZ;&1+_STC=D-:=>9Z&?RI@:6$" ML@1T(4#\7T)N"7DL`5L"CB402R`>(1MR-Y5;44GGTYZ?$G&@>C_!1P7OM8A2 M3E2YA!F:!1EFW^#H,]DY)-#%)6/J;+3P,!Q@N$.=D"PBO#YYZ"` MCD_PI'CR0'F$C]_!$#D2.%@Y"[*E(P"54;7SFQTZW8Z#NWMA09?M7408^5<,B4$'E04>W7'O`P:MI7ZM=3A#;>N82#YX7R)O-QD MYW\!4$L#!!0````(`">';4?AB/KIX`$``$\%```9````>&PO=V]R:W-H965T MR`8O4^^HIV9>847O"K98.>]8%C/TKY MY@8_JGT4.P3&V5 M:2QL'(&*U?3"S:L;=L& M/!KP9$#)IP8R&LC*``.9K^N9&EKD2@Y`]]1];+2S3T8_OA]`5@'$!R1C`%E"=J&, MH'GT&O1$DBU1N1!A_'0?)5FA)`N4S54.09,&S6S#YB1S#2'W.=(51[K@V%SC MD,XYXAAO@BQ$*/T/E&R%DBU0LDV4;+;Q"L^VKX*!SX,C.QOU]=TAQ9_`5!+ M`P04````"``GAVU'1-AWNT<"```%"```&0```'AL+W=O]@`X80$:2&JFH7E4:S:-=.X@0T!E/;"=.W MKR\D@QFWR09?^/]S/F-S7(Z,OXJ&$!F\=;07F["1)U[:4R/U1%25TTYMG/>OT;^:Y2K\'1:D9O17>Y"- MH@5A<"!'?*;RA8W?R+0&I`/N&17F&>S/0K+N:@F##K_9MNU-.]HW*)]L?D,\ M&>*;`:;_-223(5D8(DMFUO4%2UR5G(V!&+#>;;A61A<=R-%LK2:V&I^B=A3H)HD4@)"!0[):<*PCU:X&W`%/CF8% M>\`G\@/S4]N+8,>DJOVF[!\9DT3%`D_J7VS4G7P;4'*4NINK/K>WE!U(-EPO MW=O-7_T%4$L#!!0````(`">';4>CQ/G9S`$``$8$```9````>&PO=V]R:W-H M965TA(]=.9+)22GVH2RQJJ70$M'X@R3,$PPIVT79*G+O2"_6E+ MW1BS88!*J.C`](<8WV!J86L%"\&4^T7%H+3@5TJ`./WR:]NY=?1?DMU$6R>0 MB4!FPEQGG1!/A/A&<$>'O3/7UP^J:99*,2+54WO9T<'`I14QRL@THUSHCLMG M+QE)=BF^6*$[S,ECB,-$,P(;]=42Y+[$B2SH9*U`OD0DS]]7B!^:B!T_]@;W M^^\%-@\"&R>PF4[A^=YDY]OPF)W#[+=A&*ZA\B4J(LD2YMW@Q?UPD+6;6X4* M,73:G\&$7E77;*706VDR/&YQ*"`W&7_BT M#5!C'O4<,*BTW>[,7OHY]X$6_?75SG\=V7]02P,$%`````@`)X=M1X3;&;N+ M`@``)`L``!D```!X;"]W;W)K&ULE5;;CILP%/P5 MQ`28B_9F!>PS9QASL#(SDT)ITSX./6_0(V)0P%1")^U7BDL[$CQ.\(>1.3'X>MZPL-N,%[)B@0OUUP MB9M&,/$W_YE(_[]3%,['5_9OLETN?X>`C^C/I82&E%"3`A\31`9!M-:,V""(+";4?,U*1:_%OB05K#6#F!`+ M0R:0ZC:&BX9H&!#8.&*F%NBQM:$PTP;"U8Z8>0.1C2/1K-O(7W9DCDF!A10S MN4"/;FQ!828.)*L-,3,'4AM#TEFST`^6'=%`5F+,_`(]P(G%YF(&#_IK+8%F M\""PL&0"3=TN8LI[F/M2/NR5>H!3"PHS=S!8;8B9.QC:&!+.=M,TO./(')0! M<\/T9N>9'IWP3S2BHZ$,,RI_"<>P(H?66^3!A^9&"9\/*A# MG)HPTE_/I+>#';4=):BR/WP0``!4<```9````>&PO M=V]R:W-H965T35^?[!5M<+GP_[@]M?R%<+<.KW?98 MF+(Y5F50F]W]XBN[>]&\APR(OX_FW$R.@S[XUZKZT9_\N;U?1'T,)C>;MG>1 M=3_OYM'D>>^I&_E?Z_1CS-YP>GSQ_CS<;A?^:]:8QRK_Y[AM#UVTT2+8FEWV MEK??J_,?QMZ#ZAUNJKP9OH/-6]-6Q<5D$139S_'W6`Z_Y_&?)+)F;@-N#?C5 M@,>_-!#60'P8L%\:2&L@J0;*&BBJ@;8&FFH06X,8&81C=H=G\Y2UV6I95^>@ M.65]Q;*[#E[W3CK/0?=`FN%T>.3CU?<5C]-E^-X[`IB'$<-'3!*Y,(]3#+LB MPBX"9Q@C; M#B1R(`<'PCZ\Z+8#A1PH$$'L3#O$),Z4^C#>0#0*1`,'Z6T',7(0STU%@APD MTPA25.3EF(H1$X]%'D?]QX5;CS@VLHHI"/1&E**(4A`1@50LPN2.YF:%?=(' M1LB+!:D!E$C&T\29%XNSB8D5+2^,XY@XB(D37&#J,3$[,YA\3((HA#LS8C2RFY":>Y`;?\03X;(&7W&AJ M;C#%&>2X26C=8*H2FU(T& MZ5/NNO&!_,%@T1$QI6ZFHL-ERIWSSRI&1K]3-Q+KC:3HC812XIY%>$'^8+#>2(K>R*G>,*7PRH.M&PN[ MM"J1I)3T8,&14'`(\QKYZ85_MN!(+#@2"HXG+T3!D;\E.!(+CH0R09@A22P3 MD>24^:IU::*\I-89XJT,Z9<_[[H,`[!'6=2&%"*]"I MF7:/E4Q7(3AM),Q6!=D:NT=*YS\JC4FM(S`29:D5DUJSN230F(H:OJ*[5U(T M:*X1PYP/)SL5A:GWPRY4$VRJM[(=U]6O5Z\[75^'C2YT_9'=/8T[(!]N5LM3 MMC=_9?7^6#;!:]6V53%LH>RJJC5=>-&7CCD'DVVO)[G9M?UAW!W7XZ[5>-)6 MI\LFW'4G';4?GJHA`FP$``*X#```9````>&PO=V]R M:W-H965T;`_@R(>2VJYI[]RP8LQN M>U#FO_)54P9$!/P5,-J3F`3O M&\2WD#RV:YH%"R!AZX("]\L!&I`R"/F#WR?-SR,#\30^JC_$;KW[#;?0H'P5 MK>N]V8R2%CJ^E^X%QS\PM;`,@EN4-G[)=F\=JB.%$L4_TBIT7,>TSK-W>\K@R.Q`X\/':^\G`31+PR\8_*W8(0F>8^X0I(J:XAFC.$,L9PKR!JRZ*"Q=%Y)?)19%]+U!>")118#$) MY.*#]0A.O!*V"4B2$.JJEU4&LVB73N)$]``IK:33/^^QB8,>&#(;.('YYYSKKGF)KDQ M_BIR2J7S5I6UV+JYE,W&\\0AIQ41*];06CTY,5X1J9;\[(F&4W+4057I(0!" MKR)%[::)WGOF:<(NLBQJ^LP=<:DJPO]EM&2WK0O=^\9+<L^P=KK*_)X+N6/FG.,I+D*RZA[A.1=[,6-1ZO)DGX3UL.@!U`:@/P-&G`;@+P%:`9YSI MO+X12=*$LYLC&M*^;;A1<-Z2*&9')2/T4A^7V;VF&*'$N[9$(TQF,$ACPF@* MLAM"8(_PE(%)%VCL(D.#<(SPI,0<9E8$6ZEB38`[`G^9P+<(?$W@=P3!V&5M M7!I,8`X"XSB.@F6AP!(*1D+AE%!F,&LCM)K$[.8PLT9"RT@X,A)-BAA,I#$( M8A\`L"P464+12"B>%(H&1QO#AV1B2R8>R:R7"=86P?JK-02!?>'`M`III"`!YZR]"^Z1`/I?`C M%/9=A_Z7W[1]B^'H&F,X?;#!(&&(/N;K#;[G%>5GW>>$SOO_U.D_P%02P,$%`````@`)X=M1QN-2^2J`@``;0P``!D```!X;"]W M;W)K&ULG9??;ILP%,9?!?$`!=O\C1*D-=.T74RJ M>K%=.XD34`%GV$FZMY]M2&9<')S>%$R^\_$S'QR=+B^T>V,E(=Q[;^J6K?R2 M\^,B"-BV)`UF3_1(6O'+GG8-YF+9'0)V[`C>J:*F#F`8)D&#J]8OENK:2U.H^=F@9W?Y])32\K'_C7"Z_5H>3R0E`L@UO=KFI(RRK:>AW9K_PO M8+&&D90HQ:^*7)AV[DGX#:5O<_@^G_ M>\I"_?SJ_DUM5^!O,"-K6O^N=KP4M*'O[<@>GVK^2B_?R;"'6!IN:"L`T=T"-!0@HR#HR=2^OF*.BV5' M+QX[8IDV6`AY)TV$LRC10H'D#9!@@91`I@S@?,[;]+GI)K"0@SU`<3\G6N@RE2)=9:2*# M)M)HDG"2)G*CB3Y!$QLTL4:#4#1OD!@&R:/II(9!.I].JFTT2F$\^=36=I65 M)3-8LOEL,B<6N\K*DALL^2@9AVA!:'Z^X:/9@`\=`,RG,VCZS>8HM3R2.S([ MC]D+`)Q/:-#,\MAE=AZSM0`T2BEQL##[`8@>3LG\B$'LD%*L=XM,O]'HJ=AE M=AZS)X#$(:7$C<*U M#1U>7&CV!AC.1S1H[L&,),XP9I>!8)1/YF#Q84AX>$J`YK<,'>8$.!X40@BG M'XM=9N>&DB=E[XVG"*DGR`MXX$A6EF/_;`6'UUO&=V\9[?LFDWG#3Q.UXIYQ" M(7)6(`[GK?/J;_9^I"$&\3N'6O3F2)L_,/:A%S]/6\?3'H#`46H)K(8K[($0 MK:1._MN*WL_4Q/[\IO[=E*OL'["`/2-_\I/,E%O/02&=$)M*&V>F MKF]8XC3AK$:BQ/K?]C<*SK6(4D:J&&&6)JYF]YJ&X3IQKUIH@-DUF,!@_#'$ MOH\((Z_#N,K!J(U@:&,7]`2"T2,&B,7C$T*KT-#PH[;0&0*1)1`9@;`5"!\+ M+"R!1=]!-!KD;H@93V(*,VDDMHS$@RCBQP)+2V#Y;!0K2V`U(XK5C"BF,)-& MUI:1]2"*Y6,!W[,OD/=L&/Z7.^C/B,,"C>/VGDL*_&+:B$!'5A6R>1>[W:Y5O0;FN;W#TZ3$%_B% M^24O!#HPJ1YM\UZ?&9.@7'@OZM)FJIEV"P)GJ:=+->=->VD6DI6W;MFU[/0_ M4$L#!!0````(`">';4=DU8,#$`0``#D7```9````>&PO=V]R:W-H965T[US1Q$G0` M9X$T9]]^^9?4GH(ZW#1`/\^,S7P_P)N;K7[69V.:X%>1E_7+ZMPTE^_5=F.O39Z5 MYGL5U->B2*O_7DUN;R\KN;I?^)&=SDUW(=QNPL>X0U:8LLYL&53F^++Z)I]W MNI?TBK\S7E>AJ,+G9-UV(M/UY-SN3YUVD-O._8]"/ MG-U`]_@>_?=^NFWY;VEM=C;_)SLTY[9:L0H.YIA>\^:'O?UAQCGH+N#>YG7_ M-]A?Z\86]R&KH$A_#;]9V?_>AO\D8APV/0#&`?`8\,@S/0#'`?@Q(.IG.E36 MS^NWM$FWF\K>@OJ2=G=;/K?RJ@O21@[:R=3]:;]1(OCY[,D[A++U`PIK,F:=9>FFC2"[XF_CJ)%-1QP@N13%O. M%ZT9>3XY6[HAM)C.XXLD(P_0/."%@,F[,XK6O4@],7I`4@-+]/J=$X):6*JE M'2^IZ:1F]/PH&IH18\VRMZ3VE!&C[4?1O>]9B:B-94"^%R(&"$H%V`Q%X!R`3A<`)<+4O*X M`)0+P.$"N%R(6'DH%H"#!5^D.:M/L0`<+,!B+`#%`G"P`!PLS(KFWT8I%I"# M!5R,!:180`X6T+6[;+L%I['@Z[14DF$5I%A`#A;0Q0(GRZ?W?1\+C#%I!B`3E8P.6O"TBY@#'#KT3$\"M2+F#"\*LOFO'KK&B^ M&`H/7'/\NE[J5T6YH`3#KZ-HN(LS7YBN)&HMS;G5BM)#2895E5S<4XHR07E, M*I-='9I(?'26Z.37<8M\?5 ML+,[G#3V';4>I,MA4@@(``-\*```9```` M>&PO=V]R:W-H965T33-9Q\2X+QE3P45>- MW(:%4NU3%,E#P6HJ%[QEC?[FQ$5-E=Z*C1!M551!!:1C4MFS#/[-FK MR#-^4579L%<1R$M=4_%OQRK>;4,RG.AS$&49]$0=RQKULB2-X%@IVWX MC)]V)#40B_A=LDZ.UH%)?L_YN]G\/&Y#9')@%3LH0T'UX\I>6%49)JW\MR?] MU#2!X_6-_;LM5Z>_IY*]\.I/>52%SA:%P9&=Z*52;[S[P?H:;(8'7DG[&1PN M4O'Z%A(&-?UPS[*QS\Y]LT9]V/T`T@>0(2"Q.I$3LFE^HXKFF>!=(%MJFH>? M-%P8$LTDUC]-U%ET-T02S8($$"26(.X)XGF"%!"DXPR6:'I+C2O38386DRS2>9$E$%E. MRO0@6`&"U:-EK@'!VJ-,AUFY,N0M!XV,=Y`.31/@*M1WRL M!T`>=T^@]FL/"F@]\K#U"+0>\;$>&5N/>/R>$>@]XN,]`/*Y$>@]XN,] M`()_Z-%H`*F9.-LY2P8'?FF4FS2&TV&6>R9V@/F$YUE+S^P7%>>RD<&>*ST& MV0GHQ+EB.@NTT%D4>MH<-A4[*;-QLEAILW_`U!+`P04```` M"``GAVU'51ZT:+T"``"N"P``&0```'AL+W=O_4/;.2T*$]]'4+5_ZI1#'11#P;4D:S&?T2%IY94]9@X5< MLD/`CXS@G0IJZ@"&X3QH<-7Z1:[V7EF1TY.HJY:\,H^?F@:S?RM2T\O2!_YU MXZTZE*+;"(H\N,7MJH:TO**MQ\A^Z;^`Q1HJB5+\KLB%#\Z]KO@-I>_=XN=N MZ8==#:0F6]&EP/)P)FM2UUTF2?[;)[TSN\#A^37[=]6N+'^#.5G3^D^U$Z6L M-O2]'=GC4RW>Z.4'Z7M(NH1;6G/UZVU/7-#F&N)[#?[0QZI5QXN^@L(^S!T` M^P!X"X#)EP%1'Q!9`8&N3/7U#0M/'[$W=,&"REG71*9V9/-<+54MTOO MGHLH#?/@W"4R-"NM@4H#7(KU4!'%]RR!K,!9!C3+6,%!`NA$&(KD,2&R&HU4 M?-PW:K71ZBJT)M&-QE$4HL>GX`QG(UE_(1LM!5CG(*&?N+$=K,OT.SN;Q8TIF43*# MDCHIV;3["D+[DPX-B/.6K7K1\Y1/Q@$,2N:F@(D4:%/@D()"-P6./9?A2S*N M&B_'-A%@N`ARNT@O2I]NVK808'@(/% MV&8##+=!R%V,*UMZ:H6>@VZ[M]'T!:KQZBXO\B,^D%^8':J6>QLJY)"FYK,]I8+(*L*9 M_&Y*.3S?%C79B^XTE>=,CY-Z(>CQ.AW?1O3B/U!+`P04````"``GAVU'&MO6 MD%8#``"E#P``&0```'AL+W=O2I$ MO&N-LM1%SPO<+$[RR6+6[CT5BYD\5VF2BZ?"*<]9%A?_EB*5E_D$)M>-Y^1P MK)H-=S%S;W:[)!-YFG2;X%RE?F\7/W7SB M-3&(5&RKQD5!L#-7WJ_?O;;IU^"]Q*58R_9/LJF,= MK3=Q=F(?G]/J65Y^B#X'OW&XE6G9?CK;?N\=-\$O#P-NR^#W!CXQ<+OS`IY<*CA1>.D]NS4Y2K;9?N#=+MO"S;%F?O6.-(PRPZ#/8:9,&L5`S>$6T=@#`/U M,):H47`3Q4K'^,8P5`Q&QG0V.H;=#Y:1FK'6`>L#">X[X,0!;QWPWD&H1YEW MF728L,7X/+`(TR;W'$Y!1WIM!T'`P5+S`-!%YI(,@8:#H0J&0'-A(1N@ZH1P=$FH]""R.8Z1SVHKWW`+=2'5'VHJ0]L M;@I4?3A:?4C5A[[%44.U-W(>&=OTIDCE%#I3(56:03!2'=OHKG:T\ MYU47WFWW-F$^8C/#D/TE/*S`L+^N)])NYOEPOYB=XH/X%1>')"^=%UG5DU,[ M-.VEK$0=MO>MSOE8S\RW12KV5?,:-L7HILAN4:+_U!+`P04```` M"``GAVU'MGT!*\8#``!P$P``&0```'AL+W=O2"'*=_7RZ*(ZDB M;%X,R&=WCQ:=@T:+*Z]?FA-CPGDKBZIYF)V$.,]=M]F=6)DU]_S,JO:?`Z_+ M3+2/]=%MSC7+]GU06;C@>9%;9GDU6R[ZL:=ZN>`74>05>ZJ=YE*66?UWQ0I^ M?9B1V?O`S_QX$MV`NURXM[A]7K*JR7GEU.SP,'LD\Q22#M(C?N7LVBCW3D?^ MF?.7[N'[_F'F=1Q8P7:B2Y&UEU>V9D7196HK_Y%)/VIV@>K]>_:TGVY+_SEK MV)H7O_.].+5LO9FS9X?L4HB?_/J-R3F$7<(=+YK^U]E=&L'+]Y"94V9OPS6O M^NMU^"<,9)@]`&0`W`)N=>P!O@SP/P(^KQ#(@`!;(90!(;9")`,B(\`=FM6W M>I.);+FH^=5ISEFW`,F\A===DC:ST_:WZ1_[-SB,OBX#$B[@L5J"$@ZW`6D5$U,IA,LEV.DFJ)0FG9^(;_?3[>%_V M,YI.$!@)@CY!(!,8W:Z&=@V8>.AV%`>A#;5!H5(=%?C)-.70H!QJE*F5\H`) MA[YZ2F-4QAA0JH,2Q&J+#+Z1QC>Q\HV4*M0GOI4O!I2.@D;YQ@;?6.4+GI5* MK%2)/4ILH&VLO&L:)<$T%6I0H0H5:IWOBBI,0FMSUU3A<4?L;V"CYKD#TW?D MC+1BWO1\$F,^B=9:Q%HBGFF@WE<53_[S8(+0O`0-4TT(V#6/0J4ZRJ@F2B]\ZL0T"DVJ8A"+HFKY,?(3H)6A"]2A4.HX:)VU^"TB`4+X$R=Z` M]45L-1#Q42O=M'D23HI_0U1WO@M#L+/14(0"@HUIXD1W<E:_HA MH1CIJBX5!R,?/Q0JU5!10A&?:V*:'DDPTDW4%9-`8">-0:4&BB+V56#Z+'@( M`4O04,@NEVE(.@(9YVH:.A"$;D$UX8@0:^NV&BKV8X2-@&G5`-/"!=5A?=_: MWJT&`A\A6S!]&'0?QJ0P71&"K\H63"N#$"%;T'>:=@%@0*D&BC"OT'0[B!"2 M!76K:=\?3$-2#8+XU()IJQ!CE*KN14<$$D\KU9YEG*OIWT`Q2E4]=TP:](N> M89HR)`B1)NK&.1QQC.23GKC*Z4#)ZF-_D-,X.WZIQ""IV^CML.@1NM,%8WQ% MYFMB&=^0^78X"OI(OUR6[6\/ M!3N([C9N[^OA0&AX$/S\?KYU.V1;_@-02P,$%`````@`)X=M1S:Z=7*H`0`` MV`,``!D```!X;"]W;W)K&ULC5/;;ILP&'X5RP\0 M@T.V*B)(3:MINYA4]6*[=N`'K/I`;1.ZMY\/A(8HTG:#_?]\)Y_*29LWVP,X M]"&%L@?<.S?L";%U#Y+9C1Y`^3^M-I(Y7YJ.V,$`:R))"D*S[`N1C"MCI@'-\:;SRKG>A0:J2++R&2U"6:X4,M`?\F.^/ M14!$P"\.D[V:HY#]I/5;*'XT!YR%"""@=D&!^>$,3R!$$/+&[[/FIV4@7L\O MZM_B:GWZ$[/PI,5OWKC>A\TP:J!EHW"O>OH.\Q)V0;#6PL8OJD?KM+Q0,)+L M(XUJ>JX+2DIR#T`IS3!@:,?F"(%[]K@5=6QSI%9T^T'\+;&\R;J-`,6?99";OXC9G'C4JQE0N[?'272[Q(XU' M]PFORH%U\).9CBN+3MKY"Q#/OM7:@0^1;788]?Z9+86`UH7I5S\WZ>:EPNGA M\HZ6QUS]!5!+`P04````"``GAVU'$8#\"R4O```J[P``%````'AL+W-H87)E M9%-T&UL[7W;BS]RLJM.-C,J*)0>-&<"1/!(:7$64.20\Y MKERO."+UU_%WNNO MDM=GX2Q=N4$B)L%)EVS$9<`S>&$@CD2\="(W_NIE\OJKESB&QYV(=V&0 M+&,8,W?GQ6_OW'5']+N6Z'7M8?'+Z_"Q(^Q^]9<:'A.(OUYY@2LN$W<5_[_B M``GS>_?!BY/(@9'7SLHM/O7.G7N)*TZ=8.9&XLQS'H(P3KQ9;,%"LT[-I*<` M2.3X\,C<_23^Y&Z*SYVF483`7GCQ#)[[OZX3(4+$F9.40#@ZLGM'?;MFJ0O/ M!\!.8=Q#&)76N5LY/G[_WEV'4>(%#^(T7*V=H/3@?>3,\>N[S6H:^B4LG%W> MUVTU7*T`TW=)./MHB3LZ$[ MI>D6CA^7IM%KW+J1%\YK,:NH[5]^][M&DI*G)&>[@(]+9/WG?MMH.N/*L:[,W'PXE"\$%X@ M[I=A&@.*2[.=N3/8E$U<,JBC.R>.W21^5?K:B9,O3G;A3_].._ M$^4!$99."6A_X49X3C&+R!?=3K=K(Z;$H^.G[I?"[EK=+OTG=:9PTF0)G/2# M.X=O3\96?S@DN/O'??I=/N;%,9X/<5,F<8&D$&<@W$#O38'\E#ZE!T$\R$^E MB+"0%];N+/&`"3;BP`>3P9NS_B0`<3+0(F+F(ZW2W.O\IL0+V[)[-LW_HF>- MC^W/@N&PZO@`FEH$]CM#`4?O(\@E#.(*UO%H9/6Z(UK=/K$&O6.KW[=_"026 MF01X$@`#`D49>`2B>^:L/2#8LJAQG3B--KS/"@9-5RESF12=H,DC=PFL"0L# M>\W#G+XT@7;RO$/ MM]9V)?;29"$.8-P\]'TGB@5H"$D9)>+*9LC;,!--0:UKYMAQVZ?#>ANI!-*5 MP9/\)8@N4,/?%C?:PCH[(R<_O,1;-8_G$`F&JI]ML!QK".GN'GZ\.[\& M(KJY$#>WY^\G]Y?P@)AY.+BZN;LS24R=GT%G M5@O=];=V8THVV#7HM-CQJ[143-HN`G,D2"N,C`AX'&1ON/!*^OL&#M$A`[]. M6Y^Y("UF'A,1J?<5:M,?^`,YJBQ!MC.3[ER0OL&#)4"GNNCYT`+SE1>05G*[#(%`C4#G&0AQ:&/,H<$%_Q@ZPF-L9S>V>)0=AAP`3CU'@)I\,TV:',' ML2^)=OY=&K,55R%,MEWB7.I"A20M_8H/OG%B;\:$[_EI8JC1UJ%_@4TL<83S M",3[X(II::YV+;"5O#N=W'TM+JYN_K*]@XA.GECXX5,L%E&X,EC001NFVMF8 M9+A'6@))$H+Q#(05E*@.OL8/9[A,BK0$P%2MT22@RJ&?@"?T)".7-K5TP)XG M&%2&[R7W2?FV5R]/@2UP_9V]%G'O@+,=M.+]-0?(ZTN36GFV%E$'#$=`_ M=_FW0X*JP?,L;:$*G+8M++P`O+^6+>!*CG(3#S`,L"$:.A1PH%6.:[.7>H]? M!&'BBFRJBGC`S'7G$DI4M%)H&88,$2U8)0@7?!6S8'O1&S?"3Q-FFP!"/VQS M?#6F06NCU)Z+Z:82Y!%_VBA0!*0E'GA64[)P4-0YH!M.?J6?NPE/U*C<'$$:WYRF??Q`&1PQ2$?F;,E`AL$,4R[A)T=_3J9H"LZ2 M8B2^)N!RC6QN=\1G[$.\.S^[O#^OC=Y;XN"G'_\#@]L__?B?EL#?:0#\)8#0 MD.[A,QDQAP\/Q9,3$_U%ZS`BO@=6.P,1\.20+9@%!^R3DW$'=#!LQS2?8*R? MSEV:VE$*"#;2#BCR$`;Z-TEX"D:2^KP$(VWCR<4M(++@CS0FT/$O#U9[`MO/ M!^P]86`@3J>Q-_<;%>5W[Q=C7]VA)OTNAA M'D8+2[P%`0UP%+Z_<_P?IO",!4XUT(#GZ.^OG*FX"\$B@L.5>U5;!1CE0_CI M(;B&D0][""U@D(F>(`9'ZP<1=D*`Z=\\T![.T5LX&@MI@!0Z_(^N'4P"^ M!MX.K"$FL$%?1G00K62A24-9B4&)9\(1DB'9>&RDHC@)495*--K=KK"'.K(G MX?7`,!$K4'>8$DC&A1P^^R0":#\'9!&J.W M!;"G"U@XC4B@P5XQ5.TF4K8#-ZV\=*77@XF\F:M#H+`#-'QBDJIS-W%GS.!P MSA_)JROF4SQGZ`".WB%24G;ZZO"\8([,LR&I0L*#GF;45+IM"RV�FTD(*-%7J,.A[C3-6Q M3F0&);/F`@Q*%^UK`#T-G!03H\Q@2W!SP*IP`Z0XL(18+B*(T9P4%)V9DPEH MX#0`;(VT)P,&/FY[AE#,U<8_!+0`J1`BNPE(!4`%">VWD\DMBK4.J`,ILYKW M#5K`P/+1_P(/&5$9 M.$A+2M60!>6M]/HX#NQEO0T/P)9KH:,LI9IZ&K8X=2E6,2,\2B`7G,!$2Q') M!5: M#WE;[*ALBTDQ8)BW=*)'2D5,'9]]4E(SF?EA$BM0S@H`E&0],ZUVLG>887![ M27&_51NS##D)J\3P)^QR)KD;PPA(78H]IXRL M@A0U$,EF1T;LY,4;>5L0+5G0!ZT@:=AXT2Q=85`-\;-R-E*\X5,1&$!XB@5H M01V33&4IB$/F'@`?, MA!B=5L_-='-F;.'7:YI7^59L>W7`YZ(9]*(>%6B$0#`_P`:?ED``J,O(,)+4 MMP!B"Y^(GH$#`'"'!,C*35Z)`YO"F2#(*(+J4HAYYLK30Z5/I@X=OOL)W8,O MQ4'O$/;OP_/LC9%"4QM#"@EG%,>=PZ/]0\:#-I/`$"V,P2TLO$\L7-$+63;YV32&LZ&$Z<1+9`"1;&>JMHAC9DRD(ZD99J#/PY6TG/%T6$:I MJ>3L=-+ZA#)^AG/JH"@$*R!&)4D"@^LC*)UD58H8M2;0TD/DNHKC:`3Q$[KD M?,PYV$FPT+;T+M)U&.36`)_]HY(?'A;9$07'2U6"$[NPY`.;[]DS.,IYD*8C MJ")OL5$/G"H$*6WG17(0$BHJ';:5U][L8[HNGTT$IA393KP]G,-;J?@?Z'R. MU.'RRE_2(#)W&3M!DE#9+$T.&>-KA$J>?/20WU M^^*=,UN"!Q<5"I9$'S2/O.M"_XE;F](>T\3S%D9 MTPS%-1N)6*^9N`&906R.K,%PY4/*!B!F00=&>")`IRI3Q8$.8E\*#``AY-31 M"B.:;F:=RJ(&E#ZLO.HJK&2\%;F8AU1EW.4`V5X@D*CIB^LI$C.6TXX MK&VI3]6Q/SJL"B7=Y?UH62-FF38YO'W_?YS5 M^LLSBL=H@TYS+,^'DBH*TX>EF*8Q1LAQRZLI:G+2IY$K#3D6:>B+R)P^"$`X M(3Y&"I(2Q6DPC)K%*DA_+4#L M>BR%I;DD%7J!%%C21=H2DEX%G??PIH^M:B=32>S"Q$JJ)Z@!TMC%*7UOH=5:<4.6X7"HN3)IP>Y2%CXB(0T" M'N9(/&+F3'61=,G2,8J5R&EC'TZIO3D3,47\'V3.,`Z&` MKQ"C(1"D"+^%N%YA_GL1@22!9]!E6YACI)<9@KPA>\'BS$<4)S*TA$<(C@N0 M$/NBR'_X-&Q`8P>U*ZE(CZP#6M'W/KKD?(-5@@2J^8DL%"+D7\R*Z/=X4EMQ*?7&XEC"5]C_ZC0@0>!L]$%GGDEAB] M?7OD[N2VI8$!0J,`ZUQO<3=@`_.4R53(FYZYC*BTJ4%8)LQ@TG$1=+%`H!N% MI(1&%`A+4$N/G.*(9)B0;/N\1:]")1FR"S!RC$4B`HUY/)DIFU>8CJ<"9L.7 M*?AF+F)"6XQZ$%N<:&M1;(8D%&RK%1L\>099&J!/(V6AP<1MF%=@2E&BY<0, M$W[Z"YSF*<*X!)9W/07(3=GQ,M.7"4D/75$%(@LEUR/.^SX-$5*.*[/='JOD MB(J'ZA(PU@,8C":).'V8I`"RBA-R3=#A#]F->52-:#5@I1O7SP6NQFB8$\L45N0;J M+SIGU.:HZ,'VYM*)&9_CU^$3BB9+L7(9:O+BGB@Y1HOP!LR)LY.LEN3M6Z%` M`$MN&I'3&`7C"+F758HW\US`7!>R#3Y(*]+<"F1NIJ4!JBQI@[%5P,I?LTO"U8. M5=)EOGL5A^8!R$0[1D6*"U-<6IHX5+`%\EW=Z\`#1=1*^S5O&U4`ZJ/I+PXR M10A^)BL;$!1`!OS]U,7ZB%R62SYW6`&-.#`"G8?2KDN>T/>4C[$9YY'Z(];C M"$R%H)1!3^*E)PKJ5O(:D&\ZJR):I[AAWDK9XE#!Y3J)/:/%5#FI$.S89%`2)E5RR^2^E(SAREZ,*8K\!-EO1& ME8557917P?_%@0VBPI)>MNF6A2635KEVQ:,KFT(5CR'?9T9-T7(Q+3@,SRW# M.67S<7(*WCK^)LY409RC*X7:V,2M7$ONI&0[J1(-F'/NKC'[$5""A)(#>,4$ M:Y+A<9PT/Q4B):NM(R,+D1N%3R#G4:2A1%0T534XY^"BJ:[-3V77T2F1P*DY M&%SBJ5@9.Y-%[S)HP.>2Q>>I0A%+KAQ_1K=?MA%&4G`0IQ`OP`3T4^N6DH=B M*0L74SV>+$H)3X8-&&WT4>9QDY"4(1_B)NS#`.S%/%F12V MJZ'D6`5-`,$1VQ.2/&!=FG:.0H5+7/J64>4REZ2`O]=4^V"&DPI1T;`H%B`Q M2BDTS-J5@R,9&J2_I$(K7"MBLL\1L0]8(<$#D@+BFY&9KCG-IN)AY2(%RF,1 M01"GY,W*-7B:4L(\>NZ3\G0T8"J8D3?02'MNLR8RVY:KVN``%#$'H#KR M-[D"$/HL%P/4]:ULX\D#,[/+X`)%7/Y#%G8@ODD!/MPI;^UB7%S?*9X[P3IZ?>Q;U1@GW MTB+`*QP;#NBJ`>PDQ<5%?!#[1QYLAKS+(ZQR.L"%#W==62^99:CT&*V`=#"L M#2R&I@#7A8++U`*%Q&KHLH/&-C],CQI5]P(`\(AQ'"U@B65GK`YEFJ`Q44_\ M=>%.HQ3)J(7'NKUBW:ODL[&-?#;)L">#POF')](2,/0WI6;F,EC/R13P/Z,' MRE$Y2+PZTIN;Z@$O`J)ABQ3'%C#Q)EI32M1BXE\5I8.%B0DYY`KYJ;*_D'>X MCE6*0^0U+HZ0U;:Z5"TN$8ED0T20H=;RH+J90D!@,[45&B6]R,CN,-E6L M2B-J?^=L#,U?0>B#H^X)%1"_5]EM#`.@>@5.^YK,FF35;8KV4 M%`&1J^J]\';?P@S_J!@MVX`,(!D"P-4R+Z;RWM(+("0T3AZ[`"RCS3K%T??V#BT/"V)7`,+\R-(P? M92_5$_LZG8(/F`D,?>D"Z)VKI2F.4";X:E+G^_3`.6C:-<]5,SC_NL^Q`]3(^;:Y&1Z`1*APW*12`R4/_H MA6E,5?]14V4_TH;+26TNP*:J$:5R5[AF%D*LO)-`Q[UBX'0,U$%V!2B.Z)/8 M4^D;LOJ5D4%U%VHRH.T$JT]4@9G9GV'M;*(0"W6S*C*^F\/[A7GU+#H+CLM[ MC^CL@%\PXQW11A[4K6J^-4;^)-Y;7J4KNA2&11>=H1B='%N]_@!^']'?)\.A M-3X>"D#Y:'QL#;M=T;=[]!,K__OP6\\ZQK]@P!MPRE.9IVD_`FZT@UA;`UB? MR`X&;AG;'9O]'7FQ4TP*H2&Z)_5"V$+>N\WUS1%V3U3WRH&9Q7W6VT:\3'33 M&V%;O4$75CVZ;:MP`#STNEG`M&<-AGTQM@;=8W%EMHU`#PPU3O'Z):4R2SUG M`)$]F/:]<-@>@B>V).8>B$%.V#2@]DA%I7#AS%Q&17: MS;E6[RY<)'_B(*?RY*XZP>BY58B.E`OTJ3#Z0%_<.!3OG2=M=<8H-JP3D&_XL]<[$7_!^S), MGJ`!``.]WA#+URZPI0,6!+TE*Z1G=8$'>Y8-S/X"9(`]LN%GWQK86(:F)31% MI23<["R'4[S[D^3"!SNUW2DIX9QP.Z^[+JV>LL2M[\B@C'[X>4IYT!'5:^]^ M)E?40@FDV!#_!71GI8.V?=+#LSFQ:TL(AX.1&,+9M541GL#*HV%62#C`NL)^ M536A;=OP7Y>D*3F#,LN@J6((`GYQB2Z_'`E(X1HA>34X`M0O72CSNZ-\&=]"[$S=RI3#E?JIODI MW30O=QZ8)I_#AD0%X/=ML?3N)/$U&.6D`68@D;X-_8\Q"->/ZLX\WJ$7_VH3 MV]JC$_HY'G>W&M43_9,3,0!*J'F:MN*#?L451D`D_6T>[8EA%TV*]B?[L%OX M[QAK6E&0.^*=K(^_V\1H#4J#"+@+[V:@C&`KV,;_G\$8/*VS?R..`^:[E?$. M^L5#KX]H*L*4@Q@/;'$"-A"2W?%@2%+J^%F7MCFKOM>:M8A";,?()H='H M7Z!-94`7V9;5*9QB,-XLIOL)N'Y!!C^@'/T>&BO2W7-W)-_W)NU1G"OX6 M?GF>1B%8G6-P%KK27!W#D?`UU.&H:XWAQ-&6M#M``9WC8S'N=+N,!P`)5[:: M[LP6<%&/A-[.2'C`/JQTI7;E?"(+?!I&$=]9D%VGN+"$]CB0>QH,QM;HI+`7 MS5F[G"M-6T15OS,`&K6.QVCA`Y/U#%3M.'49XA'H5;)P>P/KI#?&J:^QKEI" M/G[>])UC[),[/NERU`?M%ICL).\<%F98EWDF-DZS8#QC.>Q4,B!?L0.?[X`V5KLCG:@*0P2RH#AZ-BN.#OAMH^'(Z@U1B_!GH)).RFX] MJ[);\CI4N\OFI^[-RUC/4B2CCJA>&(LHMV]*:"(\?'+Y-@C5)YU>W/"]^"6F MN!R=XN5Z'HH311Y:\6K="E2.I0[FWI5-O=V:^[Y=Z^"MZ@`'>Y9][1!&]F3/ MC&M@S\+I<2?7J%B5OEZZ81#:?8)6)%.@HJ@BW9Z?\"\)5E!4_]8L@,^-NI6GFJA+2$!\1>Z M&%;5A:?0PO"7/^@F\'8WNV072.Y=*(,359_=X$5!I"6CCCO?;IQ]8G5[/?6#.^T5STHUN54-;B<[=F`UV7/IS$TX MLOX]R$BGBRVP(2CST"KWO#M!##UAZU!L*HXG1+6;. M\0$0UGWR\_17[T&>OQ+84+<[&/`$WX:T@_=D`+P"\0GB\4SA2/YM3DZY`G#] M`/.:CI\!.L9,)7E5@E[\)H-\T.7A+8"#%\N6$%--UZ[;!=V'.BT3,C>7@YTX MG/'9ECHY^/$"O/,Q&)%@BO>ZU@CL2LVY.V.KWR'56X^M41VNX'S[S\!5[]?& ME0VV=[G__ MC[__.07C#JN&_O'W4[K[0`EM6:'5_9]!.ZC^43*^'&!C88VL`Q%Z% M\'&7D%2!\=[Q\!DXYQ4+.#]'HXO0P7=1=7[5Z.BD,@"LUHOTO_D?H_XA6-%;B>J?YG(NAG]\X&O,6/7#.4(G7_"8K+8!;66@(6"#4A5)A]1 MHTTCQB-C^@K+.P_P517Q8O'P MM_Z_`J;XZ9H25^9GA54K<%>S;%O3_].&IO_-#W].;+!Y8C/=E.7%?6JEA0F[ M1Q6B7/^N!966-&+*B57`PUB%.1):,B[A6=X@Q:8+%6>AK&/$&0*XJ MME2Q(.YBIW.)*C-*#A.6ULE>F+)U!5";!%EMPHM+ON/0&HSZI?M1,>:U-B$_5VY`9EEA0IZ/PT[H$G,+.*SP52G*&?PY M=;G3AN_G;L-Q_E$&//K2;<37/V!/`*IF08;BUG-RQHV:3U7\UD\8>Y]X2CE= MAYN,4X,T?C='OH>7!)U:,.;6]&2M*D>%."8$XOA8C"B=:X/]T>43EDPU0BUX MC&EKE#L#JW\RP`PN?-ZSAG!8%"&5?#^F%U8,[<+=GCA4!W9Y+[X&VY=Z(I*C M&BX2^@/A[A^=@23![*FL@M%%IEJ$*=KBXUH;?2]168\&0S34RW;_U)TY*[ZH MO0`A[,@[34`S3W&*5U2(L.EVU)F\-WNO+[6[NOL@6.5GQC5]U2\CD4&G:_=) M?(,%&-R)8DKWXU5O&NJE01=S],=4V$:)V$=LQ:#O-&`VF?P+ARJ,W0=WCET9 M9<<4&0+NK`#F2,;8&#*=V9(\WPE4!AYP-^.O.*.;2`HCCSW8HRC M2_^'8D&@T3U)XG+7'8T=3)VZ+G7XF#LK!\O>*;<)&GS$80,VJHH,)\M"R)4& M6*\ZWW2PR2-*=-G[9!+'(69\D+MI>0??+H)%2`\`;)PO\P%47&()<.@1IUWA M)3UZI1DX'"F5*D7X=U0H(#4Z9[D\._,$\AH6H6(SN42VKXMU%RW9C%"G*64: M6L$[-^[/X92E).2=O.=EO(6L[I'LG5S/:XW:!:R65\OA@$4?5TV3R"O>,S.N M-R8%>6SN ML/(<]*U*6FRKV58WO8/[V]@ M%IR^`DNR;P"EBBKLI[)*QFR0C,*+`UCC)[X''+7VJ^V1:/[Q71`@9[8]*]_9Y- M^+/M`>&S?XS(ZY^0ZX@?=,?X`":W!J+\/HJ#X;`'_]IC^+QVDN:WUJ&V\3V79[7ON:R5T]6C?Q-]<,NN MM;R-9EP:^SST[C+COBOOOBLOXV_?E7??E7??E;>Q*V_I3F(V14BUN-04!S=& M-YNN2"+(\/JE;MMPP1XB8>QO9>^,%WD M%<547'A_C^2@+N_OSKG/76G?)7G?)7G?)7D[?JODF7U/Y7U/Y7U/Y7U/Y7U/ MY7U/Y=J>R@TV(E6_R,(]C);-*9.&P%\&HBW89G';*.IW)'\7U]1""A]\MC7Y M*\"T[S+M[+M,[[M,5V9"9FZAG"X*`_B=>^9M&=5IFV7?VWK?VWK?VWK?VWK? MVWK?VWK?VWJY[VV][VW]S]K;^K,N8-Q3Y]G2]0M]O89[<$YR33,_L%>,5]'_ M*8N7FIM_U^[Y#@LV4J[P>Y\E[BYEU"?+3ND?"#'@+)G MRJ]BFXB#6.JLK"PQ9\3#BB$EU;29"^$P_,V>'A?)R>X*G)=1#J:ZS*"E#6<* MR!,D@0V4&+B%PG"^I6=5"!9LU;,3K%8.4-.5#W(>::Z^!O<7$WFKI#FY?;IT ME*9X'@& M+8"U_,_7A7F[-LFMHKJR7_(O@]]U-8-\-JI_B\V5G]$=N984S,XL=#%+\3L& M`J<`%D8HMB>)7(^.;:;F'KFQI"6E8#Z;+/8-EG_9!LN[M)&L%^_XJ&S=]`<% MSL&9"[SH)8<-=W<-:U42W!_B8B.K+E#"@D[.)OXIULSEJWG<^86;Z.IVYF M4(.54^LH6-W`8?4X'2U[UCY;1K?LI27`MP,K-[;!`&ZB?P13`:Y,Y%R&" M3#%4RZ'F%WB&+9[2'>]UI&7(H/9UMY,LM=+(*QB3`HLA*PBLW6_5U!8:6EAM MYG`716G=7=+;C6(CGU:F630N?]^2S@,TG>MZK5N52F-;9<*7+XHXPR:-!R\P M%NMAOQ:I(TLXS.>-2D=;D3UJ#.6[-4'YUS59I7*2I36]M,V+C:VJY*9CW`)K M2V]:\L%2Y+J6SJI[@5,^KU6.G!LIKE\)$\:'91FW2VJME-0F"SK^6)5KYML"D MV"Y$O[878ZHE%5%CGK31%*CNB10ZM_)=Y7?T.O.<@B\92^JJP4YT4#1"T&S8 MD>3-_#KHN[MRFB-+SAK//D/I9;7<309!+B=>BFD44N+%[_.I\5H`+/1+MLV- M[[I-S#37.1LMYG>M&F^V&NL,[UK3N'9D73:ZM,?&I/2._M#V9[&#JBK.6/6B MX6?EQW9;_5-F8*]7^U0>O1R[%Q/]>MK<>VX; MCF^*CZ)\8[FCO$3**U@<=9L;QE`)Q_@JVI+Q\RS80$_CNV*1DF^")HJ;8OA, M@8QW!%6;EY\;C/NGL!8,:5+DWT)<3]_5`L_2`8TW^K7.I\X:ODV*I7HM"P+4 M6A:XL*5,%IQFXBL&(22K'SSC)=^[0WVI7K>-W0+HM\-*E?4KP+Q%4&A<%=7X ME4!K"T!VCH]_&=!Z.YWTE\5N'ZYIWR.\6ZFOR:FK?>]_HUYRE+N+/'$RU3=7'EWMI^\X6<94E MFX4OJX_GU'?B.#OJIJWP$Y*/Y!OEN>C#TB\YQ]?%T1-Q+4%PL(TS"G\SPJN[ M+$>A(W.UY\`JO\6+BH8XR=8E6 MD65J![3OO`+V"I`;ZH[KJRVWR(L>YU^@YFT`7RKRMRA)B[`143C966>7/W1L7 M`%?%7UM6L,J5>*TCBH5T]0,43O+E>L7G90UQ`S+D/(]FG5[9E`AV`YWD1$2ELO[9C,J(M:U0!YSGQZAU%5`6$5..5@19>* M)W]^4MR2V7(ZN5[9E5#AEVH]UV[$@]NVHO`-=AJU.IEMR`AD&[/,J+^GK/&_ MVD/[2UUY*XS"VWQM>"O@6BRH&Z?<@;8ZFPAS4RSL7W[WNZK)\=)".TR]YEE+ M7ZMJCIJO&Q;=-"RY:5BQF=CT;YBLNY%]E*2"Q_P?H!,/$(L;,9E`YONY?!,V M9:ML;;CE=_Z"L1ZU_0!>G-CVRKDKI M&@]P;K0.F&+AKB[.)='>OIFV\75[;!M7O_7VD=48:1W7B*BLD#FK6I:F9@N* M&D;6(*=A1"U:&L=4(J1IQ&XTDY5VFW7<6,LH*[:M^G+SUR/9CF8H7YXN[!%( MQDTM?^4R_JJB>TN0JE+Z-86*E*?L6#-S%QP_AGSTOOHU-L?@SD]KU]] MMKNO/&JT@;])@]:<4.Z9VZOKW0`^TR]R:W2?;G1+Q2MZV3P66>&[3^NRN51, MHM;9@.TE7V1^2_TD*@W@+&1T12VHLLJ-W8"QL+D:O\,>/ZXH9;C#7KDT=.J@ M)96%4"P^#="W/%19*^4IU!*U):(M,*HX7PV(-(CH3]7CG%68]#>S)+,@[%'I MZPBKUT,C\5T#[#>IGQDJ]KA$04NP+1]"X3M3;.V%V=I%^Y1!$VB7]^)K)YH_ M.;*@XBY<)/1'W7RJ(K_67>5*_=K,0R&^*_XFML9.1:7/UF,K+Z'L&O%KO)'2 MR+;5)9V-MRM*)U6\2E&.1_(]A>+G^1L5NR"HMD0Z0UUCX2,8IB#?`QGF,D3$`UGQZ,7/G.# M4+WKLWJI^^5OYIWUV=9?QG'R^K\!4$L!`A0#%`````@`)X=M1S>YP&C/`0`` M7!L``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$" M%`,4````"``GAVU'2'4%[L4````K`@``"P``````````````@`$``@``7W)E M;',O+G)E;'-02P$"%`,4````"``GAVU'NYA#.K&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4```` M"``GAVU']\?SC=8"``"F"P``$```````````````@`'=!```9&]C4')O<',O M87!P+GAM;%!+`0(4`Q0````(`">';4<2?5\6/@$``&D#```1```````````` M``"``>$'``!D;V-0';4>97)PC M$`8``)PG```3``````````````"``4X)``!X;"]T:&5M92]T:&5M93$N>&UL M4$L!`A0#%`````@`)X=M1VWC?L=_`@``O`P```T``````````````(`!CP\` M`'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`)X=M M1\QF_!!+`@``\@<``!@``````````````(`!3A8``'AL+W=O';4>WR:MBR@,``.H1```8```````` M``````"``<\8``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`)X=M1X64IN6S!```^A<``!@` M`````````````(`!0!\``'AL+W=O';4?MC*XKS@,``-P1```8``````````````"``2DD``!X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`)X=M1]CG]$F=`0``L0,``!@``````````````(`!&2H` M`'AL+W=O';4>B&'NH MH`$``+$#```8``````````````"``>PK``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`)X=M M1PJ*GNN?`0``L0,``!D``````````````(`!F2\``'AL+W=O&PO=V]R:W-H965T';4>HNL'MH`$``+$#```9``````````````"``48S``!X;"]W;W)K M&UL4$L!`A0#%`````@`)X=M1Q4Z;E^@`0``L0,` M`!D``````````````(`!'34``'AL+W=O&PO=V]R:W-H965T';4<*E+:= MH@$``+`#```9``````````````"``&UL4$L!`A0#%`````@`)X=M1[T5`1VA`0``L0,``!D````````````` M`(`!HSH``'AL+W=O&PO=V]R:W-H965T M';4=Z2?[1HP$``+$#```9```` M``````````"``=$^``!X;"]W;W)K&UL4$L!`A0# M%`````@`)X=M1^SQF1ZB`0``L0,``!D``````````````(`!JT```'AL+W=O M&PO=V]R:W-H965T';4?1)M'BH@$``+$#```9``````````````"``5Y$ M``!X;"]W;W)K&UL4$L!`A0#%`````@`)X=M1U_0 M#1NB`0``L0,``!D``````````````(`!-T8``'AL+W=O&PO=V]R:W-H965T';4?->)!EHP$``+$#```9``````````````"``05*``!X;"]W;W)K&UL4$L!`A0#%`````@`)X=M1XEE#ZME`@``;`H``!D` M`````````````(`!WTL``'AL+W=O&PO M=V]R:W-H965T';4?L"DK45P(` M`%H(```9``````````````"``9!0``!X;"]W;W)K&UL4$L!`A0#%`````@`)X=M1_K^L<*C`@``U0H``!D``````````````(`! M'E,``'AL+W=O`!``!/!0``&0``````````````@`'X50``>&PO=V]R:W-H965T';4=$V'>[1P(```4(```9```````` M``````"``0]8``!X;"]W;W)K&UL4$L!`A0#%``` M``@`)X=M1Z/$^=G,`0``1@0``!D``````````````(`!C5H``'AL+W=O&PO=V]R:W-H965T';4=):BR/WP0``!4<```9``````````````"``5)?``!X M;"]W;W)K&UL4$L!`A0#%`````@`)X=M1^>JB$"; M`0``K@,``!D``````````````(`!:&0``'AL+W=O&PO=V]R:W-H965T' M;4<;C4ODJ@(``&T,```9``````````````"``<]H``!X;"]W;W)K&UL4$L!`A0#%`````@`)X=M1^F0,]HC`@``O@<``!D````` M`````````(`!L&L``'AL+W=O&PO=V]R M:W-H965T';4>I,MA4@@(``-\* M```9``````````````"``5%R``!X;"]W;W)K&UL M4$L!`A0#%`````@`)X=M1U4>M&B]`@``K@L``!D``````````````(`!"G4` M`'AL+W=O&PO=V]R:W-H965T';4>V?0$KQ@,``'`3```9```````````` M``"``8M[``!X;"]W;W)K&UL4$L!`A0#%`````@` M)X=M1S:Z=7*H`0``V`,``!D``````````````(`!B'\``'AL+W=O&PO#@``OK`````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-term Debts and Lines of Credit - Additional Information (Detail)
1 Months Ended 9 Months Ended

Feb. 23, 2015

USD ($)

shares

Sep. 30, 2015

USD ($)

Sep. 30, 2015

EUR (€)

Sep. 30, 2015

EUR (€)

Jan. 31, 2015

EUR (€)

Dec. 31, 2012

EUR (€)

Participation Rights Agreement In March 2009 [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 12.15% 12.15%

Participation Rights Agreement In March 2009 [Member] | Tranche One [Member]

Line of Credit Facility [Line Items]

Debt instrument face amount $ 1,700,000 € 1,500,000

Participation Rights Agreement In March 2009 [Member] | Tranche Two [Member]

Line of Credit Facility [Line Items]

Debt instrument face amount 841,298 € 750,000

Medite GmbH, Burgdorf [Member]

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity 2,000,000 € 1,800,000

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member]

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity 1,800,000 € 1,600,000

Line of Credit Facility, Increase (Decrease), Net $ 560,865 € 500,000

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] | Maximum [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 3.77% 3.77%

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit lines 2 Issued in July 2006 [Member]

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity $ 1,200,000 € 1,100,000

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank term loan 1 Issued in December 2006 [Member]

Line of Credit Facility [Line Items]

Debt instrument face amount $ 560,865 € 500,000

Debt Instrument, Interest Rate, Stated Percentage 3.40% 3.40%

Principal repayments $ 31,162 27,780

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank term loan 2 Issued in June 2006 [Member]

Line of Credit Facility [Line Items]

Debt instrument face amount $ 448,692 € 400,000

Debt Instrument, Interest Rate, Stated Percentage 3.60% 3.60%

Principal repayments $ 24,928 22,220

Medite GmbH, Burgdorf [Member] | Hannoversech Volksbank term loan 3 Issued in November 2008 [Member]

Line of Credit Facility [Line Items]

Debt instrument face amount $ 448,692 € 400,000

Debt Instrument, Interest Rate, Stated Percentage 4.70% 4.70%

Principal repayments $ 15,581 € 13,890

CytoGlobe, GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member]

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity $ 448,692 € 400,000

CytoGlobe, GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] | Maximum [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%

CytoGlobe, GmbH, Burgdorf [Member] | Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 3.77% 3.77%

Ventana Medical Systems, Inc [Member]

Line of Credit Facility [Line Items]

Notes Payable, Current $ 21,000

Repayments of Debt $ 38,281

Dividends Payable, Current 656,250

Agreed To Convert Of Preferred Stock For Common Stock $ 1,750,000

Number Of Stock To Be Converted From Preferred Stock | shares 12,000

Long-term Debt, Current Maturities, Total $ 38,281

Hannoversche Volksbank [Member]

Line of Credit Facility [Line Items]

Line of Credit Facility, Increase (Decrease), Net $ 1,019

X

- Definition
Agreed To Convert Of Preferred Stock For Common Stock
+ References
No definition available.
+ Details

Name: mdit_AgreedToConvertOfPreferredStockForCommonStock

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number Of Stock To Be Converted From Preferred Stock
+ References
No definition available.
+ Details

Name: mdit_NumberOfStockToBeConvertedFromPreferredStock

Namespace Prefix: mdit_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) of the credit facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the required periodic payment applied to principal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
No definition available.
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLine7Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mdit_TrancheAxis=mdit_TrancheOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mdit_TrancheAxis=mdit_TrancheTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mdit_MediteGmbhBurgdorfMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLines1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLines2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLine4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLine5Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksBankCreditLine6Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mdit_CytoglobeGmbhBurgdorfMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLines3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mdit_VentanaMedicalSystemsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mdit_HannoverscheVolksbankMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization and Summary of Significant Accounting Policies (Detail)
9 Months Ended

Sep. 30, 2015

Building [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 33 years

Machinery and Equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Machinery and Equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

Vehicles [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Computer Equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Computer Equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 5 years

Office furniture and equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 2 years

Office furniture and equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 10 years

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdit_OfficeFurnitureAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Segment Reporting Information [Line Items]

Assets $ 16,745 $ 16,745 $ 16,439

Property & equipment, net 2,016 2,016 2,091

Intangible assets 8,313 8,313 8,313

Revenues 7,081 $ 8,694

Net income (loss) 59 $ (119) (267) 50

United States [Member]

Segment Reporting Information [Line Items]

Assets 9,125 9,125 9,387

Property & equipment, net 87 87 98

Intangible assets 8,313 8,313 8,313

Revenues 928 1,321

Net income (loss) (552) (182)

Germany [Member]

Segment Reporting Information [Line Items]

Assets 7,416 7,416 6,989

Property & equipment, net 1,924 1,924 1,985

Intangible assets 0 0 0

Revenues 6,114 7,373

Net income (loss) 339 232

Poland [Member]

Segment Reporting Information [Line Items]

Assets 204 204 63

Property & equipment, net 5 5 8

Intangible assets $ 0 0 $ 0

Revenues 39 0

Net income (loss) $ (54) $ 0

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_DE

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_PL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants (Summary of Preferred Stock) (Parenthetical) (Detail)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Convertible preferred stock, cumulative dividend rate 10.00% 10.00%

Series C Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Convertible preferred stock, cumulative dividend rate 10.00% 10.00%

Series D Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Convertible preferred stock, cumulative dividend rate 10.00% 10.00%

Series E Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Convertible preferred stock, cumulative dividend rate 10.00% 10.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 19 0001144204-15-065395-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-065395-xbrl.zip M4$L#!!0````(`!&';4M@P\?/GH/GI_^^C:S.Z_(\RW7^=R5CZ1N!SF&:UK.]'/WQ^-5;]3M_/7+ M?_['I[_T>IVOR$&>'B"S\[SH7.B!_NCIQD\_>;XC'\E'XP[Y0^U]=U][BB3W M._\M:2=2_T21_J?S[[MO_]>Y?'CL]#J_?OTZ,O$;@N@-1X8[Z_1Z23EGNH_+ MP._YQ]G]34?N2Q#,3XZ/R2N-1>`:KH>3P>'T=75[?Z5M&-^*7R\3^^W3P8+VBF]RS'#W3'R&"Q&-CI M^RW?U11YR'HBOB-YP$1S#QFD>4N?&1_KGN&Y-CI^OSEYW'!#)_`66;)\9!Q- MW=?CY472'FI/DGNJO'HL]#RLN++GEE?)@UKV01-9Q<_@"P6WHS?CI?A^_'0Y'.7?->]Y-L]>O.QR([QBV+S<.XZ`7H+ M.@_("+#5B4P#+B(V#L;RHH5%?"?)3_@?HH5'5QH_J5+T=PQI]01R`BM8+']; M_6J9Y/>)A;Q.!!MEJIE0?G[]6_>+1/XW[&OJ^-,Q_7!2U#%55@;!''F6:](( M\-?L!=C(HB^)F"4Y><_[M>15J>J8J8?&/55Z+]Q6#/D1-DV'/]&G&D)9T_?$`ZKT26^P9M[EH^^H=DS\D*?9`%GH6\YR/=/ MC3]#R[?(BT_?+'_+/--^#TUQ98-5>FX\/7O]3TNPK6^,+3-.*!,^B,GYC8G`__:,804"NC8GAP:R?7D ME.%M,G+64BK"?VM"17NB(JV.BL@_6U"1&JOHU#"\$)EW^L)S;?L!!8&-"`L9 M)>DVZ==\>$$HN'$-/6%>2'!]"=9"4=(>2QCL)MV_KT'=P->P#,R$+6VM+:4# MM'>CV-H`[>F;Y5BS<):^]5YWIFB_M9*J0O)3IJ(-&[?6*[/5L6+AN("P;RU7 M4Y1TB\P2S+:25=H.?@&AMH+R3\ M[+>(BNH2Z8>/D)WXRLWVIO.+0A&B*"3D`XKB$7FS&U=WA)THHN,#"T+8B"(Z M/K`@5"&(`CH.6Q!W.-3%E9I'O5CWUO0E\#^<"DHY..RF_QT#U!V=9&.&;C\L M_`#-/E[C,U@XP.9_GW4BTLH]2BNW-.$&%(4(&5N45NY6%"*M;%U:V0Y!"!O1 MFK2R'8(0:65KTLJM"4*DE6U+*[?6]"*M;&-:N:7F5Y9CW5]GSR]GH36M6"FA7*'ZW.'P['@=%NHO^A`?$?XR]+?2+^.@?8/XB*"/**V, MP_Z(SA>!.[7=9SYG`@E##.*5,++I3X71C$*_C>E7!%/[(VX13[7\4V)$7^)3 M.LA/Z>-$54!K:Z)C:N\ZIK2#U&V]H02A7Z%?4+^',Y#0%W+?.[GWA;D6^A7Z M_1CF^BQ#W4#(?0_D7MAF']1<"_T*_7X@[F!=WCK+[<=)OH,!#$$7A MZL'5+JF''0ZRZWY@[2XIJ3Q">5)4T?YM:7\Z#E?JQ.%*3]G8_OE"+FV22]9< MI-M]B]T.N)U6+O,C-#ZCXB)A9PCF`;\+^1=W'IH@#X=6#X%K_$Q'F@\!!D!X M.;=UW[^=1#?LIWJ2@)-1I=4MY;0(.96?(ON$"?.C9KN=_'`L8VF+;R?G+Q:Q MS(=OAS@(V)V`VGM:KA!.JX2S_9&3P;L2;BC'\Q6Y4T^?OQ`^]K/5R9?QEL-5PY)Y1-W1O]V?7TP/465[IAV;C&Z9#E!ND^.O4\,CV5 M4/2XF.]Y)VUYC>(9OVQ6]DQ16PZ`PV>;L/NA!90E0>B%=8(78WG0TZUGZX[I M?@RCM-WCZ``%%S(OA,P2,FMI](<7,M\Z%B'D%@CY0VE5J*=A]5QO%M[N#UMW>P13BVSVTUA5A_0["^EU89M&Z!_7MKK(O+95]"?^[ MHX1*JY-0:9M/S;/B$.Y;B*.TWT98CIV(HV5=,27B$)9#B*/4K8C(4KB57+KQ MAT[ZPX/":?&7?X:XRN?N;.XZ^#_]`]%(<;62VS*$'&HRDO4:0@/MT$";?0K5 M!R4DTP[);'>W8FEN05+YN(A@<6=CRWCJF&20;TZH M.5OL_YI7KLHE-V?9$7:)N<6(\6(YR%ND.:VHJ@,]CWN[F^=4$CBCU83:-ZYV MQJX\AZ7VS>VP(]2^\WW0)A/+0%>AYUA!&&T54?>#."S-[]C"QUL$06TC9%][ MUS0A^S::>B'[M67_.WJQ#!OY'T;&E6*(+#M"2*P-G-W9/`R0)]+!M@<+R60XHIGWLQY7-K.VF)F>3MG4F^.SV(N7EMG)NW.SV( MR51MG$RU.SV(Z0IMG*ZPRRT61%S9WKBR9>E)Z%BQEOP7W4-T^\^0[H<>^K*$ M%]V2O"ZYEBZ"O*WD_3\>+DI>;OFNILC#$WQ'_7<_X0H_/1"`5"FF]8HE1[<" M>?1[.$/1*5^TWKBAI0FGWUA0X`5RW)GEL(N$J*;+S+\TN9JJ.0>'ES_N@?;! M=]1LG[N;[\"[\1TUWST/I9+
Y&\*YT_"+S2>Y^D:7>WS\=TV]*:D5^/\4_FN3" ME:U/*Q>A=+],=-M'<1F9=Z4+20J_BPS$96P\*A>F=C.6J/3%125?6;ZAV_]$ MNG>%?_$KEZW%96=+I5Y:7FX,KU[)_>Z7OZM%Y:9>FB[Y,O(+]VAJ^0'9J^.[ M/JM.]:#[A9QABAOI7'<,[/PN+'WJN'Y@&?Y_=:X=XRA&5%18'LPYQNSI]K5C MHK??T*(RFF'6IY>^.%WR>8B];;J)ZJINU/W22V(IUHOSU;ZR;.2=XTM3UZM> MZ7'WR\-,M_$K.O=H[GJ!Y4P[I*-3=Q9I#C*EI$$\>CJ9Z?BPF#V[=G7C(6$) M7%P_QD5EWE70P.YLYCI1:!.Y0_\V#$B\29[)EAPE$_*3K!:4*'<[Q"Y&-RXC M@XZ)#`NSX'_N7G^_(M_@<#!0I$%&!(S"$ZBKCF+=?SEU3/(OTE?\JMN(['$3 MG.N>M\#W_Z[;(D.0WS.V+&25#5E1 MI?4AGQK1EH3^/3(0?N391M]1L/QN^,G5V$AE55(R4%FEKH>PC,L^@'`\EFLC MO'9>\:_XD\:W\',V8"/2Y$$64;J4:@C*.!E"GX3)%) M'[?!"_).?1\%?F4YC0#A2Z,,+HZR&X%;QN,8T%9?6Q=N/1X5B0UL(,E9(M?! M4$*.(K,Q](=CB1]#Z4ACE2]/`5P!?F!`-5AYJ>LA+",-LOP29:VJ(/SJNN8O MR[;Y^0*LNZ+UU0R:I`3^DLMX`*PV=\FI+^R[ZQA5OR/`5*OC[&=46%I-2&7, M`+8;,U,=4GR=GQ;`3,N#(84B+H"WV+*J0^9V@#,/CF)O+`?'GY-SCR1/54VK M"IA6>3C(&OVBTNHA*J%%!0RMTN_W*R-*HJ`[?4%"(&Q9\"]>B,P;2W\F!Y^2 M<;:JU`'F5Y.4?F$HQ@&B4?QE1`/&69-5K2G\%R%Z=.^1C5-&\T[W:M$-6.]1 MENSR$M?!5D8E%)7+4DUPZ^@3L/;]T9#^M*%F7$=M@*$?#,?CJFA<9_J(O-D% M>@YJ>$,5,/OC438V*2ZN+J@RFB"G@$.F.JC>R>3F1X.B[E'.$*\*J51^"14: MX`APK#+B+3\[%%:MQT4#[/QXH-!I$5U6+3AEM`!F6]9&PZIX4MU9%;F!0NKL M)T274QU'&2E@MT@E'*C%XTW+>HH"+#"JI)5<[ZH.F#*^`&L;W4P.$(*9V'DZ*/4 MA72F>^B%#.J_HFO'<&?HQO5]G-[>3A[U-V[:^H!Q[FG#,1V\50'2>#U*&.\# M1KXG:XW6XQX%.LX7S$O==X$F9$($?Q,`?D%6A]FH#RZ[";1E1$-N M8Z".UD0;?04OKFTBSX^W].?G$O`CXQ'5NY8OJPZ:,JX`;S+25+DBFE1L@O.F M=9@"7$N^LP(J>GVH930"WB;?P<$+-5J?>67A=Z,;_-ECQW3GN0;R_7OD(]TS MR/#1!7I%MAMU'O*3"S@C+0KU,."*`,IPDR%.--.]GZ2ZT7^0P6S^$+T/9@M: M,=Z2@AOCMT01`\!K[8S?,KR`=ZK+;SH.M8)9-+SIF.<8%;:TR#&JI&F#G!MZ M\ZT3Q[(_=P,O1-W.<+J8&$P`SD+;:SR8RG^]I;#?]5Y M@D9MY2$5CS!*;P(J@T9H'%=1JD.-3,8#LFW\R7]%#O)TF_2HFC-L1AU3-\QX0.]WA8!CW$(&7!JL+91%T84[(`[Y&8G;6JLAIHFI,9KO@-[SE% M9?*'4')#A=P%9=:'Q>`13%R4JK"N,0(/^;6-P1!P*4-Z"DFFN'IH&`0!#D4; M5$$3I:G?7<=-:*Q-$N!9AEE;7E;NFO@8M$$##L-:^&+5X5Q^>;VN*1P"#JAZZ##T1@2\7M$$H<91[Y0;AB``C]N3J2[H M[;!34$#]YH>\-C6)@5'V^C`9+0&X;^PJ26EAT& MR*Q.*>764TL*4Z@5#%HZ(FLV.7$T`YNQ.$7B@2UUOTBU(5\@W":&I2]%?SHC M2V#^%?UG99;'0"2@92,!1M'KHV20"BTGD>JBC$S-,CJM'D>-P9G#.;.6E%4' M"(,@:$F(S(_D#VQ?7[#L3E]QQC-%WT.R]/IV$BDSM8!HW>][G/:8^45-\7P( M5>LKU"A6/7@;K22C709@)15)&VEC*BAJII)?/>PP[SRW3AXZAH;%^M0$GE1A MU7$P&(0R3GDPYL61BB(\=Q8/9(28QF77D>OX9VB"XXM5VHK\;Y;C>E:P2'I/ M,-G9M\1#?M]0\.*:9,5.W71F#&2Q0WIQT-:JTCX6RU6+347%"&>'1+)'E'@6 MH@+.>RA1DT/7&N*2.=@'_/1H,-:J`&*-*_'P`\T=EY2&!KEXN(&Z:[7^@!], MN4GEX05(5E6)7NA3Q[;S<`*MRE2HL0<&$/YXDX95!H%9_5[\+`#^)5!A8X/ M'B@,8J#U_W*_8.2;B04>[N9@"-H20)$+EE,W-R#/0QS4NT=UGE<;DM]%HLK3 M+-"HGS(L&DO_8!D_CWH`#T>)9^+0#N<]Q094;FB/"TR*`%U6*6F2M M22(\G$$C=,J`,!PR+(<"']B5^*+6G6/"0!GG7K-!V,$^$@VQH\XC\?D$[ MF2C"T1S0IA,]M=FY%>4"S17A$`764 M%H3T+9HLPB,`,/T=4]LC;F*Z"$]3`)Y\O*79(CR<4OZ]%=-%>"@>\>!>:[Y( M(V/=/$V0CA;*!KNE/DZ4-S'8W6@M&0V6V7"D9-["<#!2E9&V@5JF>_#QWS9J M9!P!VL2$-8Y0AJ(@O2#[$*`+%/_[VDDVN,RM(^2"#"T/D?JYF?+EY<-@E]M( M7BR#P\+M)&O4`EKO3F4"]7#!M>/9-*M&[0!/WE/'N<'X&L`*PE:R*^^=YY+8 MW3Q;_/#)VMQ59^TI1O=:MTJ0Z\8^4Z6#5DXTN:1(7T1YQJ-[:OP96AXJ/-.] M1AW`#1:I[2ZY<'"V0MP_LFXK0,F\.LYET)Q@"G88-1`RHWZ>:]\/R:;OMY-4 MQE$#/31J.]+HO9H`#)S<7UD.?G1=[J&UFL,1UP=0`"87;$TFR,#QX^6;\4*. MV+S7`W3K%&^\7;TBT.8TU#A&%3"YH+SPKOB8`MKFU:@(Y+TU:HBO`AJ^FO#O MN:Y2T`$O3LUZV^8V\:5L0W-^Y08PIWJ?R996-30!30@N6:@7EU:X\$L.M][@#VB M1X[R2H[LFI%JQ3_C=$2N@17P=IG^`Z#T?(1$MGO[S2(#,K%F:N`#_!G5.YPK M,3\9:;Z,EVXGF4U_JT.#-J+I14.WF9E()66S0$9R2&_060,HY(&H=:_,XFLW M,J-K(K_]3*D(X19>PP:Q($*]PH-1;EB/VPBMDX2S,(-CKY#=W%8.SJH$X)[Z MN>'*MJ7@K,J!:R\E7E5M-05G50E._I0V9."L*D`9X+@-"3BK`N">"T.N))`C M`:_J3QFHP:UYJ(X/;G=:MY.`A16:MB7U<\>F;+F3@(4>[)V5N;[1[702L"I2 M=:QVQ]T$K*J`:T1YSF3CZR;@2!A92*&$45*K)(PHY=]IPISU.ZN2- M!2,M8V"&=B/J4_N_%RA-@@^LMXT2SHWM02QI_B\VPOR3-SS_)1 M^FCZ@N*B4]RS%4X[R>@$Z.S4A=1TBWKPBW:DY3]5M=&JIIUHR5&L\:`M-3&& M^R#6XCCNSL,..$!WMFX@8-1/3C8)SM76QW:I>HU9SKB_JBT4B-(5:*3:6JK: M^&^MR6JSW'YSU8XT06Y'YD7H83G$\56LDA1`VF-1-5?CFB\3JYM/Z`@ MB`]0S]1>MPFTAQ>$@AO7T)/J-T3;$/X^!N.AHFK4OO0\'&R(O$9E,^*P#]I@ M1`:V-L=`-*:TC^IA!5G]Y:@5!W&Y^E=2SG?T*[JT1=F,V9/*(MF,^WTL&T[1 MK.K`$3_$RU=63C=^Y:T7&3%R$G-ZIMKRZA:9X3C[7)65S.?43!TW&'DURY"R MY>AK]Q'*TS?+L6;A+'WK/>EM*6"'U8$SB+?H6L./1^E>@A*'><^6$]E$G$W[ MEKE<4I:*]F*!;4$4''&JVI?(25'+G+5R)=:C()F[O`4JJ`"V>(:UC#^4HT%= M+I+:9#@A6[=X/BKYV*+["ZUI88K9$!<#AJT@XZ!'(UE>DL`-O\Q0IMB[1X8[ M=:Q_(?/:Q&^P)E8TE!3UAR1FYM1)CRCA:^$,FN^.7M5BGX+,45\9S0H48$K:/A6V70(D8)- MC0DR-;@<2\1?-O8$6^OB4"29'N^/I=(M[_=75 M157&%;1UH4I/G*@$BAP=Z;_$<4(%JL`]"25)*8:5*;`NK%*NH&%:>L,N/E@W MNE/4Z5?&3<75).3M?"665ALZAY+22%&)9Z%EF]%QRXYY/9M[[FO4*>9'V[-6 MJ#Q\""7M*ACEK@FRE"_H=$IE3/O^"B`+9W)6I1&:`$3-PBXOQU1 MUIL?W57HX?>&'IF2?&6]D;\J*Q"RXM0LI-(BU\!61ARTGZ`RJ(@MBBY^1R^6 M85LJ;R]GQ3,QNX.\IED7%2$>G&Q$\BS#UNYX+`^KTU?;6XE M[1KKF%VM69_7::\VOXO,Y$*ZP1T7&417?%9:5"K/8^ROOQN.X_*-*W/PAVM_ M\[N&\TVR$+@)CMN'<- M9S4"+C#0A4;^^X=N->(M,.:%WD'[AZZQ$G0+/(!ZX1#(3L##K39FLI'(4F)# M+W\EF!9X#9U";\.=P/0';ND[!J8R3<-^&OL!':X&U0+WH;XKH%(K7ZX96-BO MI[,K25L>PM4TR:(>".VB"[$O`-_KR")_:]F!18W^ MZN=[$+X-[<"BMG\7^JXW^-K`#J-'BP]?P.MST&W\TOF,-Z'O7 M\]Q7N//:&,$OP7@.D/5HP^ZW87?P/O3ZENOU!(069?>T;]BW3@"/F`);UANY M_?(X49G>*921KK+B* MIQ:DX(V]86N>-[4+22H>SOW@>N+DQ)(S./>'N8O9?%:+PKT%>)L'^]XX;8&S MLS:^<@T>I\FE7B*GY=<=GZ'`[@]/`2_23&JG)9'*Y<]0U',-)HM5XTVL&J\U MSL]G6?9YN)`5BX+H4U&S/CO..ZY.D;6*]#8K)KT[1N0<62\@LK4K`<[?">^GF^\+-+=E9=LK M>26S0-N/)=@:4L[GL$I#R%QS6ZI>>'3,C-K&??:8@ZD*NPSG=FL(Z\SEHOKY M>6>!MI\%]2YDJ[4MK,SW^(M&4"[9VA92>:`/CA1HRPL"XR^FX**18VBSDL1J9U"_OSJ+@/Y?!?X?&XAQK[-]`),%""= MY]?R$$BOZZTR%,0G-Z#QN>_H5-?J50S)::R%8CPG*5V;V+F:LK9Y5WZ/4 MPKFDO*4F=@_)SI3]X'JS6P/7,]JM_K7>*`6Z>=O[393,5J;L=Z753_!L/"]W M(>G*`FY>4V<@7;O5KK>RPC=]@;O=.``MDDCBDE#.V>.O\7[*%YMG_CGYDU9( M2-YG]SU-&L-B1YP\+^R`=W.=I&+["Q8SZ-WE&S)I@;AAY181M^'[LRA>'F9%.`%TU8*@AEE((2W28U&N=O-9?KU?> M!7 M^WAM=&6THR'NGB=,[13S]P69^8VZ?<\8#9``DUC.];S1FU+<0 M`L_#+2100>LJ6>2U@O`V0KT\VH> M-H=^OKM2;^4,R7+0]96J?#E]Y^[36/FW4EECY5C3*S>UJQGOQ7MCF:J1TR_?U+OC=\*Q7@Q_+ M?W)[`7Y M26LR.U9XY\11YBEC9@IAPY>GE?A_;B-C<68@?XIE^K29)1:VHE=]L:CLO];< M8%V9`PJK(FS!`<*+1N>\G(6MBK!%$Z4:2RQKYM'R!9TE5\;B@L-]!1S.6U9I M(*R*[T4=:'8$P0:LO.!\WD5G]R"L1H3&HH:OZT.`W;@">L]>L,=D`&:4);T" MRY6%QJ(^K)V&GA?=^4LK$9!5B;'\..3M@K"V2#06-3+=,2TV$(P%YG,/[%18 MX`([NC=,%Y:YZ&S]9LM=[4V^7X)ZLN;(&];%\4)I&7[*&L MNMQ%[=MZ*8O,R^JJBUQ@1'\:^.!@ M:A65&/R(JW`=W.Z8`O@R!47-!H1%A<*;,N$K&X&_(4+\.T?4.4UI;CN#Q3=$ MY1+3;XOE2^4"N5+M&O\Q>M;M=^J9S%]R&-^&:+I8#4TKPU`V-WUPO1[EO<43 M;.\`38TEAN*6R$U3@-R#6BL/>TL,SJV<6LN\X$^*;=>H=?5"/:-/8]Z?4:Y9 MFK4H=LR=6:E9/VLWMX+9>8"OC&]_)16[/,ZWHQ"6JK6OK:85RL-`ZUML'I?:7?^V=$X#+Z3-S M2O57N89U04%BMBPD+PMRR7@>X<3-_6-Y42/O\K"\#,![U+KE873Y#=NM:]WWUV0K4T^]8$Y^!S^W]:'_7V30&INX4UIQHB MF++/X7J<%OV[68_;A=0#'WZNQ>-Q-U[Q(O@3%2L1!IH+,+#JFA?C@"M`B3#0 M6HB!558LK\HI%6EMR51.6KR4/?U^SP`2*QJ8AC]0QZ2+#9\X2?]^TY/TC>:< MP`,/U9X7"Z^66WO>`\-K12<*GU\*01OX%AS/NP%RJ0/FXO1MXD7-6?1\BHI^ M1IG.,4G7E3MD-&IXJS1+*`'Z1=SBP2+P',MK"1]S_*PD9K_EFR5KW6 M;K>VAHVI$K,3&6CI2^9PFFG.PYQ^EU_7]FZH2@%PVP=U>R5*5(9LE M`-=>1C9;F\MFN2:X!,#G>UEXU*%1%1-<`C;F]QO46WI3;TAG@DN`^V))O=U8 MUP27"_'&?;H:[=I*CK<5Z[8GM8XK`1L+,FBM MCGXNG\.Z.=S%[M*SZW[JFWJLV%6;!;P:Z\JQTAY(K'B.9MXI^,D^T=]]=NDP M^Y>3P`MAT3]/OM;G+XSZ8RW5Q[7PS@5GF_1:(]\DIOC*R24YOFO'"(-/YO@9 M5O3>GFPYO<3IKW-8PO^U@W<6>R%^,+;I+RL=_>[K[WUOQJG?/M__?\^G=IYM;?'GMK,6<=R19&G/$OU%P M0@R;]9U?3OX3^@'KC?D:<`D_PQKVL9[DG2Q>20^($K^]\%1^=8ZB&GEO^,PG M;H]@ZUPT^/@U,1R+/`&@K,=,`YYW"]`.04I]#BN^(@&<[1D%[XC/_J:7I(-7 M$%T_@^]3M"S"QO\UAJ-W_Z6W:^\F(:LB/,\#2@S3=(-`!%"LM%CRATC!`GN%C\LH'Q0DF74H>,/#J"WRV"U\$2/'OX!;#LZ]5T-8LVF0-X*@ MG7J]]NZWJZO/R9_ZN[=GY"DT!TO@`>R"3&=L"A<$6O1%@@ M,?@7^'N1*LS!IM:P^#-R!2OP$:;L,I`&>"MQ7`\T/SS?##T\JT0<`X_4G!%@ M$I_". MP9%`]L&WWL#S!/OH$?O`M7@]<"@!*8)?!&AGY)IZ@0%(9TX/UYZ@J.>Z`2R- M$@L>;[L^'@R*P..+C)@P(M=B`F^/%5-V3P4/0'7!G<"K("+S0U2H@#Z.S1`? M+KB@']H1[2-4/R'A@$^B*VZ_FP.L"R#<._'1I^>DQ+]1VN&U-J,O<'4P,`+^ MA"RZD+R&1?\*,;\.KQ\:WRB_*.:#+-(C[H45(T?`VVQJ(#%CWEF,8G_@AK:% M/`).)4<6W/.?T.'=+P6F@W3ML9CJY^]@I9'Z6/R2"+Z4&(]TY'H!@3=\`%A` M+9[^^^>KA#ECKH3KBTS9Y"@6W-AC-H#JIXM<@A"[M1[UYED++84RA]LTAY%> MX2P0:85$-F.90WY@\/7KP`7E<.J^.O`T/^SZS&(&QCV1DL[X4ES>3LU8:`T; M=8_@K"!M$)M5)2#7O!4PC>4H=>#.R%UL61&\H`CO-,"TC!6#M_CP)T!I1KJ7 MQJX>7Q$$9.%0%!L)M6+T>J#Q0:A1T-#&#P5>(@&)5'7_@)X<)J>9U38J/P%HO!@D&F/7>( M"P3=E=RR0&CC/_!S@/.)2!<,!?4PRHYY[I59P>!2K]5^?$?X-:>V,7;#X++' MOE/KW0E@U;9]G'7M]/E]^/?(L*SH[^3Y7O+)2A:3_>BE'_$U^%7CC,`:\1SS8K'<0A:@LFL"*AHIU\0P!I0J>=/(W,-1!$HU\M=-6K@9H>/*&-UP MBP:BJSZHT'<<0V^:F6>9`"48-Z/+F_D+O!B^BY>/N27T,.C*TE"$!0'WN0$= MQG]<#^^$)62I.D%+YB!97&^XMH'&+ M@@D30D`7XF!A"H&"PIV-'^6E>B*E8NID`"W/T&N&P-''N(I[,33`M^&R04U/ M\WOB=P*_83?VV`W@=W![@K7'@@-R:^?>#@!,F/DM M'$W2Q@,;R<-M`1X^`Y2*<&>&$";R"(^_'M_(Y3->HI#`#"3($E%0F;)#NF8> M=<--R/EQ.-EC'B@!TAWGJ'TP7LP(*(322>S08W7I9XEDI\4`&_2BQ2(5L8D")<36WY&?D MZ+ MI?L%B7>&_0'IACZH7]ZX<-B-II+A:Z-]`A'^X%87JEN(-2!8`O&` M14)HPIS8.T[7"0O_#S5YWI29`XU$[X_=:?Y^L46FB1`%MR'`03<'^$QJ#AS7 M=OL\'NY!B,9$Q"8\]C@CR:NSC!$+0%3_CN(!O@DB4KG1IA6W1Q;M\?[AIQA_ M(F;C#N((",6,*01#N&`.#^`(/7'J(@`Z"07A&@)G=;)C+(Q'#'Y"> M[;ZFII[O"8HMPCA$MH21[=(^;KH-72]@?T4C->%J!O]%FWRC?WS4P"KRS#?,'[D^3LJ^=YT^'Z,@AB?<<183?4)R4Q7$,S>O"#NO MA"-XT!5A*2.@'HU9`44:F>&4OS'2K-K]!&]D:N%MH#\?!T9:&# M6]219YAQ:1;9GGB9D6.5>$WP")K^@(]Y];`(R"&6^^J@7Y$:..$"39K3Y-8A M^#NX^X!>"V75J=@*L1@L"VG( MG2"#Q'@@GCB*.P0J!NY^J?6;[]RI ME\SS>W=)A#1UPM(#,N0S4/@HMT`FMZ!'4A:8,/FQ;\#9@"`? MD)@1]I:^GY6X4[[`DM4)N/$H:I^Y0A6A,A@M$2TO'RKC,WC$S4L!T!2])#5A MT_V'J-!LF9AV8>8&'R'\`!%80J#8"W"'/(GY>=K$Q1R1\")F+4^;$7IGULI+ M9EY3 MJK<_)/6'5VD=]Q/V2#-P]_Z]"_\'^+#2'?:GL!NX(V:21JMVVJA5WC\HVW@7 MTP;Q95?.Q*/R3UC#ZE]4PNK/WA6JX,;[OBVU.MBUNFV&2,D5EK(?40\UMBC) M%ML1F&/E32-)5%.5_[&0HW=`/P1IE=JTB"J?I$]#<:P1++Z8']J)DO.X"@;Q M>,QF:&90X4>[+_FL_I2%VIC%)&_2U*U/^W&FR@7C)'[O4@A@\:43U[V=LAKR M)G/ZXVVT*Q&\8I55=)G8A&`\7<$=`E%]."6PC4Z"<`O_RD^\3/4`P*B&YC13 M:A0!%J!,YLCCDS>S(FR3OSP^LF#D3AQ$BXR"XI2\-L\):(#$/FZD"3=.RR`Q M,M_P)H_7-7J8.4B.MG'@LJO@8,8_Y*$^G/Q!5=3)H:G' M*ZR#-G.%EHEN+/J:D9OKD_^$5E\4#[$DK045IT4;W'%P'+,6 M<)G-1$H2B[(GE7+QQCGZ6XLV\[,[O>[$SEB\6UR4I\E\XI3+4!FGF<%B^B^; M!L7JX(%KX:8[WV7G]>6&/?;3J,'/"7N,6C^+V^A=$203"4@MRIS",RTZPG-Z M#C_*QP],.:BA0+7"Y?C0_*,0*3;N52"R1-H2D>NYKQ`2H)U!,Q4+^K2;!AFG8)A;8+N4'1SXK=]*X&P8/X/^?A#43Y1Q: MO!F&AWRYLQ89T>A8M_!OO#(/L!LK$?EP"";?=$UC/R3(`9.*TM##*N1AZS24.T$A"I8BOR M0O!S5,)WBXX,7(EIUSO'/,-V$,#G\([NF%R/`_<:'!SQDQ;Q.3\4):)M4>J7 M\F:TWQT7"E*KZ+F=_ M1[;A1,[M"P,*13O5R<+BLKQ\&IE'T^-"M/5+LVYG=_LA3=KONTDQUFS<-LN)RMKT` M??C?(>@TY'&A#C]]*]]N@!F2K]N+8=C$_!"Z-F`*1C1[ MM#2(PF0P9.+(JB\TIT-Y:3WH1J[MHFSCIRG?\N1MQK6S\B>ODR8@H"_!+?(P M=@L]GUO!-/BVQ8&%Y%SUR,.#[4+3BF-?Z7E:GE^THN(6+6V1@KY3E)9^PE/* MO.8[!E[4>Z.=B!.&/-.<("*II1()C_N[#P]QW91'`X/9N6LQ[3&!^RC+:(Q& MPLJE-XCM8+_X$MOP@U,&P/!]]%,P%>0-OOCMJF].7IF>[T[N2?(G25GXHF6) MU136]2%>5S:)D<__6RX56]%B'P$>CPFA>)6X/&Y\C<1SYF;?%-FB4/U M7N"`]SI@(]0@T;=QJA7UC`Z0B"]/!+L1QDI;O+H[%OM" ML15P0NZ#B^Y(F=#&#@"B[S04S^@(R$GW#:: M`VR$&)D:C\:-',6AADQ!55P/+I)(8H$\:`6-&)U(C+N31)LUG"M]ZKUP?P>3 M6FD#%-'D1I0FB8XGHH^HGZ@49D5LCW>FA^NBU0C!2EIK.KP_"C^Y1...@Z+- MC^O3:#%"UXG5"/S$L?UL13$*NQ#5I$="5_#\E]@#GU06T]5$F]\$6@>S M8U94+AA5JHTP]@^"8M<U!,G>6Z0UHGV9`C0:.)+YHZJ)6HJZ7Z;% M=LEBL#ULAD%Y3BY25KF^?&NX*!,9I$CTR4\%@?U)^\E'4?TI4A'%S-F!I"16 MS2@4)H*A60C&GVT@!_8D!UO)$SQ?^.[O19WSE)OF(>B7R$7.ZCTBT.;0P M'5RB@)"\CY4#G98GZAB4<WCZ?O'YZ?'SY>DO^J\?^\(]'W M]['W78YH/;L2I M+YRU+`@ZHCIZS?/#Y\EW/XK71%\O5..$VX%?3F`E&5B]]*-5@+D`V^>KFYN[ M3[\EJ*@A?\1?BFOY5Q'`#00^_CE:*O]]>9#2^_G%G&8O$=&`JN!<)4#!VQ;I MW*FLG*-(4:=/(4I]%2WW/F0V8G_*P=><#1`@;:@(&Z)`B80[?M(>!< M(A:(/?;-(.H`1"TY`(H=KEVHL0MYU-CF8"^MPBYJFU/[";M6AS9]Z#TF_0?O MHB/&<:.VN*LW//$^/4%\A:%K%7X^^F*MGIQ_1=^Y(1W5HQ/[,0; MO;W,P%@MMZD;]QDHG@HW!%&CF4/8ODCL5P=\'I%'L?`IZJL5GR>+QP$G%4FB MTQ,_8\2/Z@!+.+0P6G5(O3XV@9HL/AH9S%IIK5INH=F3>T[NK%.N;SO?C0^' M.,_L[W1":SI)C+N\EQ/47_.065F<0_*LD]E\PWA@N?UCX##"BX<*V8+,]YE8 M,_>"Y([KA_O[J\]/L"R<2F:,?/J.//QQ^_CA_N'/2_("6.8SS++[K).OC4/C M^(>E(I_^<>EB_&-!<"Z8!3 MP0$J>)P*!,!]>,PD/R;(`J`_WUU?W<>O$CF0Z,(_HS4V:YD=\/.%FYV9VH%I MK+4X52$K[/KV09^V,5,..DH`'^!'L8'5.;^G]U_>_?'A^^?+H!3)DFI;U>B9B+N/GF]OKA\>KY[@$N%8=1 M(7[>1,=?7*\XU%*Z8!Q`?`!2I)F7#95#`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`_\O) M:>/DUTZS=@Z\G.*B_,5N$QW92L_E<=*8CY-&H]G8&DXRWRP]ANB&^:;M^J&W MT;"=IJ3#=M[Y@,9+TL%I.$37SW`\9JK5-QMG/&LALJ9@G7S.S==B/C&B`5SC>'@81-$@>S;UY M>[E;#,_CEN51O#OVV/V\L/2?8,;H=1<--3RLM,BYW5'#P[8(^@$/#WNBHX"/ M%4V1TJAIBB6.F"5NJ,DY@C1TQ0A;VRR1"4W*?"A=L9ZNP'R28H#C9H!U]E^. M@@&4D5!&8B,=L5JE9H6UR)O0,4(+$&"]59RB.$6IE.K7<6VO]'8-0W1O.&IT M]:;2(P=;[*[H5JY1JU6JOZVO%10J:9,'&TK:*B1M#=7MO'+NT?:J:-=PC]Z' MS,9=4=7H10JM+5-YNFKTLAA'NGZA.KTHR5&2L\XTQ`LUGK9RSHM4N9V/ACE@ M#O4D&19>09=81FPZ#DL"#TJASM302=91FP!4SIV1 M*BWS!QTPTU:S7.30ORJGY9)< MF68X#,5<:HN./&HRWFM;>YVF+$K4E*@I45M1 MU"XNE*A5SF62*O=3X3!-8IV]U6ED!]BD0YIA997JXZ'5='7Z2DFMDMJ*2>W^ MCK#+*;7\)HDG$$Z')X=W>6?`E`U)D8S5?+XD;"&N$8_Z(VH&[`50<3:?ZZLS0725 MT8U+CWW<9-AC2]9ACQN/8)-^CIJ:=J:FG:EI9U5,B\D$NYI6HJ:=*990T\XJ MMM$B$YJ4^5"Z0DT[4PR@IITI(Z&,A#PZXFAF6*EI9XI3E$J1Q>K(40U0IB%2 MT\XJ7PLG;Y&(J@"9"`K4M#,E;4K:U+0S":5-$O=(JE.%:MJ95%J[TF>6CK(_ MC9IVIB1'28Z:=G8DSHM4N1TU[4QBA:PZU%2L0XV:=J8$1PF.FG9V%'Z,5$D8 M->U,?JVLXLMJQ9=JVID2'"4X:MK9<;@S4J5EU+0SF?2O"B>K%4ZJ:6=*;I3< MJ&EG1^&W2)6&4=/.Y-3$*H*L5@2IIITIP5&"HZ:='8<+(U7J14T[DUD?JY"R M6B&EFG:F!$<)CIIV=AR.C%2YMK'0]I$8PJ1%,*V%,33M3HB8CO@Y2U-2T MLPJZ3%+E?BHGR1!=/ZLQ)^/F;S:VYO[NT^UI$D#H MK1]STW'FSJO)\?BU8;.NQS3?$G.R1(_W%"N]?..@A._*V`!XA"7J+!5($[RK5_7<`,4T8I M%=!;9+8I&*YGU8*[3CP5MT32F3VY`2>ML4N_D'[.$OE\1N9V+#9$+#Y`= MN?=P[6E`O2%!3>7S0Z[WS*%\P->U1RT6K(WX.?J_!+53Z;%?I<]NVYZ)QZEP M6(1K.&.!H$Y=/W\'_!$&?@#L@K/B'!31D3'FVIXY%K`2M8")?/)J`$_YT5@Y M_A'X:J\3XDK!MAH0IP;$52F3*!/L:L"+&A"G6&(+`^(R'*$FQ6UODTHF-"D[ MHI2&FA2G&$!-BE-&0AD)>73$T\:SC=B\IT)8C.'DO]2V_V;BI<ITKN5%RLWJJIK$W MEZ:"@B.)2U.%1$W&I5%I&BE4LXHVJQ5MME0+9R4W2FY6QE%'S0RHG$=3L22- MF@\DA696P6:U@LVZ&JRE!$<)SAJ"UXL[]C7A1BJ0JYR;I94*:0*1W82:_&MSI?8F'_D.VTK MS7R)_>%VG?D2YTUU=$5)K9+:*DEM0SMOK]/M[H"EEM\D\528Z?#D\'Z\(P)6 MF?8BH+MSR'^']IC4:[6V1C[>WMP]WY+?AMW?-?(^]/J6Z_4TPKML48LP)W") M08:&#W^+#@%N+VX88/0]2G'H#?DO'1@Q&)#I55YG!$<'%&[F\P#@9HN_!5:C MU_G,"?P>1TI[R:^P`N;`789/20`/2MH5#.%_XQT3G1<.GG%?#SX8=>G?X4@HR#QL11MC2/TW7!$?56.H+T>-0/V0H7FT\7W M9^2]ZWGN*W/Z<*>3E:1YBJY+#<]'Q0@*TH??X+_DQ?`8'[OA@>8B78YC>"+@ MF'5=C[SAR+[#6WC5ZP.L![7K(US]EEAT1,7TE&@1P7C$WVY8+X9C4D)M6#U< MWAT+_2=FL'#Z6K0'2^4:%']*%GHFWH8+Q"7YR[_$,YP^_%\/_)=RV:-Q=GZ> M)UQD0UMENR"=LX(<_D@LH`3`CH"/X%;7(L*V3'++5&,U`-YR7%B<@2@:&@$\ M+A@3"_Z<>CWSQ3P4((%AL[]3VAFFZ89.@+K9I.R%\PS2D3DO0#6L%8*'S+#) M8(9=+^@;?1K3L!LRVQ+L^^JD+[G.,`BLI`_6P@!N$!=\9.;`H+9!'H*`7Q%] M@7\+:](#QQ80`LXW)?[`\.C`M2W<^(.E91Y_M@U?I^BEDCG!I:2N%3`".C,: MN1X'[F^VVZ7:(O=JMKJIK^Q7]3FM+>ZT?6?#<`C(C+0<,<)@X'+.A>O+-P#- M[9O`9K.CM2_J2YK`M31\??\:_EII^,/6$EJ*&B&+:MLC=^-7W`X\==[]Q5N M?#*^N\!O;WZC'F!__!8=1#\D`'K#TX#:@XBQX-1/V%&<">5&9AF!N)) M/"M%V<<0E*0'OI;-'HC?X`:6U7?X_)*55[.@44:8@W"<<"@40+IRU!5&JB-R MD`*4;2YE'H1=#)9+?#IDI_@<"#M'H*.P3,1IY+MAJ``NBD_*Y MH'ZNG7>VR@0-[`:\O%7.HW-[^H[?/.DVCZ+AS0L=VA62@-/3@3M14.ND+U-/ M=9_J23J',==A0PJE5$BRK:25XE@$*)QH([TS0R%Y=(4,X=[MH;OL[Z3TMFVX^>D_JJ?#+CK#`>C@8V`\]'I.,7)N9\(8I0[UWZ>-5>0=HW2'1E3!2 MGT#UQGYT1SI#%1F7Y>Q)0P)[TCS+!^@KF9,DIFF(!'I'RSNZ?X%B@_O!7LRR M*EO8."4AI-GIKQ,S%PE%%!ON)VF5BT&QW!$:J!#.G??QL.9J%LS&QY MY'7@QKD]*_?F<)1L\.EGK7A_3"M]'ZZ0[%N\#X=`OKHD0-L_H%M2">>M*;J: M&N:@;`1TFKI6OUC-$^PQ#W1[A`"^23\R6+(]G;AR`3%MU\=$B<^S]A1T\7D M771KE^*O^!5#AA+9Z-D^&@-FP[U@9C&#>W0#%@3\"1`(&T`7L`/(>]PI"PRO M3P,?5^SZR9_D%=B9.&X`G!BDB<3\LA`BA[Y@,0*XEM024*>\#-8@GUGG6FX; MIDZOG^FM6<:.+Y_;-E2LP81I:R]0HZH^27FG5XFQMR+^[3$;1$J++/<0Q`HE MK&O87*HFHNIRHU)]4NE%Z2X062YX?"L"-,W\MA4HP8`*B_:,T`[.R._N*\JS MAD_[0+N>*#UJ:)GRHUAM>:AE,<;,)G>Y`EOPR@&H`W")D*C"3J*",EZBW2Y4 M-""C"YX!Q@?W7D#QDA\:':W>T0G7KN/8O/9"N`)TG(AYP\"'I_'MLM1;Y=&L M:7JA,-M<20D-%C\2O>(NI>BGFW88U:Z9H>?A2W"[!`T@4-IVG?XI]S!!]P4Q M)4!5\I)6[NG%?.$/*(6W7/D<=,%3+.,::`L@YXYZA"<77P'4"LIE+C#UK>FV M/MHO>S'LD`K#QZW+#?GLT1[UT/_Q`]?\%B4*\HB/40W2S2SP:;A`E;KP=JNM MU5L%L4`>*-G43,H>#PJ*X8!0RIVZ?OX.0X+AD&,0T(/=8A@L*_(#Z'=JAC$K M%;DA*W$#PR(]@]F"]D/C&RUPXT;K_U&[()/T\U1 M(>2`,H_T(.[E[A_N:OO9.@CTY>+`V)^;L>B6;,'`@.D7>2%R*->'0K^:8UAV M:`:A8,+)W9K%?^!G7FB.-3'`PK^'7G-K&&+3598]] MI]:[$Y`-&R<>FX`V?A_^/3(L*_H[>;Z7?+(2\F0_>NG'N.;]7S^'_FG?,$:7 M-V`M;IB/WC_XIL_T>_#>!OWPZS__\<]_$/*O^+(GM+.A31]Z>,,S/B>Y%DU` M`'\\TMXO)Y]K^E?X+_+#LUN[^-JH\<\GA%E`+<,,F/6U<7%^\FN!N]/=[V"U M'7"RZ!S"EOUBZ<7U>88YR!K&G,?&''0AJ`6"ZHNJ>1],F&V[KWX4;;[AR0,W M].%V_^UE!=7O[H(5DE\\+OW/NYOGW_'G[&DBH2:FG[2JI4>3HE_N;S\\Y[Z? M0`?^$YB*7G?1^#&Y_?KA_O[J\Q.LD><)1SY]1Q[^N'W\2T3[#LXL/DZ8`$]15:BEX[[ZAFC_-'" M]=%1`O@`/XH-K,[YY:2^*BZ23%V*E$9-4RQQQ"P1)P,S'*$KCMA:4P^9T*3L MB%(:ZRD-C*H4`QPW`ZS35^`H&$`9"64D-M(1JW6?J[`6>1,Z1F@!`JRWBE,4 MIRB54OU^@U*U=9ZQEY/M'**FI6\L7G+PC7P=RRK2(G:'[C8OXT.I\>Q2Z'0UMJA:8XL:%WMSAI3@*,&1!46K M"TZSK5J15\ZKJ4)F*'.`6>6%I%#-E1XC5)&(M$S5W%8S@I3<*+E9/573V)M+ M4T'!D<2EJ4*B)MOC2SG-,JAF%6U6*]IL[2V%KN1&R8TL*%IC6*^:REXYCZ9B M29J&\IEET,PJV*Q6L%FO*<%1@J,$9W7!.5?E-)7S::3*TLSO;O49UL]\'UN> M?G(#JOQG&92TBCNK%7?65=RIY$;)C9*;(_!MI,K7W$1MCV_^E]S^%6(?_<^& M%SC8*/[S9#]PY4BOH996._`I.8M)AZ\CB6([357>M1>1#6W?30Z-9.VZZ(1HECZ!T>R*UKYTUU=$5) MK9+:*DEM0SMOK]/M[H"EEM]4VD@1CL[9XZ=F^(/I1`$R>8]5E1D(\X8;%`T M,"4Y?O8,Q\>7NHX_91+%RM,E4+XDG2[AL[_I)>E@6WZBZV(K--P7`]JY*[L=Y:--$":Q7(M"F"W84*?6V4=BXV1"D\ M0&*41DJ*;YR,R948?.JO@^$Y)K,$K;+L=!024>`_H1^PWOAD63PL.RSE0*8L M!E.&J?(Q5<69G5ICIS4Y,0Z75^Y`+7W*(%R/^B,*AOD%8%IER&EUW,<5G)G8#QI: M++B\YO/XGG`<7SE^CZ[\'N7W+.7W9&^IO-=S+H'7LSQ"Y?9YA$XB7"E)[NGL M=&KU8?@VT;!./D<5NP8"J8.!3ZB#HU0GO9Z\?\-\'V?GZEJCT=$ZYZW,Q-G0 M\6B?^3CY-1Z_&[CDKQ#8O\?XR&(+)^["WSX9A9X?&K!.N()^I\.1F/#:\]PA M$4_Q1(62F/GZ2/NA+;ZXX1[+$^76E33?U-_&3A5\!Y#QZ;%7)I_@J5\T&CAG MO=0%0:?&0TG+]PVG3O'NX-N;RACEHGKNA./L)&.<)VQ,&P/-=5@TGMI'CL$QEF+]Q`)_*_1],4V; M&Y'.&`/^OAXPQS@37S-_YOAK"U4+ZX8!``%4YW=QC>)REKCR M&41I)F8KD94.*U19(MZ8F/B+U]UQIA:"\1EHYUI_X.!U("G_Q2\$*>?3@I2O M"?$>>E\<9D:4>^AQ"GSD(F51=D_[AGWK!"P87WUG?B&TJ<].1M=.?FWS#9E, M0G^9M2\)\!,7MED0+Q.6-3)K%Z*;7?[=IP\GO^I@4\&D+H2@L)A<.)EH/GZO MN'+#0_N:-G@6)SYAS#P`\.Q%*T5K8^!UI*T!-G;'/!I MRCZJ0+N**LX"W,A=@T&JU65FX^"GVGQ0-C8D[K]4UEE__-P\3VH:J\0M2CB4 M<"CAV+UP2.)M;*\!V1QWXGW6G=#@!3\2,QSR$Q$OE/!3%=2Q]L4M.VN,(H[:9>/GBX9V?@2S_Q1[*_:N$+T/W]9OKUWM'%M_+;6ME]$SE!'< M`U*&NVO:C)\;':W1./RA>(J]%7M7B-Z';^OW$M??2&WK9?0,903W@)3A;@.? MT\J16G&VXNQE.%L_3SOM58G@AV_G]Q+3WTIMYV7T"F4$5\(S$(<2%ND76JU^ M^..8E``H`5`"4"E_8;=Y@6T:62Q]S$G,8?3/^5?N"P/;GDM3`BBK+'M=.L;GAZ[3A.'4 M>&!U6JH1&]L=L5%O;3@'JUX("+2/ER_E25\JLC?-- M,5L,M67$;`Z/:J''M-!2&^@WSXJ#`D;4$\,"M)(G4^AUK5UO32J`U?KE3_EC M9AIP`UVRCOZ0G7&NT[$6GSUF;E<9'R("RYV44=,:M<8,V5N>,HKCE^/X1R-0 M#+^.32R+WVMGM5JMVY]<1]F#KD>8FR^6P)8)HLWS^^Y+R^2K1KQ+]*M%?[41_R9%N M<5;JMK*]C+6)I*X M*)HJAZMRN/O'GLJ>J1SN_E%7JM^3U[8_IE;@_X6&%U#/'J=?7;O#(74P]B9E MKN&CX9F#:%!Y35>QADI5RX?!*V:YS"SS]617`I_`,PW/HX;G$R,@R31O MTJBAF.HM8C@6B>=!1\*K-\DK]6BY*8A6LZ.==SKYV`Q?7NY;ZC6MWWPVG_0KI/(/*JF?-+!4M>LJI2VAXE8I[4KDWQH[2VF#)E`I;972 MEA*!I3)Z6R6T54);9OR5G=!NR9C0GC!L/__05NELEM(.RIJ&7)NF>\\[)\S=+--^J1+-*-,NH_E6BN1(IL7I]9Q7; M3;VC-0LG@)2WJM+,,B"P5$;OU"9R9RK/K/+,4N&/G-7JYRTY4LV3-NCG'SHJ MT:P2S3)@[_:OT+!YJ&_;<&2,+'J5VF.QR";'#]/F5:E^):E956 ME=B;5&*/51VVRG5+C,$JY+H/LPZ[U6EI%\VMMQ5I=33]O#`>:(7\=R6GT4X9 M+YL;1OLG<(#A!/Y#&/@!H!S6L?$PVK8:1KN_VO68H,1-*;KF%H(Z=Y`%A>1A MR22L"YL+V8V7#*S+;Z`\_''[^.'^X<]+\L)\W!):2FU$;E'\YF3OIC[ZGOE] MZJ!QDX*(>['67&74>/F#Z%ME3**7%;B#A@V`0R8&-@5!KA\PH(J(!P"H(N(! M`%H"$5\'+*"G:%OII>.^>L8HLO0;P[M]0OY),1U,K:,E8SXCI%P?B8$[:-B4 MPE4*]\C(*"UL2A:/0Q:O7JAG].G14E'Y/I4![J!A4_I6Z5M%Q`.&C;E_QR'QKW]3CV3^EX[0(A#3,(#?MH*:E*R@=.97[^5%'YP*E\SWHT1KMRT3(G1_`8T<1YH36X8;]8&#++LNF6U<)J*D`.MLBV:9JR M8(GPY6&9SG2$%4XN-N/32-(CL3:)1;W9T!JUCI(P)6$3^/I!"=;Z@E4_:RN[ MI:1*V:WMB%?:;$()F1(R)61;$;+V6;.MQ$NZX+S'_[.KX/PW3*FO=5YAO\#N M1,W*`ZX,2G0W*G)_*)+2#U$"H@1$%A0I`5$"H@1$"8@2$"4@2D".(1;=[49Q M7$"]MVA4QJR$C.#N_#R'Q!FYBBD[Q>**Q16+*Q97+*Y87+&X8G'%XM6+RG:[ M0WC[?<0\M4,H32'&]JA_2)466\22E.I2B8D2$R4F2DR4F"@Q46(B#T*4F"@Q M.<88=:]'3"#Q*/'0/^T;QJ@P>_QI8'C4O_/]D%KY M,>)7_H,S6,'*TQQ^!7'I5/_*G_W1YXF"7U\\%-@!'1(G>#: M-GS_H<X#M>G/8]"68LM-H M-'8.V\WFL-47P[9[FMUN#E=C&557J]=WI^E*TR.H-*70(Q.PE:!'6I+HD0G8 M2M`C;4GTR`1L)>B195P+(%MM]X0K09DLX96LK4P>1M0S`O#_[JGA4_\15G/[ M?40=GWYD#AN&0_P&WI.'M*9_K7$H6\]NK9VHS\_W!QR,Z"50=5@Z/:)_JM=-&+?*WIZUC/I=]-KP'C^/1X@V7/U./ MDW%Y=[NNY['[%1#XE3\CB^<&&-BS6DV?Q3NSUE'6ZF>YXO7Z_E8OY.4J#`:N MQ_Y>)<2I+V/W13R[0!.E;]]TK3,QO(0=W\9:LWN^RR-V"<.\3.R8>?G&:YV) MV&4,[1)1Y-)KO6=_APGE+7TF MOCOSEU[OG)>S]&MW.'2=LM3SQ7H*;HE%E++N6=ANU/:Q[O55,'7HBN/+KQ7S_BE?2W87?P/O3ZENOUQ`T69?>T;]BW3@#+ MG/3X&W-,)P0#K7:MT\Z8^E5A7P9W'XWO&`*]=SW/?05\7QNX?1",YR:[%N&K MOBU\S;/7+6"M>D')K0+QUK!U/0[#=W0"39AI.:6^*A96TGN9H&V#,<(863F9V.,-W_VF&.RD6&7H9>V MAAY]+GH:NMY>P#2SH-X%T[2VA97Z2K(D*]-L#3V-N>BI-R_J'7F9YGP!5IX] MPS$']/G5%1=B;B[Z;@HJFG-1T6GJ]8O.ZIQ21NA>VEY.LS6?W'J]79^9I5@< M.//<)[_VVG60;/Q29BX5+I<'9'N9B!43SK5&K1%E;.>M.@=>?GGI'8\3J>9M M@9=U/T=A'JIS$8?#?YK-"+)Y"RX3LLTW/IJ=.9"U(\CJYZT5`)O.R3?LA5G4 ML?!*(#+.K#/Z2VX4E`7KQ1Q8=81U9I)[^NJW#/'F^Y&M6K4@WGQWN:5O"6+. M_O$E/EA>K.7"/28PSA"5HU[&U>T6V#JF6FKZ::UQBFF")=>X/9!*X-@&!ZDN M#4B;;YRWFC%(S72WI%WNUN):J.+ M\F-:__[_0L,+J&>/200(9OD^&IXYB&9TUO2IIG$V/-M&0@DR>,Z10!;#7I<, M]A*$M5-5V$N0ZHNYL(\WA;P$IZ'Y[&ZA)*TML9LT#>+-1;R]+3=I2Q!O+MCM M>K4@WERXD]T24J@[=* MRQ*@7**.=L=0;L&';"]SS&=Q)?16:5D"E$N<]]DQE%OPB<^7./FS3YDL`<(E MSO\L4]N^54)N[A&<+W$4:(DJ]ZT2LP0HRSD8-+=`R0_\*\>*BN.+A?OGJ5N7 M$+%0_G,^9^.+EX*VZZU"$5K^E1.(%Z%6C!4L73(5V9.; M]^(2%CD/A^VM++*<3=/WN4W3]I:VDL_GET7)N].^(_3,J8+"O8W77Z>&P(?[L.P0A,I5II:U]0 M,91?^Y2U+;5]+-AVA>3AYB%JIW[RZY4SYGTG%FP6B]5M!Y#-X[-.0PI`-@]. M.DTI`-G<.^^TI`!D<\^TTUX3D.E^ZA\NGM5\Q&XY2_EXYP9A<\F^J.T9A,UE^D)?'X0;ZIL>&V%U'_@FK!?5 M][VGP2NE#C@NKA=02_A=$/N)+["RG+L"YOB&.BX_[AQ?M'JD=P%F^WE`"7-Z M-N[:X2?BT1?JA!#7=D%7P8\^ZSNL!^X.OF&`9[.)V^._F-%*"/T>_>!AY5I7 M0$#`P2$00A-P.!_@*?CXB?[#35CT<`01MT4"=TI[8L)\8HQ&GOL=W*2`VF/R M@WZFDR&S;<`;>0/O^)D_/[\$6"!)^P1^ MN!7:$%+<@5)W`M<;`Y\(A`7Y3E!KD`V_5XV76#0;ZQ6.%1[XH= MPWBKLKM/-[?X\MI9BSGO2+JT%99U,KW[EWQ+1/'IN;;-#WUP;B5^.!P:WCB1 M$F!P4!$0@N`W+&('4#_D#4A;,'!#'Z3$?WLY`6T/&",&MP#&R936:GAYF9@B M>50AHOZ\NWG^'7_.=K03;=B*C`BP)?\$EJ.;+QH_)JWTKA_N[Z\^/\$;3<"A M,?+I._+PQ^WCA_N'/R_)"_,9/'JI?FT;M'7'#4[JK=-5K_P>[NW.CXL$4GS$ M1PVF<<%J_01E@EW?/NBO`Q;04V0E>NFXKYXQRC>?7!\=)8`/\*,8P.J<7T[J MJ^(BL9TI4L"(*I8X8I:XH6:1(W3%$5L;#R(3FI0=44IC/:6QYE`8Q0`'Q`#K M3%080E*F(7HT M7@GN"'C,L/V#'Z2Q;3&2@S]*&E*S!+*6';]V9(-IEL"(HI6U\3U^MZ&I2O!48(C"XI6%YQ&HW*<FMOKE0%Q4\25TJJ M5%"%HS<9]+@\V-A]#G];H6XEL+6ZMJXP;RE)4Y*F).VP)4T2YTBJ/-/^&:F" M7O;"H*T!4F^Y..[[P*/<98L<5L33D42W34UOZTKNE-PIN=OM[IS67.O`UP'+ M';]IHOE"#-%/A;X)/VD_^=@/XJ>)9:BE M'^,5IWU65FB#4NR@\N#U#8?]S:??7;L.CQOX'U>.]=FC/C;B$_U;/C#'<$QF MV$G3'O^&^:;M^J%'X>JGM('-E6EBMQ:`\3,\SV34WZ0-2[.2;5CBIAPH5C[[ MFUZ2#EY!=/T,OC\AA@WX^N5$G*PXFSVKD;\^*BACN?W(`2_6Q2 MHW<7ZO:U4=JYV!"E\`")49I5\[Q;V%/:/2FCN$FJN4FLNMAF#=!R-(K_WA[<_=\"QK6,:E';IC1=US`H0F&]LXQ MSS3R1N"H4Z_7WGV$:Y,_]7<:R?[&'Y3YE;@>[^>5N>8:>]ARXUZY'X^\7\E6.-5]IEBU1:69^#/T<.^*O M#%;W.@!7!+3JJP,LZ8==GUG,P"YT&OS$S`&ZOS[S-Q.W8-?(;A/XQ7A#S_9`*5G0S0U#$3)*Y4O9*/=0K?X4, M^Z)VQP5U@8`D[4Y[D55BT52+RY(+>T6JV&__)^0@H:XWUXAT/`NH]] M<+&YZP+"G?%6FG!_:`?B)^;GR(>&-88V)O9"[88O[E)8"IUS#;RMB#(#U`T9 MA5WP-$6'6EP@<"(&4;B:Q7P(;S6&PD0,C?^X'@O$N[VI[Q.,*:`7/@/>F`6_ M2Y%[(FL#ER`J#&PWBOUZ/;!/H#S[U--2-L:]!*$Y_"2@N#Z= MMGC'?5UD^B94T0I:;-JG@]!L>2AFI_VK`D_$`[P)[E!,R"`!-0>.:[O]<2Q' M8+PIR$#H_S2;MXN268 MEG$!,04CX_<>>.\H<1:(B0%WG*6D>C^.]#0?DBO`CWO^]O'V[#58X\UPK-0"`;PFA1RSY8&;&O[)KD=`'#EC4A,LSL!(GV4 MR1G=`EG0$9R2*6)2(_S0&&B)`)M[-EPE1),"+9QT)W2X(#RJT6G>3.P3COC0 M%!^LAP673ADE@.S!1PY$X;M%!N!HPW(Q,Y.T*^.7#8P7G&-`\,)\#I8 MHF=Q+YLK9B/-28[$;#"T-'T*3IZ!KB;\CJM(W+DO#G\!WZ;BW'L%/ANP:BXG M]=O5U>=L!']&GL(H/)^/!X_V;#!O6OPV=\0&NTBPS/QUU"1*UCH`'AX8&/&33L^31,WH_W.6Z0@,%@V=&[V$LR MJ2*^FD<#$#R!!Q+[T`)&'ZW.&.PRL@^^-4G3B;'WP#YP+3==8+1`BN`7`=H9 MN:9>8#",+S&%D:JBGNL&#NX86,ENI!^!QQ<9,6%$KL4$WAXKINR>"AZ`Z@Y9 M@%>-0@^#RR".XKS0CCPLC_9#.Z)]A.HG)!SP273%;1RH0EPTA"`5+A617AHG MV0R\`%@`;5X^N^?KQ+FC+D2KB\R95-D%S@W]ACZ9'ZZR"4(L5OK46^>M=!2 M*'.X37,X*S<].VUR.ID2B91TQI?B\G8:>^U=PT;=$WG^:98BJTI`KJ,1.9$< MI0X<3Z4(=8;@!45XIP&F9:P8O,6'/P%*,]*]-';U^(H@L`N'HRBT0K5B]'J@ M\4&HQ6`?8@P%7B(!G(I($1*FJ@B#0I>K6.J8'$?77*!$3&;$<9#)/#,<8KH/ M\3,TQG%.2XQ68DC%PFHA0N(63]@HO,7B(XE$V!APW97IN)F@WW%'\QUY4\_<;(%A>J'I?*X$5#0JKLF+$RVX MIY&YAZ,HR7HQDQ9N1NAX826)THP>FCY>4HP8>M/,/`MKPL`8&5T^8UK@Q?!= MO'S,+9>'05*6AL*-#[B/G-U-Z.6H.D'+>-38./^TA`KIK9P:`0O@/N[58W(4 M'@"6+]J"06,4.?\FA&SN,$J-(@6%^QD_RDOU1$K%U"D`6IZAEXMCTC`.XEX' MY1L^N&Q?F^JGQ.\$?NM[E,9FF]_!C;('-E1P0&[MW#OA8"50A"/7R;UC9)C? M8B>$X31GSN7^@$7):)_"*_LB+9M>@W<9_2A;`-$&ZXWC"ZYC!,4!#?.BFY"9 M,:X0.=`1,[^%HTG:>)8OPF,!'CX#E(IP/X80UO&(C+\^3H@G2Q02F($$62(* M`E-V2-?,HV2X"3D_#O]ZS!N*7<CFPF466L=^8X@?T#,Q4(:;O] M*Q3Z1/E.DOM.VV.(K>G)'*?1F-.XM>'AK(4VQ'1],&9@4'P,M<-A&.UI4O#> M(/)-DI80&7M!5(_+G;A9CT[NA*>$?FS\?#"T>&[J%%PE[KD-7/")7J@7[P^R M870'[84VL;EO&MDLW(X->`Y9.(+^Y>&PU(ZV^3-GFI8]W+'P7$1R*"MW*B+Y M=O:9B`X>B=CLW$/QW5']>_3UT@<=.@O/.4R';<52_49K2JD^_KX\2/.*^L7I MOP0H>-ONZ_H7\?K[D-F(_2E;KJ6?C&C/0O=RYR+:.\3?VGY7B38C:L.:>-=C M;P4BY=M%E"Y`*H)"&'^M,R'ZW7MBED M<^:$*<&;D:C=2 MU=H!YR\9$RJ)Z`?\$%$4;:R./N7C2UZ?-/%;BN)OJT^N-P6-2HWMQ]X/HGJ MV:&!]5H.KP\5=9HC@WEB:S.?QC4'AH?[F('+RV(='_.P6$3&M\'YP33,#&8K MP88CSWVA:=FN:8Q8@.=YJ*6V"55QTDZ+DZ*C5,CC-^D1LGVA4NVR+0D/5I=Z M6>)ESO_QK2JA62*-9&55TAEYG']CU,@`=Y5R!PGC4IW<4<,`MZ3PU^C;N*0" M'24K+?K('T*$)^%A`RU;`H]U%?%!0;Z.@U&%]7-582"E]KN*.P3<.:>?!4L2 M"32B4GZ+E%],-^:<1JIDMC+,'@V[^_S(_$_-[DN+\G9F:1R3KP#*P8]-^P/ M2!?WZ/%-ICOL8ED^+X[W:'1F1I06XK$O5'TAWXP'.1:.(;8S$I5GZ3IAX?^A M)C]#P,R!1J+WQZ5J_/U^U"J!E_\Y+M:"&M@0,CT4SFM->]3PF:B&%-5P<75^ MP;D4]0D>G6R"P!R+]A@>:3K%B@+$;&"`[L=-;5%5H&&A(2Z8PS-$;YBC-]+_ M!,].V7&!':^C@P=WL?&,PZ]+RSTYU&?D"]81^J&)U,-*ANRM8'B,%$5)TYI7 M9MOB`).1UHB*P@L_KJX,L!(S*8[H)76F18"TS-FN^%EIU9XXF9;O!(&%EO", M@/'P("TAY55^AC\@/2RY2,PN/Q\GCLO%Y:>6,'A=VL<#:+DZD6P-(Z+4)SE> MY73*8!V8Q0:B8[VN$R(,&N(;GHA5K!"?P#5X0JZ7O2C4$M@=! M31"=XT8$-?Q2O6S4\C]>%"HX^(W<3O6KX81U_U?7DWB0HF'L3GMG_ M"X_LQ,L MVR`A.BQS,$Z6ZCP@JY=UES*EBXUM_)'K@PH%<;EWG?[I/;/0D9>5\9=6*37<[6=F=Y4\`B:_H"/ M>?7PL+E#+.Q&`S8[-1["O9@T5 M<9.#Y&%I66K:&2#D!0,92$6-*^^UP_%`T"7B3C6,+?O3# MF.KVQ\=G^+UY7UW9T\/6=Y+9TQZ8QCARF["5L5%]X`+]C`H&YW]C%+6W_*Y* MA6UX'!5/FHGF-%P3B?@-.Y7Q$&[Y^(V?)L`PD)_]1!W^DAS:GVYXHTX`RP1: M"],)^`AA0$6T`]%+#W?ZTT"4Q_(N)BZ$^9VU/&U&/)A9*RZMQ/5J(L?`$8CQ MX3A^!P;>W'1@*@*S%+W0X[@6K1W.R._N*WH[6NP=3*Z:'P5]Y=TD^4L$`-D' MIY2<'GXN!H6?.!:A)K\C%^86,COH$(AX-Z9)YHV)M2ZZ+%/:ZR0C1K)]Z)^P MI:N!QS7?N_!_@`\K/5+Y%'8#=\1,TFC53ANU@S&LJZG`=7*\%=-^$IC4K7'0 MONVMZI^WNH6%0,$5]JX?40_UKNA\(S+=F+[K&KS'EQ-%B]D?"^E?!_1QD#87 MF!90Y/._:22*K1V*+^;'#*.\+ZZ"03@:LQD:"U3;46(_GS">LE`;]TG(FS0K MZ--^G*AQP<2(W[L4XK=\>]7HNK=35D/>9)ILO8T2WL$K'HZ/+A/Y;<:C=6[6 M1=.(*7%=U'"+V^E7WEALJAT'TQB:TPRB4018@#*9?HT;G,T*,$W^\K@SE)$K MYXD6&<6$*7EM'A+CD=$^[M$(9TS+(#$RPMQ(ILEYC1M<&D1;/]A*@;>C\#!P M3CH(*9%1]@.T>$=$WE?.@^PJ./=H9-%.QH$^[.;<=B^G>)(49YP8YE;@5F$$8?,4KQ8/QN(V-F=D^ MY65"HF,2W^(^F!!!J25I(H-,LHU/31-'4'FQD,6;&B+_WSED4?F01IX]PZ*8 M3O>CS^23,8P:&*HPH1KP/&=:<."&AG#Q3<,V>3>093S0>.H,ND?<`8('\/]/ M`HJ)/7HMWH7!+J8L&OF4Z5LK/,M<-\U"R\N)GI["G\7?/";:&XO^GKPW75'W M9HN:X#G3+#\OBY]B*0^#[`?(QG[2+8;/2L*L8>03`#-P6O.F-V)N5$/+C(ZR M(ON/GV<-P1F%H`)Q@W+*+"7!Y[R+G(AS1?U6RIO11FM<_27FAF1]IE/N,QE# M<$G0_J,0"`X/1Z*M;URR-]G"GO?-Y5+*W:-\\GAD&T[D5KXPH%"T19HL+*ZU MRJ=A>1P[SL7:V'LGZNZ;&]PA:N2X1P2H]NQQ;@8(_RY7NL@]7G2\1"8W(EBV MU_AP2#TQ"F8_1T>47R63?EAE7O:ZGE=)QTZP?U)N)*WG.O#9%*>BMNOZS`1\ M?Z?7RJ$([>U=,7_LNIKJ,NCGM9OGD6NRR-VMO+ M[!C,)]!H=J8KYT=1(Y+N.T.6)/K%5AA,(Q(/030&U M/J+9OII!%&R"41+].GVA!1W*:Y]!S_$^6U'.[M.4;WD*--H/8&O6++[$A]C]E``S?4S[%P5=O\,5O5WUS\LJTN6UR3Y*%2.IV M%RU+K*:PK@_QNK*I@'P6W7*IV)85V7C"QR$FJ\3E<4-J)%XP-^&FR(E$IZ#F M#@HX4[II-=WT@7:]$$5N@7ZJU362&U<5ZZB.CCKJ*N6TJ.8_?_%5E#K+)+SX M65XK.HLA3M^2`(_M\FP2"GI2R)][5#]D8@\;I5/D\;D>P_1C[*;BD`;14=@+ M<#CE@(U0@T3?Q@E+U#-BH'7D2J)>$N-%HM'MR:0W?T*@(I6%",K$:?FETM29 MQL6F<9B;F0\?O5AH=A:5.O)3@2`17YX(CDZ*E;9X=7E&5;4#!^-<2;"G*(4FJ>U MB]P$[WBJ`B\N`?GG#\D&&VT1S@U*;(U'@TGCHE M*N,SQ45Q4;%("(D%\@`4-&)T9"QNS1YM>7"N!&=FG:#5"L)(Y8`YO#F]-&:B,DV[%8H2N$ZL1^(GC]-F* M(AH7XM4E:%UA&; MN2CQ'_A9^+-=\(2IQYN]QDWRL+WGI5[#[K/\FE/;&(/;=;Z7 M?+*26"[[T4L_QHU0_O5SZ)_V#6-T^9"Q6SD#?^58V:&5#[VDMNPI`?PF&3L$ M5V]LUO_WZSW_\\Q^$_"MY?YR&O>+R>?:_I7^"]:IF>W=O&U4>.?O][\9H@.7IY@3$W81PQO81O[\VFYWS M#**67&@1P/=1N'.=[LRG:$O0L@QXA<6W3WXM6)_48@2K60VRJ,E2.2;4GM_` M&99,./\5VG5EOI_=Q%G(473?]@V?=1"4W\BY<[$A>6/ M8ZQB>-*$JN'$.8OFY&REZ#3<"W-#\+I?,?Y'5V[6OA@?&B!J\OF\>CZ,*4Y' M#9&QTZ)Z?A3<*VR?<1>57^BEIP(,##%@%:?\&Y_%9R3Y#EF<@./CC.*'@3\> MX%"G>/@C.'<\2N8!N#'V7!QQG$YXA.@!'`$!+SPW>4K2U`)?SUYP8W!D&R*' M+P#I>W@TDO?HH)88;4R&PBO!/WXH']^3QQ3X40:`"1HP# MQIWD*:R8')IE&.^:E.^F3K+F3KA!I+VV0/:+5DOKG+>6)7M.E:3HRZ,X448K MZ#B!8"1AJ>"!]FUWSK56K38+P@P_Y.9*YZ&^`@I8HHH&0N52E]C0ZS/7YU'L M*)ETA(D8H$M-(_13/9P6^$#P;T4I`^J07FCW@'VF3R[G>82L(4G4LCCCETG+ ME$N1`J@_)D?0!'"\0BDCT4+;S.&<9[['A'C"RR-LQ@@492KBR8"$!S-P,<&3 MYH#SN:N1P2RN\[.]?=+*DWPJ.^:AS&*3XQK3S?"$CBR7D0#PNG9>9*68D2=7 MVZ58O,O7&TDTF.FMJNT:YLW$4L@;WAT)S&HTV3/])=JXP/.-48IU4CD[O,^` MT75?Z-NM),XWWM)/8VHWQXC=_0S?;J.$*=;%RB*C$;7 MLLR-YREI2:CT!N!N?-G8B8YPY(7^IFYU)+8 MH5+;.7.*HTJI$/K"B^&XZQ'7$L:S\'H98FII'Y/,V:/B21%>Q"=V>J,!L:*Z M,>"C94&9CN*MAZ32E4_1BWD5]U*AT#S=<;FX,G"Y^+TLGB1YILSF M#/-9R,TRM!F5OWQN]N&/V\\$Z2'I_ M=?WOWQX?OGRZ`4R9)J6]7HF8B[CYYO;ZX?'J^>X!+A5E\A"\;:)CKO(6=PVV MVB^^ALRR;+I?W2,/-F30Q%EL>'@F569TU(Z)._8G*Y)HY1[_CR3>W;7A#_;% M0FLCXB#5[?;88G5L_%"NEBV4/33C+,;^,;.ZYM4KQQ]'KW"W9[G74+BBTV>< M:Q>I)F7#95#`Q^#O;JB)I?*!]7KE..7H5;%4ON]G#\\/!>,I(].5?5?>L.S* M6"JWN*/\XLHI8ZG\8M%OR^']M@`_<2,N9>)ET,;*-:Z8:ZS5F[7*,FG"LH.I(H9ZF\Y5PW6F7C5],YA<+$ M:/%$3RL%Y<&7##IZ-7P=B8M=UYJMAA*_JFEQJ5SL"ON.1ZK'-V:?;&GZE`57 M!YT2.^MKXWB-M+?6K)TKX:V:%9#*E]^_%:B@.R$C-BJ@XR4LB]ZAMJXP;QV] MRB[=<=_669;[R9.BRD&00?:.(4\N!SJJJ)DK*"N2:&:IG.FH>ZR/3:GX872. M2_R7M*NBHO.J*BV10NXJG1D_PKQW0ZOO;_>R@J(CB9*6*N_]2&TCGL>!W=Y? M^"0V9?EET,?'X"7O.T%=IC[6:WL[!E-!P9%$&TOE,M^[.%,S\I>59:_&1F2E MW699=AJESM!4T'9DT2/2^555]AW/%(EKJI)*N"L[W!_LJ$UFGNK*:R@ M\$IB!:3RYO=O!2KH3LB(C0KH>%5-4E'>.GJ5+97C?CTY%B/I"^X-HSGVR7P4 MY1^4YXTV0#-8;LB;ALN#L"VD:)9MZ++P5]! MVH8FTX4&)XTPQZ(]YN#H1IL/Y6%.8#A]G#@1S4R'Y8T6=$P`2XYC<,"PASC_ M?61X."3$@(7YY(WQEG3Q4P`^P`COPDE-^``OVB_'@27A$)D>KNZ^Y2JCRUQ< M(C[TC?F6&/Q+GX\JPUO?6&\YN$]N+_@W"\[(%R=@=FXP'V6B)64TDLS/K1?G M\G3A03COS`\!H,R/8EH*"[ M>J$=.4D^S;T*UO(?:@:^AI,$L=0+/B^]3C[3O4MQL*87\`$M2"X^!C2=P%2J MZM,+TP#'L#!`1X].&5&KQ\>4G MH:\RQ'RIN5%KS,,I^AXXN'J*<[1HT'@.@4O;4;BF._/B->4R)WV?<&AX0TAD M=^+7)1W#17/`-X,]E@H6U5&MN,P]CMQ>;Z19=XH'U9T*IISKWX[K_)R;)<9P M[IX8-C:.!Z6AE7<=BA72.'$VY1KRAIO3:+#/V\,803;A/>(_0;_HYHO&BM/% MCFE:6+NCIH5M$?0#GA;V1$*R55*JC"T9L,>EP>;.P^AR]! MKYHJ=1:K,&\I25.2IB3ML"5-$N=(JCS3_AFI@E[V?CL^R13E5J[CDU31;5/3 MVZH?MY([)7>[GB[57.O`UP'+';])KDYK6VFR,K&8$II&'&*[MM7[C7QRL:$5 MGXKX2CW*VU]YV'"KYWK$[4(01`.:]`(98V\NMT>2(_RD4=,('L3D[;+B8]RD MH?-OFV>37#3M#RZ[4K>CFM=8*FY"-;18=1ZPGZLY;2AZFRE#56N M&4K!XM32^#?ZY?[VPW/N^_N[3[>G212FMW[,]5Q9V&PJ40O7(')=CVF^X?BG M7"'D]8&.2C4;HT^N+>Z4%/]PDF6C!>R1VJ-WS!/2MY!+SQF!\U M(O,7-+*4$OF[8YQ-VYHM;Y&/NI/9>2NOL3=.L,H$G%X";%5M(8*?CZ'9V-$1 M]0C:A>UT@TPF/"AM?,"">W@MNXZ1A`?6=$NI6J5JCZW;$7X^V,97:]%Z5W3= M`O0+Z*Q$6NGMZ@!W(/[5VE6EB_(9`\.C?HJ1.]\/J97!$'["?XH-%!L<,QNL MI_(W]_C6K3;:CEEXZ/6HQYS^T;+!L3CS#V'@!X9C*5HK6A\#K0_E5,BZ#L(T M98\57K#6*RPQ>Z%>@!NY:S!(M>IE-PY^JLT'96-#XEKRL@[JX>?FN59OU2K' M+4HXE'`HX=B]<$CB;6RO0<<<=^)]UIW0X`4_$C,T(J]%7LK]CY&6[^7N/Y&:ELOHVC,XD4J,[ MS%!#GMZ/:W?]E@6`@Y#J?)]9M@H1MM,!_RGMA5KLF/M,O>&45KG)HN'>KVU83?N>B'/L\S<=ZYQ1W4]#M[?T#>5YDZ)L#"'+1%$ MF^7SWY>4SU>)?I7H5XG^:B?Z2XYT:SO*]C8R)[66S/8J]U&E<:LG4OH$FZLL MKLKB2H6_LK.XS8):ER2)6YM(XJ)HJARNRN'N'WLJ>Z9RN/M'7:E^3U[;_IA: M@?\7&EY`/7NBWOFFOX:'CF(*IVK^DJUE"I:ODP>.6,I1PW/)T:P]%$5<3ZC5(^PU>QHYYU./C;#EY?[EGI-:[?S M96T:\:@_HB9BQAXO.`VR0BK_H)+Z25]65;NN4MH2*FZ5TJY$_JVQLY0V:`*5 MTE8I;2D16"JCMU5"6R6T9<9?V0GMEHP)[0G#]O,/;97.5NEL&;"GTMDJG;U_ MU!UT.KNNX@R5SI8/@RJ=O:]TMMZN:;7&MM/9H-ZTIIX_EKI2.EL5Q^\GCWZC M\N@JCRZCQ5!Y]$HD_>;5L6KDAU(=7=*JJU2Z2J7+B4!5'5XM>JED^F;X.ZOI M*NKTVEYRTUAJZC^\/@ZM&[@V1!)\`J#I#H<@&UR_3YG6I;A6 M9:55)?8FE=AC58>M[#K,-N=5K:17/K;45:'4T_+XP'VJ2KR)KK MR"]`9=9W4=%=)OU(#B%_@@@9#GB3;ACX.((9#.>:*7M5YY\%A>1AR22("\G\ M[$9'!M;E-RP>_KA]_'#_\.6$^;L$LW%;(N"'QFY.]DOKH>^;WJ?/J3>J` MTQ5SURH3ZU<>3@]X#]QA=.&TX?2M]:?3RP_<0<,&P"$3`YN"(-'=/B'_I)A^I=;1DC&?@5&NC\3` M'31L2N$JA7MD9)06-B6+QR&+5R_4,_KT:*FH?)_*`'?0L"E]J_2MHF)EJ-CO M>[1O!(J.U:;C(QT:S(GW]HZ1CLK_J0QP!PV;\G^.0^/>?J>>R7QE.*M-QCLG M\)CC,U/1L=)TO':!D(89A(9]M)14+E!E@-N6N!9.TD4#IS(_[ZFH?.!4OF<]FJ+DS?_@X8VW1TOUS?TQF_:"=;#P_NKZ MW[\]/GSY=`.H,$U*>[U=N6@/Z3D#/+8S<3YG#6[8+Q:&S+)LNF6UL)H*D(,M MLFV1IBQ8(GQY6*8S'6&%DX+-T?>*(+$VB46]V=`:M8Z2,"5A$_CZ00G6^H)5 M/VLKNZ6D2MFM[8A7VMQ!"9D2,B5D6Q&R]EFSK<1+NN"\Q_^SJ^#\-TRIKW5> M8;_`[D3-R@.N#$IT-RIR?RB2T@]1`J($1!84*0%1`J($1`F($A`E($I`CB$6 MW>U&<5Q`O;=H5,:LA(S@[OP\A\09N8HI.\7BBL45BRL65RRN6%RQN&)QQ>+5 MB\IVNT-X^WW$/+5#*$TAQO:H?TB5%EO$DI3J4HF)$A,E)DI,E)@H,5%B(@]" ME)@H,3G&&'6O1TPG)\.I+(8DBE0=(Y`A%ZC.F"H)4V=,9<*=.F.JI$H2?!V) M>.T_?%!")@U_*"%39TQW'9T7!K#G[XD?BRCB\X*[KF=1C\_VC1N'X6(NQ;!@ M?LVI;8S=,+CLL>_4>K?43&"1)4@^6?&GG[,?O?1CO.)__3RT6'#YV:,]ZGG4 M>@I<\]L-\TW;]4.//M/OP7L;OOKUG__XYS\(^5?HG_8-8W1Y[0Z'+!A2)_"O M'`M;M,)BJ&,RZD^YFYAP`?SQ2'N_G'RNZ5_AOQC-/[NUBZ^-&O]\0ICUR\D' MPPR8];5Y<7'R:T25&$W)A.51`/\B61*D)X61SIKX0B-/.$V;Y(@D@Y.N":Z?E9C3B8/DYT(7=`CM53RHE_N;S\\Y[Z_O_MT>YID>/36C\M/ MDLZ)T[5ALZ['--]P_%,^4#PO+#H*2U8[3*XMTEG)#R=9OEW`CZD>R4W+]J;H MBEA%)DC"Z=GQEQ%^L@.U]1\GU&KMK(/@Q-\*>(`HY"6:-!ZXHUR7NP7,,&5H M>0&]16:;@N%Z=F)[-Q:[73TG_Y`:47)SEON-_)$M;0J^O2*O.Q8:T M@@=(3*N,`B2&8Y&<"EP'T7,L2@E:*S_2'I77.S(%>RDBEN'5/(A9P*1<<=ZR M[VWMJY@N`=WS@`)_#4>&,R9F"&;:">PQ^%:&#W?J=?)"!\RTX7//]8AOX"=D M2>#U%V920H+35)!AX;M@?D/\.'8K?=,[X(J/%@>/EL&$X)$/`\0"6 M.C+&*"E\??!2G\9+CH%@L.+1R'._LZ$14+CCAS)U84MKMALYHI]M@>H%)BOU MJ=7BT8'A`_/A%#&;N".*_`1L%)$:><#M]8`Q-6(;X%48@1LQ)#PZ[&&G?P^O MYYUTS[(/%LCMU/7S=W[QP>*YP(UNCS#0R;]1B#,<`H]C-@M`)Q,3_NQ2_#_T M5ZA%NF-"F9`!PPO&0@`,TA!LZV?>!E%+P!>,3_[LVKC8Z,GC^+D!O)`YP+TS M'^RS[^+1T>/.R,=(/KC01$+BQU(2@X`OR[\3H3$\2FY#SYVN^M84%-+4(++* M20IY4ZHH-K5FYSS_`F`6H-GD5M];`?G]IW)!;&OUYE9!U+5VNS8-1*XL4^@\ MZH\H1#LOH.]FLWE&1!*.`\MW#>K3Z+L:N;M/.<\O%5/9Y;8+\`!A//I7R`"& MHI+GH):,T-IY'J$Y=!'#]EWBA]W8E@@1&@(K15B:BD24LE*7V=`NFIT\GD!% M"?2(!:>**AB`Q4N6DB'@@QFX&2%H3T=U7E^4C>^FUKAHSL9WCCT?/%1,;@H+ MZG[JFX8M=+/'5YCS)$I=:UUK%IDS<,M^1:O@/:1TY>39FOP!I:/>VITIY`C< M`.RK$8]Y3)A#<%G"'6\<&B"+H$6)A>1MS%+@!#J11[833TRO:;66/L\5FYU^ MD]OGX4HHPN'=,_G=\*Q7M-'(($]N+^!_H.@W3F_(#?4AW"6OH)X&,2D64[)\ MO=INM@JR$_GU'PT/5L8=^PK0H5),<^?P9OD:%\B8>[K4-(;``A"@]:AC&4!@ M,/(&&*Y7/V0!Z7*R!.A9WG!H\=\->:;FP'%MM\_P)7>.>4;>Q.JY7GN7N33Y M5G_W%A_-M4&`S`9O];^KY5%C%KD<-H#[\8$:CMS@7IU\S""@9Z`X38D(' MUPK?]5T7_5/T=(.!`7>`B]VG%G"Q:_*PT,+7`N0-_@ZXT@X]5&+(W_RKD>$' MR1M#4&U1_.H+=>=Z#&P(?&T"SFR#P6M?P=98S!\RWX?'=*='=@@&$B1>Y(H]",AI[PRY@I.$ M`@(L\E<(<0/%.(G[BGE>03BSH'"R(/QP=Q#8E$?:!N@2\8D''W.9IGQ7")9< M!!R)B+9EZ(81Y48&LX@E8CV$#WPB+P%=J9W<8NO-LQ;F-LLQ5CD/+G*5C=!B MX""3^[/_/@.#96,R'[\&9KOR?==DW+\1@F40$P1P"$P&8@A"F^5.$/([VV:. MRW(!]+WQ#:\!VH_)4PC^$X-WP=]>D/?ENR@/+_`F?"9_BPAUD8O=,""P5";4 M$3J:A@62)-P4<(]!7<#BD)E-U\>T;+QN2PA!\LA)YJK8GMUZNW#%/;PGVL=; M'^G(]?#&,C;N6K7:5C;NMK(MHO;LU)[=C'T@/_!`@<1/S@YZ'LE3DNRP.]JQXN M\PH>9Y.&%L64\+[0QH0;[=G4%)X9O*B+Z2E`"084R!G1RQG&5J4FUQ&/S.G9 M(3@A^(F#Y(3P"`C&>(`#"HCUF(E1HSDPP%N),?/_/GY M)<`"X3*]I9,7P)>N-5KMVMNS24^B-"SF'LU9$WP&]Y4'2JBR('8=N*\<:QB4 M?[/<5R=&XYRM,A0)1&$D+%UTFOL<<,[;;@B^A^6_O9Q4-=D_#EUEI2O>:GA' M\HO/.DQY%RSKGF:`6][-?/CC]O'#_<.?E^2%^0R>ME1PLL&Y0YE&?#9::M3X M7-BF3:V59B9M*SN3MC4!K##L*Y9"B]$NXJ<52;G#36SY-05.2M-3I1. M)9,5)Z*2R8,BI[*8!T5.)9T'14XEG0=%3B6=*J5P1$2>+[.K=9>16*K7[,:I M:%PM&J_3N4[1N%HT5G)\^#16.3[XP1;3 M\B)7O.9Z#9H?;`=5&<'=8^?\`^\IW)[$S(6FU]4\%\G!51*Q4XEH1,W1JL0B M2B(.4R+V(0'G23NO*K&$DH##E``9;$);N^A<5(Y%E$0HB=B61-1K:IJ6Y.`J M>=BEA6A4CC^4.!RF..R#_?6V=MY4>23)P3T:$9#!(H!(-!LJ:)!OSVGM.?-K M[3E]]K#Q3S`F2?-7WGAVA+VT-%ACL"\.61L-U52:VZ-ZV>!N3SUN#P=3]-_^ MDNB*LQ5G;Y.S+SJ5([7B;,79R_BLVD5];WD]Q=R*N;?,W)V]I2@4:^T"M'[9L[ M)\"9L]@[WU!';RH`[@&INY6K(59R2K6&K@I^)`?W`)EY-Q&78F[YP3U`YMX* M,Y]6CK**D:O.R#O1THJQ)0?W`!E;,;)BY(-@9*6A%6,?)&.K@%`Q\\$PL\IV M['NGHC"<7?[1P;L;>ZQ&!ZOV]C*H9)E'4JC1P4=(5#4Z^!"HJ$8''P`1U>A@ MY0A5`KA#%U0U:DV14Y%3D5.14Y%3D5.14Y%S#CD5-0^)FDHX%3D/CYPJMU`9 MX-0<+#7K3-'XF&>='0^-E1P?/HV5'!\^C94<'SZ-E1P?/HV5'!\^C8]7CH^R MI\DC?:%.N%:5XL&6C,L(KIIUL<-9%Q?UO;7I4_*@Y$$Z>="U1GUO[<^41"B) MD$XBVIJ^EJ>L)$))Q&%*Q+G6.%<'3R4'5TG$#B5"3T4:RO6WB9KUQOURM%:L;8LK"V9+]U4'HCDX$K,RU*KZ;VUV5>, M73W&E@+>:0JZWCY7&EIR<&5BY"IIZ-;>=K+WR-D3K>KC%?]4Z"S_D_:33SW6 M^VEB6>D;9G>R7Z=S?_P'1SYO3]]U/8MZO)5\?&H+P;P4O>GY-:>V,7;#X++' MOE/KW5(MZ,4^3/+)2@#(?O32C_&*__5SZ)_V#6-T^43[0^H$CW3D>@$\^8;Y MINWZH4>?Z??@O>V:WW[]YS_^^0]"_I7<8@ZH%=KTH5>\^<[I(0<%S'7>CZ,? MD\<0$S`,?SS2WB\GGVOZ5_@O'N![=FL77QLU_OF$,`N(:9@!L[ZV:OK)KQ'U M)]K[CP+X%TFDH"4I4%T37VCD"6E/VW5=`HV`'G_@#]Y4$ M\$O7H\8WRWUUB-OC7UR[PQ%V`.?RT*GKY^]\XHZHQU'O$\.QHG'0I#LF'NW# MM^0-K"D8N*$/O_IO+R>87J+)#^5/K+;!*&'M:FJ%:J@D@YNR%EIB<5XY%E$0KAQ+*`DX M3`F0P2:TM8N.ZL8O.;A*(G8H$?6:ZK4L.;A*'G9I(=3L(LG!/1IQV`?[ZVWM MO*GR2)*#>S0B((-%`)%HJA%>$NXY[78@Q6_T$8\*1A/\(_2MD(VRWI,$: M@WUQB&IS5Q+559N[Z?-X]I9$5YRM.'N;G'W1J1RI%6;N["U%H9A;,?,XRL'*458RO&7F8'7:OMK\I*,;=B M[BTS]\7>QM/+R-R2['WL]KS-G1,83A^[W4<3#M1NF-S@'I"Z6[D:8B6G5&OH MJN!'22% M&AU\A$15HX,/@8IJ=/`!$%&-#E:.4"6`.W1!5:/6%#D5.14Y%3D5.14Y%3D5 M.>>04U'SD*BIA%.1\_#(J7(+E0%.S<%2L\X4C8]YUMGQT%C)\>'36,GQX=-8 MR?'ATUC)\>'36,GQX=/X>.7X*'N:/-(7ZH1K52D>;,FXC."J61<[G'5Q4=]; MFSXE#TH>I),'76O4]];^3$F$D@CI)**MZ6MYRDHBE$0*P0W&H58X]E#0H:=B>NU3KJ)!:VZ_MO]\41,DY=D!%"=QLAZ1S&R[.#*Q,A5&O34V%_23K&V8NUMLG:]4:\6!2`ZNQ+PLM9K>6YM]Q=C58VPIX)VFH.OMX^SJ,=; MR<>GMA#,2]&;GE]S:AMC-PPN>^P[M=XMU8)>[,,DGZP$@.Q'+_T8K_A?/X?^ M:=\P1I=/YH!:H4T?>D^T/Z1.\$A'KA?`.^Z<'K)#P%SG_3CZ\9E^#][;KOGM MUW_^XY__(.1?\6,^>^Z(>L'XLVTXP95CW?X5LA'>\=FUF3E.[B,FH!G^>*2] M7TX^U_2O\%\\Q??LUBZ^-FK\\PEA%E#4,`-F?6W5ZB>_1BPPT>-_%,"_2"P% M04F!])KX0B-/R``DQU&ESE:H-\]:R.93ABN\(S[[FUZ2#HY?(+I^!M^?$,-F M?>>7D_^$?L!ZXY.IK%?V(F2JU$X6(M%XC5(X8W\,4>:39W,:C3F-&![.&#$":A$C`#7F!QI84-\GAFF& MP]#FOUATY%&3<:7)[S>&J$S_YE^RJG-'$J& M-!BX%G%?J,=_I:`ZAM$=M!?:Q&8O`+7;X[^*>?#P?Z3GVK;[ZE\>#DNE4,QV M_DJ`1]Q'Q(USE+@X;#QC(LWTD]A)GD[F8H0JP!S M`;;8HXY1P6?TQ%^*:[-C>QH(?,$+Y[\O#U)Z/[^8T^PE(IKPLV=6?DSAG:FL MG*-(T?N80I3Z*M.6WH?,1NS[R[NH*1%61'=[%KIGHS!P1VE4LD/\S7*>=FF- M&HT<3XG MJ=S'HH]#QJ:01"#LP,@@0S<*8-N(L-1Y[[0O$)OGB$,6(!"/G?U#I;P$F5V65< M=GLPWE8<6BRX_.!Z%!!UC:ASS/'M=T"NTZ>/1D"?/?G#=X),; M4/)$3;XC`.\Z/8UAM)GS[;('ESAPR3W\0;[SKSP7Z38(@M'ESS^_OKZ>?>]Z M]IGK]7^NUVJ-G_'GG_'"D^CZ8#R"ZP%VZEC4.OF5/_SGB:?#]__Z&1_%+O%_ M^2K^?U!+`P04````"``1AVU'Q-'$P&0+```(J@``%0`<`&UD:70M,C`Q-3`Y M,S!?8V%L+GAM;%54"0`#DEQ&5I)<1E9U>`L``00E#@``!#D!``#M75MOX[H1 M?B_0_^#F/#O.Y6Q[-MCTP-DDBZ#)QDB\VP)%<)?L4Q^:0,_QFAL/A[=.OS[[76V`N"*.G>X?[!WL]3!WF$CH]W?LV MONS_LM?[]:]__,.G/_7[O2^88HX"[/8>EKUS%*`Q1\ZC6-'W#OVZ!\=''[H_?/@YY.##R='!__J_7=T\[_>Q?VXU^\]/3WMN[*&(*IAWV%^ MK]]7[7B$/CX@@7N2,2I.]V9!,#\9#%3YYP?N[3,^'1P='!P/5@7WXI(GSX)D M2C\=K\H>#OYQ]WB?./'R')[V(@9-@.<>G>X+X M[)(BZ^>#C\8&B_VG$V1SS8#FD[L5_0C+W,0WV>JJ^;W=7 M&;:=9<`OY.LS\WU&[V63CS78R5!MA0OJ8BJP*S\( MYA%7:?,9\I1*W,\P#D0MYJHKVP+/=UC9%[[!?(KYA0B(K]H9A=R92?T9<>+@ MH>KWVC)M M4/<6)-*93FW6394TI?_WT@UC/^Z:V[GR\!)J(3E0?<;Q3!*0!;Z2PX*/KYEX MM8G4;Z\-R3\C,;OTV--6Q4M5NFU/L*F-;]MZ-[/++?6'%SDKI`S&72B_6X<= M/?F:+P=Y3NA%RGDMNMQ,@Y$'9CS;(TE[ M470Q0>(A"C%"T9\B-!^HGAI@+Q"K;Z*^ZQ\<)I'&3\G7OUT3]$`\$DA4I`U& M8^V,>:[4&.6!@N6J30\]8"_BY#=[TE5O[DPD.^XSC*:`'_(LSX@[JPKEQP+J MV3@O*3$0:@Q2M?6)=`PK^@EG?MW>3%AA!CE"(5EB<]4!O8RKG_" M9#H+Y&<`J'P..8\B2QMPUH5A860!QYIST*A0K$8JCJ5_M<%%5QP6,CDIB@#I M1``,T=!Q6"CCB1%:H@B`U8:4L#`,L>'JT$@".15#ZV"IQBT4XA M4V0?L-D,71G)1GR-$'&OZ&DI+_BX'8R1L_FZ5:]FCJ%:VWI]*!_ M@&"1=VI]A6+W`G%*Z%2D9#O'$^(04S1O0]PI9&T$TH/YYR*84N)!+H_>7'I] MDZ7,'>3;ST*A$E!"FLP#H1$S=]AA4TI^Q^Z5*V=39$*B/(80.)#]+^&2$>(7 MQMPGXGDR_$]/!H34`.Q*.S/H:&,M[L9>-Q1'*X;=2D%C+0+P#`VK8]Z]--:5 MU;.FW445VQ0ZR8FE?\BF/UO28PL^NJO=MKZB2>VVZ.!&,@7%=7;US59%TZ^\ M%]2VI7;?CYJVU*&`,R7;%/XE_9WZ+9T?;\D36_#Q?E1\1QT,..&TS9Z(B[2D MUZO&NJN\$(+D52^^$Z>L=EPFFV<7R%.[,-N*AS4-=U=S+:R_T=A7TYF`E\4: M"/OCDE%NM=T)7:;A'PJ\Q68:IBU=4&I@C*[O#`DOL5.QS MCA?88V6.LWT6?FAI(]T*>%U\-7LUC-LO1=Z%>A3%AKD27O\`[`[6P5=,+,V+ MU]EBN[&$-0]WZ.D&!9@3Y)GR"B7E`=B(KM/SVEW"/>#Y]YKCOS/^N':Y-@#E M"+J&4(Y]P#/,-AB^<&4>' M"KJ.PE4A%>"QXP8Y,QG9\XQ[J@+11-11!$TB`5Z`O@PY)4'(U<'<2_*L/E6: MH(&FH^`9)&HS;?4=SXCCE0.@*]2Q'M>)T$B:I:2+U4P[E-.F^$8C/Z0DWG(N M*GU7/?(NPF(MG'5B91>'(*D(>.@HWJ+)UU2:_3])BN:VVNBH[JQO0[0*](OFIW]K4Y.BITA01R#DM>N:3?FGF'35AP0AK,K^PN:E[`QI60&AH9RTOMC2&9Y(2XS+C=$S%C>$,DZ"Y165<046RGED M:XG/.][@8,9)+?G\D2^O!LPWHZ@->& MD@%>,(S.RWQEE*V&A&JS*R.E?25^-?*`D`]BHU+B98TX6Q,74 M54-\I&M#]]]A=8JZ3B70T-Q$:..U/8J\&/9T/+NYSPK%M>@&JE^+`?6G0I4 M0M#=I3_3/;*7RHJF-#Y5[RS''%&!G"2G$/V7H+%V`!:JV52#W524IGK#.F"" MY85?7N[;A:N-KS]1?U)7H(PP)VJRYZ@[M?$YCO^:?&^M:G;FC!5_(\[46.Z> M+;$=6IVG0T>2C5;5-W/6J<2"-:Y`;P:OVXM,F"GW]VQN+[B=G=HMMG`9[F6 M44[^)C"U$Q5P$B%^2.-O1.4;XW24:1*J*?PF8-0)!CAAGA\TKNCJJN`[[&`Y MP)BOA;8C?Q/`VHD*^862H@299Y5K@*Q]COF-H9N1L?H0$"181QS/I1LZ3S)> M+TMX<:JKZB;632M\HXI@)WSUJ2-(&F+S[NE&;M]G1FB4WR'`GQ+]9--@UK4JP:`,FQC.EU/:,#Q>XEE7!**J//*?(JVDC>B M`'5$!CP3N).CW#))85ZGWSDW;EDKI0$`;GV%+FYD*Y4/\J-!:;:C(,7R:8D* MNC<'J49&V*O_S,'8C39Q70D1JC=3HMOY5NO@QD7_2MHW`:^%G(!]<)K[M**F M'\NIL&'[*MXWU5+R;8[81M)D`K.690S`F84VTV1)U&RT;`+FVS.T.>"B7N M9UBQOH.-'9596XW:M,Y>\G9))9?K<@!TW'Q?=XY?P"OM^@%U*`V8\Z6TU>_( M,Y^RM:,'@UA.UPHG/>W$`0QH<7E1N>-J"S.2=04^LQ2`LZBOO9L>-"I9KD%/ MI*,U.^U:7;4)65%W!3,K82#/CAJ^TAMFW&%FO\T3U.H6^@!?D\7&CPW5J0$L M,+4E:?-ULQ1?T9M6/N*/(MY@'[]T53H'M:'L#":E$@!V;UU[*NEUSQN!>)TJ M-0"^O,]MZ/^2\N#!*.'[E0]/?1JHQAZ0P)'\_P=02P,$%`````@`$8=M1V@< M;U#%,@``=D4#`!4`'`!M9&ET+3(P,34P.3,P7V1E9BYX;6Q55`D``Y)<1E:2 M7$96=7@+``$$)0X```0Y`0``[7U;<^.XDN;[1NQ_\-8\5Y=U\44=IW="MLL] MCG&5';:[>SL?]7[I_3(Z8C\,/GY-7S_VCWLG M1__G>/CK\/_>_0?]U_^\^CSX]/1QZ/OW[__$D(+>=G"+T$Z/_KXD7TG MCI)OSWY&CD"P)/OMPRS/7W[]](F5__%,XU]2.OW4/SX>?%H7_+`L^>N/+-HJ M_7VP+MO[]+^^W#X&,S+W/T9)EOM)\%:+-<.KUQN-1I_*OT+1+/HU*^O?IH&? MEZI2RG4D+,'^]7%=["/[U<=>_^.@]\N/+-S(!67"?/.9:@,GGY9__`#J.CKZ M!TUC\D`F1Z6LO^:+%_+;ARR:O\0,8_F[&263WS[,PR@O&3D>#8[9I_[E*@V* M.4GR<1)^3O(H7]PDDY3.2X`?CEB[?SS<;"$-%GD:I)1$2<`H^\3*?)(W\PFD M;"CG99J$),E("#]D:1R%K`M>^#'C\7%&2)[5D%:G,0LRW]&IGT3_+)4`BGDL MYG.?+NXFC]$TB291X(.^@B`M0&')]![D""*279'M=]08,9#/5[&@5D',>K.:0V9*/6 M;:.RPYY^DQ;DOTE>87I**72`33>Y3.\PP^?!LE!#KK)250M#8"K=9<2VV'#/-/6!G5\WF:/()8W^R@T6W0RO@@ M$T)!3%?/J6P!K_-BMLE#(:)V0KZJ\T MZG+F6/\??G7W4K)]DV4%">^*/(M"`L,;=M/7*?T,7TD7A+".`'*;[AX=2F'E M[!B7AU2?[7##5W:,L#2QU&[9R;BR@Z5FNZV.0*LG29TO;-#Y-%@#7/U8_?#& M)!HE^:NP_D[C\IJ>JX@W?5-6RV$_^\QO+:I'+XMY@2]PW;L=T6W#H7^NF M5UVMUJ0^H>E<7X&K#Z=Z\A<9R)*^+%?>#TYS"BO?;AYP6I!EY$S][+C519!^GOO_"&#SY1.(\6_^F7-`K M5*Y^[6W6V,O8SV"=7>X,?T2\+JBLX_6.AWV'O$JF127/&]:V.=;%Q.>ZWQ5M M52FOMI9=#E_[A1DHEP-0M"=X8TE7[WRVA(CX-`T.F29O;Z?FDJ[M':=COMZ@ M\7EK:4E;+OX/9!IE.3L&?_7GHN6,5Q2@N.2&MV-MNJH)8?!Y.&F3ATM`0ME) M-B0__ITLI$3LE/5ZO<-D@H>#3\5I.U1<%I0=LZ^C#$[9_YOX]',27L'(%[`A M*N[U7&X'G!`BA<+GY*S-X7$=Q81>@D#3E,H'QU9)K^=TO7$ M)^JS<,?'Q?PYC07JWRKC]8:'IOA]^?DJ'[6Z++RYIQ]G/B49LTWG?L(DE:\1 MDHI>[^30R-$$)3B;'K=K)'B"9A6&`5;$.S@6=J47J+O7CKK'($K(Q+F.?=%@ MV"KCG1Z:PO?$%VB\X8F\;@>_)S1*0_GFB%O6.SLT!H0P!$PT/'3796*Y85L* M=PV_4]E0]\I[HT-EA`M%P$K+5N*W;;0^)YO2WOEA,[(%1,#':N4#>)^V_1O. MO!X:=QJ,?1\6[-`R'XBXL'?2\!!F07*1&X1?T#MQ>2[@>D`4ZE,8QM^DQN/W MT)V.;LG4CY<[9X%O@U/*.W&Y+=7R94A(V)]\>.([<5O4.[@)[=Z[1;P3I[M2 MI4M"I$/1&:PBM1.W@SLUXW`I&.O;L=O`?"D89QDLG^-G9E0/>^DPS.!1-%3J(_,B2>BP7!;WI[-'DA` M0&S8I'PE^0JW;-1)JGFG'3KS3`E4`G+BO##G;7WC=`%B2GBJ%O-.._3IF?*R M!\")1\.'P(TGI,G(6MZ89C=8\NJU:?F,)ZOFG7;HKZJ]+50BL>=) MV;\YPG[C73/MD-OHE80W"8@3D`P6R(P`8K;;N2*O)$Y?YORQ4K,%[^P>P+:GEGI3VM5[9E'Q-DT"YZG/+>Z<=.H1K\R&&(""G M,UO#4DCE'LP[/815@R.S0-^=&0)N(_\YBD%SA$V898#2+(U!J(SM._*%ABE. MMPGO%,&"4LML6@N9@-G.3`45X?7-JN)*WAD"^UPM0I2<\A`*6.S,T'!;S5&D M/J'RBGMG"`QS"K6+N!*@$;A)NS,@K,R(]_Z"V1"A;\)O:$'"?=@:UE6-5KPS M!$8](T[K@A10W9E]XJH@3VDE/846L^)*WAD".Y\1D0I,`MXZNX%9:R3R^B(" M:Y_A),K%(N"GLZN7+#G?TRHYG]:QC%_!.T-@ZS/C28Q'P%5G=HL*/KU!Y)TA ML%XT'3TE"`$5G1DS)!G89!YY<2WO#(%AP\(^7P510&1GA@^CH[=$,V<(#"06 M:%0@%+#8F3EE.V.;*C"&4]H[0V$DD2I=Z/SE@A%0U)E=I'(53QFXM%/4.T=@ M`S$BAXM$P$QGMHZWM'CW?A3>))?^2Y3[,N^(H(9WCL#B8<23#)`@:+DSH\<3 M)7Y6T(764-HO[)TC,&$8D23`(N"G,TO%.`B*>5&>STO_CR`G[5>2WTV>_!]R MPU2=EKQS!#8-L^%G`%1`>V>&C@>61S0AX6>?)K#ES2J8KH"(())M*-65O7,$ MAA`C)+@$7`#P9C"/>0T\!SZIWC,IM8\+F) M<0IX;?_";9-WMSJXB2N,%[S5N)FKKNSUNK/9LV?]PB)F^EVF49[Y?JBB&*6 M].S+UJZ30^YV0<"$P"ZN/EUFV[5$ MG!(?L@O;?Y)9%,0D4Q*W71"P(##)-N2*!PG9Y6MF52QR0O4'F*`&H$-@:6U( MF!2;M>O7@AM4=Q,XT)/K@H+6"DJT9CV]BM[I"($3RI";.A"1W2?;7+F^:%'0K4< M0$%PKM$E85]R;%>AA6O>'QF9%/%M-)$'TBEK`VS,>V4M4[\V3#3):XU\:;+G M43MPL%T4&;N'EHT#4'>VUH[2M2:KYO6Z"]MZVV=R),PN%I5_Z3O7])J"SNG2 MKR)ULJGI4+G7ZF!\#VXV#E[%N4I0`U3BTLMB>,JJ0Z?(GBN!B\R5QI.5_4B) MVL^BK`N(G=XVT#ZF21G1)Y$##IGCS#F=N$Y]KGAUX"83&!J_L"OLY#/,^O2% M1IGX%"XI#1(C<()I#AB.05&&"ID?C`/R'A896*+]*:P=?Z9LOWK#D)`LSU;X MPWJ#3J-!V)@@..J;;IV:8$;F4:OYFIE.-6^$=#1K<:M&)G6ZM7@$?2"OA++) MADX)_9SET;S,6%#08.9GY)Y&`1G'9==YAZ?,SF[9=7K*''06RJFFP]8IHJD\@Q)2_UO_\->;XC`-^JZ+[GOP2+- M(CL;6X6\2LQ4EBRO8+?5B_<^[)UCB(9]![U8H%ED0;DV(0O]]"UU9N'W0?.( M[(F'VZ<5"G8=M6P3RN:-A/*'+S[])G)*N/VJ=X[AAD^[7;,UM5J+T6ZA0QH^ M.=.B"##(?[K];3">SLJ:VL3T0Z4C[[6^)0;T(GFAX)YUY M3Z_8WMDT!+NVI/!'L/1%=$=?!/4BLM.W=(+34XK\!="N0IY_AMNTI]UEY^XR MSOG$I86Y09PSHX,__LPPXHES;BTOT8E+&Z_CB.<380*#'8#([L@:I,WN"([O3:J1^'('137A`&QEMF)SH!($M:J^K\YG@2(XT0MA"#H:3 M`\[!(%Y1I'"1!LHZNK1_@CP'PTF3N_HGPC-]YT=Z9W3B6MM<\:I:_^R%3>[F M'\ANDJ!>'H:W&B`Y3C,(;^!PO"8J9,BRNE[X,7/&/,X(R6]7=[55"Z&@"AQ/ M74;O=;<22O%BBZ3C2:N>-865`*33P';]U4_*@CYS55CH`NCLJ\)4``"PYME MG@4HL<6D2'OI5_*]_)/Q:-XT`.`1A3]9'UKP73XMUD"6_YUWKV((,/@/(0A135[2`V=2`/Q4#1@;K))WF*TVIEVD&T M,0LZA+TKL*N8&X%L90\5S@+U&O!Z9XBNG^J2:()1$!]@8+32OQ%P";N,"+Y3 M_J.2U'(YQ]0(\9(["B$1#K`(R#:Q8MLB$OE?^8(W4=8,`^`"/UC8P M"TBV9]U27!L?SU.:LUA.%L0NXK5.&P#K`(_/AC`%[`U:#V"]25Y!PI1&)-L\ M&B4P3E@7K;E+Y>W>1K&LA%ALJ)/NU_<*PQ'5VGME(L[J:IPI-Y98'`"YG M.6G\J4B=_(VC1/SW$%IZ7SS'4?!'O@I+WZ!5.$AEU4`Y+J>]6DY2"7L"V[`2 M&++`4Y'`;X^T&M!8?>'US*EI4-LYJB:F'J&[$)$%M+9`*RZ_J5M^T0;*;N1] M\+]_\7-"(S_6V@M4RP-"!+8[PW5U'PBR.-J-I'^E]-MF8ZS#T58%P(;`?F9( M$@<)L@#9C:C7H-1LMKQWI\725@6O=X[`0&;($@<)LKC7C:CR^Z?58H`#0=Y1 M0T8V\DOC4UL\'5^F4">!8P>SS*1Q%+*<%=7@F.S>9QOE&85O2_W8;T3??0%J&4A&4<"RRP=[0< MPNWE.JBIJ`%L$)LSEW>Y"L78IT M0>!M]'?!CI\LD*?\`X$C:#GK:S,I;@+P(XAH;D*I"ANR2Y:5-WT-]C<:M0$U M@FM$]1C5AH7MAN7>"\U:^QI)+8")(&3-F#T^'&QW*_<$5NYG!#4`'H(8M(9L M5:%@R]'OXDGXW@A!L%E#SO;PR.]7MF@W7[_:57VPJ[OP,>$;8CHFAB+D_:4K.[+@D",WPMA'@,]`YZ_$49Z:$*5U/7!G4C M3.VA0Z_H-*$)&5L\FQ"Q5N23NC:@QI'N0YNAF@3O0L46V=8&P3A\&>TRC=;] M<0L[.@FE[,\@/X+S8;-%^0T',D?%11'%;$N=`:2;^0M-7\N%/ON=IM(X-FD] M0(K@C-B,,0V`R+P67_Q@!LCHUCE$Q:.X$F!$<&AL1J(*'3(OQG5!0<$%)2#N M=?2#_:0//+,+ M>$5.*`C*C#Y%$BU3<&7*2:Q.=<""(`"B`3.U<.)S&B193HN`"53&BD]A)"OG M-DDM@(D@$J+9[*:$A\V),`Z"8EZ43]E=D1=*@FCUZ,M+3$K-)^'J]N_*-RG0 MCH1R6Y_P^AC>4F_6/^SJ`IN?0RBN//Q?5@V`(@C6:$:Z&A]JOP>R5Z&<.T.Z MRQW6IC.DW^OL#H(N"0V=(25"/,X0M[<5^CT\MQ5J$;1-LA#:0=UCZ/?PW6,H MM;BO['VY#^H>`TB,P_;?0.5H#?G5':IDR:D6`SP'*0&_A9W9^S) MY7SUY')6/C":D.QN'9536:WY_RFM-:4AQQY1,E^85"$RP#E6CLN M!5NB:8X/"5F`R+:87_VY.FA`5`7P.?4Z:X>"B%2O0]0N'&3A'I;IPK&YL\^; M@SV?P!7S;WZ2I&4JW6#V9QI_RY[]Y-MRJF#31D_^UHM>;4"$(#A`/DXX[I)C1U&]$4W^#!('[WS9-6^"LQ6_4H8EE1;U-_<1D+.W4!10(?&!V*.)" MLQ:>84*0R2C:J0N;9@1.*+L$;4%S'8`AE630@*#!!@4"AY%=@K:@N8[=^!,$ M]A.?O?H9^/'C(F-G13DODBH@,X)(S]IT*!'9B\80T'#OTSP*HI?2#/4036>Y M@@1A!1`8P57:VA0H\&`+I-C&=^E3NHB2Z7B>%M+@"%DU`(I@OV9L0U)#D\>=N7_*PI'L=$*W9#(,9V=A>-"U1^U6\WG&7M[2T-:^& M@"R?7&.'_="ED\K=]E(%"5EJ.*L>X*%3`T@CA_U0T_"Q"P?;/2[+?.'8V=HG M3K7A-;$\FOF"LV8^^VSCCQLBN$PL'RNZCA(1.GL7I`RI:N:WSS:>N2&"*\C6 MJ=I")[\"U0)5)K['_>H`!D$`M'6JMM`)J&HM9FG8B*GA!@KJ2`LSHK;`"7AJ M+6CII!%/)VLH)Z@#+LQXV@(GX,EAU-+%EC"G-7GBU@8HJ.,N='F2@!/PY#AX MZ4V8LT;CZ6P#!74T@-EXV@(GX,E>#-,3]9-@)LI"N5L$A$)S-[.6X8$/1*!= M>P%(JR\*3Z'[A4"P;B]<\C4EUF95;(&3T%XDD9D^<9SCS16K.J_W[9W75]^^ M2XA\@MXM!V)V>*P3]4>Q2R>,_)W`>OTY]=5%E*%\5U0`^`=9H"'%BX!;9U=8N4(JS3L"NMXYZ=. M3\O:EG@I!=JL54$)>.LL?:MUWG"LY*X(5*[SG25OO8X2F-XC%C:JZ;04U`"8 M+M`MLZ2,+%%.9O`27.N)&?]/RB%K\S/> M^9G3,[WV["PEFM\W[.M!T*$ZBULXT`Z%:]E`T+.4*TUG(1=/4<[2;=TD8?0: MA84?*]89;GF`Z-*`ZWZ5D:`2A`=W%G.Q)^I?43Y[(/$R^^\L>GE*%4'%ABV! M.G#LXR5D:;*K`U3`>V>7Q#KE'=>$WD8'4,W8W=UY>O"3JZ'^KXO5/$63"X*W?MSIWE.6P!+PAN2MRD^2$DBQ_\'.R M?)3]'G8\[.;15';)7+\1;^0TQV>[W*J!"MCNS/[!`PXR1VD8!??^@H&ZIU'" MDHG$$K[K-`/='D'XJ#'C]:$*KOEV9D+A(5BMZAGW*)E>^B_PEWQ1DW-1 M,]YYEW$%3CB70Q5PWIGYA(?@)@DH\3-R19;_OT[ILB/+WYRIVQ0HY+V-=S5< M`?^=64V^ICG)8'IB]H;+@E(BW8AQ2GOG![T'$R(2$-6=186\+!>1[&["-A>R M8_U.40"$X!AI3!$?CH"?[EYV8"94DH3Z@TE0`^`A.&^:;WQEJ`2DV;L^,YY2 M0L*G]#)-7@G-V7LY9$)`@O`Q3X-O,!^S5R'3I/R7*/BQ5B/>^=DA#BY3H`(& M[5VL^5HPI'>3\IM/Z059"4?":T"]+:"(P#IM`*Q#'&Z&.`7T=68,8ED"GU99 M`M4S)J]BM%.IB48JH_R+A7BVO[W0ZDR9KE*F7W_N50/#D:6S`,3/XE?E:*_I1A?N+ MZH!:7-[+,GR54,">@'0Y-F2/Y52%5(:0[!<&3$XO).E'^N`9M"$89FN9G)LUO)<6F+O34:6(>!N4D9T^T&YCU=> MB5)6!LPX8F$5K`BHU,1G+7GFP7"*;'5T1ZYJM>PL^L+BC>%SEXMD6U.N$!FR MU)UVKYX.SYW&Q#2_,GPN-'0I0&%+X6F=-WQ3J$T"7:3R;.^5C.&YRWQH+J=$ M(1I[:3K;>+ZA=WS<[6U;H1[WUTRB0 M^LLVA;S1Z#`IVD%@+V^FTQ'VIQ\7I,$`VZX//1!!J(:U\<4#9R_/9@LSY_+W MURE=IH(PGT'W&@)E($BD;WDF%:"TE_S3_5"VP#B_'5`%@G3\=H>V`*0\.6F+ M<3W;/J=Q$O[E4^HG>?98S.<^7>R&`QYZG,_@787YC%R:+`S"?`:&43XCL;&B M@R@?QZ^QCM"D`U)RHK8SE6@.ZSW6$3XK4ZE%A;VCE/NPWF,=(38Q::H<;^2, MW8!"IR=BEY.2)C9D`32-@]5&3N/=;004CH3Y*41XD(7)6.`(Q_3G@"S5M-B= M#:H,I1L;!11R:P%:9/:FZI`1S(4J.-CB6DIY+XQ(X]8"E,A,1[JD2>!@"VHI MY;TT(HU;"U`B,__HDB:!@RZDQ7K`=7^$('F'"6L2.&[B5YJR]MF(-6XM@(D@ M[88):Q(X;L)=S%G;EK1J_Y>0)J[D#=S&QS0QCTL,?RI`;N)F[+)V5^19[B=A ME$QK4E>I"7#1NIUK\K>'2AY^@]B?<>^SV]8SDK,PEH-W;G0876/=N3$X=KF% M-W%N],3!Z"H7>-Z9 M7-`D^^`5S%8Z?QN[: M/XCD!24G&G;7OO#`C-7NZO:=(C.[:U]]B7X@>78(K:9Q&!X:J/QGL;LZS<3H M[*Y]'*^O*K2N;\KK"\^HAVMW[2-[H=4B65]9)8?7=(D<'#:7>UF\1[@O`N@I$V& M!YOEU8&]O(_S,H"2-@DRHHFGC0R. ME5[Q)@OSIXAHD-4!L9'YX=4TJ/%@2]NX+?&?:1XETX=H.LME-BEQ)0")S`]O M,*/M`\*6D;$5G^X`V1G:@$D9-'OI'6M.B,OT976GQ&4M$!W9(=E\4JPBPI:3 M<& M"&-GAAJ!',.#BYT98HZ=T5/YSQ([,SR,V)G]24D3VWN+G1FBCYT9U@K'&+[# MV)GAX<3.U"7K9XJ=&2*S^U6'C,S'*('S_F-GALC,@KJD2>"\_]B9(3(SD"YI M$CCO/W9F,$0:.J-B30+G)XB<&2*-G%&Q)H%S@)$S#2WG@Q.\\3)B4Z`V,N>A M,GSOZ#4MWQP.F#G<7ZR,C!K.27%]@(,WA&:?*`-LSL-I-NXR^"RS!5S!6>9N M$-K!/3HHI('V+3H>V*B13D3+!LGX66:L*`2D)6=5,(P M6@IXDTQ2.B\G`Q-/DZ#O2#Y]%67,<5!0(O,I&;3B]8Y-5IXF"$2NI)HM0+]Q M>7CBNI7,%\U'GR`J##_;LH`;)9^^@.ZT.*B6`R0(WG#0Y6!?)<$6C<5*10GLPK-E M(*=@,1:6]0:GG0>&6%B4%?BLN8LT61`Z[B2EO=&YT^.@<@%6Z%!#X54@UIP] MCE6.8]&UJ7O5(MSA>^LK3_#O))U2_V7&0CMU@T=VZP#2SI\8MGB:4.#$Y]"9 M[@JK#%80UO%&;E\?K!]7PB=!Y""0PL+GU+','(X)U!V%JNFTJ:=G'0<9L)L: M=,&8'*S_P4@<5$A<_=J[^LQAZ^V/(#8"G[9B8&Q3L2N\FP>S3'1]?RO1]?TM MB(O@D&BDZ[7P]KPH=J:H6^)G9,RNB$S+H?P$'U1L$T15`*#+.*JV=PERF-AN M-?.D5:XUXDK,](XC_E1.@SYU6[BPW6YVP1ZNO8(#&I6;!7LVA\<")@L01FA/ MXY1B,B*(*U6.!455KH<:"HQJ1'$#AHPH8>,OFE7PN\W.3_YM/PNT\) M[&,>TTG.?I1S(JG"I$:P?3;A0XU*P$5G1_\ERB1\8`DXXL\_7F"AE,4"\4-;WS+J\861_(.F`%W-H+%QU/ M*2'A4UI>^WTD>1Y+8T0%Q4'8#N\160V*DR(4T-&9O4(\4:P/'ZN9HF,6D-^9N>/1CTDI^K,??'N"G6#F!TRX+Z"46;Q8"K\*/I)>F@A(I4#`S<>3&$X#O./73*9Z7 MX3DT;!,F!'!8V9[.NGW<7:C%?67ORWU8V9[.D#S1WD#E:*/FV7X.=O*O)"G( M5\([Q@I*`BH$5QMK+A$\",A"Z"_3++^;K(24T+%5#I`@\/G5(X,#`%F>IM\I M;#/O:3J)9..B4LH;87@VI!X->^(CR[O$N@D[!:PL#=GX.$+DDM[VR$(0^%E`,^;TI0 MR`+W'TA&0"TSD/4*IN0X?9F_F?M^UX$UJ)&Y'#P8(OG+T6L@E0/(E$5T`2"LW)SPH30[`7OVYKWUNOK M-:AAZ?\M0.@W5^@%F:1TY0!]\G^0[$N4I#3*%^MI`W90VZU\_KLH@X?S60I_ M>84BJM"&%J4`&@[.9MFZ>K`]U[8!MAI+XJ.GH@;`0Y!(VX1]`11LKZM]);G6 M.66K'$!!8+"IN<_=!V#OAH3+5T39B;=BS618?M MXL56+QR_^E',PA^>4A;6E28EJ%D:@Y#9A9]%@>Z`5+<$ZD!@]6DP9'4A8KNL ML8%\-UF"X8>J:9@?:K8$ZC@X,Y(11&SW-#@"0T^^F\".0,LKJ:SM#48(3!AU M'92:L.S=S+!X6!;$EEZSB-5I>O8VR](:L^JH;?V# MH%P$EA7M7B`YJCM2#;8K*!)5F`!.!J:9A#U#BPW:9Y+-/$SCYL]1\CS.? MDGN:7K,,\QHK@:HJ`#XXRX@>)GLW0=R06&XWF<\_BHO\[5:#!H<[-0$N@H.T M'BEZA'(!RF^4M,_G7[!2S$"Z\2NA_I1\+9A^[B8E@+LBSW(_"0&4/LUF#7IG M&&;D)NPWP2WH%*/6KQFM,J8U?/K#:D[&!_+"`L&8-V,CU*W.72*-ZM[PN+-- M3>5M7;&D%XO5'VL\3:_;&H!WZ:&7WU/2)D=P.#:%B^=Z$Y:,PR7*1I/CG&X!&1WK\991J0^Z64!0(;`V-%T%U[%@NQ>%9S<8>.9+^YC/V$!1"QDZ&5EZ99& M#(BK`4X,,0(-.5,C1';-ZIKIF-Q&KR2\27(_F4:P[5_V/#F7\HK>20_/,F/, MI@Y&;*^DK.XO2U_'7!4!`!B\NPU)VD:#[?J46=3;2<_I^;(=8CB0Y#>H,"5\ MNO2SV76,R>;K,Z#?LNIZ4F M69U*&K8)$P(XJ*Q.P[Y3TXA15J=2B_O*WI?[H+(Z@<0X3(,-5(XVJ]-3E#/' MPTT2LD#J0NE0X98'A)T_K*0__VA`09;I:4_2OZ)\]D"6T6S9+'IY2A6#RK`E MT`:.QQ@E7&F2JP,465:I3FG',>6VR;]JCNYLZP[G-7;JN:U6\,=(/SWHCD,&"*$IDYU\Q(,>PC\&Z8,J!CLB@!(K/7 M5NZ=/:4/!$Z60123+;F?4GO#V,7GO.$`@6W8;L=QIR=L]N5J'CGX.2;FN?5$ MU0$X`KNT.TKY74A?,]ALW.S%FYODWR.62&"94T#F`]PK#*`06+O;IEND!VQ) MQ@`^92\X7)'E_RN`+_V7*(<]LGH9T6\$E(`@%LCNXE`7/;9,9OORCX,R4"2# M<4*B5X6E7Z)+50A5F8-@G(0A&2YZ@7Z&L"6H4T\6=W[ M"S93L1UH$-""A+>1_\P>_ZT[%^@T",I!$/WE>OY7:P!;$CC]C9`56R`H`8$- MT+I-J19Z;!G6!/(O,\-9,@M+&@.E(#`S6C$+*U%B2]FV?C;Q*1T'?Q<1)5_\ M8`8*H(MJ:*OTL*_3@#<_UD=O+#B=(W,]9UZ1;/74E;X3A'0P[ ME.FB19CA31.]E0D9^BI>RXSA**V+'EO*-X'\UU'B)X&EM5G2&"@%@=7&RMJL M1(DM]]L#G#@7JV!E!IS%+,/14YKZ5E@'("*PT9A2PR=:`19;]K>JN.72K`#"V#&N`/"`D++-KWV19`;`)],:WY**R+;2J M+D!&8%FSR[$F:&PIV*IB5[MI&1!&PGN?Y@O%<-9M`A2`P&GJCG4U=FRIV_1U M864/!DK`:RHS[`!UT6/+]O9Y,B%!?C?Y_".8^`ILX,46ML7],D@!_?;.%) MR-F(7T49N[U>4)UW19HV[8V0/D>A6"B;8Q9TD@[?#``K!>HZ@)D!+8-.\0).H6>"@2LG[:>+F7[,2S0P%^PS?-AP[?^/PMU M*^7,F+F.A"PE-QSA[R8L$=9U2C_/7^)T00A[58$D6=>YKQOF5^D=#SJS,9@F M6#D[=FDNJIM@9:E!P1:4(SB>#"L6F+N,_2Q;#WS-Q-*[=4`M+NT^37(AE(0I MJ.7#098SNBJD\N[[?F'OS&T.O/I9HOE:%RQ1`CS(TD-;X`A7"@*+9*'-!K/! MN'QJF&T*TJ2T'VG.AKQZWLAI9F/7,Z(8$K(L,3N"*@<=MSS;`#CU6]2?',4$ M"+P8$ES(,KS8HPSI7&F/.[39658GK2];IU;>`U'5<@`)0VBU;*CP">*A0)8T M9?T(&0FKA]HQDWM:=LJ+Q5N153CX^+M/UP?ERJM5R]>L9`N?[6_!]@"#2;7F MP="-%I!E>&F*\O?2('.3+-VLOU-Y2A\'7P.M8G"IM-NWA'K`EK^E/",LC717 M!86AL)2X!)>5?UPA^OP#]KM1)GV-L'YCH!2ES=TRB0VKS;D0#4CR#V MLKO=DUHWV%+8*,%GM=9W5]W3GA3>61_!P<]V%[6M'VP)>!HK8(VQ\YY:2Q`@ M`V=U]W%0Y.$8\=I6 MB[T438[ZU\8.U5$7T_T^J!/!W>4V>UD]S=A+".6LH\%^H,-NIO-U4.7A&`U; MUXN]Y%,6-V?/:NS/M:-7N:'K M0D_VDG()9LAUA'M%PG*G0'8//B)!19-?XX:]\P.RFMB$;"\+ES[GFW7;/NMU MF_9&!^0$LPO:7A*N.LR7BZD+WNLT#%W_<.Q--B'+$W6U>`FJFH9F'+ZRG$39 M.`RCI625JZ#=76RJBO@$RL]`F5'EN6[)3D=5U1L-NPN)"F8D+-A#>P(ILXO% MUE]45Z-,V@,%=/9$M1XY@JV9.=CW<.O*SLNS(Z?9MNK=+3#GD]]!)(B17^7&Y,ZCF2\&U^E;D:`4H&"'2Q'[O>P-;6;$&!TYM(JU.3Z:TF8@EH^'&3[SZ:7S4=G3L.& M+20$*+7.ITJ$!]EFT0)'N+9\%LERL+,3V%&OV09@FBPW(\&BFNFUW.,L]Y_+ MK$R$O* M$EDM`8R3L,K)E<-2!W\Q('@7^09X6X'#6W2TMP^-"[]AI M7()!!C&AT8,K^?\_,>SN'T"%6#/F+"FK>V98`GIGAP8`Y72ILG!J6.I=>R>Z M1/3.S@T,U*$<'`SX0FL47C^TN1)Y_5K099I)W]B056.`T=ZI$"YZ&HCJ6X/_ M\8E]BT7ME`L``00E#@``!#D!``#E M?7N/W#B2Y_\'W'?@]0X6;B#+[4?WS+AG9A?UL#UU6W85JJI[;LY8#%@2,XMG MI90M*LZ`4\H+W"6 M_N6[E\]??`=0&F4Q3E=_^>Z7^W?7[WX3_!_ M;S[\/_#V[AZ<@"]?OCR/20\EZ^%YE*W!R0G]3H+3SP^P0(`PEA9_^>ZQ+#<_ M__`#;?_U(4^>9_GJAU5VW??G#__IP=1<]HC4\ MP6E1PC3:4]%NANA>OGGSY@?V*VE:X)\+1G^51;!D0Z7E"TA;T/\ZJ9N=T#^= MO'QU\OKE\Z]%_!T9`P#^G&<)ND5+P!CXN=QMT%^^*_!ZDU#&V=\><[0OBN@'PJ4K M/F]0CK/X;3J.X3ZU>\[O2IB7$WAOT[OD_CXK83**[S:E2XX_HG'CO*=S.K[$ M:*)QX]NB/#3'IO'F]0LF$?W+/RZR:+M&:7F:$N-0XG)WF2ZS?,V, M^^E#09>ELNZ(L<^Z_X<%;2U]+7^'U1P5V3:/D)7L?%2[/,$'&Y[(FD85*YGUP+0GRP15E4Q,G@)%SU?9TP\QPD2NES_2?U#$_7CR MXF6UJO\+^5/#28N!>_BPU\\6S-3-G2%+P[443!T$L=8>X6,R]#5BS,?=%B1+ M6#PPUK?%R0K"#47*3S^@I"SJOS`CU8),]>=_D/6_1)2A\P06Q?7RKLRBSZ=? M<3&`&P,:9^`QX;^/(-8$9$O`&A'K0YIYA([Q%-3XL1S_N2P--W2W:(6I?4O+ MCW`MLS+#39U:&`FW?6Q4J].^':`-_=H5U4"W;8I^E.>%PCF!8@Z32[+=^OH? M:*?$@M#6`QA$?B5HJ!H"UA*0IB'@03+:(B"40ST7(LZW>4Z^^PX7$4S^CF!. M#L<7Q%Q)0"%O[A07"JZ%180W!;PMH(W)UC:F#BO/YD(W]&V$F(W[O&;C'4Y0 M?DX^NLIRM='HM?1@,OJ\2@P&:P;J=B%8B\%!%FV%8H3G`L%]#JD?^&ZW?LB$ MP:]DZ+5Q.O%]_OI37OT.>`._E5#.34G3%4,^- M"'XBX0R\(W\;\D-JVGM!QA#?4G149\<*)*QY&`B1COX02C1#[P8I].QJCI-6 M:X\H:?.LPPCS+P2'$&'4Y?B0#+F[&XZ;/-N@O-S=D'%F]W2_;?&&W=G)+V(M M:)W?>)C(TT=53;,`C`I`>A];TP5Q#6L]6_U+$?2W/ M"`N?QT!QL)MP4#DLI1U`]WV`3[07P+J1H'6RJ&4K`&9N>;N"!JQ^"K`::Z(6 MJ>Z4\@(]M-@Q6`ED!,X53"P-K.ZU;YVHU<12$*^;. MG0'OD84ML3[)%HD<"5FW#-&LXY:J%D%9^D,`I*\#AT/'A!#?%A-FJX$1E=NP M7JT,*F2&M"N?+LU,7,>5+X0%>AZ,\?M'!$BGF(Q\O)^$99:#B(M4T+Z>>PZJ M-M.03CBUC7JX/,&C).A7@4KGK\-A:\`X%%/%0?$"D3 MEKTN'Q8KGP&AV\7/1!(-5H-;`@\A$U6QO\&^%TEBG.FNEI4*Y/1/BDLYO02S2>4;F(UVA-,*HL'*Y6?;CY=1G(^?0 M]K.B9W#L]!"JYV[4Y`X=X$;.;&`P-G'_V784)I!U!RDS)`?C13RXS%&[BR/1 M4ZVW<0IT';YA1"O*XBW:9#EET&!MD9.X?\$HY[Z/N:HI:-H&M33HID%XQF@T M!_Y@9&?EC:B]@\O,MHDX"^B@(DC&B'VMB@QL=]A[+7UJ!1WUJ:0=*==M^@)I5MTBZ*,C#-E[`(_ MX1BEL2H;B)+*N6ZI9>C#L&H-6LT7H"%PJ&.&I];)TOE7%@.0]77%&&$!!/6: M+TKF7803S&MBV!6!O!X6+T/%.H#$1Q/*:[A"C<.GR]6J0&1('@EK%\1`)!EC M[NW7#4H+Q'E4KEH&U!Y6+Q.91#O/J1@"6W2@(@Q7[0XKKW^=L\"DN,A9`M*= MIEVFQ!9$J"B&>=3JFB&]7Z8E. M=O]J:`78OB*.0*M#55QO(,XI']3%3"Y7M)`]RO\A.+3HD!E<9E&R9:F MX;@DA^=TA1\2Q'_@O)MO46?YFGLUGV7,!*/0?`5D+#J-?8>Z,=@S!/8IP+M< M@.9K8/^YYL=`+4=HH]@:Q'>8'`L1X+_N/QV`:VA&?17LUMS*.B%JL,7;DN8C M7+()8WSU&6$1C/>/,'V?9?$7G"1ZG/DD179W-C[;%O1Q=W&>K1]PRK!A$G&B)G-^ M6M5(T4=HW1RTVP<5=V(R+?VSC/F<.`P/C!Y1O$W0];*ZB/PG6:9C^MIDB>OC M5>TF(VIRA>$#3G!)HV:*@IBK6+MNSO8E]V&'!Q\K(8ZO^@*UQ_MO@/U'ZNUY MX[GDV1^:#X'J2^Z69L,[D2,:.__&92:E%*(LY]1(#\5^KI?OB%E-(PS)0:+` MFK)D=N3^2@"II1*TH"8#UTO0$(*:,J@UU&;BI-6"C&?-`R!EI M;`\G[S7)U*,KQ<B+>JZAKZK MB2F&M9V<53FF\Y:"N,C6$`O']4XE@KJ)A_(.#7>20@Z?>`//,SPTDF)IAJ%A M]K\@9[I+\TZB68*NQ/^/>YEAAX&DSP-J%9.6%X99:>LE8.WP:Q'?,!L^! M>@W=/P'J4`KG*9T1K(EV"&8SRK2VS2>6R!$H$=$H>$4 M_)O^C9N5B1">/-K;!^>/U8M;%"'"VD."/J*R,LRJM5Y)YNO!NDP*R9-U&LI= MMU\`0K&H-P/SFC6SCGJ2,?@0%SRNY5)W+M'`\4NF9$[2-5L(%,`^E(*57]=K&5\;=^'U'1^JW^,T4TQ,EX MWC@>^!IUCK'^]<8"CP.9BNW`Z,F38^K!\>VYD7IL7.W23)8%'<>,P>!0;H3G M()`K#<)4;\+49.'DE1C>3&AR282R<1LI53=N6'%(<:/!!Y^;(*OS::;D7^%Z M\R>C20DBDX=B4VNN^1,>B[QK/UA1OIH>L%'6/;A]'F(E6Q]0O0>I8KJ`4Y,G M\W,;L.ER7J8GFTJTO)T-()Y=-*,G(`',H;/''O:ZV'GE,581#V,][G,8HS7, M/],TT^P_/L(U&HH;,:;T9BWDLB@1MB=CP&+_"1AE&,;!7*Q]RP4HF1CIC&+8 M&@)'T^-#[S5:)--W(Q5R=]2I7[@JCC7[)LZ/,"WN^GB9^?6WT<9W-'LN][/] M&>[O78>GUQT"6\\WS*-^5$3.4:J40`AC;CWL"2L(R$J,FO5D3Q1`.)`>2WWT MFP(IB$HX"H504H54XV8(2ZJ"-L$6KC$0Y'BJU$BC2$QAY7*]2%%QO>05Q?6W M"\/-/:P1@UR+JT.*]O72Y[Y],U0"0][O4+2ESU>3NNA[Q`BX)E3+!:N;D:7T MUZ2I%Q^CAP#\?BI0,D54'[8?6CJ[X#+7N(#*#34MD6(E?[T,*&3'BO1LWTCK:^T>\^8(0CMVG MV6#OR0;W@NQO/Q(Q]2B7$+A'NHQS`>W-)IXV78"W7^LLP;6#Z`,LMWFE#@'L MJD9(%C/)4L22:_8.,@$HAA)D@G(8(,S+$F!F^_T:?9VU#\G(2ZU[J%;=P)P' M`%-RO+@KL^CS8Y;$9,=)XWS*G=U]A:8+GP#72:>ZRV`5`UO$@%.'=[=Q2"'_ M]5_^^.KE'_Y4R1J4/ADA5:%L%C!UF>QDA.X%I6U6T`M7GT:+46L,XM($<&=H MKR7AZ<4-Z0N1K1Q765WJ@,'6/AXL#?`\\(J'M^)VE[__]QV!;L=X09LMP.]> M/'_QXB7U(8$G2O,G\/+%XL4+]G^@>(0Y75^VY6.6TWR7Y-857DWCXWK\Q4"C2P,LKM1:Y#1G(4B/=%YMZ"0[H<3MTD4Y@.+_* M&U;;-F58JNJOG_\$R,XJH8W$`<7Z;G<(/)65IUG2JC<']U*N5=O/"H M6P+:%.`45(U#2$PQ1@SZ,O:$B!'QQOZ!KP&2<+=I@B)W:G"?(UAL\YW10C/4 MV#GX!SD6(^AYHSF7FS>CHPUH'#:>Q,]OUEEV* MLG?S9,$A6]Q'E!9DI;Q,HVR-KK*B^(C*Z^4]_*J.G['KR4<,C:6L`S$E=0]5 MDHA.'X!W`I[1;KYGKU+I)H7TY3V0YH""5QDD.H(GA-R_`HX$\T!`S7@DNRQ( M7T*QL4TB7XV,OQ;VG!MV7B3:X#5=2^4L< M.BB#--\E:%7&#JERF,&42/-AZN;#1^W-?;+.)E9P1%U-@UX\ULPTD5%5T[&= MA+7I(>`ZEP>3U[^ZC0"JO-:D)4H#R$9HHH4FQ.%D)C2I@CZ8`R^0DN_S">A? MVO.*4 M/MU`,:UM[E]_3+`F7YUT0'.G,\9QM]YC;2T#4^E9M7(2/JO]YD&=+LRB4Z=& MI$KR!W;#W>Y8#)/68!I3NLT?:"2++A*5DP%N.S]YWGB,%^MNNUY#R M]0:F.Z8)!>C)ZS$OXC'*990H\8`X])P7T=PZ=/(BVIJ&@]DO^@9RE/D:)/1I MO88ET8&&485KN\R$:JGXH'S!F*R@Q1EAJ29@+B@[I;`""C.E-0$^SJ]W:$4G M\1:QA^GIZC)=9OF:S>G9KOK1[FAKV:/'4Z^M[*H#<=4<-)V!5F\+\+!K6H1[ M:G8V'OZ/1!,50'[>GH!^'^HO=[%1D!KINZX+CPJNE6Z,KSB``[WM_,GA:C-Y M`=Q5'BSH<+'9D&H5%3ATR&L5Y,[]WDDR:.S2>;7%"+RP^L(>:"N#U M&SK'F,"I$,U9-0"?>),`,#,\NGUXJ(;6'1(^P.@1IRC?M0&JA862RCE&U#+T M`=.T[F_+@L&/P9STP60\(>Z0]2MZQ%&""BV8^@V=XT?@M`^9ND%`&!D>W3XL M5$/K-#_$9ENBW-R^2"E\9(N0\#Z0@X&U#-*D:*9@(/.!?OP=/K8CXZP[KK7: MN'\ZU^)/>$)&?POF<"6,I/!(;'@8'<^UUD!T6OF9;ZDAJ&8\F"/,P(@.SKKG MC2A.\7J[UF\]N^W<;S9[?`K;2_Y[0+9_<&2%#:1\6%T>1KZ:8:#;SL.!XZL: M`_SWD#`P-++B(4(ZK`$XRJ[(^>:R1.M1/ML6<3ANLK9$EE<(E!0PVC`#S><4 M+0CWGX!&8^^?!(H!:-@O!5INDRN\5&?O-*`.1\T"KS56#0]?(=3F$:89CS8^)>TM-%H+14?E]AI>SH-P])O-B M8&2\NW@&>+I!9/;)>65%-G>_9CRFG"@#*LJBLHFQ'?*,.@P!DV:2FZV.^[[H M*8'W!IKNZL4S]OL4XV!CT)4V^Y*BO'C$&X`;@:%28,^J:P%Y`Z6VQKM[=3_/ MU@\X92Z)6Q1EJY26][B,"==XB5EY\J)`>W9/TW:5P5VBRMD),AK60/SQS- MIY(RDS6W/AZG63N'Q6-U]?$$$^J?=63:ACY\U.9M<"0=F3CZ[>:6KOKZMV/E MC$:6-OJVS)M<->,VM2H]IY4TU.?C-);MO[CU\PU^^:@- MY/!8.C*-[3]^BVX_L\'M%+7AA-^6)53HZYPV4*NLQVG]J@UP^X(%0Z]@623?!H_T9J$0STQ1X&MAZ##1L#..\8&.4Z]C`(IVMJ;VB, M3SXX'"#>(@"7-+E)EB*P0Y#$P?E(P(I34N:`'I:ABP8*MI%"5H`O`1)EJY0 MOJCWY`"6C`*VHO]B\K'GGH-(75G%3CBJ6Y-XG!OU?2&TUF]7!%0T`S8M2.-H MHV[`QU%OU$W&V=%&O57!L+-7I]R<$/.S9A6COIV=^IBAO\I@VFS3OZW]N+'& MS[D?MU3WX[2MK;^X=_T>N;WLCIU[5Z_/.MW?_C@>J^TBSTT&+N#ZO$"U%]<*#:-:*X=X9PF<<10TA04.&8';7)V MWD`<`YRR,S4M#D*/[U&V7I.?"GEEN2,P;Z8*>B#S9J>=!WPC7%RFD=T[X3:% MW[?"'=ZU[X7)"0ZG4:BOAL5Y4+X(4'E%/V.0_D)*XG[I MD7,OK!V\*6!M0=TXG!08FGD0#)31)/C%D3[[A8(H""S)\UU(T!1.G@OM?)@@ MZL"9+4[Y#?`-W!%1DCM4E@E2YG`WHG*[>FEE&+@-9]?>%078DX2RB)E-2V :4$Q_`1+=)/`"&G"N$T[$&3TDRR@>A>1@CH MG(.:E!=F9<2@H?;K"C^0A)M*JHU:*L?9-BU0.9!PTQJ2#A,#TM,A90O%%]L< MIZL;E.,LYN6OV_G>%$IGT8?[5(`6\@DY`%FI8$X,.#7@Y(NJTOFBDQ+0<\W5 M"9)^W%*K3XU*P9H#S(6FB4#G%]`HN_04\3Z@?$7$>X;32K[O_1L5:\43TC.. MTSKOIN57F&S1-,LRT$4HAF5(.AN[PNB/P*R8R,G:'*-1,1&.VY1@[8A4RPS- MB$;%O%L1;N8^HB_LI]&[DU8'H5@04;(Q^Q)"SUN$:3[T0DJV)`%:"X,)@SR1 M=/M&YHAV(X*666U%)"KF-?\A?<%9[IJ4;9SUZYP=SQX2Q+%WO>0"\%\-;H*G M?B"$_(CC1L8L7R+ON\F06%NP+`=U]\1N-6K//Q%&>-_!!V@O)HQCUB],QFR3 M/"=5G*!'!DD6)RO1!$_W+7JB2X(DY2/[I-0NV';@UO]M(YGX0(+1=I+VMO*" M7E=:6VFVSX<3AY"R_3AAT\E^RC15N2-QYONW!FKG&F`D2MTMWI?I$^$FRW?5 MRSA==1))>^=+JXSO/M::=ON'J<$4$E&.?=]^&PR\PWND[4."HU_**GZGX4T3 M&*$F`_]PNB_*H`S$4&-_JUV;8P5\KD*J\R`?;ND:)QEK#Q"YA5\^0')`PC`Q M0DFWO3^@]/A6;(M(2]`T78#W>59X]@J8"D$Y7]>_!X3S(T_RW+ M/U^F+**B,()[C\`?WON<*P!/F])8_JIQ6)#7R5$SO\FS%>$G)-@/@D>*>P5R M/`#_'4YQ\ED:9TD"\X*Z8L.Y.+7#JA@;:@]4 M7WI8!99MR\M4'M3S$"D3LMN"(G407D M^<_.\5UQ):3<)G_V"UIKQEPBL3V7?=B)$^GR%2!.J+NC.$WCR_4FSYY8WI6" M!1DHP*>A\_!F3RV'^!2O:L]RIK8I@@BP&"V.?Z0;(4I\YF8,)W>Z\0%&CSA% M^:Y=W%2G&"HBYUJAE$!(W5`W[E8/#D(?)@@24.E?/:#Z>F&*)G=*\6Z;I[C< MYHAP]`Y_I?_2+A8*&N)?B%ZKVS(@U:V#4`@;,:Z72QPAL.Q($Y!::"'5 MUPI#/$UXY_PK>L11(D?V4".W[Y7['`I9AJK??8+5BE&?SZ)U/%;%WQ[0,J/J M$Y$NM[P(7(PV.8HPOZS(EJ`D9)AFZ=^@O&#I"S9U'?IM0=J7&?U#O"7ZN*+! MI$P7"Y0_$0TEEN6I8L1WP;=!_'>>2"O`/T'OR`E\LRU13A2;'L:W*>8)>POM M_LN.W*VNFDLUX%YAE`PF7=K]#LV[BA]`/LURY,8,'$".4\4\*3<.SE3;4L4Z M2C]*OURZC=.BS+<198D]4F%O;72[4R65!_>Q2H:A8G_604F\&W+#9FDLGWZ M5&C2X3[A7.T..#H#B?*;[6*[[P5H>F?+>[O_!:B_L`#L&XNN4^;0BOV&CU** M5I3->Y.+TQE'[(KHRL_@5++-]F\0#JU*?>LQCQY-V)9?X")*LH*UF?92L?03O.P&LEZ9HVSZM7:LC\*GN M2I+WP4X+Y+V# M$X0.*]!0BCG7WM,[O6G"M?5''/A_.J-!(UZK5%"<2Z=&;/F M"+0!Z8SU>K.'U>RKS62=L5YMS(4+0V>L5QHE%.?2F=<3=.9U@#KS>KS.O`Y> M9PR$D^F,3K@P=.;U6)T9A.*DH.>TA"G\0/9^$4SN=@5-Y:Y6%26)ZX!H%?=B MU#%K#:KFH&H?@C8<1)`%N$RCYS2*9(V+@E87^)B5*!1],$!:+]C8$&9^+W:N M#`I3:.B"N.!IRV%\R7,54O$*H]DQN>V13,T$*TM!7*+WZX?'LVV^BK-\J3:Q M\O9N[:N";[$(-&T*2-N_+D#=.A3;HQO_CN$Q&_PI#QYV9;9*L@<+0"A)'#]L M4'(O1/B2UN]IZT6@T#"8C&XXO.E,S.=R+J;=VA0ANANWAED/62KT. M[;/3?._'2=KU8Y#*]>,4X/UX!*IE+6#[9G6O5QTNMDE![ MUBJ93'K0@;9:46*@PY@?M1HOH7!%NU>KCS3K7[5@_7%NL8U>1'J=67_60ZF3 M:NMAH)#SKI@#/=(7U*L< ML=R@X#(%'PC,'ZFY>!.L+BD1:K,2#\)S@B[=YS"-'I'D#9G8Q*U6=+GK(Z/Z MU?L[,=E`=N95.HK3)T_ZLFNHD9<)E+[>:J;0^WLM^8`.3>.!WV15O5ZG2+UV MB>V\3&>;3]F,DC:A6&/9Z`Y-K&1HI\_M_9?,:&Y;[;S,;9M/V=R2-H'-K3"Z M0W,K&5IWT6)WVX<"_;8EVY:WM*3\/?F>YO&VE,)YA)B<]SY*]BT!:PIH6^^+ MM.$<]*/!C";`U[/N=S!"/"FM`D)R$L_/NCO<:Y]UT]:`-_>=*,5."+Q/:+"D M,D"%#/X>IHM04C],E^'(ERIPA+Q&F\WB,Q_6L*5*LF*32>>U44C MH5:!:GI`.UC4Q0SW?82&2),956/4?#K]!HP3KG`6X^@&[BC;-SE.J;]#@(8F MLEG>31#AY`HI#:/+%Z#N`U2=T`2953>>JTY-$[CY#>1HPYL'D/%V#%9-HNG- M@.IP6T[.!O$V(7RRHF]GN_,$%H4N/Y>2ROWV7"F#L$6O6E,EX]4X'W:`4823 MILM@5H3-NNF4.$Q&3CFH^-%F8!IJ[#[U^!#'0A`_PTJ#'O_N._UX"\FY-8/M MUBV`8PSSW1ULP&O@&)#0>'$-R/@7+`]L6YV0G`+*&1AR"Q@,OT,,[=F@.<.N ME]3G54"6>EYK=TR(W:/*1"(-O((Q2^;3(R#-PQZ5[!V$?)W67Y7E8FSUS1I1Z&HG%Q2&]WKEI\'RRP'=4_!HE-RMNQGYFS[ROX1\".*OY'`AQWJ.]JX`5^ MPC%*8QJX;!3&;D;N7"<,I1*C8;LFMB9DD>O:B'4W^C)2M/9*LFG$9#>K"U"5 M>\=/",2UR#GIT>^:>9A)7#2S.-=5.!G.HL[D\7Z+8YB*@2E!3:!+RVAC7_J& MTMZX3'@MR[[!![D@$\D"7LAGV,WF@`$TH''[BE;#__`]]KX]CT>B-HY?8WLK MF&;^=;LO5Z.UJ,>@ES(H=)PJ!I$[)P-"-&!LB)*,[L MCXFF=^R/N9K[.G#]FI4X7?'<4L;'K"Z1Y\-53P*=N>+-JVQ:X9RCC*6HK-63 M7@Q_N^PA4*GWUG)$S;`P\Y!!VZ6YI@IC<6YDL%B>.4UP"[2I*`MGLDQ:V@X] M,]Y7MZZZ&*UO0[KB:X7CN3JNE\U?&W?,97I*_AOFY@N?45^>UT,S>;6ZQKNA M_N[]3TU/-%MMU5C54G*A,=7""T6AV-:1CFB[H`I8T;56V7E/;I#(7)I1N#861+$*Z MP&936U$!2D;-0IO0F]=DE$R"36C,0$QEJUZVSRR;B=T[7NF,+-YA`+FP0*0S M*V=N-SKVS=9H3"DM3CK%))K&YUE*7P!VZW&/A*M4S+\HWR-4Z+"!??X M*HNI#+9UG.E_F%\AVW_3K/+,>T_7IAWM;M9_[5`[3/N+8($('F^IIB=OOVY0 M6JB\4Y+V[A/Y2OCN8^5Z@W+([F(91;$`MRS_/R?P[[M0CK^0LU8_^.Z0TXPL M'UC*4\71!YSB]7;-N53=WIAWX1Q?%M+906X!J@Y`U8-_#-K.9!^6XZ;1'5(O M4W+@X(G6Z?)[^E"4.8Q4I2FD%,YQ*.>]#SO>$C1-R:)8-0[@`8QF"OJ(,AI_ MMSE,":R?4$J3L:F`([3TDIVTRVL?*-6/-`E@N0#W6>D[1[V>9?)74-!6_I$L MP<)0=E0I$!P^6LR*\GI9\:'`;:^=^T>*/3[%HV+!@AT:[`8`6U.><]XB`.P. MHD%X?BB'@CO8[?+8GWWV*^`_S^6=ICJ@0ZD)EQL% MER[Q.3#K?71*I]RM3:4NG&J/6QCL)^4D7BRMA/LA`\8]2AAII)! MK%FV;[T`Y+\2Q$)AJ&ZT2.DN)-8VW+`V^[WJ`8T5DH0$3P1\+.!=EH)=EFO7>:*'1(0^=Y1N4RH'WC#;\ M?EY-,#HYV/*/*_X3RK]_\"L@(W5@R_#B#NAD_Y!UN:DTS^"484#K7`E,Y!&\ M?2V:6BLJJOD/((:+Q!BYKLM'E`=T#C'&6E]?+('F\J:'%];5[Z2$EAYN=OJ\ MBCAYJ)^JROVN5TV[G?W_3X'#9W=8.9 M-S0F;B,SAL.QSX-`$/8NV[8EBT.ULU:UEG@6W&U_+64@VEEO*<"SAWEEL#!D)A*P M#5O+RJ@W]&[V<+;._>>IQZ?0S%EW5W- M:5GF^&%;LE>&909N8$Y,?0">6!-1#+ROSGQC@;!K9%!"839NW@`9Y(C6,7V+ M-EE>HABDA'O*-7B&4T"V,-L"IG$(WOE!*R+X&>4FQ'<&?!J/P8[>I_'_V>J/ MIC:=!)(-7R*AZ=-_'CC$72JM'F:RIF^XI"E:00)[G( M6(AMNH$X[N>4ZJ62W^>8\F]"[!73+(&\7BL];;9.GR!.Z.;D/J./2;.4L?V8 M)3%9Z,Y@@2.%!;+NR>^&S4A6@RU=W0W=S_&.0+NG!6!]A;;'&RU]9Z<"X&:3 MX*@6/^+B%ZVN@MEX';G`XS=OHP5GNSJ=O/Z-]$@#IMP)VEHOAP_%ZA=KUTO. M+GOIOR:+Z",YN>.GRO-H$,MAW9/[AV;6LHKU+.JGBAG+G;(GK:UX*-$>TV4] MS\B>*BW(/HHH3I$E-,TPX#:P],/$YD&LK2(BED'*=*5B`"7]+"0N,^">3(R1G9^?`U:+2V` M*KXKL42IXQB8`?[8K5R6([Q*S[&#?J)RYABY8=U06H?J>Z#^(&A]D3D:6M]L.8G:9L7ONN]L,.N1BNJ1*ELC M`_=^"/_V9E[-'(QNFEDM@]A4C-M,A+6)./SFP:=#9HJ@Q[-'&+$W\*4];V&> MXG15U!4";_*,F(`U--B/ZTF=ZY&!-'V,U23[*IP+FF``,+I@SLI3!*O<>`'E MEC<%75]_[!#G3XF8NXP^],*;VKD"B+B08Q*OX@E=/Y/*;:B[1G M/^9M`++3)K?.;WL!12__AI_)F:\[3"LAT2J=D5"JE$,O=O2(XFV"KI=W:$7W MS3R<013"2ID@UH_%W$#/`OY'MJ-?&>-=EX M`J1W".K1=P@A#N,V.Q?9&F)5/AP%C7L(*?A70X@W"P%$NBD00&0V_K8@*E#T M?)4]$;:W:9GO*(9>U_]!X?.Z!9_JS_\@PRKBI/VC,T!T..K/_"\?+^_?7H"[ M^]/[MW=^#IEJ_E)T?D"Y1VB*TUMC4#:WSBW6T*I\A5/$WN'I MC9>&W)<=TTDE;-M46S7PB9+REXGAV#FCB9.8/(M9XF';F/88EQW`\YV@'9$3"O8YX+<]Q5(_.=! MA&>"+]DNA&7`V63RT!YY=3,*UP^/C/D;N/KM%=*1P@CK/1NZS MPRG\/)]S?[2=9]2$0^C^,^2P#)H/`?'!'OE9,"_/*OORO2<#8WH&=S^89!N1 M-X.9"A?EY&?ZQX@.Z):.(4X';99_DS6G^@IG^=EUUT\IAJ8LP;B:#')RK\49 M%%*-K=(03EF&D<+YUU<;W*GJ,9B!SF&R#XB)HO\'IEG@>$(XA?8,-7:?O&.( M8R%G!6ET@M,3VFSV;(HFVW$CKC\2W65K%U9R[#3GA!0?0FX)#3B(0$W=/R4+4,SD&]1JF`Z!/W:))>U/R-:Q,IJ^A M"T";NG)(U>A93?$]M?,MHM`42">/AG&_RC(`*KV62!'E4SUNPT[R!.[I,4[=+%.5;`IW],6#4WE/=80#J;BBYH;HW M.[NJ.^YDY!V"5H_>L]4?9A0:<3ZYG@/,:;A(+$, M0<VA60<>;A0-)1-O&7=-6$I%"AI:MF-LJ#WG_Q\M(6'H$=+S M;K8$2"V,VVM)&S"*5Y7V2#11M'6,2Z8^+]Z\?L&4A_YEZ()&Z6HR(7*F)$82 MF%TQMIQ#?M1AFBS/XO9YF/M^5#Z?R5,29]&6`G$PJ&FL./>/+%N;(%*\S>DR M2VA!WKP*)9M)G,5]<4&:E:!`&TAVFBC9@2H?#M]OTPZ*=I[KJ%G2G_NS&^9Z M6-L*6R5TMQ#?DI'G]NMZ>46L%OF?\QS%RIJ("AKGRZV*_X&Z3O4:2Z#$6K/< MZ:R]WS751@RZIX?Q$TT558!G>4/Y/J$;+O7($8/`:RW M6LSUEUA#P'D_C;[#*9F5`YU&E9V%DGDF^JK9KFXD"X7 M/M9%$WGH3W1'R?:=%:5_C3)"EVK1TT#+93G'+$(H9K6]+XMB2SUQ%2 MN6STM!Z*-^KE$6_O.0TWXC55586G*9'F-3Y\LE0%Y"_^VT6Q%OR-5"UOE!7< M:OSNU1_]JY@Q,,4JAE:H=)AK>+E$47F]?/LU8I''M\1>7J=T/:4U?\C_4-_2 M$YDG=>U4NV[<9R&VDU)(2$[P?2B!42UP MSA*V5:\]_&OB&-P*J7U'@]9A.8I!;FZ8DZOOZE'HIUTW[@M6V$DY>.094L(% MX'V`@0BA`,(&)HI=9=WF@N%0-',,8H7*%J/AZC)NCS\9HX_(E-%X[68>8NPZ M7(HW!?QG0'^?62/,WDXIV67ZS8):EUD>T)/#(2R(86HR(#B--[P.7'/11`JL"0.PYU=_&G;[X&7,EY0@!``/`F,@U%*."H>Y%K>; M3<)NZV!2Y^=KY4DU2;MHVH/[#(S&L@G)&%N4^V2,W32Y081='4C$?4V3SITM MT:RFJP#\W)98%3)1C@&JPQJ@^0JF53Z(\Z9H,L\5<4,`5(<"7"\K=SQ,FMR: MQ44S@:3U'5ZE>(DCF)95^#9.5S>DOPBCXAY]+<\2M>///2ONZX:Z'VVAHFB+ MA07H,,%.8&TVJ%HVC(`])V#/"J-I,0/VW(":'?"),@081YXOZ`*;`#YZV_4: MYCM6SD8]D/Z-H2]S(90L]6HKW)GGLVU!`QF*\VS]0`1AV7P:[DV,JFD'SDVA ML61"+;:*$+0HVP8I'&,S6L1;]$2W8>`#RE3AK*Z60/?S?A:DX(Z4)8H4TP9-X*C<%D\LC^D.!?ML2OMY2YN[)]_35 MMN0T'H[A_^_`/JOE"^1JF MNX!*QNTGM%\RKC^;[@PE.:[B$EWA)QH!6Y+QPS3_`7O[\1&I'.(Z0N>F4"M) M'R">X1%P-(-N`[:[$!1CLX?PYTY%WF=9_`4GR6DJ*&[] M$_-T[A0Z9-&',!BQK M(J8^39*&`#;W=G/4>7EM.4$.O2>/,$=GL$#Q>;:FF0_Y55>>TZ!GRM[9;M^D M2C1Q^@7F\?6&U8.[WI8%T8V8'*D_;B40G?%;[KTP,XR7X*FA'9P\T!Y`^RN@ M]1F:^JS=KOH48-]:@.IKY!_[[Y%C#OOB3$L+3ZYP5\*\U"TP+@;Q;Y!V1Y?; M:_(%ZNPZ@PE]6C.K^&]3[8-"M\*_90W5LCOUYLUE;P2/W[S&YG@L]'N&A,N4 M>SS?YUFA](+/\;6CL]+#8S:GG>9?9(FH*Y\\^ZK?D[*;8=P;*]8>24*UC\E* M*73NT'9*JW#>;^(8^P7[L>+Y[5>41YC(8W\=I^PLE#LYM<1SFI'Z.RU+XMF$ M'&*$6MN9NE4`-F(TV@TO)XVA?CQ[D7=9OD3L!-Q8K!GW(H-?.[J]R/"8S6E$ M6E^1`V9CY]._0^1*MLQV.E6D>_OR&\>B1;TE.RW,$5 MJ@WP38[W,)_7TZ7FX.BLF?G8.O.*U7R`BI%FDP$8*]^4N\QRS#5#\RW[U@X] M4M^P(\[$2,[HGC.WD`$M0875L7ZN9>B07(2W%!UTC,E0?L%9 M1UYK:H_'C7AX*V!M9^U>@.^$J_=;L[=?SU MN]R`_+->S,+![>\$FW!4)GB#,RC?LGAXV83,ZI%7V:\+KD,-&BC58T%IX MEQ]W^TK%U8@.VGQPIK;Y9Y7-K]IU;'YM\FO'\66]:P92%?>S7?8ZS`ISIW01 M3QX4HTJ7?L''-Q)1&WRPN^$H6NVJ.D``,O!E%?A6S:U%55@3-@..FP%_HFSX M+I7IU'1V'GYYL)L>EYC&_>=IE3'__G$M-!;C.M]:TS#QC2\W$P9;M<%6>\:/ M8\WY5G!X-`N/K4$]Z-HSSIIZ77Z8P]/;XF/V]6-;>@S'=$Z%9RQ\\\O.R(%6 M+CJ*&X!C67*.'W]'M-S8&-`#+S;VUM/QCQ MA0FML?M*=]?BFAL_MS#.Q]S?LX.&*]!B"U"^O+^]\CX+AH-UA9?HV=\1S(OO M%ZT/!W*=X<=^#%YT^#0>#BL0T:+E539),D_;/">R*.RJI+W[6CX2OH6,6;3= M/HEIT]1S(1PK[D/)7ZK$BE`C1@^4*<=@E)!&J_['3C]<`W7<+[1]2Z2V+EDD&4%67!1'W@=`7(40+IGJ#,0%'A M`((ESM<%V.19O(U*UKZHTKHOB*T!7Q#-RTDZ(O^3,0,D'T6`.*_%3':##S<4EC(,")JRX8;%!$:TR5_V4=/G%:91L8\81 MI+5:*%=IEIY0#@MZ.UED:8J2!:!V>@&V)4YPB2DC4;9>;U,<,4@O`"HC.GRL MMZ+N']#5@DFW&R3QL[T;YGYXC]1N6Z]G/FO36PC`JH97EK;6W4`V>PK\#.[WM.!Q MA__>P8LG*+Q>LG-;ZWQV!@L<$6V]P,FV5&;;&MNA<]T9+;G6H\"[8J4R:6=% MUUO#.F2+3M7E7%NLIDS7>[K2I.);EUD'`U:#09=%LL85?"0RG2O%U=%R/H$? MFOF-.9&Q["[MUC2][UNU0RA]$!4'^O\]I?*`K*^0*A!(Y;6M1##P)^0'(\I*[Y2CQ>ECJ+4,RRG=%C"[WEHW\I"G"+"D0T])';??2$DHRE M;%^`^QS&:`WSST7U;_`1KJM3R5&40%"KC$4I!!-]F>`+&ZCP>HNB;)7B?Z+X M,B:304Z>L/GZ:40.:.3@31B](G^NCGGDM^T:Q6RBZ#RQ?WP@LR?SG,W]5;=^ MMMG'T*2.\@+LOPG:'ZTL#Z@_RW2H]6%0?;FE9]4_Z=<]NO*<#RN7.F6&YH>R ML4`^G7WNQX"Z!M>TEA[=J>,VCO;#TQH=D.]1!YE?B/IQ(.6CP,R/$\/2>WRZ M&RO7KB?W@*)86@W'[K[?0&)K3V58=*UOJSD]Q2!%Y M$X4C8XZ/.?=TS#)B3A:;1=70YV7,MSIZ+ATE\^ELWY,RM\*ZLW/,^**X>$=& M\Q95+X2+Z^4MC\JX@7FYNT`/JG@[\RZVJR*?@>5!T` MU@.@7?CUJTX0]",J:3P+O:2JAU];S/:U=QQ@W>DD MF9%S6#P2-I_(_C4^V_W"7N^](Y8FC7"Z.HU*_,1,B$(K;3IQKI=6$@X!EE*# MFIP&[C^C/0"=BQ&G;LE@`(.%XC<8"QH1Y-E*#* M/;FAKDLZ4O`AVY;,/?FE'KQ6E!-`S>!]Z4=)YQ=&/E60K0[/2=OBD8/I.LM+ZKA7[=3M^G"KP);RB>$$VE`+T/3A?8\=B+#.E'$, M>#OZ-QZY[CS>5QFU#RE]DX72:'=: M3!!'6X+[#+"V8-_8ISF>CW]G%E8#G(XQ-4*-0[M)=E;7RW.6H^`=C&A@P>X# M_(K7V_59EN?9%^K'@!OR2ZEZ2&77C7N+:B>E8%X).8WDXQV`NH<%J/H`32>@ M[B4`8SMB9@7+.WI:_2+X,HUR!`MT@?C_OLMRGD[P(U+%H=AW%022-=(:H[GN M!SRK>_I^`4@?86+99(Y-\&P^P0[C-[*2;G!V-`#L7)NN;+"U^XB,09Z%.`3: M"E3-%N!DEC0T?B[`]!] M#M-BB?+B-(WO6-(]HVN0-UA/^,)1-\%^`3 M;Q\`Q.<`25\OYD/(`;R,YUE*4T!>+V](:T0L?GQ79M%G`.^&_R$$%V8``COW>5K!>-`3.@+#$]3O M5SJ9*?R`8AS!Y&Y7E&A=7*;1!T2S7LGT34?E5L&T,O0!5A&`B@)4),SE`SYQ M,H]K@L7$=!!D,RONMC\MU/)PA%9\@F([HR9SOCW12-%'6-LR+:IPE$ZA"_\[ M#I-YZ>\@S"?%X?D>/93[[GS57<@F<^BH,T"0X+(RAY+`R$]FBL9O4M[]M M<;FC-4VRE&[?-;X+#9W[:D<:.?JPXLW`OETP3@RC&1&JTIA/QX1-('V@2PZ# M&_[NGD;O%^K]GX+`[=9/Q;GP`+W=%N2LL6:W-YEY92TI:PDNR,QOH M<$ZI4_(-,"!<*#M9+;HZFUA#:!WZ^1FKLC?'XS.[C@-X>F8Y$H8/SWBIR&-^ M=A;TN/A]4#9&>?3/R<9KS@3CT&3[IF><^^P,5>X8%-/D%EV7C,P.V/7A5N4M MY1/B%7@U@.MEY86[S\`9`DT?@';2=]7YU.1@Q'6FH&,`W-'%\>AUZ5,J2GJ+ M4=4;41UHQ*8>?$<"MZ*_J"[C];8I!N4]PXH!WU4=FZ8*3SBU;&00$5U:*GRX MC%W:YTIB%W4T!TV6%J)6Q1?=9BT^,BBKXS6`5,"%V?ZUA(I'@YMK2ZJ:=E)`L MY5Q%&=1R8#YEPJV!Y7PYO#N('E&\35`W@6-;9\YVG5]HE*;J3F%@P`U9,0(-QA3)]^[]NA*YRB2QI.8;\':I&& MLO%I2V.\VP&?*!E@=`%`U'2B#+9L4R8MUT:7#6B#[=8L91/>$7`R4%-#^H. M`.T!M+H`O`^?=Q\'DA75(N94Q"U-@$D.9V750UT;J``Q7BX1_1("#ZC\@E!* MDVMF[)ZDJA]$_=O\;RQ79CV(,4HS#NJZI>^TF6/4H*.FXW7@L($-;"^M^#.FUA[&FZ:(<5&KFO3[&9?J$BG)B?8S!3D*I MCS$LH65]C*:3HZB/82XRJX^QY5*2_U<+>02U,13`-:R-H46MPU@'PMX[8BT_ MDB$A_]QSEL8#%3SVMQD&5P;3NW8?2S%]-(38"XISVN<"5+VV5)IN68<*X'2N M_C3W$6XN_F88F;OM9L/SL<$$%"VO=IJE)VR@A)(YNY_]6X5#:8P0*G)0=7$9 M+44#N`J:&IA'=?%S1Q/7I?(H&M!ZB*?2RR,&6-4T%+_5NSQ.MX_G\ZJ^DX7: M-'&(!0M6)+OHB&^9"[];9FL6`E)W&? M/$_.O?#>D/G66VW)!I>T#N9QE6XBA,QW1K-@"Z0"1<]7V1-AFJ`SWU$%(>#QU?77Z\<+/"U,U8UE"]VC^WSJ)$UJ# M3C:;4U[LD6%FI=BOE[^D.*J>_%\OSQ\Q30"@?+MG0NKX%9^1-&)!V8IJ05>_ M7SY>GC<)':BWB-(&``O;Z>H^AK.=*Y<9YM,5O8RBCY_U*?4&6WO()#_$L^YM M?1UV]@&6VUSOW7&Z[,DG0S'?;2AI9R"HZH"Y3CM=='RF5[I@0CL_59N+;/`HWA74P7`!K(3'1[4C@U1C>B$Z62(J>,DB>F_@*6TINAP6[=3 M*^%W6+E;[0!MZ'/M-&2<_AE\><31(^`(S7*:[6V[H6X:]I<"X`(4J&2!A76` MZX*&'9R?__WO)Q\^G%Q<@&66KZ'WR$`5N#K@UB-K`L2O<^KTS)H:1$K#)6GL M%N0RCH4X?]ZN*<,3BCE3CGAGX@V&>\HIA.@17&57\"'+*='.#`-:,L?G#*T4 MPC:;4X"D(0'+P"!B.#7=;;3-O$RIV%O^%>;Q%Y@CFOL]6Y;TGVK(*$DP[P-T.UD`W@'X5/UO(*DD#B#W+8KHU8E4 M=/\GTK%0%@-)I^#8G>K>-$6Y6"3-95%L:8X/E@9)H:9J,NF8I3)7Z-8>8G*4B.?LNM<@$57V-,8>4.^WH MI5G6^@HE[9WK@XQO77KL@%R#RJ'O8\=@W-V!IGK7(]U.2]HY!TF?3\EKL[ES M8AO6$S#D5I?"VR6$!X'0AZX"!2Z+9A11CC9DM. M';?UH]WZ0>O%_LFN0:6-@W_+0WF.PX^7F-V]^0:K]BJ^IZZ_4P>NT]-M\ZG] MH_36QY3/T)WFR9H+<&(QCEG1-C8D.$:8:N>/]!]4*7]L*27YTS\N*H?[9&UL550)``.27$96DEQ&5G5X"P`!!"4.```$.0$``.U]6W/CN)+F M^T;L?ZBM>:XNRY(OZCB]$[[V.,95=MCN[MW8V�)"1QFB+5).4JG8GY[Y,@ M)9F4<"5!(=-P8]%R9^_IT&E]+?AINS@\__Y9&WGLM MV@RKWF`\'G_._PI%T^#G-*]_'WMNEHM*VJ\/W!+T_SYMBGVBO_HT./XT'/ST M/?4_@@P^?/A'$H?DB4P^Y!WX.5LMR"\?TV"^"&G'\]_-$C+YY>/<#[)0+2:8DT>C83CT#/;F+W@!HG`0DU>A'I9:!7CPF M\8(DV8H*_*]EL*#"U^@.N[J!?MW'T30CR?R:O&8IM'X?1"1]F%PE!(IJ=%#2 MCA&-"NG<].A2,?AO=)3K$,JN;J!?5_%\'D?/\,D_-;I3J65$O\B$)"#MO$D@ MX`\W2=PHTQ&1H`U#<@HRJKA4/ZYBF':B*2Q&>N-2V(J!7CZ3*6V\WJS*JFR@ M3P_)U(V"?^8-`NCGY7SN)JN'R7,PC8))X`%%%YX7+W-9/,9A0*6Q^5>C^PV_ M8T1'(I]$*:'$IM"P3X?LI1O2T?H\(T1+G54:L\7.B_L:ML_-YBNFUW/MWC-K MFUW;M?O$J-O2.J_=-5$C;:_YVIU5:JW-%:Z&>"4MM;*.:'>3W\1!9EK8*<'7 M9R2#R24T.NWNM&QK#KXFF1OH(&OTE;8X>X9#-LGW0P^3AP4]OT/OBKW1?)&0 M&50(WL@='/KGY#Y.&R^@^M^SQ>^%#^U`!3.0B#-?&#&W(M5HWC^I-FMV-;-6$CHHX*H9+Z>_:0&JTW=)N M1KOKHD9:ZJ,9Y=%NN>V]F38"I=;:[K49,NI_HB7;DZD)2K-ELQ8K,R!4&VSS M%+"=%:LE:@SZ>A^P@*VRCVX=*/-K%E"_P"2@OWXV^HHME(3F9NHZ M'VC%(J+=>WX3K?3/C,@UVSV$G>#*36>W8?S-J#&@U.A!,1BU4ZE\P98]HVVC M10G9(B$I0,[KPT;[SPI$\CTC(#I_`Y)^L6'$01X5`=\-8Z_RJ=S($"L M2WQ>Y(/BDS<+PJTF3))X7D.JZ[[$:J"6*70O7A03Z,*3Y)>/@X\?%IO% M_;Z0$!="WO]<6>`<>LCX5$(ADWE M&6(J"[6\#4*27`&*:9R(AV*EI#.PNL-I,A#W<;"Y.T?,W4OBTLL@SZOY:QQR M6*N4<088]RX2OO81L)D:(V9J/?F_N]J>9R"IE%JH,S>B\,3KGZ"B,SCI'J>* ML#CF@B/$3&]D\0+-2@X7M(C30?)V^\]AR8951Y6E"^B_3S''T2)(@]L7;3&99YZQ[Q'&!<`CL@O&EV"\7B&[A=S++RUYY M9]Q=(IE@.&1B-KQ4\=##CSJ5V]+.>=>)K$#AT-C$``-2^;SKQ6O1NU>]MJOE MSC-C:;]0&.+L/\ MYJ@.,$8#`-&J&4R=!K:'00>E(;\AZ/EKG))[:T.M?#/=PD#;?'[U+FB%<2:H M!>P,;0TS1K=4!I>H&L"Q:B!1ECA[1,FA]64<,5,J6!A0FW[0",.LVQA"O;WKC2J,5`&O5M*%'"GO<:HX^Q-<#WY5C) M2&1I8=BN>_%$%G%"9:\P0GE5G.'(UF#<[9+>"%2H[0RM!H`IB9X]PE3!]6-1 M;)9>U<+X8^0UDX]`?B7'GAWG_8HWR#[OUTIM^>-761FAA-'1O%X-Z/`%%(-X90+Z&01'&.>B;[S2K#RFP"Z<':6UG MA"(,I.8TH0;/T+5?#/IP%\%(\$B:LK%+-4*IOG-^A"+Z"FOD6%KP`<*FTP]C6M+'H9N2S?13XYQO01Y0B]X3P+8II$<[BZ^W/[\,G.C M7^/8_Q:$H5S13'\"I-F]G4\[0C!T:]O^E+=!";/[KB2J`A!,9,IM@.RZNTO2 M1&GH;CAJ#6'/P?4TA=V6,S@Z1F'N-*TR0KB&;JMCV&A_)=]*HDOB"'[TBI2+ MNOLEW::6%.WWZW[DZ5/>=GP3VVRHCU,;H,(^A*X,..G03F_ MH1X(E]WUV]CJ-)^VC@5GQ M7I#^D5_8.4'A-)2.+@D"//D>&WBW\VVVBD>[4M`Y0;&'Y!##9I&!H#,IL[Y9T3'#[=?9Y$A+)`(#!M&@K9<%/J8:#_4)_DFQOF@7C9E9LD*S@" MY6&XHM@-E?K.*8H+HWPZ.>$;RM@,F24Q&`[6I]_TB7@$(,.Z]95D:YG)XY&8 MU1P8D(4;^.OX@QA,);G,XLP-<0;7 MB>=I437G%(7=27D++L5B*E-FLQF<$V=P6_9W"^-Z>&$$ZBTX9^3/^EEIOQ_Z/,/+.N58DV`WXU#LQ8>4QDU,>R[-MYF!?^[ M07(G195&/@@.I]J&+`SCL``H MW>XZI]U8)AF]YK"E'_YF?6=['[BO01AD-"@C*J[JS^(0X*1T@Y>M%"S,JDTX MIRC63RU/@A8VCE9TT`Y5@JWN:>!7<_)EH.-QJ6[X0;/KC:/JRSCZL=/AF5W#.4)BPZW',1\3A MN9,FL9)LU(:O<.VA-N_#]H(#QZ`;^773E+H+,%3DJ M.36<QV52G M)><(B'_C)A$<3M*2/*[))/`"\7,QLLK..0I3 M6RW54$3'T09]TYOUY6%?2EI'-^<>_I62R#.^#")NM\VO\D M_IT/S,%4MLE.>>&!EH&2Y$^:OD_T:;J<$U\Z0EOZDG."PF@BI96S;6I!&'UY MMZ7T-KR]46[^A?B=^T-6QOC[!=VM=[S&^)6VXN"X5"-C0S8TU7#V9=BQGI*W M-_[:?5!^;.U5,V[?&KWE4'J+%H6E68T!GD-0"60_]K3")^/MC3Y3#\>/[3U8 MMIW%:==J+'+[U9PQ"C.=0-2R!8V#J3\K&.<977L#23F@9\?4-C9I92E+I7@! M5M6L(JOIC%'841C"8]I.E.`@>#1,B4D:Z%J+2$9%9XQBPUZ'1QX:0RE46Z!Q M,RL]++,TON/T=I;E$P^23LXLG:4>M_7 M[/:N).7+U?J/>KL_K1;I^P88AIV8)-GFL`;DOFPD?8`F3414O+XIB']7?)57_`$OTRSX%5;*XG>]_MOZ!W4@5KN3W"=KO M]H^$_518*&Z&R<>8#$,?ER@=%.VQGY0H39(#(>)4DL? ME('UYW&!$F2-7:"@%@@(R27#FLRS`1E[A@`?X]+='Z<&"`:7,;0>TV4P.)X? M:(EGM7V?J!H("9?MM![C>XA,/4=0,O-TX9+8-;TW:\6[U&ZT[>`(01@@/ZQ4 MYG%2;`)@HAB,BGS(W,$J8/&XJ%I0_L[TZ@-HD+AEE%F55,I=I'VP1-WN011PIK]ALLDKS42TSDJ@/9TX-$`D*`UI#GH7H#/G7:A+. MB9-_F,!!F=PNDRC(Z$TGE:E9K:)SBL-95I-2'9"&G&=6A_*3&TUE![%M&5!H M'&$O!HY;.Z`,.;SLB#<^S9#4E*D^]&2_*5"&^95TN""'`<,#CD<*AD@>C15;.K M.,UHVMD'4 M(W$/@*G+8-:?EJ#J2<]C-]\7]/"FDD6<5P4$B.+$KC\^^6AZ<^_KFD"/O6`3 M#'PQIPEVBMA@`=6"6LX9CDN>8O[8G$MA]>A:UQ.P`A*=`DZNO/@RB@P+/@C:R! MP.\OH01[7:[5#H@&1:2H#N<-@)KRO&&8`W9%IK&X@S!0[-?JC'0V%E-N.?M[ MM[5!G:;)V]K/^SPXGXGZ9<@BI,@6VVF.MBK5ELIDIA_(=DL]NE+ M4&F6QU)(0Q,.T@L@L(/V^(,+B*/A^C9$)!H.(EF/8+Z!05(#!(/BFGH=S>&` MX;#<29/A5Y(IG2@KY4`,*$R"FJ>*?0BAJ@BX^C'NIVP7&A'A&9T@!)/`/]XLT-POSMD[B4 M'6?]A/JEFP:>ZE0@;PE$B<*JV&"R4`7)T9<.FAM+#PP48F"'\>J]!*'2$@BR M@V;*6B`YVJ)MPNSP-@*'6[D6>TI[#+Y_^;B35DJ&5`#QPP0VRDK!)-+:(#(4 MUDS=N!)%8!Q=T#9I(K%\<2YVW-+K(M/H*G_"VEN])&Z4@@B*`(S\_\*"S^U^ M:R,MF=W,^`>!%A0F5F4-$MC=6A(.1V<[&<(H$'.]>0M$A,)JVU!_I`@Y2M!! MT^V-FT1!-$TW"9T?D_B6OCNG\F:NI"J(JH-&4C54'`70MFQBF`4L'H5QY,]5 MH]S0P9B?8/=8VV)J?]^S*[H<)`TO#,)E)LRB+:D)@D)A4VVB&TH0.??-.I@[ M_P_85\T`UP5,:NZ4?%W2?!`/DQQZ*<>TNHK4:]`YP[$'::(Y39!S%*I[S\(^ MU$GB?>'[00&]]("NO90SOR0$*0(\ED94>+GW/&Z"P!S/2OC,X/K%F6=UF M'[EKTO^I9PI7:PI@HUAB#'+(,A`)-T@7O MX94DLN/4`)'@)(4F&6?_I@0>?YP:5T0$PH_GI!%=>(9V.QF M0N!<`?I"X+_DAH8C+9(@Y>"B<:HH\5$F4XNI#S@.&9.X54EF(JCF# M(0[O6KLS^`[>/B0(9Z"$,Y5'N9N"&'^/B]C<(D`Q78\@T;FR7H,@4!2^.#GI MRLJBC+HG&._J!H0C^#=+PNG^B$*IX*<&E.' M]2&JI\#:S?XW&*(PV=0CJ4HX%QZ>HW=;^0$'0ZO&%*[D]PG:[W8?\@.V<[Q" M80XQ,3+5\?;IK%U:J)Z(%T\C^MKSG0\R#R8!%=5%FI+W@\%%Y-_#KX,0Y$)2 M^-MR#K\LBM3:N!CZ*!#3A3TY-Y5EVY+I42I%DZ*ZY2%TJBX\IC8K"B9Q]`>:@SL?=@YQ_&Z7P_&`$>VABP[ M?1L#W%9#ZO8!Q,LBGRN!U#GNPC&M0>-L9.<'D*W)5V`Z>5ON*^W(V4< M:6P-)9J/8_];$(:"'5K4D+EWQS6"LWX,LQ#*"Y`8C!%<\5C*G,QAI6Z!;M-^0_%99?TT5U) M8B8.V@^@$6O`A7EM/9B]3B9O',F>#W"N>R)A'K'E)MGJPG]S(X^9,?@@WP71 MHP@_L:#J!Y1OGQ)=FY38USCR]B:'^SB:OI!D?DU>#[73D?8#:$1Q6:HG*X*B MO$VE$>_;L"G]YO!'`:`&15A43X;"GF3[DT.]II@V-B_VS"%\+K:E+P(QJ/PY M!SKUJHFEK8SH-F]5($NYT,I5BI.!K7G!ZE6*$ZS>A!UJV".Y'EX\5RD:O'SI M1E,BR72P+0.P4=CGZ]'%IGX'')XK%0TYY5YW9Y0"Z"C,SSM<"`@K][L/]RR^ M!%$P7\ZEI%7*`7P41J8]1MC$,?K>IUL1!C+'G*`PAIB<7850>YIRP&3FF!-4 M-@$FB^K$,[#931>@F#DFO8L\O>PQ[S4`)M8S+HL/ABE?ALW\Q7\+H]@-J5OA M>49(=K^^XB^;Q#E5G,$IBM@]H[.X$*NA,&AT"B"?O[F50#`X0O"%Q*F3749E M*$S8[)1]X7G)DOH(5]!X^$RR+,RS'HJG;7$M@(O#J"$AA#%GJP`S%?B*;?NU M-=W6OI]^VCLCAQROJ1A8J]J0AWL3/W]N]"Y-EW38/$P>D^#-SL_ZJWA:WQ M`1`\5@NCDGJ9E$(?P^*L9$]Q6K]K*M>RJA-!9RU$G>_#LOAX,K'!G<&TFO` M&9RAL(?JJD`=E*9BMLS:QAA!,?3QD``Z5[P6\I[*MY@4-2Y-B!MRSH]1F%)J M<5\3+4<'+-M'M<%LWJ(RI@N;!D%*G32>F$#-"2XZE,F5HQN2-`D7\SC):$0K MO43`4P>=-D`6G;2,U`3*(;V)9?7`,;QWT1NT&"2505`H3,ER,O648!=A'$]M^!4G-7[A4$0*(S"V@.=!Z4/<*-VF9RQF9[1D>N$FB%
K!Q>LBA5$7AD$A>*^1JN3Q0[:/AA.[MU(%'E$_PQ@ M4002J-+")O4=28^L(I=+D%@035,0Q]U\D<1O^>V!]-$&9&D#4^GTJU,=Y(#")=6`5RVD?7H0B`8G9LG2HV!RI\T4N)/.RH): M("+5D*T-1M:`PZ<.%YR_DR3Z%^3:#[7K!.N[D(2^PI;,2WKW*Q/BIPV]5L"\<"JT:81.PU= M>CET/"Z]E'@_3>.WSSX)J*J,Z`]40T8E#8%?.?>P*(0W419DO+AC1BD`B\(R MHT=.E6`N+#S.-U4."P1Z]/&E;/WX4IH_^!&1 M]&%RE="DJO9BUFAWM.[)L2LXQ\='UKS&(,F-(&]=C]X:6Y0:[_*`H#BK;+PR"0!$6(F&*-R^RX>#9IIKB]:L[EP>& M\:J`4%#$A_#H4B%W%XW=O2['C/)O;A3%>4X4;_9['/Z9OKK1GX5.4_T>B//M MJM4&^"B"/\3T,-Q,.O`0;%GK47SH=; M":`Y#)FCMP(.=^05B#IRZ;,KGAL^KU)J.Q&S*J@">!'NC!7(E&+"')E%WZH/ MO&!1O`D;3&>9A$%N!<"*XO2JS9\$D:DH*_LV6]:Y7L64+ZP'0D)Q!JIEM%!` MUHOG)JICXLI-DE4032_F\5(8+26J!M)!<3!2H%#%IL$"9^I%"7OY\(1&?61O M7!NS]`_/,$VP#2S]0Q3N,I&8M2W]0W[8,N+`A9K!)T,4I@4)&_O!#$P<>,SX MK46;C*R:"KB2WR=HO]LH+?#%72KD[J)!^;2RQ.6=-HOY2+=>U1&*"_]B@O0C`JKX<-PM MKDETL\B/=.M?':&(3S=.=`4?C@O$-8FNXT/>KPZ"0&-I,TIT!1^.]Y'K$3UJ MQ/-H*P84!CG3-%?@X7C=N![+)XU8/MF(X01YR$\]EBOP<#Q/K,KR907(J2;+ MS-H@!N21/ZHL"^#A>&6XWE@^:S26S[9B0!Y24F\L5^#A>,R7P_)+XD;>C);<(`$)QTM6R9K!!F'H3U^P)=]U-KBEBOQ"@L7I:94N7ST"YUS@?J5UW]"$B MXBENMQQ@LGJ[6H9T(:867F5%P;/4GLZMXYR?HN!:2)LR MTV5,'*Z[=5OV-HA@O@IH6*&B7XQ3`V2"PBY7:TP+,7%X[E9Z&+HLI=!9&ECZ M3)*WP`NBZ<.$`3RE>IZR_R2=!DQ^QCD_0W&@%"H'6Y_,BX&CA-UZDN$ER&CF MGKO(#]X"?^F&DJF&61[D@<*:5&NB$2#B,'RH,*:6&/XCR&9/)"SR(L^"Q4LL M"?6LV1+($,4V0T"PHD:HX.3HRJ&"I\SHRI,;364'B&T9P-W=[<4."@Y[W8JE MRC%Q3_&,4LX8QY71'3($C)7[S>&L6W%27]SOP7PYE[)6*0?X442][5'"9H[1 M=PYWA[*%&>(NB-2X*Y<#_"AL_*K<[?>=Y:*Z(" M,@[SW3*E59V1@)1HWN-]K^(H[NBDGA, M@HCFN@@UUPA>,S#24!R2:RN*/EB.JAPX^*H]C5EO=R_C)(F_!='TREW`7[*5 MIL;PFG'.[3I>6]$8,5B.QG3+#L>"?1=Y"7%3AC(@4ORD]::K0' M`D!AO56EBCU(&T#'DV+0=F3;V&Y&+@-0]Y72J<"AHTJQS MO&.[LG)'1`+BGQU4N8XA(MQ]6&S7T8FW<_O%P9!H,A3)V&*32\/3A]VYL\D@:W% M==60+(VV%M2"[0F.%X)YK'&&L!11'W;:]&IWX`=NLGIVM[.<0C(#9AT0)XH@ MJ;J3MAB7W>SJANA^!T830CU,2J<0>6H#:640%(ZCMYA)#OV*\.SF:T>7P>0< MQ=S>8,AS4?4AT[O9%":C&B%KRD27,>%)_M[NZTZC)W83N M=6B3^#_VWJD8'!U9?YR&*?I]AAC]-I6/W6R\$6SI4QHCD<$JH6G M0VV8(0'979HNB7^]3()H6MQ/*.RX7\FW_$]BFZ1*`[#90!'@+^*39YM4QV-XSMTQ#89SM3YH.PX'E*G1S()G M*C,[1G4H9J_B][=Q4N2:JS_-[S4$$D3ACS(\W7-PFLKNCE%3\I%A0%'8[8#\ M4+BUS$XD')@MI)L_<,A)U;MS$?E_N$GB1EGZO)S/W62U>ZG&7@A*M1\FHU`: MM@RJ,+8VQ,T'HHQ1&,B,<%(C%F7,?Z8'L5&MYDOW8_SG^#'3TL9$@B>FI+6W M[L?H3*&YY"6FT+S;O8@,,1O@A>.4K3G\%''U(32D<8#7&$7,M80IN96T#*<7 M,2!Y8--%K0`O9BT0#3KC29DTS@B6`3(4YY'1!]6LILLJD%[6(IQ9"^2#SABB M2K@`D*%X#RR$7]4BG%D+Y(/.JJ%*N`"0H:@/+(2;C-D]'J.(Y*Q#N`"0H7@1 M+(3?U"*<60OD@R)RLP[A`D"F`E#L,VXF>&'8@=@%_J%+@,E4@(I]HJO*7';3 M*-MPRY5`/"@"=`7[A,1:?L#GKD3JC'7.0SDM%HO1\>J7WOQ_#HI#\>J>$1BK.V$4[T/5(Y^K^+ M1VIXA.*4+>5#[I'*D?3?(S4\LGI*YDI>XI'*N_W#([7K#Q@>H3@":PX_15P_ M/%*@]P,4P1T2II0]4CF<_GBD3#HHA@,4=@X>:?H.BAQ0SSQ2)AT4PP$Z*XI0[@`4&\\4H;\$P,4D20U MM^`"3/UQ1.T$Q*_?&:%O%"J]YJA2'42&PN8EX%/%:BT"UY:_"KGIFCY?D/XP M63/,HX/S'IFL!R@,*48XJ6&R'O`##Q#;/FN:K(]QF%1D?"B8K(^YUI1>F:SM M/I',E;S,9"UX[KA;MBZS)FL.N?=DI(!Z9K(VZJ,X1F'KJ$.X`%#/3-9&?13'Z*P:JH0+`/7, M9&TV\?D014!/'<9%B`P9K3%$WK;@ISC&>G-&RKD`4'_LUX8<%<G M;][_XB7L-.]^X%&?2V[L91`LK0.`T440"1E51-36E0DS:9E+NOB.@KK/>!2* MZ@!@%,8Q/0KEB$QE]<0V0_\>9T$T?0JFLTRT'O,K@7A0&,L:SL+[D$PE[L3& M>$O!`SC>^FRH!2)PIM)S-CN`:4[C13I)W8F\J`6PT=G*ZD_E94RF4FAB&]H7 M\WA)WQ78_G:CS^D=$)80-U&?XQ7:`F&BLZW5&/3*2#EJTT&KF\()I-D!C=JL M^J`;(G`<=6CR$$X7`LE^7(2613`-^Q15-D1A/J#*J]R@,91*FY+ZK M,IP?465,Y^T(G3&L3)K(&RT`]".JC!^$-4)G*5,E7`#H1U09/PAKA,ZZH4JX M`-"/J#+^1?$1VJ`R&>$"0+VY"-U"1-D(;429C'`!H!\193N&X!$*\U;-0Y<` MT]\JHJRAKV)X@L+P)6"SOJLBQX8XA(SM?[]-R%]+Z#_U0+@K>EA56[9-<`YWE=Z,Y#&^]J=!7.J%=NQG,Y3C5.4TZ#@$"[0S>ZC9.;^2*,5X2`A!8D2O.^V7,\WL`T MFZT4_(C5@L[93IY9&X9JJ2>P4A"ZC&(/S!*DQ`I=ZC\>]QT63\,9DI2K#+)T MG0MG_"RK-CQ]]IP+9]BSK)YI95D]XV=9[:B/L)C$Z!(61X0N>HJCEU7/&1_A M8EM]!//A],%%N(-..I"9Y6EX&:X)FD\:FVT1K#YX#-<;5ZE]L5(.\.,(L!&Q MP^:3A<.0-Q#%=>2-GJO8$?<+4]&AV"?7F(YW01AR^=E=:AE+Z-3>7W*WOLOR:Q*EPIC+_-6`%163+@;63*XD^Y>2@IZ_" M_G:]3&`<%F"+$.O\CVMAW'PGB1>DPI<1]1L#>:((H='5K)I`3?EA46A.P]%U M&R<3$F0T7O^.?V&QQ:\!)2B".PX\JW$ET1_?<=>W@BB"S!!L!?FW[;2MO,5> M\";R^Z*8?Q":M(#X%[`6N%.R66CR-"2'45=1#X`\7&?C@RNQ7#JF_/:=.>:D M6OOMMA3<7"^<,R0)V0TKN6D)F0IHZ,2N5R:\C7RLZ[E61X!(%'%4AU;U&D(R ME4"H)]J^"!*W"/*QKN]:70$R4<28'5[C:X@)1Y*D'WMTW5TH+G\SMCTZ/YY> MVS/6N^/G790E090&GBRM:VO?A)GG;^XR8\G#5+*JYH=*7O)8HTZ9B^DT(5,@ M0*J/A_LX$-$E;]FA!6,J?U8K"16;RF'K[[&DH*K?!RJZ9&2V(!M.=/&!776M MJ2EL\BTJJ<.+AF.@FJ[ZWIVYD*Q,>UD3$.[\N"H:Y<=>:]R8;UJ M'T*?"(W+A=]?Q5%^\6GIAC0!Y[%,E0_;&R"UL\8#&Y+BJ#^&MR`V]S%+V/+M M/-DU_/$@\O8)C1MVSCOE=3`)FJ,OA[H7HZXJVUVU>671;=H9=RJ@RRQLCL(< MZH:-CL+D>]PVU$6G81AF7?+OF`3-415M;XV]#.8T:4*0Y>ZLB\BG(`$KB3R: MR=`'2>7([J))G,PMIPT0]/0]8;5"5@&M=ISART`U_<[\%\.9>25BD'\%'$ZNXQPB:.T?<^Y!#X`OLU)>K*Y0`^ M"BN,*G7[?;>;%X"SY:%;Y2""?7FZML.SUS-N66=X:C4PV,"Z)L%F*`U`N[1Q M\W`(2COC+O5DN@M0FEN'6\<9CU&<+26\<<@6HS)T(=T`V9M'CSSZN&*RHEP/ M-_]#:1Z6:%[_VKF^8?#Y_D>`B"-61N"DI^39?X(.2A9-7!81C-:;1X+HIAFCJOK'5=9,%4;IP M\BLY@R,LS2^==]F]NXG\#V<`VX#F>9/1',96"*A0JBGUK'1KE MN$S=8#,\(E6V"O)PU6J$"L6_;,V"6K07;U,4P!!O;R'^BK(4WWVD$IRC& MFUG>&9YVQ`:XRZ%HA\L$:>JNE572'Q:$7DB/ICG0E,)<@US[DPK@HF.M:A,@ MM8X<<]540P^WJ2M/=J>(.$W?9;:Z=N?NE*2/;N#++H1(:CKG=I_W-3YMJ,`U M=(%T&-J:#]60V MJ+40[#;BC,\[XL-ONA2PD9NZL&+7@>B&),?[ZGI_OL#)*G4]BN@+2'(6K@K$ MZVL^0G^R3CM`PY%5NX!IU:F#'N?]E1S%)F""QH6[&3=JF566BJD_:X8`80NW M20Y\16#M!41Q"6#=ER>RB!/*E4*\/Z^*,QR/KP!*2PYE$Z\+MPZT`LS%/MPH,!O/-3K"=8&/ MS1N';#$J/'<1ZL0)_?8LB!/Z[1D@HH@FD'!0)6ZW^X:N')@+$VHC\`ZV\IC6 M6SVFMOTW=,4`<^3="9*G?>OPM.E^GUX6Y.\'1#Y-G>H@41S1S(8W0@*&T?Z8Q`N29*O'T(VRB\BG#ZTNJ*"^ M$M$)7U0-9(0BLJ@IXW*,AFXNV']SZC:(@HS?)&HB41)D%8%P'H.*P9#0FNXNG3-0K0S[O(B^?D M7OSP:J48[R!D:MD?]I/23@^PV%@U!^K.QCLI@KBA*7DF08WB87`<3Z#>@)Y.CU*XS#P*<2M;&'EO'+3V6T8 M?TNMG)8V'2GU0^7$)*CFC';>]^W`J6F$+&,Z5ZQ*)Z>1X$%5B\$0/@DHDR/Z M`R5P5"(0?N7D0?@W419D*\[IB%$*P.*P&#$HJ)+%[3R>$Y`J4P4"[DEGMPC` MM!JZPI7\/D'[W>[#.>8ER*BO^2[R@[?`7TJ#")GE01PHTF3(1YH"C#[D/MV# M]T>0S9Y(L:=/9\'B)98,U)HM@0A11%$(^%54"!6!>F?T50?Y3EZ_,1`D+FOE#L5< MCUPMG(8"INP[U^OY8TY(R%`R&(6CDFD"?O6`=0K`(24YY1$V" M21;\,_^]T!@KKPXR0V'K:4\?>`9:5=F8"BC#H%`T,<==].]!1./G"#`MC"W= M*PP"06%=.K2R\"1A*D#-_CH)@DOH1>YK4OQ;$M65NP@R.$S*5S_U1D!\*&YO MF5W3=/&W%0.'07TNO/QJ3@JCDP1O$O>#2G40&0I[FR[)JJK"0]PXL_"X4)(H M?P/>[H/7^ZCOHC>0>9P$PC!G83T0$PKS6UN*L0>U<3YCU!KQF)`%++?7:R3K M]$*P,WO(9B217G:JUR`(%D6<:%LZI"Z#QKF742O79I)]=%=TAJ7[?<]+EM#/ MP'VEF8MUYR&5!D&P*,S%;:]<"T%C($X4EFPC7@LI3E-IJ^T?M#8)\E[B"^^O99"0+RY( M."+)JGPQ5FC446G`&8TPVYREA//,..K8&R>]-K(/XKU=L+^2"S?'\DK.>-PC MPE7Q-LY5C6BSJRXY(PL)C!+,%KR:,X0N?E.9K='N1VZ#R(T\0_L106,@3A36 M/2/[$2E.4ZFT,9R#GLABO:P^3*C0:`@_]#\0Z0>W#H@'A2VO+K%L-9'`;9PD M&]$J5(::+[?W<32EV8&OR:NJ1NS5`S&A,*"TIQ4FV!+@\//*89.(_ MNDFVDDPDJDV`Z%"$,K2G,7+T',7IDSF6(4V<`QB8I=<37MSOQ1.IXDBS1SSA&O[^TIS#7-VW:&8\[NF5LCIJC8!VTD5[%(($D MS1.+%1DI\_Q@Q:\SXHL>KI76!6&AV#^:(9VC4&I"X&B,MG'4H#XD?FN:]PDD@6)[5&?$[J+H0\JWQZV# M.]?738S$59P*O72B:E0Z.([:/.(XGG\Y)O.9VPZ\EWU(IFZTSLT!)X'GY7SN M)BM`'$RC8`+;UBA;WT6#X\$C;';I8_8V=K+ECK[ONXM>/Y;D\C!9GV;<\'U+ MKK#E-=*^,SHYLS5P&P$H'?=`"4378;BV+)#=P7$CB)RQ*`.L6'-D550)``.27$96DEQ&5G5X"P`!!"4.```$ M.0$``.U=WV_;.!)^7V#_!UZ>N@^.XZ3I;H)V%T[BM`;2.(C=[@*'PX*6:)NH M3+FDE,1[N/_]9BC)EBV)U@\GJV#UTLHBA_R&WW!(#BGF_6]/.CSBGY]]';\Z/3\^.C_Y#_WGW^'^D-1Z1%'A\? M#VTHP=,E'%KNG+1:6(^R9FQ.B4?EE'FW=,[4@EKLP\',\Q;G[3;*64O/M5S) MN+!0L(W5')V=('2'S9GPKETYOV(3ZCO>AX/O/G7XA#/[@("N0IW/;>[E+$\+ M;.1]/#ETY12R''7:?WR^&6JT4%M0:1`!VJV#D[.VOKU"BKKUI32A>KS!.J MQCIKF*`;KG74:9UT(A'+]84GEYLZ*F8=3MV'=IB(8B=;8KZ48(99!A)3L[,F:I>?'E!1]N'A@RDL7"=)2M!&46RI=1B>A2&=31'$K70`2 M4K(#`=YRP50J-3HE11?E+61&)9"24HO-%I)9V/\S[>NL3:4E78% M0P7U7+F\AM^K!G&%\.?IA=B>;"/B-F1J02XFN;62VRT4"H`G(>0]%<(%%P.N M2?_&-XL%%Q,W_`DOT+[/$?`(Q`D^?+GO&[V#UN[*M7ST-%UA]X3'O64?2I5S M7=L#AC#%/!6SER&?F[!B(&D*CLI"TR\'M5>]VV+O"I^'@IG_5 M'<&/B^Y-]_:R1X:?>KW1L*&N$G5W%(8!;\8\#A#S\K@I9";UI`RIY,U&%3\U M)!=7D:C`9+'#&":@4>+]+=PZM,P,!_L#Z,$V=LQM7F;IPX:+,!O$VGT$, M1_#?Y]XM&,/@F@SN>O?=41\RD.XMYOQ\=]_[!&+]KSW2OX7?/?+F9C`<-J92 MR50NJ9I=.^YC7GM8YS>3?EJ&],ON\!.YOAG\WCCY_9":U]GG$#;3_:X:W8W[ M+T#_0$ZIX'_I>L$I#_WYG,KE8#+D4P%K=HO"_-G2RT0NIG=`L<59V+W+B9JI M_QEGVUQ9CJM\R>!'O!)"8?H=5D/<"8E51-8UD:BJAG<#[_<,0T;L,Y-3)@,^ M-U^9>?IEFZ=0F`323=,;FKXO'D!75ZXZ4OR%N=G/MIL])MJTN:'-[Z0+7&I8J1YGB=.7):.8M$=/($7%J2*RTZ-[L;^9,9O(2$1'3`KQAK=P:+TY7 M9JJ9IT2@)&6]U]#S;+/\*^91[E28Y8<%F$E.!%HJS?*#*AMCV+LQ=&U;ZTB= M6.>K;"&F4LUFDX@%53&;%GFS1A+W+C\U%E5XW=A3'I_K/2)?6C.JV)WD%NLZ MCFLEC*:,H-DN$C&DK74G4+VJAT05$5T365?5\%Z<]YT>(G=N,\,[#J/`B_2^ MW%!:,.2PU3CA*D0;XU-QY$Z"L/W4UGKF(':2?F;.98W/*54K63'8BX&7>M(@MD+8R-DNB9S&` MC:_0JEA#6D%FTTC$O"J8QN;'=(VI/(>IC&"ZI:J82+P`LVDD@F5E38/H.AN# M>#Z#V)L#R2S-;"J)D%ME4VE\R1Y-)_H?7@T6B$KUE?(!C>\I;C,P`H>*:U?V MY@O'73*&(5$F5$H\Z/DJ,!K8VY18H,G`5D]X#4^(B`202(B)#"9D-&,$D1&` M1B)L)`ZNL;RJ'U/D6LZ4D#7;2R+6:/P$HUGO5&(_>40GSF]FJIG!1'`Q]0!/ M0T\9>G;VR6(B9B(38<,T(C-/4?P3*<9_\.[)>S8A^E+'<[PO[\.!XC!$X660 M^MT,1L`/!WA!9BNZ!/-/4/KP:>Y$6;`&P_62VCJVVRFL."HBO"+0?.DD%*)W MO6 M+P)BK6,Q$)%<"1#I-][FK#X2P'I/\]9HO+(VHV)=::I@FSF>BMZTUD45TM]P M?:P)4(I8^-Q:%U$*2-JUO'F0Q.6B'Y6QI%WUFPM,7'#UJ[4NIA2:"L MA/1353-)WABK`1;(J[E_D\ER/EAA2ZKS-TFYUWE6'D=)XQ"-Y>JC??^9P74KR4WKJ0$@B- M-W_GL91(!A]*^`SSW=2Y&F1;JBI/Z==J%T/BBMO28,P7DI759V3XU_(,` M&I#Y3N[N6.'?(@![#::E^A[]94/PMSS,?6C=/U%5`F'XH,U,LY[_\R',D/%V$;^ M>H$\8D_>A:/OZ@F4"RY@/_>B]VD*3JBCGDG#72`S=-O:I:ZM>CEP9FC8GR\H ME_@"CRB'JTUVPQ^8W8?UM)AR@--5BGEJX,V8',VH^.BZ]B,@U5^/+.O6%GO5 M*-,N@C.?&';WXN=*OR@V\6%A.V'ZH[RZM4T)W!DM.U@W+U!+V0>EK3B^I=Y!U'-RV#@W$QGB97M[6**+#[F88 M26K#D"*_X0:`_J'_ELRK4#\3>RZ_.)Q1&5[$4#^#WPTTEXYZ1_<5J)B*,T/# MSWBVE<&(S^1"7B9>H M_PDW>'2/L&9?7>>;&E/Q+?@>Y09\?J:,YF`64;'D]>AX\D.';_BJ"LHSJ,LZ@R7"LI6M5'-B,XX7_TX'\\N M?#FU73FIC3K9T+)F!DO/G3KNN)[J&-&5&P-4S=UC&M*2FM;<2:8A+:EIS5UE M&M)RFKY]+8J^K:;GZ6O1\[2HGA<;XN_JJV<&T')\_EQ?/3.`9N@YDK!^G;'N M$U_$OK".>2`:3O1D?,L6.UJ"A?X=P^EL MB7W='[.MX;0(ZBS?S^0<=]&8"FR]=C.&5'Q9)WN$)1E5[(H%__>%/NX2A*3W ML&N0K5C%//+AG\Q`O@;(:G_F.##T?62"2>J` MZ^K:,!9Q;`Z//S`H'2"A2[N`'!.^CV-_S]:2A55Y@8-'JU-W^N$SE=_VT(+/ MM+/_W'J_0'._VD.K+]H(&41$%Y/@)22@HXV="5\P^W?&IS/XOPMK1CIE]PPG M69",TW%L+Y\Z.(G=6AV%_?R%5TA[T")_^ZS&OU?>0L7UR-^9013OM`E0Q^H, MCNUN+<3TNY<-]Y2`O"_EZQ/%JP`]-I4R;B'1H&$41O^Y*V:U=N_$WWVNN=4X\B1VKJ=&AZ%\"LL"\% M8[?X(IB)X)A0GX-"!FQ%1FZ];GKUXW8Q+3+:Y];'YAM,@F]-W`L6=@IF7TMW MOMDQ*@_8U1NB&-R<4>'Z;,9F`,OZ5@VOU)J*R_!FBMZ3-^3MZ+;_NRH$S>S\.9V7X&>P7P:W0KP\FES..7KXN+CH/ MREWG5ZP96QT+J8UF1G15=M[PR`NJ\O);4ZF?U1?!FQ5;]*%N6J,/$+"^ MP3R1%X8BKV*'$OZVC=]T4%F[9A*4PLC0\O:$)"!*ZO;S,!I3-T;.G9E M=`U,O?39B3!K;>Q]HM)^I'JS<.A./'RLC59&=*C1^W9PSXI6[O]02P$"'@,4 M````"``1AVU'']G-]].H``!E4@L`$0`8```````!````I($`````;61I="TR M,#$U,#DS,"YX;6Q55`4``Y)<1E9U>`L``00E#@``!#D!``!02P$"'@,4```` M"``1AVU'Q-'$P&0+```(J@``%0`8```````!````I($>J0``;61I="TR,#$U M,#DS,%]C86PN>&UL550%``.27$96=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`$8=M1V@<;U#%,@``=D4#`!4`&````````0```*2!T;0``&UD:70M,C`Q M-3`Y,S!?9&5F+GAM;%54!0`#DEQ&5G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`!&';4?WG6T&'D\``*%7G``!M9&ET+3(P M,34P.3,P7VQA8BYX;6Q55`4``Y)<1E9U>`L``00E#@``!#D!``!02P$"'@,4 M````"``1AVU'3,K@Y?`Y``#RZP,`%0`8```````!````I(%2-P$`;61I="TR M,#$U,#DS,%]P&UL550%``.27$96=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`$8=M1X^_YSD3#P``^J4``!$`&````````0```*2!D7$!`&UD:70M M,C`Q-3`Y,S`N>'-D550%``.27$96=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``.^``0`````` ` end XML 20 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories
9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Inventories

Note 3.

Inventories

The following is a summary of the components of inventories (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Raw materials

$

1,934

$

1,229

Work in progress

225

33

Finished Goods

2,002

2,153

$

4,161

$

3,415

No amounts were reserved for obsolete inventory as of September 30, 2015 and December 31, 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment Information - (Additional Information (Detail)
$ in Millions
9 Months Ended

Sep. 30, 2015

USD ($)

Foreign Currency Exchange Rate Translation Amount $ 1.1

Description of Difference between Reported Amount and Reporting Currency Denominated Amount The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560).

X

- Definition
Foreign exchange rate used to translate amounts difference between reported amount and reporting currency denominated amount.
+ References
No definition available.
+ Details

Name: mdit_ForeignCurrencyExchangeRateTranslationAmount

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Description of why the actual reporting currency-denominated balances differ from the amounts reported for financial reporting purposes, including the reasons for using two different rates with respect to remeasurement and translation. For example, in certain jurisdictions, companies may utilize an official exchange rate and also a parallel rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521

+ Details

Name: us-gaap_DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories - (Summary of the Components of Inventories) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Inventory [Line Items]

Raw materials $ 1,934 $ 1,229

Work in progress 225 33

Finished Goods 2,002 2,153

Inventory, Net $ 4,161 $ 3,415

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 23 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Reverse Merger - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended

Apr. 04, 2014

Apr. 03, 2014

Jan. 31, 2014

Sep. 30, 2015

Business Acquisition [Line Items]

Number of shares issued 1,338,875

Medite Enterprises, inc [Member]

Business Acquisition [Line Items]

Proceeds from private placement $ 1.5 $ 1.5

Number of shares issued on acquisitions 14,687,500

Number of shares issued 955,875

Number of additional shares issued on acquisitions 312,500

Percentage of ownership interests acquired 100.00%

Reverse Acquisition Percentage Of Share Issued 81.10%

Business Combination Consideration Outstanding Shares 3,502,700

Business Combination Consideration Outstanding Shares Per Share $ 1.6

In Process Research And Development Amortized Term 15 years

Medite Enterprises, inc [Member] | Accrued Payroll Settlement [Member]

Business Acquisition [Line Items]

Number of shares issued on acquisitions 697,234

Value of shares issued on acquisitions $ 1.6

Minimum [Member] | Medite Enterprises, inc [Member]

Business Acquisition [Line Items]

Proceeds from private placement $ 2.0

X

- Definition
Business Combination Consideration Outstanding Shares
+ References
No definition available.
+ Details

Name: mdit_BusinessCombinationConsiderationOutstandingShares

Namespace Prefix: mdit_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Business Combination Consideration Outstanding Shares Per Share
+ References
No definition available.
+ Details

Name: mdit_BusinessCombinationConsiderationOutstandingSharesPerShare

Namespace Prefix: mdit_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
In Process Research And Development Amortized Term
+ References
No definition available.
+ Details

Name: mdit_InProcessResearchAndDevelopmentAmortizedTerm

Namespace Prefix: mdit_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Reverse acquisition percentage of share issued
+ References
No definition available.
+ Details

Name: mdit_ReverseAcquisitionPercentageOfShareIssued

Namespace Prefix: mdit_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)(4)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdit_MediteEnterprisesIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=mdit_AccruedPayrollSettlementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Property, Plant and Equipment [Line Items]

Land $ 215 $ 233

Buildings 1,192 1,291

Machinery and equipment 546 529

Office furniture and equipment 295 265

Vehicles 42 103

Computer equipment 111 110

Construction in progress 521 559

Less: Accumulated depreciation (906) (999)

Property, Plant and Equipment, Net $ 2,016 $ 2,091

X

- Definition
Computer And Communications Equipment, Gross
+ References
No definition available.
+ Details

Name: mdit_ComputerAndCommunicationsEquipmentGross

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of tangible personal property used to produce goods and services, vehicles.
+ References
No definition available.
+ Details

Name: mdit_VehiclesGross

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_BuildingsAndImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_ConstructionInProgressGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_FurnitureAndFixturesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Land

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_MachineryAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 25 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment - Additional Information (Detail) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Property, Plant and Equipment [Line Items]

Depreciation expense $ 95,000 $ 126,000

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Reverse Merger
9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Reverse Merger

Note 2.

Reverse Merger

In January 2014, the Company and the previous owners of MEDITE Enterprise, Inc. entered into an agreement to merge with the former CytoCore, Inc. The merger required as a pre-requisite that among other items CytoCore settle certain outstanding payroll amounts in stock and that CytoCore complete a private placement with gross proceeds of a minimum of $2 million, which was later amended to $1.5 million. On April 3, 2014 CytoCore issued 697,234 shares of its common stock in satisfaction of approximately $1.6 million in outstanding accrued payroll. On April 4, 2014 the Company closed on a private placement in which it received gross proceeds of $1.5 million and issued 955,875 shares of its common stock. The merger closed on April 4, 2014 with the previous owners of MEDITE Enterprise, Inc. receiving 14,687,500 shares of the Company’s common stock. An additional 312,500 shares remained to be issued because certain conditions had not been fulfilled in accordance with the agreement to complete the exchange for 100% of the issued and outstanding stock of MEDITE Enterprise, Inc. The remaining 312,500 shares were issued in October 2015. The consideration paid was determined based upon the number of shares outstanding from the former CytoCore, Inc. of approximately 3,502,700 common shares outstanding before the merger at $1.60 per share (the same price per share in the concurrent private placement noted above).

Because the owners of MEDITE Enterprise, Inc. received approximately 81.1% of the then issued and outstanding stock of the Company, the merger was treated as a reverse acquisition, in which for accounting purposes MEDITE Enterprise, Inc. acquired CytoCore, Inc.

Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

In thousands

Assets acquired

Cash

$

1

Other current assets

12

Property and equipment

81

Trade names /trademarks

1,240

In-Process research and development

4,620

Goodwill

2,453

8,407

Liabilities assumed

Accounts payable & accrued expenses

3,220

Related party advances

102

Loans payable

21

3,343

Consideration paid in the form of common stock

$

5,064

The Company is treating the fair value assigned to trade names/trademarks as indefinite lived intangibles. The in process research and development covers four separate areas (a) breast pap device and related consumables (b) new biomarkers (c) a new stain and (d) the SoftKit. Until the Company either completes development or abandons such development, the in-process research and development costs are treated as indefinite lived intangible assets. If the Company is successful in these development projects, it expects the in-process research and development will be amortized over an approximate 15 year life.

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-term Debts and Lines of Credit (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Line of Credit Facility [Line Items]

Long-term Debt, Gross $ 2,745 $ 3,764

Hannoversche Volksbank credit line 1 [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 1,169 1,880

Hannoversche Volksbank credit line 2 [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 399 465

Hannoversche Volksbank term loan 1 [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 62 135

Hannoversche Volksbank term loan 2 [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 50 81

Hannoversche Volksbank term loan 3 [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 203 270

Ventana Medical Systems, Inc. Promissory Note [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross 21 21

Denture DZ Equity Partners Participation right [Member]

Line of Credit Facility [Line Items]

Long-term Debt, Gross $ 841 $ 912

X

- Definition
Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLine1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankCreditLine2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankTermLoan1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankTermLoan2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_HannoversechVolksbankTermLoan3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_VentanaMedicalSystemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdit_ParticipationRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) - Warrants [Member] - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Warrants, Opening Balance 143,308

Warrants, Granted 0

Warrants, Exercised 0

Warrants, Expired 0

Warrants, Ending Balance 143,308 143,308

Weighted Average Exercise Price, Opening Balance $ 2.64

Weighted Average Exercise Price, Granted 0

Weighted Average Exercise Price, Exercised 0

Weighted Average Exercise Price, Expired 0

Weighted Average Exercise Price, Ending Balance $ 2.64 $ 2.64

Aggregate Intrinsic Value, Opening Balance $ 0

Aggregate Intrinsic Value, Granted 0

Aggregate Intrinsic Value, Exercised 0

Aggregate Intrinsic Value, Expired 0

Aggregate Intrinsic Value, Ending Balance $ 0 $ 0

Weighted Average Remaining Contractual Life(Years),Outstanding 6 years 5 months 16 days 6 years 5 months 16 days

Warrants Outstanding Granted Weighted Average Remaining Contractual Term 0 years

Warrants Outstanding Exercised Weighted Average Remaining Contractual Term 0 years

Warrants Outstanding Expired Weighted Average Remaining Contractual Term 0 years

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value
+ References
No definition available.
+ Details

Name: mdit_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Aggregate Intrinsic Value
+ References
No definition available.
+ Details

Name: mdit_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodAggregateIntrinsicValue

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options grants in period aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: mdit_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregateIntrinsicValue

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The element represents about the warrants outstanding exercised weighted average remaining contractual term.
+ References
No definition available.
+ Details

Name: mdit_WarrantsOutstandingExercisedWeightedAverageRemainingContractualTerm

Namespace Prefix: mdit_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants Outstanding Expired Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: mdit_WarrantsOutstandingExpiredWeightedAverageRemainingContractualTerm

Namespace Prefix: mdit_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants Outstanding Granted Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: mdit_WarrantsOutstandingGrantedWeightedAverageRemainingContractualTerm

Namespace Prefix: mdit_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash $ 347 $ 230

Accounts receivable, net 1,302 1,991

Inventories 4,161 3,415

Prepaid expenses and other current assets 208 154

Total current assets 6,018 5,790

Property and equipment, net 2,016 2,091

In-process research and development 4,620 4,620

Trademarks, trade names 1,240 1,240

Goodwill 2,453 2,453

Other assets 398 245

Total assets 16,745 16,439

Current liabilities:

Secured lines of credit and current portion of long-term debt 1,764 2,555

Account payable and accrued expenses 4,025 4,134

Advances - related parties 85 110

Total current liabilities 5,874 6,799

Long-term debt, net of current portion 981 1,209

Total liabilities $ 6,855 $ 8,008

Commitments and contingencies

Stockholders’ equity :

Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 and 373,355 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively (liquidation value of all classes of preferred stock $1,121 and $2,871 as of September 30, 2015 and December 31, 2014, respectively) $ 962 $ 1,487

Common stock, $0.001 par value; 3.5 billion shares authorized, 20,766,206 and 19,427,331 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively 21 19

Additional paid-in capital 8,343 5,763

Treasury stock (327) (327)

Accumulated other comprehensive loss (479) (149)

Retained earnings 1,370 1,638

Total stockholders' equity 9,890 8,431

Total liabilities and stockholders' equity $ 16,745 $ 16,439

X

- Definition
Finite Lived In Process Research And Development
+ References
No definition available.
+ Details

Name: mdit_FiniteLivedInProcessResearchAndDevelopment

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Finite Lived Trademarks And Trade Names
+ References
No definition available.
+ Details

Name: mdit_FiniteLivedTrademarksAndTradeNames

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Line-of-Credit Arrangement

-URI http://asc.fasb.org/extlink&oid=6517033

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_LinesOfCreditCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Payments of Stock Issuance Costs $ 28 $ 28

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 31 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Common Stock - Additional Information (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2015

USD ($)

$ / shares

shares

Sep. 30, 2015

USD ($)

$ / shares

shares

Class Of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares 1,338,875

Share Price | $ / shares $ 1.60 $ 1.60

Stock Issued During Period, Value, New Issues $ 2,134,000

Stock Issued During Period, Shares, Issued for Services | shares 81,000

President, of UNIC Medical of China [Member]

Class Of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares 1,086,250

Share Price | $ / shares $ 1.60 $ 1.60

Stock Issued During Period, Value, New Issues $ 600,000

Series D Preferred Stock [Member]

Class Of Stock [Line Items]

Stock Issued During Period, Value, Issued for Services $ 12,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=mdit_PresidentOfUnicMedicalOfChinaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-term Debts and Lines of Credit (Tables)
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Outstanding note payable indebtedness

The Company’s outstanding note payable indebtedness was as follows as of (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Hannoversche Volksbank credit line #1

$

1,169

$

1,880

Hannoversche Volksbank credit line #2

399

465

Hannoversche Volksbank term loan #1

62

135

Hannoversche Volksbank term loan #2

50

81

Hannoversche Volksbank term loan #3

203

270

Ventana Medical Systems, Inc. Promissory Note

21

21

Denture DZ Equity Partners Participation right

841

912

$

2,745

$

3,764

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants (Summary of Preferred Stock) (Detail) - shares

Sep. 30, 2015

Dec. 31, 2014

Class of Stock [Line Items]

Preferred stock, shares issued 198,355 373,355

Preferred stock, shares outstanding 198,355 373,355

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares issued 47,250 47,250

Preferred stock, shares outstanding 47,250 47,250

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares issued 93,750 93,750

Preferred stock, shares outstanding 93,750 93,750

Series C Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares issued 38,333 38,333

Preferred stock, shares outstanding 38,333 38,333

Series D Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares issued 0 175,000

Preferred stock, shares outstanding 0 175,000

Series E Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares issued 19,022 19,022

Preferred stock, shares outstanding 19,022 19,022

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment Information (Tables)
9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following tables show the breakdown of the Company’s operations and assets by region (in thousands):

United States

Germany

Poland

Total

Sep. 30,

Dec. 31,

Sep.30,

Dec. 31,

Sep. 30,

Dec. 31,

Sep. 30,

Dec. 31,

2015

2014

2015

2014

2015

2014

2015

2014

Assets

$

9,125

$

9,387

$

7,416

$

6,989

$

204

$

63

$

16,745

$

16,439

Property & equipment, net

87

98

1,924

1,985

5

8

2,016

2,091

Intangible assets

8,313

8,313

-

-

-

-

8,313

8,313

United States

Germany

Poland

Total

Sep. 30,

Sep. 30,

Sep. 30,

Sep. 30,

Sep. 30,

Sep 30,

Sep. 30,

Sep. 30,

2015

2014

2015

2014

2015

2014

2015

2014

Revenues

$

928

$

1,321

$

6,114

$

7,373

$

39

$

0

$

7,081

$

8,694

Net income (loss)

(552)

(182)

339

232

(54)

-

(267)

50

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 36 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization and Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1.

Organization and Summary of Significant Accounting Policies

MEDITE Cancer Diagnostics, Inc., (“MDIT”, “MEDITE” or the “Company”) was incorporated in Delaware in December 1998.

These statements include the accounts of MEDITE Cancer Diagnostics, Inc., (former CytoCore, Inc., the “Company”, “we” and “us”) and its wholly owned subsidiaries, which consists of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany, MEDITE GmbH, Salzburg, Austria, MEDITE Lab Solutions, Inc. (formerly MEDITE Inc.), Orlando, USA, MEDITE sp. z o.o., Zilona-Gora, Poland and CytoGlobe, GmbH, Burgdorf, Germany.

In April 2014, the shareholders of the Company consummated a transaction in which 100% of the issued and outstanding shares of MEDITE Enterprise, Inc., were acquired by CytoCore, Inc. in exchange for the issuance by CytoCore, Inc., of 15,000,000 shares of its common stock to the shareholders of the Company. The result of this transaction was for the Company and its wholly owned subsidiaries to become wholly owned subsidiaries of CytoCore, Inc., a US public company. In addition, the shareholders of the Company became the majority owners of CytoCore, Inc., which resulted in the transaction being accounted for as a reverse merger, in which the financial statements of MEDITE Enterprise, Inc. and its subsidiaries became those of CytoCore, Inc., now MEDITE Cancer Diagnostics, Inc.

MEDITE is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. By acquiring MEDITE the company changed from solely research operations to an operating company with 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name, a wide range of selling products and the established infrastructure necessary for a company acting in the medical industry.

Consolidation, Basis of Presentation and Significant Estimates

The accompanying condensed consolidated financial statements for the periods ended September 30, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings

33 yrs

Machinery and equipment

3-10 yrs

Office furniture and equipment

2-10 yrs

Vehicles

5 yrs

Computer equipment

3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.



Goodwill

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through September 30, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.

Recent Accounting Pronouncements

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory”. The amendments require an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The Company does not expect this amendment to have a material impact on its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of the consolidation guidance for legal entities such as limited partnerships, limited liability corporations and securitization structures. The amendments in the ASU affect the consolidation evaluation for reporting organizations and simplifies the current US GAAP requirements by reducing the number of consolidation models. The guidance is effective for fiscal years and interim reporting periods beginning on or after December 15, 2015. The Company does not expect this standard to have a material impact on its statements of operations, statements of cash flows or financial position.

In May 2014, the FASB issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supersedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Preferred stock, par value (in dollars per shares) $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 10,000,000 10,000,000

Preferred stock, shares issued 198,355 373,355

Preferred stock, shares outstanding 198,355 373,355

Preferred Stock, Liquidation Preference, Value (in dollars) $ 1,121 $ 2,871

Common stock, par value (in dollars per shares) $ 0.001 $ 0.001

Common stock, shares authorized 3,500,000,000 3,500,000,000

Common Stock, Shares, Issued 20,766,206 19,427,331

Common Stock, Shares, Outstanding 20,766,206 19,427,331

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 38 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Principle of Consolidation, Basis of Presentation and Significant Estimates

Consolidation, Basis of Presentation and Significant Estimates

The accompanying condensed consolidated financial statements for the periods ended September 30, 2015 and 2014 included herein are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Such consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of and for the periods indicated. All such adjustments are of a normal recurring nature. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015 or for any other period. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The Company believes that the disclosures are adequate to make the interim information presented not misleading. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements disclosed in the Report on Form 10-K/A for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the financial statements and disclosures of contingencies. Changes in facts and circumstances may result in revised estimates and actual results may differ from these estimates.

Revenue Recognition

Revenue Recognition

The Company derives its revenue primarily from the sale of medical products and supplies for the diagnosis and prevention of cancer. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. The Company generates the majority of its revenue from the sale of inventory. The Company recognizes revenue when title and risk of loss transfer to the customer and all other revenue recognition criteria have been met. For a small subset of sales, the Company and its customers agree in the sales contract that risk of loss and title transfer upon the Company packing the items for shipment, segregating the items packaged and notifying the Customer that their items are ready for pickup. The Company records such sales at time of completed packaging and segregation of the items from general inventory and notification has been confirmed by the customer.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings

33 yrs

Machinery and equipment

3-10 yrs

Office furniture and equipment

2-10 yrs

Vehicles

5 yrs

Computer equipment

3-5 yrs

Normal maintenance and repairs for equipment are charged to expense as incurred, while significant improvements are capitalized.

Research and Development

Research and Development

All research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, testing, developing and validating the manufacturing process, and regulatory related costs.

Acquired In-Process Research and Development

Acquired In-Process Research and Development

Acquired in-process research and development (“IPR&D”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, MEDITE will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the IPR&D intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

Impairment or Disposal of Long-Lived Assets Including Finite Lived Intangibles

At each balance sheet date or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, management of the Company evaluates the recoverability of such assets. An impairment loss is recognized if the amount of undiscounted cash flows is less than the carrying amount of the asset, in which case the asset is written down to fair value. The fair value of the asset is measured by either quoted market prices or the present value of estimated expected future cash flows using a discount rate commensurate with the risks involved. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

Impairment of Indefinite Lived Intangible Assets Other Than Goodwill

The Company has the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, the Company concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if the Company concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount in accordance with Financial Accounting Standards Board Codification Subtopic 350-30.

Goodwill

Goodwill

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates our reporting units on an annual basis. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (December 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. Unless events or circumstances have changed significantly, we generally do not re-test at year end assets acquired from a business combination in the year of acquisition.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The fair value of each reporting unit is estimated using a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, and determination of our weighted average cost of capital.

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

Impairment Policy and Procedures for In Process Research and Development, Trademarks, Trade Names and Goodwill

The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit.

These assets were independently valued at April 3, 2014, the date of the MEDITE Enterprise, Inc. purchase by CytoCore, Inc., based upon valuation assumptions such as projected discounted cash-flow amongst others and updated through September 30, 2015. In the future, the Company plans to review the assumptions annually to determine if any impairment allowances are necessary until the underlying products under development and long-lived assets have been commercialized.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): “Simplifying the Measurement of Inventory”. The amendments require an entity to measure in scope inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The Company does not expect this amendment to have a material impact on its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of the consolidation guidance for legal entities such as limited partnerships, limited liability corporations and securitization structures. The amendments in the ASU affect the consolidation evaluation for reporting organizations and simplifies the current US GAAP requirements by reducing the number of consolidation models. The guidance is effective for fiscal years and interim reporting periods beginning on or after December 15, 2015. The Company does not expect this standard to have a material impact on its statements of operations, statements of cash flows or financial position.

In May 2014, the FASB issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supersedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.

X

- Definition
Disclosure of accounting policy for the impairment of indefinite lived intangible assets other than goodwill .
+ References
No definition available.
+ Details

Name: mdit_ImpairmentOfIndefiniteLivedIntangibleAssetsOtherThanGoodwillPolicyTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.15)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InProcessResearchAndDevelopmentPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for dividend revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51742730&loc=d3e46105-111621

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionDividends

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 13, 2015

Document Information [Line Items]

Entity Registrant Name Medite Cancer Diagnostics, Inc.

Entity Central Index Key 0000075439

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol MDIT

Entity Common Stock, Shares Outstanding 20,766,206

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2015

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 40 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization and Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Property Plant And Equipment Useful Life

Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Buildings

33 yrs

Machinery and equipment

3-10 yrs

Office furniture and equipment

2-10 yrs

Vehicles

5 yrs

Computer equipment

3-5 yrs

X

- Definition
Tabular disclosure of property plant and equipment useful life.
+ References
No definition available.
+ Details

Name: mdit_PropertyPlantAndEquipmentUsefulLifeTableTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Net sales $ 2,662 $ 2,785 $ 7,081 $ 8,694

Cost of revenues 1,493 1,198 4,028 4,456

Gross profit 1,169 1,587 3,053 4,238

Operating expenses

Depreciation and amortization expense 30 48 95 126

Research and development 222 317 825 762

Selling, general and administrative 785 1,260 2,191 2,902

Total operating expenses 1,037 1,625 3,111 3,790

Operating income (loss) 132 (38) (58) 448

Other expenses

Interest expense 46 71 157 221

Other expenses 11 2 61 153

Total other expenses 57 73 218 374

Income (loss) before income taxes 75 (111) (276) 74

Income tax expense (benefit) 16 (8) (9) 24

Net income (loss) 59 (119) (267) 50

Preferred dividend (23) (18) (69) (54)

Net income (loss) applicable to common stockholders 36 (137) (336) (4)

Condensed consolidated statements of comprehensive income (loss)

Net income (loss) 59 (119) (267) 50

Other comprehensive income (loss)

Foreign currency translation adjustments (170) 45 (330) 41

Comprehensive income (loss) (111) (74) (597) 91

Earnings (loss) per share

Net income (loss) applicable to common stockholders $ 36 $ (137) $ (336) $ (4)

Basic and diluted earnings (loss) per share $ 0 $ (0.01) $ (0.01) $ 0

Weighted average basic and diluted shares outstanding 20,484,936 19,345,231 20,051,206 17,683,284

X

- Definition
The aggregate total costs and benefits related to selling a firms product and services, as well as all other general and administrative expenses. Direct selling expenses and benefits (for example, credit, warranty, and advertising) are expenses and benefits that can be directly linked to the sale of specific products. Indirect selling expenses and benefits are expenses and benefits that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses and benefits include salaries of non-sales personnel, rent, utilities, communication, etc. Includes benefit from the liquidation of subsidiaries.
+ References
No definition available.
+ Details

Name: mdit_SellingGeneralAndAdministrativeExpenseAndBenefit

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareProFormaAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents a sum total of expenses not separately reflected on the income statement for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.7)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4,6)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_PreferredStockDividendsAndOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 42 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Related Party Advances
9 Months Ended

Sep. 30, 2015

Related Party Transactions [Abstract]

Related Party Advances

Note 6.

Related Party Advances

At September 30, 2015 and December 31, 2014, the Company owed its then CFO and Chairman of the Board for prior advances of approximately $85,000 and $110,000 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Long-term Debts and Lines of Credit
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Long-term Debts and Lines of Credit

Note 5.

Long-term Debts and Lines of Credit

The Company’s outstanding note payable indebtedness was as follows as of (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Hannoversche Volksbank credit line #1

$

1,169

$

1,880

Hannoversche Volksbank credit line #2

399

465

Hannoversche Volksbank term loan #1

62

135

Hannoversche Volksbank term loan #2

50

81

Hannoversche Volksbank term loan #3

203

270

Ventana Medical Systems, Inc. Promissory Note

21

21

Denture DZ Equity Partners Participation right

841

912

$

2,745

$

3,764

In July 2006, MEDITE GmbH, Burgdorf, entered into a master line of credit agreement #1 with Hannoversche Volksbank. The line of credit was amended in 2012 and was later amended to increase the credit limit to Euro 1.8 million ($2.0 million as of September 30, 2015). In January 2015, the master credit line was reduced to Euro 1.6 million ($1.8 million as of September 30, 2015) and further reduced to the original Euro 500,000 ($560,865 as of September 30, 2015) and subsequently increased to Euro 1.1 million ($1.2 million as of September 30, 2015) effective July 1, 2015. Borrowings on the master line of credit agreement #1 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the company and defined in the agreement. Interest rates depending on the type of advance elected ranged from 3.77 – 8.00% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of MEDITE GmbH, Burgdorf, a mortgage on the buildings owned by the Company and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company.

In June 2012, CytoGlobe, GmbH, Burgdorf, entered into a line of credit agreement #2 with Hannoversche Volksbank. The line of credit granted a maximum borrowing authority of Euro 400,000 ($448,692 as of September 30, 2015). Borrowings on the master line of credit agreement #2 bears interest at a variable rate based on Euribor (Euro Interbank Offered Rate) depending on the type of advance elected by the Company and defined in the agreement. Interest rates depending on the type of advance elected ranged from 3.77 – 8.00% during the period ended September 30, 2015. The line of credit has no stated maturity date. The line of credit is collateralized by the accounts receivable and inventory of CytoGlobe GmbH, Burgdorf and is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and the state of Lower Saxony (Germany) to support high-tech companies in the area.

In December 2006, MEDITE GmbH, Burgdorf, entered into a Euro 500,000 ($560,865 as of September 30, 2015) term loan agreement #1 with Hannoversche Volksbank with an interest rate of 3.4% per annum. The term loan has a maturity of September 2016 and requires semi-annual principal payments of approximately Euro 27,780 ($31,162 as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and a mortgage on the property of the Company.

In June 2006, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($448,692 as of September 30, 2015) term loan #2 with Hannoversche Volksbank with an interest rate of 3.6 % per annum. The term loan has a maturity of June 2016, requires 18 semi-annual principal repayments of approximately Euro 22,220 ($24,928 as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company and is collateralized by subordinated assignments of all of the receivables and inventories of MEDITE GmbH, Burgdorf and also has a subordinated pledge of share term life insurance policies.

In November 2008, MEDITE GmbH, Burgdorf, entered into a Euro 400,000 ($448,692 as of September 30, 2015) term loan #3 with Hannoversche Volksbank with an interest rate of 4.7% per annum. The term loan has a maturity of December 31, 2018, and requires quarterly principal repayments of Euro 13,890 ($15,581as of September 30, 2015). The term loan is guaranteed by Michaela Ott and Michael Ott, the former sole shareholders of the Company, and is collateralized by a partial subordinated pledge of the receivables and inventory of MEDITE GmbH, Burgdorf.

In March 2009, the Company entered into a participation rights agreement in the form of a debenture with a mezzanine lender who advanced the Company up to Euro 1.5 million, ($1.7 million as of September 30, 2015) in two tranches of Euro 750,000 each, ($841,298 as of September 30, 2015). The first tranche was paid to the Company at closing with the second tranche being conditioned on MEDITE GmbH, Burgdorf and its subsidiaries hitting certain performance targets. Those targets were not met and the second tranche was never called. The debenture pays interest at the rate of 12.15% per annum and matures at December 31, 2016.

As of the date of filing, the remaining balance of approximately $21,000 on the note payable to Ventana Medical Systems, Inc. was in default. However, on February 23, 2015, the Company reached an agreement with Ventana Medical Systems, Inc. whereby both parties have agreed that Ventana Medical Systems, Inc. will accept $38,281 as payment in full for all outstanding principal and accrued interest. The $38,281 has been included in current portion of long-term debt on the consolidated balance sheet. As part of this agreement, Ventana Medical Systems, Inc. has agreed to convert $1.75 million stated value of Series D Preferred stock and all outstanding accrued dividends of $656,250 for 12,000 shares of the Company’s common stock. Prior to the execution of this agreement, the Company had failed to make principal and interest payments when due and is in breach of certain warranties and representations under the notes included above.

During 2015, the Company reduced their floating lines of credit and term loans with Hannoversche Volksbank by $1,019 net of currency fluctuations.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants (Tables)
9 Months Ended

Sep. 30, 2015

Stockholders' Equity (Deficit) [Abstract]

Summary of Company's Preferred Stock

A summary of the Company’s preferred stock as of September 30, 2015 and December 31, 2014 is as follows.

September 30,

December 31,

2015

2014

(unaudited)

Shares Issued &

Shares Issued &

Offering

Outstanding

Outstanding

Series A convertible

47,250

47,250

Series B convertible, 10% cumulative dividend

93,750

93,750

Series C convertible, 10% cumulative dividend

38,333

38,333

Series D convertible, 10% cumulative dividend

-

175,000

Series E convertible, 10% cumulative dividend

19,022

19,022

Total Preferred Stock

198,355

373,355

Summary of Preferred Stock Terms

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:

$4.50 per share, $212,625

Conversion Price:

$10,303 per share

Conversion Rate:

0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)

Voting Rights:

None

Dividends:

None

Conversion Period:

Any time

Series B Convertible Preferred Stock

Liquidation Value:

$4.00 per share, $375,000

Conversion Price:

$1,000 per share

Conversion Rate:

0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing March 31, 2001

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $548,788 and $520,665, respectively.


Series C Convertible Preferred Stock

Liquidation Value:

$3.00 per share, $115,000

Conversion Price:

$600 per share

Conversion Rate:

0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing March 31, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $160,038 and $151,413, respectively.

Series D Convertible Preferred Stock

Liquidation Value:

$1,000 per share, $ 525,000

Conversion Price:

$1,000 per share

Conversion Rate:

.01—Liquidation Value divided by Conversion Price ($10.00/$1,000)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing April 30, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $0 and $660,000, respectively.

Series E Convertible Preferred Stock

Liquidation Value:

$22.00 per share, $418,488

Conversion Price:

$800.00 per share

Conversion Rate:

.0275—Liquidation Value divided by Conversion Price ($22.00/$800)

Voting Rights:

Equal in all respects to holders of common shares

Dividends:

10%—Quarterly—Commencing May 31, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $585,948 and $558,173 respectively.

Warrants Outstanding

Warrants outstanding

Weighted

Weighted

Average

Average

Aggregate

Remaining

Exercise

Intrinsic

Contractual

Warrants

Price

Value

Life (Years)

Outstanding at December 31, 2014

143,308

$

2.64

—

6.46

Granted

—

—

—

—

Exercised

—

—

—

—

Expired

—

—

—

—

Outstanding at September 30, 2015

143,308

$

2.64

—

6.46

X

- Definition
Preferred Stock Shares
+ References
No definition available.
+ Details

Name: mdit_PreferredStockSharesTableTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred Stock Terms
+ References
No definition available.
+ Details

Name: mdit_PreferredStockTermsTableTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The Company had the following outstanding warrants to purchase shares of Common Stock
+ References
No definition available.
+ Details

Name: mdit_WarrantsOutstandingTableTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Reverse Merger (Tables)
9 Months Ended

Sep. 30, 2015

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Under the purchase method of accounting, the assets acquired and liabilities assumed are recorded at their respective fair values as of the transaction date. In connection with the merger, the consideration paid, the assets acquired and liabilities assumed, recorded at fair value on the date of acquisition, are summarized in the following table:

In thousands

Assets acquired

Cash

$

1

Other current assets

12

Property and equipment

81

Trade names /trademarks

1,240

In-Process research and development

4,620

Goodwill

2,453

8,407

Liabilities assumed

Accounts payable & accrued expenses

3,220

Related party advances

102

Loans payable

21

3,343

Consideration paid in the form of common stock

$

5,064

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 9.

Commitments and Contingencies

The Company currently leases 12 vehicles for sales and service employees, delivery and other purposes with expirations ranging from November 2015 through June 2018. The current minimum monthly payment for these vehicle leases is approximately $5,463.

The Company has several operating leases for office, laboratory and manufacturing space. The Company’s operating lease for one of its German facilities can be cancelled by either party with a 3 months’ notice, its Poland facility can be terminated by either party with a six month notice. Monthly rent payments for the German and Poland facilities are Euro 4,000 ($4,487 as of September 30, 2015) and PLN 6,240 ($1,660 as of June 30, 2015) respectively. The Company’s laboratory facility in Chicago, IL terminates June 30, 2016 and requires monthly payments of $1,070. The Company also subleases its former Chicago laboratory facility for $3,948 per month. The lease for this facility terminates October 30, 2016 and requires monthly rent payments of $4,394. The Company’s Orlando facility has escalating rents ranging from $2,416 to $2,563 per month and terminates July 31, 2018. The total aggregate monthly lease payments (net of the sublease) required on these leases is approximately $10,051.

The Company also leases IT Hardware and Software for 3-D Design which require aggregate monthly lease payments of $1,645 through March 2018.

In 2014, the Company became a defendant in a lawsuit brought by D&D Technologies, Inc. (“D&D”) in the state of New Jersey for breach of contract and breach of implied covenant of good faith that allegedly occurred in 2013 for failure to pay for past contractual services. The original complaint was dismissed and then refiled by D&D. D&D is seeking damages over $86,000 plus equitable relief. In the second quarter of 2015, the Company and D&D reached a settlement agreement with D&D Technologies, Inc for $15,000. This amount was paid during the third quarter.

The Company’s former auditor L.J. Soldinger and Associates filed a claim against the Company in Illinois’ Lake County Superior Court. The Company believes the claims are without merit and has adequately reserved for costs associated with the claim.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Common Stock
9 Months Ended

Sep. 30, 2015

Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Common Stock

Note 7.

Common Stock

During the nine months ended September 30, 2015, the Company issued 1,338,875 shares of unregistered stock to qualified individuals pursuant to exemptions from registration under Regulation D and Section 4(2) of the Securities Act of 1933 at 1.60 for proceeds of $2,134,000, net of $81,000 of issuance costs. Further, the Company issued 12,000 shares of common stock in a Series D Preferred Stock conversion as further discussed in Note 8. During the third quarter ended September 30, 2015 the Company issued 1,086,250 shares of common stock at $1.60 for proceeds of $600,000 to the President of UNIC Medical of China. UNIC is the Company’s distributor in China and other Asian countries.

X

- Definition
The entire disclosure for common stock.
+ References
No definition available.
+ Details

Name: mdit_CommonStockDisclosureTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants
9 Months Ended

Sep. 30, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Preferred Stock and Warrants

Note 8.

Preferred Stock and Warrants

A summary of the Company’s preferred stock as of September 30, 2015 and December 31, 2014 is as follows.

September 30,

December 31,

2015

2014

(unaudited)

Shares Issued &

Shares Issued &

Offering

Outstanding

Outstanding

Series A convertible

47,250

47,250

Series B convertible, 10% cumulative dividend

93,750

93,750

Series C convertible, 10% cumulative dividend

38,333

38,333

Series D convertible, 10% cumulative dividend

-

175,000

Series E convertible, 10% cumulative dividend

19,022

19,022

Total Preferred Stock

198,355

373,355

As of September 30, 2015 and December 31, 2014, the Company had cumulative preferred undeclared and unpaid dividends. In accordance with the Financial Accounting Standard Board’s Accounting Standards Codification 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss in the net loss per share calculation for the six months ended Septebmer 30, 2015.

Summary of Preferred Stock Terms

Series A Convertible Preferred Stock

Liquidation Value:

$4.50 per share, $212,625

Conversion Price:

$10,303 per share

Conversion Rate:

0.00044—Liquidation Value divided by Conversion Price ($4.50/$10,303)

Voting Rights:

None

Dividends:

None

Conversion Period:

Any time

Series B Convertible Preferred Stock

Liquidation Value:

$4.00 per share, $375,000

Conversion Price:

$1,000 per share

Conversion Rate:

0.0040—Liquidation Value divided by Conversion Price ($4.00/$1,000)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing March 31, 2001

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $548,788 and $520,665, respectively.


Series C Convertible Preferred Stock

Liquidation Value:

$3.00 per share, $115,000

Conversion Price:

$600 per share

Conversion Rate:

0.0050—Liquidation Value divided by Conversion Price ($3.00/$600)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing March 31, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $160,038 and $151,413, respectively.

Series D Convertible Preferred Stock

Liquidation Value:

$1,000 per share, $ 525,000

Conversion Price:

$1,000 per share

Conversion Rate:

.01—Liquidation Value divided by Conversion Price ($10.00/$1,000)

Voting Rights:

None

Dividends:

10%—Quarterly—Commencing April 30, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $0 and $660,000, respectively.

Series E Convertible Preferred Stock

Liquidation Value:

$22.00 per share, $418,488

Conversion Price:

$800.00 per share

Conversion Rate:

.0275—Liquidation Value divided by Conversion Price ($22.00/$800)

Voting Rights:

Equal in all respects to holders of common shares

Dividends:

10%—Quarterly—Commencing May 31, 2002

Conversion Period:

Any time

Cumulative dividends in arrears at September 30, 2015 and December 31, 2014 were $585,948 and $558,173 respectively.

Warrants outstanding

Weighted

Weighted

Average

Average

Aggregate

Remaining

Exercise

Intrinsic

Contractual

Warrants

Price

Value

Life (Years)

Outstanding at December 31, 2014

143,308

$

2.64

—

6.46

Granted

—

—

—

—

Exercised

—

—

—

—

Expired

—

—

—

—

Outstanding at September 30, 2015

143,308

$

2.64

—

6.46

X

- Definition
The entire disclosure for preferred stock and warrants.
+ References
No definition available.
+ Details

Name: mdit_PreferredStockDisclosureTextBlock

Namespace Prefix: mdit_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Segment Information
9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment Information

Note 10.

Segment Information

The Company operates in one operating segment. However, the Company has assets and operations in the United States, Germany and Poland. The first quarter numbers included in the nine month period ended September 30, 2014 represent MEDITE as a private company before the reverse merger with the former CytoCore Inc. After April 3, 2014, results reflect the combination of both companies. The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560). The following tables show the breakdown of the Company’s operations and assets by region (in thousands):

United States

Germany

Poland

Total

Sep. 30,

Dec. 31,

Sep.30,

Dec. 31,

Sep. 30,

Dec. 31,

Sep. 30,

Dec. 31,

2015

2014

2015

2014

2015

2014

2015

2014

Assets

$

9,125

$

9,387

$

7,416

$

6,989

$

204

$

63

$

16,745

$

16,439

Property & equipment, net

87

98

1,924

1,985

5

8

2,016

2,091

Intangible assets

8,313

8,313

-

-

-

-

8,313

8,313

United States

Germany

Poland

Total

Sep. 30,

Sep. 30,

Sep. 30,

Sep. 30,

Sep. 30,

Sep 30,

Sep. 30,

Sep. 30,

2015

2014

2015

2014

2015

2014

2015

2014

Revenues

$

928

$

1,321

$

6,114

$

7,373

$

39

$

0

$

7,081

$

8,694

Net income (loss)

(552)

(182)

339

232

(54)

-

(267)

50

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Related Party Advances - Additional Information (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Related Party Transaction [Line Items]

Due To Related Parties Current $ 85 $ 110

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment (Tables)
9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

The following is a summary of the components of property and equipment (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Land

$

215

$

233

Buildings

1192

1,291

Machinery and equipment

546

529

Office furniture and equipment

295

265

Vehicles

42

103

Computer equipment

111

110

Construction in progress

521

559

Less: Accumulated depreciation

(906)

(999)

$

2,016

$

2,091

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Organization and Summary of Significant Accounting Policies - (Additional Information) (Detail) - shares

Sep. 30, 2015

Dec. 31, 2014

Apr. 30, 2014

Business Acquisition [Line Items]

Common Stock, Shares, Outstanding 20,766,206 19,427,331

Medite Enterprise [Member]

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired 100.00%

Common Stock, Shares, Outstanding 15,000,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdit_MediteEnterpriseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies - Additional Information (Detail)
6 Months Ended 9 Months Ended

Jun. 30, 2015

USD ($)

Jun. 30, 2015

PLN

Sep. 30, 2015

USD ($)

Sep. 30, 2015

EUR (€)

Commitments and Contingencies Disclosure [Line Items]

Operating Leases, Rent Expense $ 5,463

Loss Contingency, Damages Paid, Value 86,000

Agreed To Legal Settlement 15,000

Operating Leases, Rent Expense, Sublease Rentals 3,948

Sale Leaseback Transaction, Monthly Rental Payments 10,051

Sublease [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating Leases, Rent Expense, Minimum Rentals $ 4,394

Lease Termination Date Oct. 30, 2016 Oct. 30, 2016

Orlando Facility [Member]

Commitments and Contingencies Disclosure [Line Items]

Lease Termination Date Jul. 31, 2018 Jul. 31, 2018

Chicago laboratory facility [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating Leases, Rent Expense, Minimum Rentals $ 1,070

Lease Termination Date Jun. 30, 2016 Jun. 30, 2016

IT Hardware and Software [Member]

Commitments and Contingencies Disclosure [Line Items]

Sale Leaseback Transaction, Monthly Rental Payments $ 1,645

Germany [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating Leases, Rent Expense, Minimum Rentals 4,487 € 4,000

Poland [Member]

Commitments and Contingencies Disclosure [Line Items]

Operating Leases, Rent Expense, Minimum Rentals $ 1,660 PLN 6,240

Maximum [Member] | Orlando Facility [Member]

Commitments and Contingencies Disclosure [Line Items]

Loss Contingency, Damages Paid, Value 2,563

Minimum [Member] | Orlando Facility [Member]

Commitments and Contingencies Disclosure [Line Items]

Loss Contingency, Damages Paid, Value $ 2,416

X

- Definition
Agreed To Legal Settlement
+ References
No definition available.
+ Details

Name: mdit_AgreedToLegalSettlement

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Commitments and Contingencies Disclosure [Line Items]
+ References
No definition available.
+ Details

Name: mdit_CommitmentsAndContingenciesDisclosureLineItems

Namespace Prefix: mdit_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date which lease or group of leases is set to terminate, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: mdit_LeaseTerminationDate

Namespace Prefix: mdit_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of damages paid to the plaintiff in the legal matter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyDamagesPaidValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 25

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7661868&loc=d3e34039-112682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesRentExpenseMinimumRentals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

+ Details

Name: us-gaap_OperatingLeasesRentExpenseSubleaseRentals1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6456341&loc=d3e50796-112755

+ Details

Name: us-gaap_SaleLeasebackTransactionMonthlyRentalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=mdit_SubleaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=mdit_OrlandoFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=mdit_ChicagoLaboratoryFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=mdit_ItHardwareAndSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_DE

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_PL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities:

Net income (loss) $ (267) $ 50

Adjustments to reconcile net income (loss) to net cash used in operating activities

Depreciation 95 126

Non cash interest 0 4

Changes in assets and liabilities:

Accounts receivable, net 689 56

Inventories (746) (1,058)

Prepaid expenses and other current assets (54) (150)

Accounts payable and accrued liabilities (109) (391)

Net cash used in operating activities (392) (1,363)

Cash flows from investing activities:

Purchases of equipment (19) (391)

Increase (decrease) in other assets (154) 1

Net cash used in investing activities (173) (390)

Cash flows from financing activities:

Net advances (repayments) on lines of credit and long-term debt (791) 180

Term note repayments (228) (159)

Proceeds from sale of common stock, net issuance costs of $28 2,056 1,842

Net advances from (repayment to) related parties (25) 9

Net cash provided by financing activities 1,012 1,783

Effect of exchange rates on cash (330) 21

Net increase in cash 117 140

Cash at beginning of year 230 75

Cash at end of the period 347 215

Supplemental disclosure of cash flow information:

Cash paid for interest 103 149

Cash paid for income taxes 68 16

Supplemental schedule of non-cash financing activity:

Conversion of preferred stock to common stock $ 525 $ 0

X

- Definition
The increase (decrease) during the reporting period in other assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: mdit_IncreaseDecreaseInOtherAssets

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for acquisition of machinery and equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireMachineryAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Property and Equipment
9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 4.

Property and Equipment

The following is a summary of the components of property and equipment (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Land

$

215

$

233

Buildings

1192

1,291

Machinery and equipment

546

529

Office furniture and equipment

295

265

Vehicles

42

103

Computer equipment

111

110

Construction in progress

521

559

Less: Accumulated depreciation

(906)

(999)

$

2,016

$

2,091

Depreciation expense amounted to approximately $95,000 and $126,000 for the nine months ended September 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Reverse Merger - (Estimated Purchase Price Allocation) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Assets acquired

Cash $ 1

Other current assets 12

Property and equipment 81

Trade names /trademarks 1,240

In-Process research and development 4,620

Goodwill 2,453 $ 2,453

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets 8,407

Liabilities assumed

Accounts payable & accrued expenses 3,220

Related party advances 102

Loans payable 21

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities 3,343

Consideration paid in the form of common stock $ 5,064

X

- Definition
The amount of identifiable In-Process research and development recognized as of the acquisition date.
+ References
No definition available.
+ Details

Name: mdit_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of related party advances due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
No definition available.
+ Details

Name: mdit_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRelatedPartyAdvances

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of identifiable Trade name /trademark recognized as of the acquisition date.
+ References
No definition available.
+ Details

Name: mdit_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNameTradeMark

Namespace Prefix: mdit_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 106 202 1 false 44 0 false 6 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.cytocoreinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.cytocoreinc.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.cytocoreinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.cytocoreinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.cytocoreinc.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.cytocoreinc.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 6 false false R7.htm 107 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 108 - Disclosure - Reverse Merger Sheet http://www.cytocoreinc.com/role/ReverseMerger Reverse Merger Notes 8 false false R9.htm 109 - Disclosure - Inventories Sheet http://www.cytocoreinc.com/role/Inventories Inventories Notes 9 false false R10.htm 110 - Disclosure - Property and Equipment Sheet http://www.cytocoreinc.com/role/PropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 111 - Disclosure - Long-term Debts and Lines of Credit Sheet http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCredit Long-term Debts and Lines of Credit Notes 11 false false R12.htm 112 - Disclosure - Related Party Advances Sheet http://www.cytocoreinc.com/role/RelatedPartyAdvances Related Party Advances Notes 12 false false R13.htm 113 - Disclosure - Common Stock Sheet http://www.cytocoreinc.com/role/CommonStock Common Stock Notes 13 false false R14.htm 114 - Disclosure - Preferred Stock and Warrants Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrants Preferred Stock and Warrants Notes 14 false false R15.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.cytocoreinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 116 - Disclosure - Segment Information Sheet http://www.cytocoreinc.com/role/SegmentInformation Segment Information Notes 16 false false R17.htm 117 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 118 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 119 - Disclosure - Reverse Merger (Tables) Sheet http://www.cytocoreinc.com/role/ReverseMergerTables Reverse Merger (Tables) Tables http://www.cytocoreinc.com/role/ReverseMerger 19 false false R20.htm 120 - Disclosure - Inventories (Tables) Sheet http://www.cytocoreinc.com/role/InventoriesTables Inventories (Tables) Tables http://www.cytocoreinc.com/role/Inventories 20 false false R21.htm 121 - Disclosure - Property and Equipment (Tables) Sheet http://www.cytocoreinc.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.cytocoreinc.com/role/PropertyAndEquipment 21 false false R22.htm 122 - Disclosure - Long-term Debts and Lines of Credit (Tables) Sheet http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCreditTables Long-term Debts and Lines of Credit (Tables) Tables http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCredit 22 false false R23.htm 123 - Disclosure - Preferred Stock and Warrants (Tables) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables Preferred Stock and Warrants (Tables) Tables http://www.cytocoreinc.com/role/PreferredStockAndWarrants 23 false false R24.htm 124 - Disclosure - Segment Information (Tables) Sheet http://www.cytocoreinc.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cytocoreinc.com/role/SegmentInformation 24 false false R25.htm 125 - Disclosure - Organization and Summary of Significant Accounting Policies (Detail) Sheet http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetail Organization and Summary of Significant Accounting Policies (Detail) Details http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 126 - Disclosure - Organization and Summary of Significant Accounting Policies - (Additional Information) (Detail) Sheet http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Organization and Summary of Significant Accounting Policies - (Additional Information) (Detail) Details http://www.cytocoreinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 127 - Disclosure - Reverse Merger - (Estimated Purchase Price Allocation) (Detail) Sheet http://www.cytocoreinc.com/role/ReverseMergerEstimatedPurchasePriceAllocationDetail Reverse Merger - (Estimated Purchase Price Allocation) (Detail) Details http://www.cytocoreinc.com/role/ReverseMergerTables 27 false false R28.htm 128 - Disclosure - Reverse Merger - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/ReverseMergerAdditionalInformationDetail Reverse Merger - Additional Information (Detail) Details 28 false false R29.htm 129 - Disclosure - Inventories - (Summary of the Components of Inventories) (Detail) Sheet http://www.cytocoreinc.com/role/InventoriesSummaryOfComponentsOfInventoriesDetail Inventories - (Summary of the Components of Inventories) (Detail) Details http://www.cytocoreinc.com/role/InventoriesTables 29 false false R30.htm 130 - Disclosure - Property and Equipment (Detail) Sheet http://www.cytocoreinc.com/role/PropertyAndEquipmentDetail Property and Equipment (Detail) Details http://www.cytocoreinc.com/role/PropertyAndEquipmentTables 30 false false R31.htm 131 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 31 false false R32.htm 132 - Disclosure - Long-term Debts and Lines of Credit (Detail) Sheet http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCreditDetail Long-term Debts and Lines of Credit (Detail) Details http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCreditTables 32 false false R33.htm 133 - Disclosure - Long-term Debts and Lines of Credit - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/LongtermDebtsAndLinesOfCreditAdditionalInformationDetail Long-term Debts and Lines of Credit - Additional Information (Detail) Details 33 false false R34.htm 134 - Disclosure - Related Party Advances - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/RelatedPartyAdvancesAdditionalInformationDetail Related Party Advances - Additional Information (Detail) Details 34 false false R35.htm 135 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/CommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Details 35 false false R36.htm 136 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock) (Detail) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsSummaryOfPreferredStockDetail Preferred Stock and Warrants (Summary of Preferred Stock) (Detail) Details http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables 36 false false R37.htm 137 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock) (Parenthetical) (Detail) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsSummaryOfPreferredStockParentheticalDetail Preferred Stock and Warrants (Summary of Preferred Stock) (Parenthetical) (Detail) Details http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables 37 false false R38.htm 138 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Detail) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsSummaryOfPreferredStockTermsDetail Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Detail) Details http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables 38 false false R39.htm 139 - Disclosure - Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Parenthetical) (Detail) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsSummaryOfPreferredStockTermsParentheticalDetail Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Parenthetical) (Detail) Details http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables 39 false false R40.htm 140 - Disclosure - Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) Sheet http://www.cytocoreinc.com/role/PreferredStockAndWarrantsWarrantsAndOptionsIssuedOutsideOfPlanForEmployeeCompensationDetail Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) Details http://www.cytocoreinc.com/role/PreferredStockAndWarrantsTables 40 false false R41.htm 141 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 41 false false R42.htm 142 - Disclosure - Segment Information (Detail) Sheet http://www.cytocoreinc.com/role/SegmentInformationDetail Segment Information (Detail) Details http://www.cytocoreinc.com/role/SegmentInformationTables 42 false false R43.htm 143 - Disclosure - Segment Information - (Additional Information (Detail) Sheet http://www.cytocoreinc.com/role/SegmentInformationAdditionalInformationDetail Segment Information - (Additional Information (Detail) Details http://www.cytocoreinc.com/role/SegmentInformationTables 43 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. mdit-20150930.xml mdit-20150930_cal.xml mdit-20150930_def.xml mdit-20150930_lab.xml mdit-20150930_pre.xml mdit-20150930.xsd true true XML 58 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Preferred Stock and Warrants (Summary of Preferred Stock Terms) (Detail) - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 1,121,000 $ 2,871,000

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 212,625

Preferred Stock, Conversion Price $ 10,303

Preferred stock, conversion Rate 0.00044%

Preferred stock, voting Rights None

Preferred Stock, Conversion Period Any time

Preferred Stock Liquidation Preference $ 4.50

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 375,000

Preferred Stock, Conversion Price $ 1,000

Preferred stock, conversion Rate 0.004%

Preferred stock, voting Rights None

Preferred Stock, Dividends 10.00% 10.00%

Preferred Stock, Conversion Period Any time

Preferred stock, cumulative and undeclared dividends in arrears $ 548,788 $ 520,665

Preferred Stock Liquidation Preference $ 4.00

Series C Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 115,000

Preferred Stock, Conversion Price $ 600

Preferred stock, conversion Rate 0.005%

Preferred stock, voting Rights None

Preferred Stock, Dividends 10.00% 10.00%

Preferred Stock, Conversion Period Any time

Preferred stock, cumulative and undeclared dividends in arrears $ 160,038 $ 151,413

Preferred Stock Liquidation Preference $ 3.00

Series D Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 525,000

Preferred Stock, Conversion Price $ 1,000

Preferred stock, voting Rights None

Preferred Stock, Dividends 10.00% 10.00%

Preferred Stock, Conversion Period Any time

Preferred stock, cumulative and undeclared dividends in arrears $ 0 $ 660,000

Preferred Stock Liquidation Preference $ 1,000

Series E Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Liquidation Value $ 418,488

Preferred Stock, Conversion Price $ 800.00

Preferred stock, conversion Rate 0.0275%

Preferred stock, voting Rights None

Preferred Stock, Dividends 10.00% 10.00%

Preferred Stock, Conversion Period Any time

Preferred stock, cumulative and undeclared dividends in arrears $ 585,948 $ 558,173

Preferred Stock Liquidation Preference $ 22.00

X

- Definition
Preferred Stock Conversion Period
+ References
No definition available.
+ Details

Name: mdit_PreferredStockConversionPeriod

Namespace Prefix: mdit_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred Stock, Conversion Rate
+ References
No definition available.
+ Details

Name: mdit_PreferredStockConversionRate

Namespace Prefix: mdit_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Stock Conversion, price per share
+ References
No definition available.
+ Details

Name: mdit_StockConversionPricePerShare

Namespace Prefix: mdit_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate amount of cumulative preferred dividends in arrears.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

Name: us-gaap_PreferredStockAmountOfPreferredDividendsInArrears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of the difference between preference in liquidation and the par or stated values of the preferred shares.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockLiquidationPreferenceValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Inventories (Tables)
9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

Schedule of Inventory

The following is a summary of the components of inventories (in thousands):

September 30,

December 31,

2015

2014

(unaudited)

Raw materials

$

1,934

$

1,229

Work in progress

225

33

Finished Goods

2,002

2,153

$

4,161

$

3,415

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Long-term Debts and Lines of Credit - Additional Information (Detail)	1 Months Ended	9 Months Ended
	Feb. 23, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2015 EUR (€)	Sep. 30, 2015 EUR (€)	Jan. 31, 2015 EUR (€)	Dec. 31, 2012 EUR (€)
Participation Rights Agreement In March 2009 [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		12.15%		12.15%
Participation Rights Agreement In March 2009 [Member] \| Tranche One [Member]
Line of Credit Facility [Line Items]
Debt instrument face amount		$ 1,700,000		€ 1,500,000
Participation Rights Agreement In March 2009 [Member] \| Tranche Two [Member]
Line of Credit Facility [Line Items]
Debt instrument face amount		841,298		€ 750,000
Medite GmbH, Burgdorf [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		2,000,000				€ 1,800,000
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		1,800,000			€ 1,600,000
Line of Credit Facility, Increase (Decrease), Net		$ 560,865	€ 500,000
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit lines 1 Issued in July 2006 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.77%		3.77%
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit lines 2 Issued in July 2006 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,200,000		€ 1,100,000
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank term loan 1 Issued in December 2006 [Member]
Line of Credit Facility [Line Items]
Debt instrument face amount		$ 560,865		€ 500,000
Debt Instrument, Interest Rate, Stated Percentage		3.40%		3.40%
Principal repayments		$ 31,162	27,780
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank term loan 2 Issued in June 2006 [Member]
Line of Credit Facility [Line Items]
Debt instrument face amount		$ 448,692		€ 400,000
Debt Instrument, Interest Rate, Stated Percentage		3.60%		3.60%
Principal repayments		$ 24,928	22,220
Medite GmbH, Burgdorf [Member] \| Hannoversech Volksbank term loan 3 Issued in November 2008 [Member]
Line of Credit Facility [Line Items]
Debt instrument face amount		$ 448,692		€ 400,000
Debt Instrument, Interest Rate, Stated Percentage		4.70%		4.70%
Principal repayments		$ 15,581	€ 13,890
CytoGlobe, GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 448,692		€ 400,000
CytoGlobe, GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%
CytoGlobe, GmbH, Burgdorf [Member] \| Hannoversech Volksbank Credit line 3 Issued in June 2012 [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.77%		3.77%
Ventana Medical Systems, Inc [Member]
Line of Credit Facility [Line Items]
Notes Payable, Current		$ 21,000
Repayments of Debt	$ 38,281
Dividends Payable, Current	656,250
Agreed To Convert Of Preferred Stock For Common Stock	$ 1,750,000
Number Of Stock To Be Converted From Preferred Stock \| shares	12,000
Long-term Debt, Current Maturities, Total	$ 38,281
Hannoversche Volksbank [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Increase (Decrease), Net		$ 1,019

Organization and Summary of Significant Accounting Policies (Detail)	9 Months Ended
	Sep. 30, 2015
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	33 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office furniture and equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Office furniture and equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Segment Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Assets	$ 16,745		$ 16,745		$ 16,439
Property & equipment, net	2,016		2,016		2,091
Intangible assets	8,313		8,313		8,313
Revenues			7,081	$ 8,694
Net income (loss)	59	$ (119)	(267)	50
United States [Member]
Segment Reporting Information [Line Items]
Assets	9,125		9,125		9,387
Property & equipment, net	87		87		98
Intangible assets	8,313		8,313		8,313
Revenues			928	1,321
Net income (loss)			(552)	(182)
Germany [Member]
Segment Reporting Information [Line Items]
Assets	7,416		7,416		6,989
Property & equipment, net	1,924		1,924		1,985
Intangible assets	0		0		0
Revenues			6,114	7,373
Net income (loss)			339	232
Poland [Member]
Segment Reporting Information [Line Items]
Assets	204		204		63
Property & equipment, net	5		5		8
Intangible assets	$ 0		0		$ 0
Revenues			39	0
Net income (loss)			$ (54)	$ 0

Segment Information - (Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015 USD ($)
Foreign Currency Exchange Rate Translation Amount	$ 1.1
Description of Difference between Reported Amount and Reporting Currency Denominated Amount	The influence in revenues by the significant change of the currency exchange rate between USD and EURO since September 30, 2014 compared to September 30, 2015 is approximately $1.1 million (USD/EURO exchange rate of 1.1151 vs. 1,3560).

Inventories - (Summary of the Components of Inventories) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 1,934	$ 1,229
Work in progress	225	33
Finished Goods	2,002	2,153
Inventory, Net	$ 4,161	$ 3,415

Reverse Merger - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	9 Months Ended
	Apr. 04, 2014	Apr. 03, 2014	Jan. 31, 2014	Sep. 30, 2015
Business Acquisition [Line Items]
Number of shares issued				1,338,875
Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement	$ 1.5		$ 1.5
Number of shares issued on acquisitions	14,687,500
Number of shares issued	955,875
Number of additional shares issued on acquisitions	312,500
Percentage of ownership interests acquired	100.00%
Reverse Acquisition Percentage Of Share Issued				81.10%
Business Combination Consideration Outstanding Shares	3,502,700
Business Combination Consideration Outstanding Shares Per Share	$ 1.6
In Process Research And Development Amortized Term	15 years
Medite Enterprises, inc [Member] \| Accrued Payroll Settlement [Member]
Business Acquisition [Line Items]
Number of shares issued on acquisitions		697,234
Value of shares issued on acquisitions		$ 1.6
Minimum [Member] \| Medite Enterprises, inc [Member]
Business Acquisition [Line Items]
Proceeds from private placement			$ 2.0

Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Land	$ 215	$ 233
Buildings	1,192	1,291
Machinery and equipment	546	529
Office furniture and equipment	295	265
Vehicles	42	103
Computer equipment	111	110
Construction in progress	521	559
Less: Accumulated depreciation	(906)	(999)
Property, Plant and Equipment, Net	$ 2,016	$ 2,091

Long-term Debts and Lines of Credit (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 2,745	$ 3,764
Hannoversche Volksbank credit line 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	1,169	1,880
Hannoversche Volksbank credit line 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	399	465
Hannoversche Volksbank term loan 1 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	62	135
Hannoversche Volksbank term loan 2 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	50	81
Hannoversche Volksbank term loan 3 [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	203	270
Ventana Medical Systems, Inc. Promissory Note [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	21	21
Denture DZ Equity Partners Participation right [Member]
Line of Credit Facility [Line Items]
Long-term Debt, Gross	$ 841	$ 912

Preferred Stock and Warrants (Warrants And Options Issued Outside Of The Plan For Employee Compensation) (Detail) - Warrants [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Warrants, Opening Balance	143,308
Warrants, Granted	0
Warrants, Exercised	0
Warrants, Expired	0
Warrants, Ending Balance	143,308	143,308
Weighted Average Exercise Price, Opening Balance	$ 2.64
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Expired	0
Weighted Average Exercise Price, Ending Balance	$ 2.64	$ 2.64
Aggregate Intrinsic Value, Opening Balance	$ 0
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Exercised	0
Aggregate Intrinsic Value, Expired	0
Aggregate Intrinsic Value, Ending Balance	$ 0	$ 0
Weighted Average Remaining Contractual Life(Years),Outstanding	6 years 5 months 16 days	6 years 5 months 16 days
Warrants Outstanding Granted Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Exercised Weighted Average Remaining Contractual Term	0 years
Warrants Outstanding Expired Weighted Average Remaining Contractual Term	0 years

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 347	$ 230
Accounts receivable, net	1,302	1,991
Inventories	4,161	3,415
Prepaid expenses and other current assets	208	154
Total current assets	6,018	5,790
Property and equipment, net	2,016	2,091
In-process research and development	4,620	4,620
Trademarks, trade names	1,240	1,240
Goodwill	2,453	2,453
Other assets	398	245
Total assets	16,745	16,439
Current liabilities:
Secured lines of credit and current portion of long-term debt	1,764	2,555
Account payable and accrued expenses	4,025	4,134
Advances - related parties	85	110
Total current liabilities	5,874	6,799
Long-term debt, net of current portion	981	1,209
Total liabilities	$ 6,855	$ 8,008
Commitments and contingencies
Stockholders’ equity :
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 198,355 and 373,355 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively (liquidation value of all classes of preferred stock $1,121 and $2,871 as of September 30, 2015 and December 31, 2014, respectively)	$ 962	$ 1,487
Common stock, $0.001 par value; 3.5 billion shares authorized, 20,766,206 and 19,427,331 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	21	19
Additional paid-in capital	8,343	5,763
Treasury stock	(327)	(327)
Accumulated other comprehensive loss	(479)	(149)
Retained earnings	1,370	1,638
Total stockholders' equity	9,890	8,431
Total liabilities and stockholders' equity	$ 16,745	$ 16,439

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Payments of Stock Issuance Costs	$ 28	$ 28

Common Stock - Additional Information (Detail)	3 Months Ended	9 Months Ended
Common Stock - Additional Information (Detail)	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares shares
Class Of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares		1,338,875
Share Price \| $ / shares	$ 1.60	$ 1.60
Stock Issued During Period, Value, New Issues		$ 2,134,000
Stock Issued During Period, Shares, Issued for Services \| shares		81,000
President, of UNIC Medical of China [Member]
Class Of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	1,086,250
Share Price \| $ / shares	$ 1.60	$ 1.60
Stock Issued During Period, Value, New Issues	$ 600,000
Series D Preferred Stock [Member]
Class Of Stock [Line Items]
Stock Issued During Period, Value, Issued for Services		$ 12,000

Preferred Stock and Warrants (Summary of Preferred Stock) (Detail) - shares	Sep. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, shares issued	198,355	373,355
Preferred stock, shares outstanding	198,355	373,355
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	47,250	47,250
Preferred stock, shares outstanding	47,250	47,250
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	93,750	93,750
Preferred stock, shares outstanding	93,750	93,750
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	38,333	38,333
Preferred stock, shares outstanding	38,333	38,333
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	0	175,000
Preferred stock, shares outstanding	0	175,000
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued	19,022	19,022
Preferred stock, shares outstanding	19,022	19,022

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per shares)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred stock, shares issued	198,355	373,355
Preferred stock, shares outstanding	198,355	373,355
Preferred Stock, Liquidation Preference, Value (in dollars)	$ 1,121	$ 2,871
Common stock, par value (in dollars per shares)	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000
Common Stock, Shares, Issued	20,766,206	19,427,331
Common Stock, Shares, Outstanding	20,766,206	19,427,331

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Nov. 13, 2015
Document Information [Line Items]
Entity Registrant Name	Medite Cancer Diagnostics, Inc.
Entity Central Index Key	0000075439
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MDIT
Entity Common Stock, Shares Outstanding		20,766,206
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

Related Party Advances - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Due To Related Parties Current	$ 85	$ 110

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended		9 Months Ended
	Jun. 30, 2015 USD ($)	Jun. 30, 2015 PLN	Sep. 30, 2015 USD ($)	Sep. 30, 2015 EUR (€)
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense			$ 5,463
Loss Contingency, Damages Paid, Value			86,000
Agreed To Legal Settlement			15,000
Operating Leases, Rent Expense, Sublease Rentals			3,948
Sale Leaseback Transaction, Monthly Rental Payments			10,051
Sublease [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			$ 4,394
Lease Termination Date			Oct. 30, 2016	Oct. 30, 2016
Orlando Facility [Member]
Commitments and Contingencies Disclosure [Line Items]
Lease Termination Date			Jul. 31, 2018	Jul. 31, 2018
Chicago laboratory facility [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			$ 1,070
Lease Termination Date			Jun. 30, 2016	Jun. 30, 2016
IT Hardware and Software [Member]
Commitments and Contingencies Disclosure [Line Items]
Sale Leaseback Transaction, Monthly Rental Payments			$ 1,645
Germany [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			4,487	€ 4,000
Poland [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	$ 1,660	PLN 6,240
Maximum [Member] \| Orlando Facility [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Paid, Value			2,563
Minimum [Member] \| Orlando Facility [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Paid, Value			$ 2,416

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ (267)	$ 50
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation	95	126
Non cash interest	0	4
Changes in assets and liabilities:
Accounts receivable, net	689	56
Inventories	(746)	(1,058)
Prepaid expenses and other current assets	(54)	(150)
Accounts payable and accrued liabilities	(109)	(391)
Net cash used in operating activities	(392)	(1,363)
Cash flows from investing activities:
Purchases of equipment	(19)	(391)
Increase (decrease) in other assets	(154)	1
Net cash used in investing activities	(173)	(390)
Cash flows from financing activities:
Net advances (repayments) on lines of credit and long-term debt	(791)	180
Term note repayments	(228)	(159)
Proceeds from sale of common stock, net issuance costs of $28	2,056	1,842
Net advances from (repayment to) related parties	(25)	9
Net cash provided by financing activities	1,012	1,783
Effect of exchange rates on cash	(330)	21
Net increase in cash	117	140
Cash at beginning of year	230	75
Cash at end of the period	347	215
Supplemental disclosure of cash flow information:
Cash paid for interest	103	149
Cash paid for income taxes	68	16
Supplemental schedule of non-cash financing activity:
Conversion of preferred stock to common stock	$ 525	$ 0

Reverse Merger - (Estimated Purchase Price Allocation) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets acquired
Cash	$ 1
Other current assets	12
Property and equipment	81
Trade names /trademarks	1,240
In-Process research and development	4,620
Goodwill	2,453	$ 2,453
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	8,407
Liabilities assumed
Accounts payable & accrued expenses	3,220
Related party advances	102
Loans payable	21
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	3,343
Consideration paid in the form of common stock	$ 5,064